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Abstract
Malaria is a mosquito-borne infectious disease caused by parasites of the genus Plasmodium.
Mortality and morbidity due to malaria infection is a serious burden to malaria endemic
countries. Despite the many years of prevention and control, malaria cases and mortality are
still quite high. In 2018, the World Health Organization (WHO) reported about 219 million
cases and 435000 deaths due to malaria globally. The threat of parasite resistance, minimal
efficacy of malaria vaccines and the high burden of malaria prevention and control measures
offer serious challenge to malaria elimination efforts. Improved therapeutic measures is
hence necessary for malaria control and possible eradication.
In this study, deterministic in-host malaria models with therapeutic control measures are
extended and mathematically analysed. Effects of antimalarial drugs and malaria vaccines
on disease severity are established analytically and numerically. Parasite resistance and the
effects of competition between different parasite strains are also investigated numerically.
Each model is analysed and vital properties such as positivity, existence of steady states and
their stability conditions are precisely determined. By Pontryagin’s Maximum Principle, the
optimal control therapy measure against P. falciparum malaria is determined.
Results indicate that a combination of different malaria vaccine antigens yield better ther-
apeutic outcome compared to individual vaccine antigens. A highly efficacious malaria
vaccine (efficacy > 90%) is likely to offer the much needed protection against P. falciparum
malaria. Multiple-strain infection is likely to increase parasitaemia and hence the severity
and cost of malaria control. Malaria therapeutic control efforts should focus on reducing:
the parasite invasion rate, the proportions of merozoites that become gametocytes per dying
blood schizont, the average number of merozoites released per bursting blood schizonts
and the rate of development of resistance during multiple-strain infections. Moreover, a
combination of pre-erythrocytic vaccine antigen, blood schizontocide and gametocytocide
drugs is likely to offer the best therapeutic control strategy against P. falciparum malaria.
In conclusion, future malaria control efforts should consider efficacious malaria vaccines and
vaccine combinations. To reduce development of resistance and morbidity, only efficacious
antimalarials such as ACT should be used against P. falciparum malaria. The administration
and use of current antimalarial drugs alongside efficacious malaria vaccines is likely to
offer the much needed therapeutic combination against P. falciparum. Regular and strict
surveillance on quality and standards of antimalarial drugs in medical facilities in malaria
endemic countries is therefore very critical. Collectively, results from this study highlights
the need for continued investment in malaria drug development and urgent drive to improve
the efficacy of malaria vaccine candidates such as RTS,S/AS01.
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1.1 Background to the study
Malaria is a mosquito-borne infectious disease caused by protozoa of the genus Plasmodium
(P). Since its discovery in 1880, malaria infection has greatly influenced human evolution
and history (Carter and Mendis, 2002; Sachs and Malaney, 2002; Snow et al., 2005). Today,
nearly half of the world’s population is at risk of malaria infection (Whegang et al., 2019). In
2018, the World Health Organization (WHO) reported about 219 million cases and 435000
deaths due to malaria globally. The WHO African region was the most affected. This region
accounted for 92% and 93% of reported global malaria cases and deaths, respectively (WHO,
2018f). Majority of the reported global deaths (61%) were from children aged under 5 years.
The WHO South-East Asia Region continued to see its incidence rate fall (from 17 (in 2007)
to 7 (in 2017)) cases per 1000 population at risk, representing a 59% decline in reported
malaria cases (WHO, 2018f). Although it is estimated that malaria cases declined by about
20 million in 2010-2017 period, data for the period 2015-2017 indicates that no significant
progress in reducing global malaria cases was made during this period (WHO, 2018f).
The socio-economic burden of malaria has significant negative impacts on individuals,
families and governments, especially in the WHO African region (Gallup and Sachs, 2001;
Rowe et al., 2006; Sachs and Malaney, 2002), where the disease is most prevalent. In
2017, an estimated US$ 3.1 billion and US$ 2.2 billion was invested in malaria control and
elimination efforts globally and in the WHO African region, respectively. Despite stable
funding since the year 2010, a lot more funding will be necessary if the Global Technical
Strategy for Malaria (GTS) are to be achieved (WHO, 2015a).
1
Research in malaria control constitutes a significant component of these efforts and budgets.
Although funding for malaria vaccine research and development declined in the period
2015-2016, investment in vector control doubled in the same period (US$ 33 million to US$
61 million) (Zelman et al., 2016). While targeting the highly (malaria) burdened African
countries, the WHO has rolled out a new drive called “high burden to high impact” to achieve
the much needed global malaria response back (WHO, 2018b). This drive is a partnership
of the WHO and the Roll Back Malaria (RBM) initiative. It aims to galvanize national and
global political attention to reduce morbidity and mortality due to malaria infections.
Human malaria is caused by five species of Plasmodium parasites. They include: P. falci-
parum, P. vivax, P. ovale and P. malariae and P. knowlesi (Abdulla et al., 2011). Most malaria
infections are caused by the deadly P. falciparum, which is predominant in sub-Saharan
Africa (see Figure 1.1) (Brazier et al., 2017). The parasite is responsible for the most severe
malaria globally. P. vivax mainly contributes to malaria’s morbidity (Wickramasinghe and
Abdalla, 2000). P. vivax and P. ovale can hide in the liver for prolonged periods as hyp-
nozoites. This can cause relapsing malaria months or even years after the initial infection
(Derbyshire et al., 2011). Although human infections are rare, P. knowlesi is mainly found in
long-tailed and pig-tailed macaques (Cox-Singh et al., 2008). It is primarily zoonotic (Singh
and Daneshvar, 2013).
Victims of malaria infection often experience a wide variety of symptoms. Uncomplicated P.
falciparum malaria is characterised by such symptoms as fever, chills, sweats, headaches,
nausea and vomiting, body aches and general malaise (CDC, 2019a). Physical symptoms
may include elevated temperatures (> 38oC), perspirations, body weakness, enlarged spleen,
mild jaundice, enlarged liver and increased respiratory rate (Bartoloni and Zammarchi, 2012).
Severe malaria occur when the infection is complicated and is often characterised by major
organ failures or abnormalities in the patients’s blood or metabolism. Symptoms of severe
malaria include: severe anaemia due to haemolysis, haemoglobuniria, acute respiratory dis-
tress syndrome, abnormalities in blood coagulation, low blood pressure due to cardiovascular
collapse, hyperparasitaemia (> 100000 per mm3), metabolic acidosis and hypoglycemia
(Weatherall et al., 2002). Severe malaria is a clinico-pathological medical emergency that
should be treated immediately and aggressively (CDC, 2019a).
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Figure 1.1: Estimated malaria cases (in millions) based on WHO regions for the year 2017.
The area of the circle is shown as a percentage of the estimated number of cases in each
region. AFR (WHO African region), AMR (WHO region of the Americas), EMR (WHO
Eastern Mediterranean region), SEAR (WHO South-East Asia region), WPR (WHO Western
Pacific region). Source: WHO (2018f).
1.2 The life cycle of malaria parasite
Plasmodium parasite has a complex life cycle characterised by cyclical sexual and asexual
stages between vertebrates and female Anopheles mosquitoes. Both sexual and asexual
stages occurs within the human host. This is preceded by another sexual phase within the
mosquito vectors. These three phases translate into (1) pre-erythrocytic stage (which begins
when sporozoites enter the human host, its movement towards and development within the
liver hepatocytes), (2) erythrocytic stage (which begins when merozoites are released into
blood stream, their invasion of and development within the red blood cells. The third and
final phase is the (3) sporogonic cycle (which begins when mosquitos ingest gametocytes
(male and female), preceded by fertilization, leading to formation of oocysts that rupture into
sporozoites) (Chiyaka, 2010; Li et al., 2011). The life cycle of P. falciparum is summarised
as shown in Figure 1.2.
Pre-erythrocytic phase kicks off when an infected mosquito transmits haploid sporozoites into
the human dermis during its blood meal. The injected sporozoites travel randomly from the
skin, through the blood stream, and within 2 hours to the liver. Once in the liver, a sporozoite
migrates through several hepatocytes before it settles on a final one (Frevert et al., 2005).
Within the hepatocyte, the sporozoites develop, divide and propagate to produce 1500-8000
merozoites that are released into the blood stream from mature schizonts (Sturm et al., 2006).
This pre-erythrocytic phase (also called the liver stage) is asymptomatic. The release of
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infective merozoites into the host’s blood stream marks the beginning of the erythrocytic
phase (blood stage) of the parasite life cycle.
The free floating merozoites then begin to invade the host’s erythrocytes through a complex
multi-stage process that results in the formation of protective parasitophorous vacuole
(Koch and Baum, 2016; Paul et al., 2015). A mature blood schizont releases 8-24 daughter
merozoites (Lee and Fidock, 2008). The waves of bursting red blood cells and the invasion
of fresh red blood cells by the newly released merozoites produce malaria’s characteristic
symptoms (Miller et al., 2013). The infected erythrocytes develop into trophozoites which
mature into schizonts full of merozoites. A single erythrocytic cycle due to P. falciparum
takes about 48 hours (Reilly et al., 2007). Some of infected erythrocytes develop into sexual
forms called gametocytes, which are later taken up by other mosquitoes when they feed on
infected blood from infected individuals (Miller et al., 2002). Successive erythrocytic cycles
result in an increase in parasitaemia and disease severity. Unless they are brought under
control by the host’s protective immune responses or antimalarial drug therapy, the human
host is likely to undergo severe infection leading to anemia and even death.
Figure 1.2: Illustration of the life cycles of malaria parasites, Plasmodium (P) species. Source:
CDC (2017).
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In the mosquito midgut, the gametocytes taken up from the human host differentiate into
macrogametes and microgametes in response to environment cues (Kengne-Ouafo et al.,
2019). Sexual reproduction results in the formation of a motile form called ookinete that
migrates through the mosquito gut wall and transforms into an oocyst. In approximately 2
weeks, the oocyst produces and releases thousands of sporozoites that invade the mosquito’s
salivary glands (Chiyaka et al., 2008; Sidjanski and Vanderberg, 1997). These parasites are
then transmitted to human hosts in subsequent blood meals for new infections.
Parasite invasion of susceptible hepatocytes and erythrocytes is described by Cowman et al.
(2012) as an ordered three stage process involving initial attachment, reorientation and
invasion. The asymptomatic liver stage which the parasite goes through only once in its life
time offer a special target for future malaria control (March et al., 2013). The use of highly
effective malaria vaccines could interrupt the parasite’s life cycle at this stage, eliminating the
establishment of clinical infections. In this study, we shall limit our analysis to the dynamics
within the human host.
1.3 Malaria diagnosis and treatment
Malaria is both a preventable and treatable disease. Microscopic examination based on
Romanovsky stain is the gold standard laboratory confirmation of malaria in sick individuals
(CDC, 2019a). Prompt malaria diagnosis and treatment is the best strategy to prevent
progression from mild to severe disease and death (Talisuna et al., 2007). The goal of
malaria treatment is to ensure total eradication of all infecting parasites from the human host
(Lin Ouédraogo et al., 2015). Epidemiologically, treatment is offered to reduce infectious
reservoirs (Gerardin et al., 2015; Goncalves, 2017). Additionally, effective malaria treatment
therapy limits development of resistance and reduces spread of infection to other susceptible
humans and mosquito vector (Talisuna et al., 2007).
Malaria therapeutic interventions are patient-dependent and may vary based on: the species
of infecting parasite, the clinical status of the patient, pregnancy status (females), drug
allergies or other medications taken by the patient (CDC, 2019b). Most antimalarial drugs
are active against blood stage parasites. Some blood schizontocides include: chloroquine,
atovaquone-proguanil, artemether-lumefantrine, mefloquine, quinine, quinidine, doxycycline,
clindamycin and artesunate. Primaquine is active against the hypnozoites at the liver stage,
preventing infection relapses. However, this drug should not be administered to malaria
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patients with glucose-6-phosphate dehydrogenase deficiency (G6PD), as they may develop
anaemia (Peters and Noorden, 2009).
Currently, artemisin-based combination therapies (ACTs) is the recommended first-line
antimalaria drug against uncomplicated P. falciparum malaria infections (Heller and Roepe,
2019). ACT is a combination of artemisinin derivative (artemether, artesunate and de-
hydroartemisinin) and a partner monotherapy drug. Artemisinin derivative reduces the
parasite biomass within the first three days of therapy while the partner drug, with longer
half-life, eliminates the remaining parasites (Bhatt et al., 2015). The five recommended
ACTs by the WHO include: artesunate-amodiaquine (AS+AQ), artesunate-mefloquine
(AS+MQ), artemether-lumefantrine (AL), artesunate+sulfadoxine-pyrimethamine (AS+SP)
and dihydroartemisinin-piperaquine (DHA+PPQ). Additionally, artesunate-pyronaridine
(AS+PY) may be used in regions where ACT treatment response is low (WHO, 2018e).
Access to ACT has been tremendous in the last 8 years; with recorded increases of 122 million
procured treatment courses for the period 2010-2016. However, resistance to currently used
ACTs have important public health consequences, especially in the WHO African region,
where the disease is endemic (White and Pongtavornpinyo, 2003). Effective vector control
strategies such as insecticide-treated mosquito nets (ITNs) and indoor residual spraying (IRS)
are considered by the WHO as the main ways to prevent and reduce malaria transmission in
communities with high malaria prevalence (Homan, 2016). In 2017, half of the population
at risk of malaria infection were protected by ITNs (WHO, 2018f). Other vector control
measures are presented in Table 1.1.
Women and children are considered the most vulnerable groups in malaria epidemiology. To
reduce maternal anaemia, low birth weight and perinatal mortality in sub-Saharan Africa,
the WHO recommends the use of intermittent preventive treatment in pregnancy (IPTp)
using sulfadoxine-pyrimethamine (SP) (Yaya et al., 2018). For travellers and tourists from
malaria-free regions, chemoprophylaxis such as Atovaquone/Proguanil (Malarone) may be
taken to prevent possible malaria infection in malaria endemic countries (Dorsey et al., 2000).
The combination of vector control, personal protective measures and the use of antimalarial
drugs have contributed immensely to the substantial global decline in malaria mortality
and morbidity (Nega1 et al., 2016). However, despite the success of the existing malaria
prevention and control strategies, reported malaria cases are still quite high (Talapko et al.,
2019).
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Table 1.1: Malaria vector control strategies. Source: Killeen et al. (2017).
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1.4 Parasite resistance to antimalarial drugs
Artemisinin (partial) resistance is defined as delayed parasite clearance following treatment
with an artesunate monotherapy or with an ACT drug (WHO, 2018a). Resistance to anti-
malaria drugs is associated with the following factors: (i) poor patient treatment services, (ii)
inadequate treatment adherence to prescribed malaria drugs, (iii) widespread availability of
oral artemisinin-based monotherapies and (iv) substandard antimalarial drugs (Mackinnon,
2005; WHO, 2018a). In the past decade, P. falciparum has developed resistance to several an-
timalarial drugs (Xu et al., 2018). Resistance to chloroquine and sulfadoxine–pyrimethamine
led malaria endemic countries to adopt WHO recommended ACTs as a first-and second-line
treatment for uncomplicated P. falciparum malaria as well as for chloroquine-resistant P.
vivax malaria (Dondorp et al., 2009).
Several studies conducted in the period 2010-2017 showed that ACT drugs are very effective
with a success rates of at least 95% (Whegang et al., 2019). However, as of July 2016,
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artemisinin resistance was confirmed in 5 countries of the Greater Mekong subregion (GMS):
Cambodia, the Lao People’s Democratic Republic, Myanmar, Thailand and Viet Nam (WHO,
2017b). Despite the above reported cases, there has been a massive reduction in malaria
cases and deaths in the GMS (WHO, 2018f). Most patients treated with an ACT containing
an effective partner drug have however been able to recover.
To prevent global spread of the resistant strain, it is important to identify molecular markers
associated with ACT resistance. Results from genome wide association studies (GWAS)
have revealed mutations in the PF3D7_1343700 kelch propeller domain (‘K13-propeller’) in
artemisinin-resistant parasite from Cambodia (Das et al., 2017). Outside the GMS, treatment
failure with ACTs have mainly occurred due to resistance of the parasite to the partner drug
(Dondorp et al., 2010; WHO, 2012a). In sub-Saharan Africa, artemisin resistance is yet to be
reported. It is important to note that ACTs have been very integral in the recent success of
global malaria control. Monitoring their efficacy has resulting in prompt updating of malaria
treatment policies in the GMS and globally. It is therefore prudent that multidrug resistance
is stopped before it emerges in other parts of the world, especially in sub-Saharan Africa.
1.5 The role of immunity in controlling malaria infection
The presence of malaria parasites in the human body elicits response from numerous immune
cells. The innate and the adaptive immune systems form the first and the second lines
of defenses, respectively (Augustine et al., 2009). Adaptive immunity, which is acquired
naturally in individuals living in malaria-endemic areas following continuous exposure to the
parasite, provides protection against future exposures to malaria pathogens. However, this
immunity wanes in the absence of ongoing P. falciparum exposures (Doolan and Martinez-
Alier, 2006). Historic passive transfer studies have demonstrated a key role of the antibodies
in controlling blood-stage parasites during natural P. falciparum infection and reducing
clinical symptoms of malaria (Cohen et al., 1961). Although antibodies are crucial in
controlling blood-stages, naturally acquired immunity never results in complete parasite
elimination.
Malaria-specific antibodies perform such functions as (i) inhibition of cytoadherence (New-
bold et al., 1992) (ii) inhibition of red blood cell invasion (Patiño et al., 1997), and (iii)
antibody dependent cytotoxicity and cellular inhibition (Oeuvray et al., 1994). Innate im-
mune cells such as the P. falciparum DNA, natural killer cells (NK cells), dendritic cells
(DCs), macrophages, natural killer T (NKT) cells and T cells are involved in the clearance
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of circulating parasites, infected erythrocytes and infected hepatocytes (Augustine et al.,
2009). Subject to parasite strain, the DCs and NK cells may prompt or restrain inflammatory
responses (Chen et al., 2014). The NKT cells also help regulate DCs and T cell responses to
plasmodium (Augustine et al., 2009).
Additionally, studies by Franklin et al. (2009) have demonstrated that malaria infection
induces activation of Toll-like receptors (TLRs): TLR1, TLR2, TLR4 (which are located
on the cell surface) and TLR9 which is not expressed on the cell surface. TLR2 and
TLR9 are also activated by malarial glycosylphosphatidylinosital (GPI) anchors and parasite-
derived DNA bound to hemozoin (Franklin et al., 2009). Cell-mediated immune responses
include macrophage activation by NK cell-,γδT cell- or Th1-derived interferon γ (IFN-γ)
for enhanced phagocytosis and killing of infected/parasitised red blood cells (Fritsche et al.,
2001), inhibition of sporozoite growth and development within the liver hepatocytes by CD8+
cytotoxic and IFN-γ-producing T cells (Tsuji and Zavala, 2003). Unlike the NK cells, the
macrophages have been shown to effectively phagocytose malaria-infected red blood cells
during the erythrocytic phase (De Back et al., 2014). A part from its ability to wholly ingest
infected red blood cells, the macrophages can also selectively extract malaria parasites from
recently infected erythrocytes (Chotivanich et al., 2002). The parasite-extraction capability
of macrophage therefore leaves the surving erythrocytes to continue to circulate like the other
healthy red blood cells.
1.6 Malaria vaccine development
A malaria vaccination strategy is performed to either induce protective immune responses
prior to malaria infection or to provide protection in case of malaria attack (Arama and Troye-
Blomberg, 2014). There are more than 30 malaria vaccine candidates under development.
These vaccines are generally categorised into: (1) pre-erythrocytic vaccines (PEV), (2) blood
stage vaccines (BSV) and (3) transmission blocking vaccines (TBV) (Birkett, 2016). The
vaccines target the parasite at specific life stages as shown in Figure 1.3.
The PEV induces antibodies that block invasion of hepatocytes by sporozoites and or cell-
mediated immune responses that target infected hepatocytes (Duffy et al., 2012). On the
other hand, BSV target blood merozoites or infected red blood cells. They elicit anti-invasion
and anti-disease responses at the blood stage (Moorthy et al., 2004). They, therefore, lower
merozoites density and prevent clinical manifestations and hence severity of malaria infection
in humans. Unlike PEV and BSV, TBV are mainly intended to reduce parasite transmission to
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secondary hosts. TBV induce antibodies against antigens on gametes, zygotes and ookinetes,
blocking ookinete to oocyst transition and hence stopping parasite development within the
mosquito mid-gut (Carter et al., 2000). While TBV does not directly protect the person
who is vaccinated, it has the potential to stop continued spread of malaria infection within a
population.
Figure 1.3: Target sites in the malaria life cycle that could be interrupted by: pre-erythrocytic,
blood-stage and transmission-blocking vaccines. Source: Arama and Troye-Blomberg
(2014).
Currently available malaria vaccines have shown minimal efficacy (Birkett, 2016; Birkett
et al., 2013; Miura, 2016). RTS,S/AS01 (also known as Mosquirix) is the only malaria
vaccine that has received a positive scientific opinion from the European Medicines Agency
(EMA) (EMA, 2015). This pre-erythrocytic vaccine has been evaluated in large phase 3 trial
in sub-Saharan Africa. The vaccine showed a 45.7% (95% CI, 41.7 - 49.5) efficacy against
all episodes of clinical P. falciparum malaria across all sites in the 5-17 month age category
(RCTP, 2014). Despite positive assessment from EMA, the World Health Organization
(WHO) recommends further evaluation of RTS,S/AS01 in a series of pilot implementations
before it can be introduced on a wide scale (WHO, 2018d).
Despite minimal progress, many experts believe that a malaria vaccine is a necessary tool for
successful malaria elimination (MVFG, 2018; Ouattara and Laurens, 2014). In this study,
we have provided important insights on the impacts of improved vaccine efficacy on the
dynamics of clinical malaria infection. We have also analysed a combination of different
vaccine antigens in improving their overall efficacies.
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1.7 Problem statement
Malaria is one of the most frequently occurring infectious disease worldwide, with almost
0.6 million deaths and an estimated 240 million clinical cases annually. The infectious
disease remains a global health priority with over 3 billion people in 97 countries at risk of
periodic infections and death (WHO, 2018f). To date, the WHO consider effective vector
control strategies such as long-lasting insecticidal nets (ITNs) and indoor residual spraying
(IRS) as the main ways to prevent and reduce malaria transmission in communities with
high malaria prevalence. Chemoprophylaxis and antimalarial drugs such as chloroquine and
artemisinin-based combination therapy (ACT) are currently used to prevent and treat clinical
malaria, respectively, in different parts of the world. These strategies have contributed to the
substantial global decline in malaria mortality and morbidity.
Despite the global success in malaria control, global malaria cases and mortality are still
quite high and malaria remains a global health challenge. The WHO-African region still
bears the highest burden of malaria infection. In 2017, the region was home to 92% of global
malaria cases and 93% of global deaths caused by malaria infections (WHO, 2018f). Neither
artemisinin nor chloroquine is effective against the liver stage infections. The emergence of
P. falciparum resistance to both artemisinin and partner drugs in some parts of Cambodia and
Thailand (WHO, 2012a) is a threat to future therapeutic control against malaria infections.
Moreover, vector resistance to insecticides coupled with severity and complex nature of the
infective parasite has slowed down malaria control in some regions. Additionally, current
malaria vaccines have shown minimal efficacy. The only malaria vaccine that has received
a positive scientific opinion from the European Medicines Agency (EMA) (EMA, 2015) is
RTS,S/AS01. It showed a 30-50% protection for human trials in Africa. However, the WHO
recommends further evaluation of RTS,S/AS01 in a series of pilot implementations before it
can be introduced on a wide scale (WHO, 2018d).
Owing to increasing level of drug-resistance with no ready vaccine for public use, a multi-
pronged approach to malaria research is imperative. It is therefore important to provide
theoretical insights on possible new targets, new drug-combinations that not only kill the
infective parasites but also reduce parasite transmission to the next host. Effects of improved
malaria vaccines and vaccine combinations alongside effective antimalarial drugs such as
ACTs are investigated in this study. We extend existing in-host malaria models to determine
effective antimalarial drug and vaccine combination therapies for P. falciparum malaria while
providing rich insights on parasite dynamics and future therapeutic control measures.
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1.8 Research objectives
The main objective of this study is to improve therapeutic strategies against P. falciparum
malaria by extending and analysing (mathematically) models of in-host malaria dynamics.
Specific objectives include:
1. To extend and analyse a mathematical model for in-host malaria infection that incorpo-
rate the liver and blood stages of parasite development.
2. To mathematically determine the effectiveness of malaria vaccines at different stages
of parasite/disease progression.
3. To determine influential parameters and establish their contributions to in-host malaria
disease dynamics and control.
4. To mathematically determine the effects of P. falciparum multiple-strain infection on
development of parasite resistance and on in-host malaria dynamics and control.
5. To determine an optimal control therapy for in-host P. falciparum malaria infection.
1.9 Significance of the study
Although numerous prevention and control techniques have been employed to manage malaria
infection, the deadly infectious disease still exerts a heavy toll on susceptible populations
around the globe. This study is therefore important in the following aspects:
(i) Contributing to existing knowledge on mathematical modelling of in-host malaria
dynamics and control measures. The presented models consider both the liver and
blood stages in malaria therapy.
(ii) Improving the understanding of in-host dynamics during malaria infections.
(iii) Shaping policy making processes related to antimalarial drug use within communities
and countries.
(iv) Determining optimal therapy combinations for elimination of infectious malaria within
human host.
Locally, the findings of this study could be useful to malaria research organisations such as
the Kenya Medical Research Institute (KEMRI), Centers for Disease Control and Prevention
(CDC-Kenya) and the Ministry of Health in their effort to control malaria in the country. Our
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results on the impacts of drug and vaccine combinations could be investigated further through
vaccine trials in-vitro in these institutions. Threats caused by parasite resistance offers a
unique opportunity to closely monitor use and misuse of antimalarial drugs. Our results
call for regular and strict surveillance on antimalarial drugs use in clinics and hospitals in
malaria-endemic counties. Moreover, this study highlights gametocyte eradication measures
within the human host. This forms an important effort towards the 2030 global malaria
eradication goal.
1.10 Outline of the thesis
Chapter 2 gives a review of mathematical models that have been formulated and analysed
previously to provide insights on malaria disease transmission and control. Specific reviews
are focused on in-host malaria models and key results from such selected models. A review
on malaria infection in Kenya and a historical perspective of the disease in Kenya and globally
is provided. The subject of optimal control theory and its application to disease interventions
and especially malaria infection is also reviewed.
Chapter 3 highlights the general dynamics of malaria infection that spans from the liver
stage to the blood stage of the parasite life cycle, in the presence of protective macrophages.
The formulated model is analysed mathematically; using theories in Mathematical Biology.
Sensitivity analysis based on the normalised forward sensitivity technique is performed to
establish influential parameters in the disease progression. Due to non-linearity, the model is
solved numerically using Runge Kutta fourth order scheme in Matlab software, to ascertain
the long term dynamics of the blood cells, the immune cells and P. falciparum parasites.
In Chapter 4, the model (formulated in Chapter 3) is modified to incorporate vaccine control
strategy. The vaccines are categorised into: pre-erythrocytic vaccines, erythrocytic vaccines
and transmission blocking vaccines. Impact of vaccine efficacy is evaluated and critical
efficacy of blood stage vaccine determined. Additionally, the general impact of vaccine
combinations on parasitaemia is predicted numerically. Parameter sensitivity to the vaccine
reproduction number is also performed. The effects of higher vaccine efficacies and possible
vaccine combinations on parasitaemia and disease progression within the human host is
investigated.
In Chapter 5, uncertainty that may accompany choices for parameter values for in-host
malaria model is investigated. The possible effects of the different model parameter values
to the model outcome are explored. Uncertainty in the values of the model parameters are
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shown to generate variability in the model’s predictive capabilities. Variabilities in model
predictions are determined using the Latin Hypercube Sampling / Partial Rank Correlation
Coefficient (LHS/PRCC) sensitivity techniques.
In Chapter 6, the effect of multiple-strain P. falciparum infection on the human host is studied.
The effects of competition between the two parasite strains is also evaluated in reference to
severity of infection. The effects of parasite resistance is highlighted in a blood stage only
model. The effect of single and multiple-strain infection and its impact on the development
of resistance to current malaria therapy is investigated. The formulated model is analysed
mathematically and sensitivity analysis pegged on the strain-specific reproduction number
established using the normalised forward technique.
In Chapter 7, the theory of optimal control is applied to an in-host malaria model. Con-
trol measures in the form of antimalarial drug regimens and malaria vaccine antigens are
employed both at the pre-erythrocytic stage and the blood stage. The permissible control
measures are assumed to be nonlinear. The optimal control model with constant control
strategies is mathematically analysed and its stability conditions determined. Using Pon-
tryagin’s maximum principle, the best combination strategy that minimises the population
of infected hepatocytes, infected erythrocytes, merozoites and free floating gametocytes is
determined.
In Chapter 8, a conclusive summary of the study is provided and some of the recommenda-





The biology and life cycle of Plasmodium parasite is extremely complicated with numerous
unknown dynamics and behaviour straits (Cowman et al., 2016). The parasite alternates
between the human host and female Anopheles mosquito vector to accomplish its complex
infectious life cycles. Additionally, the parasite require the formation of unique zoite forms
to invade host cells (Josling and Llinas, 2015). The invasion and transmission of the parasite
from humans to mosquito has been under study for several years. Mathematical modelling
has provided useful insights in understanding such complicated dynamics.
In this chapter, we review mathematical models that have been formulated and analysed
previously to provide insights on malaria disease transmission and control. Specific reviews
are focused on in-host malaria models and key results from such selected models. We also
review malaria infection in Kenya and provide a historical perspective of disease in Kenya
and globally. The subject of optimal control theory and its application to disease interventions
and especially malaria infection is also reviewed.
2.2 Historical perspective of malaria
Malaria is one of the most fatal diseases worldwide (see Figures 2.1 and 2.2). The infectious
disease mainly affects children under 5 years and pregnant women who are categorised
as the most vulnerable groups to the disease (Harrington et al., 2009). Molecular genetic
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evidence suggests that the first ancestor of malaria parasite existed at least half a billion years
ago (Carter and Mendis, 2002). The cause of malaria was unknown until the year 1880,
when Charles Lavran [1854-1925] discovered malaria parasite in the human blood in Africa
(Cox, 2010). Eight years later, the discovered protozoan parasite was named Plasmodium
by Giovanni Grassi [1854-1925]. In 1897 Ronald Ross [1857-1932] demonstrated that
the malaria parasite could be transmitted from the infected Anopheles mosquito to humans
(Packard, 2007). Until 1969, the mono-dimensional dichloro-diphenyl-trichloroethane (DDT)
was the only chemical used in malaria control. Emergence and widespread parasite resistance
to chloroquine coupled by the long term environmental consequences of DDT worsened
global morbidity and mortality due to malaria infections in the 1980’s (Packard, 2007).
Interestingly, much of the in-host malaria dynamics was unknown until 1948 when Henry
Shortt [1887-1987] and Cyril Garnham [1901-1994] discovered the liver stage in the de-
velopment of the parasite life cycle (Cox, 2010). The parasites grow and develop within
the liver cells before they join the blood stream. However, some of the sporozoites may
remain dormant in the liver (as hypnozoites), causing malaria relapse. This phenomenon was
discovered in 1982 (Krotoski, 1985). For over a century, research on malaria epidemiology
has focused on treatment and control of disease transmission between the mosquito vector
and the human host.
Figure 2.1: Countries with indigenous cases in 2000 and their status by 2017. Only countries
in the WHO European region, China and El Salvador reported zero indigenous cases. Source:
WHO (2018f).
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Recent success in malaria treatment and control has resulted in significant global decline in
morbidity and mortality due to malaria infection. However, the estimated cases and deaths
due to P. falciparum malaria are still quite high, especially in the WHO African region.
Figures 2.2a and 2.2b show the global trends in cases and mortality due to malaria infections
in the last decade. It is evident that a lot more resources and research activities would be




Figure 2.2: Trends in malaria case incidence rate (cases per 1000 population at risk) and
mortality rate (cases per 100000 population at risk) globally (World) verses the WHO Africa
region (AFR) for the 2010-2017 period. The cases are displayed in Figure 2.2a while the
deaths are in Figure 2.2b. Source: WHO (2018f).
2.2.1 A review of malaria infection in Kenya
Kenya is a country in East Africa with a population of about 47.9 million people (KNBS,
2012; USAID, 2018). In the country’s population, children under 5 and under 15 accounts for
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16% and 42% of the total population, respectively. Geographically, the country is sub-divided
into two major regions: low-land regions (Lake Victoria basin and Coastal areas) and highland
regions (along the Great Rift Valley). Majority of the population live along the West-East belt
(Lake Victoria basin and Western), Nairobi, Coast and Central highlands. Arid and semi-arid
Southern and Northern parts of the country are sparsely populated. Historically, the country
experiences seasonal rainfall pattern comprising of long rains (in the months of March/April
and May/June) and short rains (in the months of October to November/December).
Malaria prevalence in the country therefore varies across the different geographic regions
(see Figure 2.3) and is seasonal (MOH, 2016).
Figure 2.3: Kenya population adjusted P. falciparum malaria prevalence (PAP f PR2−10) at
1× 1 km spatial by sub-county (2000-2015). Source: USAID (2018).
Despite global and regional success in reducing morbidity and mortality due to malaria,
malaria still remains a major public health problem in Kenya. About 4 million malaria cases
are reported annually, with about 5.1% mortality rate among patients admitted with severe
malaria. Over 99% of all reported cases are due to the deadly P. falciparum malaria. The
vector species are members of the Anopheles (An) gambiae complex: An. gambiae s.s.,
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An. arabiensis, An. merus and An. funestus (USAID, 2018). In 2015, malaria infections
accounted for 16% of country-wide outpatient consultations in public and private medical
facilities in Kenya (USAID, 2018).
A survey report by the Kenya National Bureau of Statistics (KNBS) showed that over three-
quarter of the total population is at risk of malaria infections (KNBS, 2017). According to
the WHO 2018 malaria report, about 35 million Kenyans live in malaria high transmission
zones i.e., those with more than one case per 1000 population (WHO, 2018f). Another 14.8
million live in low transmission areas i.e., those with 0 to 1 case per 1000 population. Of the
50.6 million malaria cases reported in the East and Southern Africa (ESA) region, Kenya
accounted for 7% of all cases (3.542 million). Although reported mortality due to malaria
declined (by 11%) in the ESA region, malaria cases increased by 3% (from 49.1 million in
2010 to 50.6 million in 2017) (WHO, 2018f).
Malaria transmission and infection risks in the country are largely influenced by altitude,
rainfall, vector species and parasite’s intensity of biting (MOH, 2016). Temperature is
the key determinant of environmental suitability for transmission of human malaria in the
country (Gething et al., 2011). A temperature Suitability Index (TSI) for malaria transmission
in Kenya indicates that Lake Victoria and Coastal regions have the ambient temperatures
suitable for vector survival and hence malaria transmission. Additionally, these regions
receive adequate and seasonal rainfall, making them suitable for sustained longer periods of
transmission. This partly explains their endemic classification for malaria transmission and
infections in the country (MOH, 2016).
In the past 15 years, the Kenyan government with the support of international donors under
the Roll Back Malaria Partnership program, have invested millions of shillings in reducing
morbidity, mortality and economic burden of malaria in the country (MOH, 2016). Vector
control measures such as ITNs, IRS and LLINs and the use of ACTs as a first-line treatment
for uncomplicated P. falciparum malaria, form the basis for the remarkable decline in malaria
cases and deaths in the country. Moreover, in high burden counties (along Lake Victoria and
the Coastal region), populations have been covered with IRS. Although these efforts have
moved the country towards achieving the Global Technical Strategy (GTS) goal for malaria,
the achievements are still a drop in the ocean if the country’s vision 2030 of a malaria-free
Kenya is to be achieved. To control malaria vector, reduce parasite transmission and provide
efficient therapy for malaria, a lot more funding and malaria resources should be provided
to the 47 counties in the country. This study highlights the pivotal role played by strict
administration of effective ACT drugs in the country to enhance treatment success. The
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study also emphasises the need to monitor malaria drug use in clinics and hospitals to reduce
development of parasite resistance in the country.
Figure 2.4: Trends in reported malaria cases (all ages, outpatient) in Kenya for the period
2012-2016. Source: USAID (2018).
2.3 Mathematical modelling as a tool to support infectious
disease control
Mathematical models (deterministic and stochastic) have evolved together with science
(natural sciences and social sciences) and currently have broad applications in engineering,
biology, economics among others. It therefore forms an essential and inseparable part of
scientific activity (Wainwright and Mulligan, 2013). These models are instrumental in
studying the different components of a system and help make predictions of the futuristic
behaviours of the system. Moreover, dynamical models have contributed significantly towards
the understanding of complex biological phenomenon including pathogen-host invasions
and disease transmission. Such models have provided simple and insightful understanding
of disease epidemiology and virology. They have been applied in the study of HIV/AIDS,
tuberculosis, malaria among other deadly infectious diseases.
Mathematical modelling is the process of using mathematical analysis to describe real world
phenomenon, with the goal of generating explanations and solutions to such problems. The
subject of mathematical modelling is founded on formulated mathematical models. Such
models can broadly be categorised into deterministic and stochastic models. A suitable
model should integrate present data and predict with reasonable accuracy the response of the
system to planned changes (Carrera et al., 1989).
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Unlike stochastic models, deterministic models ignore random variations. Stochastic models
are most appropriate when the system under study is characterised by inherent randomness.
However, for small data set with exact, repeated and fixed output, a deterministic approach
is preferred. Nevertheless, both model forms are characterised by assumptions on inherent
variables and parameters. They provide a simplified representation of a real system.
The translation of a real-world problem into a mathematical model begins from conceptu-
alisation and ends with a quantitative model. The conceptual model is often represented
using boxes and arrows in many epidemiological models. The boxes typify the state vari-
ables whereas the arrows indicate the direction of flow/movement or sometimes interactions
between different variables (Mbogo, 2014). The rates of change in a particular process are
combined to generate an equation to represent that process. Several processes result into
two or more equations or a system of equations called a quantitative model. Such equations
can take the form of difference equations (when time is regarded as a discrete variable) or
differential equations (when time is regarded as a continuous variable).
Mathematical models have become very essential in infectious disease modelling; that is
often characterised by complex disease dynamics. Analytical or numerical technique can be
employed to analyse such disease models. The preferred method may varry and depends on
the complexity of the formulated model. Several other aspects can be investigated from the
model including parameter sensitivity and model fitting to data for prediction purposes.
In this study, we have largely used differential equations in formulating our in-host malaria
disease models. Due to complexity and nonlinearity properties, the presented models are
analysed mathematically and their solutions presented analytically and numerically. Some
of the mathematical concepts and tools used in the qualitative analysis of the mathematical
models considered in this study are available in Appendix A.
2.4 In-host malaria models
The earliest in-host malaria model was formulated by Anderson et al. (1989). The model
describes the intra-host dynamics of malaria infection; the interactions between the healthy
erythrocytes and the merozoites. The model ignores the effects of the immune system and
hence describes the worst case scenario of the in-host malaria infection. Their mathematical
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where x(t),y(t) and m(t) are the concentrations of the healthy erythrocytes, infected erythro-
cytes and merozoites, respectively. The uninfected red blood cells (RBCs) are considered
susceptibles and are assumed to enter the blood circulation at a rate Λ. By the law of mass
action, the RBCs get infected by merozoites to form parasitised/infected red blood cells
(IRBCs) at a rate β . As the parasites grow and multiply, the IRBCs get killed at the rate
α . The IRBCs then burst and release merozoites at a rate rαy. In the absence of immunity,
IRBCs release a total of r merozoites per infected erythrocyte. As a consequence of the
bursting IRBCs, the merozoites are replenished at a rate rαy. Merozoites are assumed to
invade RBCs at the rate β , and die naturally at the rate d.
The simple mathematical model (2.1) was later expanded to include immunological responses
against malaria merozoites. The study by Anderson et al. (1989), focused on comparing the
effectiveness of immune responses against merozoites and infected (parasitised) red blood
cells. A compartment for the immune cells was added to the model system (2.1) so that we















where b is the concentration of immune effectors. The IRBCs are either killed by the parasites
at the rate µy or by immunity at the rate kyb. Initially, the immune effectors form a small
population which then grows at the rate (ρyy+ρmm) and decays at the rate µb. Moreover,
the growth of the immune effectors are considered influenced by the presence of both the
IRBCs and the merozoites, expressed by the mass-action terms kyby and kmbm, respectively.
The description of model parameters in system (2.2) are presented in Table 2.1.
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Table 2.1: Model parameter descriptions
Parameters Definition
Λ Immigration rate of x
β Effective (invasive) contact rate between m and x
r Number of merozoites released per IRBCs
ρy,ρm Immunogenecity of IRBCs and merozoites, respectively
µx,µy,µm,µb Death rates of the populations identified by the subscripts
ky,km Immunosensitivity of IRBCs and merozoites, respectively
Results from system (2.2) revealed that the immune response against the merozoites is less
effective than the immune response against infected red blood cells. Therefore, vaccines
based on IRBCs antigens are likely to be more effective than vaccines based on merozoite
antigens. Further analyses and criticism of this model can be found in (Molineaux and Dietz,
1999).
Moreover, the effects of immunological responses targeted at different stages in a malaria
parasite’s life-cycle is also investigated in Anderson et al. (1989). The focus being on the
relative merits of humoral versus cell-mediated immunological responses in suppressing
parasite abundance and replication within the human host. It is shown that the effectiveness of
a given immunological response is inversely related to the life-expectancy of the target stage
in the parasite’s developmental cycle. Numerical simulation of the formulated in-human
malaria model revealed temporal changes in the total abundance of erythrocytes (healthy and
infected erythrocytes ) in the human host in the presence of immunological responses, as
shown in Figures 2.5a and 2.5b, respectively.
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(a) (b)
Figure 2.5: The interaction of the erythrocytic cycle of P. falciparum with the human immune
system. The model is simulated under four scenarios: full line (no immunological response),
dotted line (antibody attack), dashed line (with killing of infected red blood cells) and
dotted+dashed line (with immunological responses against merozoites and infected red blood
cells). Source: Anderson et al. (1989).
Hetzel and Anderson (1996) extended the model by Anderson et al. (1989) by allowing
superinfecting merozoites to invade already infected red blood cells. They assumed that
these merozoites are wasted. The growth of the immune effectors is also assumed to be linear
in relation to the density of the antigens. This implies that immunity would develop even
if immune effectors do not exist. However, at higher effector density, there is a negative
feedback.
Further modification of the Anderson et al. (1989) model was done by Hellriegel (1992).
In her model, she allowed the gametocytes (gi) to be generated out of the infected red
blood cells (yi) at a rate r. Moreover, she assumed the existence of two clones that differ in
immunogenecity, immunosensitivity, metocytogenesis and rate of invasion of the erythrocytes.
Results of her study indicated that in the absence of immunity, the less invasive clone is
eliminated by the more invasive clone. The two clones can however coexist in the presence



































=Ii(σisi + γiyi +λigi −µI)+ ε/2,

(2.3)
where, kii, lii,hii, for i = (1,2) represents the genotype-specific and ki j, li j,hi j(i ̸= j) denotes
the non-specific genotypes.
Research work by Swinton (1996), restricted immunogenecity and immunosensitivity to
infected erythrocytes. Swinton assumed that the growth of the immune effectors is a linear
function of the concentration of malaria parasites in the human body. The process of
erythropoiesis is also postulated to increase with increase in the death rate of susceptible red
blood cells (anaemia).
Austin et al. (1998a) merged a pharmacokinetic and pharmacodynamic models with an intra-
host malaria model. This model is basically similar to the model in Hetzel and Anderson
(1996). However, they ignored super-infection of IRBCs and assumed that the merozoite
density equilibrates instantaneously at all times. Immunogenesity and immunosensitivity
is also restricted to the IRBCs only. In order to insert drug action in the model, two key
assumptions are made: (1) Antimalarials act exclusively by increasing the death rate of the
infected red blood cells; without changing the rate at which they release merozoites and (2)
drug action is dose-dependent, saturating at an infected red blood cell death rate (kµy), where
the parameter k is drug-specific. According to Molineaux and Dietz (1999), the above key
assumptions grossly underestimate the effect of treatment.
The only discrete-time in-host malaria model is that presented by Kwiatkowski and Nowak
(1991). They formulated a malaria model based on the association between fever and the
rupture of mature schizonts (as shown in system (2.4)). The sensitivity of the IRBCs to
fever-like temperatures in vitro was used to modulate the age specific mortality of the IRBCs.
Their results showed that a fraction exp(−siy1(t)) of the IRBC of age i survives through the
12 hour interval (t, t +1). The fraction depends on yi, the density of the youngest IRBCs and
on the age specific sensitivity Si.
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y1(t +1) =r(1−h)y4(t)exp(−s4y1(t)+hy1(t)exp(−s1y1(t)),
y2(t +1) =r(1−h)yt−1(t)exp(−si−1y1(t))+ exp(−siy1(t)), i = 1, . . .4,
}
(2.4)
where yi=infected red blood cells, r=number of successful merozoites released per IRBCs,
h=fraction staying in the same age-group, si=sensitivity of yi and y1; t=time (age and time
units are 12 hours).
Malaria therapy patients vary by orders of magnitute in the density at which they control
their parasitaemia and in the parasite density associated with the first fever (Jeffery et al.,
1959). In McKenzie and Bossert (1997), a three intra-host populations of IRBCs (asexual),
gametocytes, and immune effectors is considered (as shown in system (2.5)). Contrary to their
expectations, all the nine models displayed a domain of parameter space that yields output
within the acceptable ranges. Moreover, the peak asexual density decreased monotonuously












Variables: y=asexual IRBC; g=gametocytes; b=immune effectors. Parameters: ρy=net growth
rate of y, ky=immunosensitivity of y; γA=rate of gametocytogenesis; µg, µb=death rates of
gametocytes and immune effectors, respectively; ρ01=rate of immunogenesis. The other
models of the family are defined by substituting the gametogenesis term γAy by γByb or
γCy2, and/or the immunogenesis term ρ01y by ρ02yb or ρ03y(t −L) where L= a time-lag;
these options define nine models, labelled A1,A2,A3, . . .C3, as described and analysed in
McKenzie and Bossert (1998).
Some few mathematical models have concentrated on the in-human and in-mosquito malaria
dynamics. In Selemani et al. (2016), stability analysis of an in-human and in-mosquito
deterministic mathematical model is performed. Using linearisation methodology, it is
showed that the malaria-free equilibrium is locally asymptotically stable when R0 < 1. By
Metzler matrix theory, the malaria-infection equilibrium (MIE) is found to be globally
asymptotically stable provided R0 < 1. However, when R0 > 1, and based on LaSalle’s
invariance theory, the MIE is shown to be globally asymptotically stable according to
Lyapunov functional method.
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In Selemani et al. (2017a), the influence of the host’s immunity agaist in-host malaria
infection is investigated. Immunity is shown to have significant influence in lowering malaria
infection at blood and mosquito stages. At the liver stage, however, the immunity was least
influential. Severity of malaria infection is shown to decrease with increasing density of
defensive immune cells. Although antibodies are very effective at blocking cell invasions by
sporozoites and merozoites, the immune cells are shown to be highly effective in suppressing
merozoite production at the erythrocytic stages (Selemani et al., 2017a). Moreover, results
of sensitivity analysis in Selemani et al. (2017b), revealed that new therapetic intervetions
should aim at increasing the death of blood and liver schizonts. This has a direct effect on
decreased merozoite densities and hence reduced malaria severity on infected patients.
A thorough review of basic intra-host model of malaria, without immunity is presented by
Chiyaka (2010). The paper highlights how concepts in nonlinear dynamics can be used to
unravel the underlying dynamical features of an in-host malaria model. The critical role of
an intra-host basic reproduction number for a malaria model in controlling malaria infection
is highlighted in Chiyaka et al. (2008) and Chiyaka (2010). Bifurcation analysis in Chiyaka
(2010), revealed that the model given by system (2.6) has a critical parameter rc for which
the in-host malaria infection persists if r > rc, where r is the average number of merozoites
produced per each bursting infected erythrocyte.
The deterministic in-host malaria model is an extension of the original model (2.2) by Ander-
son et al. (1989). It is established that malaria drugs based on inhibiting parasite production
are more effective than those based on inhibiting merozoite invasion of erythrocytes (Chiyaka
et al., 2008). Using theories in stability analysis, malaria infection can be eliminated from the
infected human host if the drug efficacy level exceeds a certain threshold value and persist
otherwise. The mathematical model by Chiyaka et al. (2008), that is only limited to the blood











































where X(t) and Y (t) are the concentrations of the unparasitised and parasitised erythrocytes,
respectively. M(t) are merozoites that infect the healthy RBCs at the rate β . The response of
the immune system is captured by the inclusion of the immune cells B(t) and the antibodies
A(t) in the system (2.6). Detailed descriptions of the model parameters are as presented by
Chiyaka et al. (2008).
2.5 Optimal control measures applied to disease models
In developing response plans to disease outbreaks, decision makers such as government and
public health officials are often faced with trade-offs in choosing among various treatment
options (Gaff and Schaefer, 2009). Searching for answers to identify the best strategies for
intervention prior to what may be an inevitable disease or to an already existing pathogen is
not a simple challenge. Diseases such as measles, human papilloma virus and influenza have
varied approved medical treatment options as well as available vaccines. Vaccines targeting
high burden diseases such as malaria and HIV/AIDS are currently under development,
Usually the challenge is to find the optimal response balancing treatment and vaccination
that will minimise incidence and disease-related mortality at an affordable cost (Joshi et al.,
2006; Omondi et al., 2018).
From the early work by Bernoulli and Blower (2004), and his argument for the advantages
of inoculation in controlling smallpox mortality, optimal control theory have broadly found
their applications in determining control strategies of diseases (Lenhart and Workman, 2007;
Magombedze et al., 2009b), especially in the control of HIV (Adams et al., 2004; Fister
et al., 1998; Joshi, 2002; Karrakchou et al., 2006; Kirschner and Webb, 1996; Magombedze
et al., 2011b, 2009a; Shiri et al., 2005b) and tuberculosis (Jung et al., 2002; Silva et al., 2016;
Silva and Torres, 2012). In these studies, optimal control therapy strategies were explored
using Pontryagin’s maximum principle on dynamical models (Lenhart and Workman, 2007).
Brauer (2006), considered the effect of treatment on some epidemic models. Asymptotically,
the complex models and more simple models displayed similar qualitative behaviours. He
however advocated for an investigation on the possible trade-off between vaccination and
treatment and how the results would be influenced by the complex models.
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2.5.1 Optimal control measures applied to malaria disease models
The application of optimal control theory in malaria epidemiology and control has for a long
time been limited to population models only (Agusto et al., 2012; Makinde and Okosun,
2011; Mwanga et al., 2015; Okosun et al., 2011). In these models, the goal of the application
of optimal control theory is to minimise the number of humans infected with malaria while
keeping the costs of control, such as purchase of ITNs and IRS, as low as possible (Mwanga
et al., 2015). A study by Okosun et al. (2011), formulated a deterministic model using
mass-action form of infection and derived optimal conditions for disease eradication in finite
time. Numerical results and cost effectiveness analysis indicate that the optimal strategy to
control malaria within a population requires the combination of vaccination and treatment
methods. In Makinde and Okosun (2011), a combination of screening of infected immigrants,
treatment of infectives and spraying of insecticides against mosquitoes lead to significant
decline in new malaria cases and transmissions among susceptible individuals.
In Silva and Torres (2013), optimal supervision and educational campaigns on the use of
ITNs are shown to be highly effective in achieveing 75% coverage of the host population
within a community. Analyses by Mwanga et al. (2014), revealed that a combination of
three control strategies: ITNs, IRS and treatment provides the best control against malaria
transmission and infection. Additionally, the use of mosquito-reduction strategies is more
effective than personal protection in some cases but not always (Kim et al., 2012). However,
a combination of personal protection, treatment and insecticides spray are shown to bear
the greatest impact on malaria control (Agusto et al., 2012). In all these dynamical models,
optimal control therapy strategies were explored using Pontryagin’s maximum principle
(Pontryagin, 1987).
That very minimal research work is currently available on the application of optimal control
theory to in-host malaria control dynamics is undebatable. This could be explained by the
complex dynamics of cell-parasite interactions within the human host. The impact of control
measures based on vaccination, anti-malarial drugs and immunological responses targeted
at different stages in a malaria parasite is examined by Anderson et al. (1989). Analysis
revealed that the influence of a defined control measure on the prevalence or intensity of
infection is non-linearly related to the magnitude of control effort. Very high levels of cohort
immunisation is required to block transmission for a defined level of coverage. Gametocyte
vaccine is also shown to be better with respect to reducing transmission for a defined level of
coverage. Sporozoite vaccines are however shown to be very effective in reducing disease
morbidity (Anderson et al., 1989).
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Although Magombedze et al. (2011a) determined optimal control measures of malaria
chemotherapy, their work was limited to the parasite blood stage only. Results of their study
indicated that highly toxic drugs with the compensation of high infection suppression have
the potential of yielding better treatment results than less toxic drugs with less infection
suppression potential or high toxic drugs with less infection suppression potential. It was
also observed that a treatment protocol with drugs with high adverse effects and with a high
potential of merozoite suppression can be beneficial to patients. However, an optimal control
strategy that seeks to maximise immune cells has no potential of improving the treatment of
blood stage malaria.
To the best of our knowledge, optimal control study is yet to be applied to a robust in-host
malaria model that incorporates the liver and blood stages. In this study, we have considered
the important opportunity for malaria control provided by the liver stage. The formulated
optimal control methodology aims to reduce severity of infection and/or eradicate infective
parasites at a minimal cost. The minimisation function and optimality system is presented in
Chapter 7 of this thesis.
In this study, ordinary differential equations are used in the model formulations and extensions.
The in-host malaria model by Chiyaka et al. (2008), is extended by adding the liver stage
and immune effectors to the in-host malaria dynamics. Model properties including positivity
and boundedness of solutions and the prove of the existence of and stability analysis of
model equilibrium points are determined. Owing to nonlinearity, the models in this study
are solved numerically using Matlab and Python softwares. The deterministic blood stage
model by Anderson et al. (1989) is extended to investigate the effects of parasite resistance to
antimalarial drugs and the impact of multiple-strain infection on severity of malaria infection.
The model is extended by sub-dividing merozoite compartment into drug-sensitive and
drug-resistant strains. This division is extended to infected erythrocytes and gametocytes.
The severity of infection is investigated in the context of parasite resistance to antimalarial
drug therapy.
The next Chapter 3 deals with formulation and analysis of a deterministic, robust, in-host
malaria model that illustrates the dynamics and interactions of malaria parasites from the
liver stage to the blood stage in the presence of host’s immune cells.
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Chapter 3
Mathematical model for in-host
dynamics of malaria
3.1 Introduction
In this chapter, we develop a mathematical model that describes the dynamics and interactions
between the P. falciparum parasites, the host’s hepatocytes and red blood cells in the presence
of immune effectors. The in-host (in-vivo) model is analysed mathematically and solved
numerically using Python and Matlab softwares. We compute the in-host basic reproduction
number and establish highly sensitive parameters for future therapeutic target and disease
control.
3.2 In-host dynamics of malaria
In-host studies are studies aimed at understanding a disease dynamics within a living organism
(AIRF, 2012). An in-host malaria model therefore, embodies to describe the dynamics of
interactions between the red blood cells, liver hepatocytes, malaria parasitaemia and immune
effectors within the human host. The in-host malaria dynamics discussed in this chapter is
therefore limited to the liver (pre-erythrocytic phase) and blood (erythrocytic phase) stages
of P. falciparum parasite life cycle within the human host.
Several studies on mathematical modelling of in-host malaria and its dynamics have been
done. Nearly all the earlier mathematical models (see for instance, (Anderson et al., 1989;
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Hellriegel, 1992; Swinton, 1996)) focused on improving P. falciparum control while focussing
on the cyclic blood stage of parasite development and infectivity. These models have been
helpful in explaining in-host observations by means of biologically plausible assumptions
such as parasite diversity, predicting the impact of interventions or use of antimalarial drugs
(Dondorp et al., 2010), and estimating hidden parameter values (White, 2004). Although
the models in (Chiyaka et al., 2008; Li et al., 2011; Tumwiine et al., 2008), have considered
the impact of immune response and treatment, the modelling is only limited to the blood
stage of P. falciparum development. In (Selemani et al., 2016, 2017a; Tabo et al., 2017),
the liver stage is incorporated in the malaria model. However, the contribution of immune
system is ignored in (Selemani et al., 2016; Tabo et al., 2017). Moreover, all the immune
cells are assumed to play an active role during malaria infection in (Selemani et al., 2017a).
This may not be entirely true. The specific impacts of immune responses to malaria infection
are well discussed in (Bate et al., 1988; Elloso et al., 1994; Ganusov et al., 2002; Rouzine
and McKenzie, 2003).
3.2.1 Hepatocyte regeneration and repair
Liver hepatocytes are instrumental in the development of malaria parasites. Injected sporo-
zoites travel to the liver of the human host and invade the hepatocytes; crital stage of
establishing malaria infection (Silvie et al., 2003). The sources of the hepatocytes vary
depending on the growth process. The hepatocytes can be generated from the bone marrow
cells (Fausto et al., 2006); this mainly occurs during liver transplants (where they are an
important source of nonparenchymal cells, including the kupffer cells and endothelial cells)
and often the frequency of hepatocyte proliferation is very low (Fausto, 2004). The replica-
tion of existing hepatocytes form the second source of liver hepatocytes. Old hepatocytes
are replaced through a process called compensatory hyperplasia (Fausto et al., 2006). A
single hepatocyte could replicate 70 or more times in its life-time (Overturf et al., 1997).
According to Fausto (2004), replication is the quickest and most efficient way to generate
hepatocytes for liver regeneration and repair. This argument is also supported by data in
(Weglarz et al., 2000), where diploid, tetraploid and octoploid hepatocytes are reported to
have approximately the same capacity to replace damaged liver cells. The third source of
hepatocytes are the oval cells. These cells replicate and differentiate into hepatocytes when
the replication of mature hepatocytes is delayed or entirely blocked (Fausto, 2004).
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3.3 Model formulation
We extended the in-host malaria model by Chiyaka et al. (2008), by incorporating the liver
stage of parasite development. The reformulated in-host malaria model focuses on the erythro-
cytic and hepatocytic stages and describes the dynamics of interactions between the malaria
parasites, the liver hepatocytes, the erythrocytes (red blood cells) and the macrophages
(immune system cells). Unlike the models in (Selemani et al., 2016, 2017a), we ignored the
vector stage of parasite development and assumed a twofold process in the generation of hep-
atocytes: from the bone marrow and from self-replication of the existing hepatocytes. Again,
we assumed that the rate of generation of macrophages and susceptible erythrocytes from
the bone marrow increases with increasing density of the infected erythrocytes. However,
whatever the densitity of infected erythrocytes, there is a limit on the rate at which cells can
be released from the bone marrow.
The compartmental model assumes seven interacting populations of sporozoites S(t), suscep-
tible hepatocytes H(t), infected hepatocytes HX(t), susceptible erythrocytes R(t), infected
erythrocytes RX(t), merozoites M(t) and macrophages Z(t) at any time t. The dynamics of
malaria parasites and host-cell populations in each compartment are described as follows:
Sporozoites (S): The female Anopheles mosquito is assumed to inject sporozoites into the
human system during blood meal at a constant rate Λ. The sporozoites molt through the
blood stream and reach the liver in about 2 hours, where they invade the hepatocytes at the
rate βs. We assume that the sporozoites can die naturally at a rate δs.
Susceptible hepatocytes (H): We consider the bone marrow and self-replication as the
main sources of the liver hepatocytes in our model. The recruitment of hepatocytes from
the bone marrow is assumed to occur at a constant rate λh. Just like during liver transplant,
(Fausto et al., 2006), we argue that during severe malaria infections, the rate of generation of
healthy hepatocytes is likely to increase tremendously and in proportion to the concentrations
of the infected hepatocytes (Fausto, 2004). This additional increase is represented by the
term ρ1HX/(κ1 +HX) = ψ1(HX), where HX and ρ1, respectively, represent the density
of infected hepatocytes and their rates of generation. The parameter κ1 represents the
number/concentration of the infected hepatocytes at which the recruitment of the healthy
hepatocytes is a half of the maximum rate. Owing to invasion by sporozoites at the rate
βs, susceptible hepatocytes get infected and progress to subpopulation HX . In addition,
hepatocytes in compartment H are assumed to have a natural life expectancy and may hence
die naturally at the rate µ1.
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Infected hepatocytes (HX): Following sporozoite invasion, the healthy hepatocytes get
infected leading to formation of infected hepatocytes. The infected hepatocytes mature
into liver-stage schizonts. These schizonts burst open, releasing 2000-40000 uninucleate
merozoites into the blood stream (Crutcher and Hoffman, 1996). The term Nµ2HX represents
the total population of merozoites released upon bursting of infected hepatocytes. The
parameter µ2 represents the death rate of the infected hepatocytes.
Susceptible erythrocytes (R): Similar to malaria models in (Li et al., 2011; Tumwiine et al.,
2008) we have assumed that the susceptible red blood cells (RBCs) get recruited at a constant
rate λr from the bone marrow. We further assume that, during infection, the production
rate of erythrocytes is accelerated owing to the presence of infected red blood cells (IRBCs)
at the rate ρ2. This increase is denoted by the term ρ2RX/(κ2 +RX) = ψ2(RX), where κ2
represents number/concentration of the infected red blood cells at which the recruitment
of susceptible red blood cells is a half of the maximum rate. The particular mechanisms
involved in this accelerated process is however still poorly understood (Wickramasinghe and
Abdalla, 2000). The susceptible RBCs get infected by merozoites at a rate proportional to the
contact rate of their density, βrMR. The positive constant βr describes the rate of successful
invasion by a malaria merozoite. This process of destruction of the RBCs result in build-up
of toxins and debris in the blood. The resultant immune reaction produces side effects which
are the common observable symptoms of malaria, such as fever, chills, nausea and aches.
The susceptible RBCs die naturally at a rate µ3.
Infected erythrocytes (RX) : Upon invasion by merozoite, the healthy RBCs get infected,
leading to the formation of infected red blood cells RX . Although the IRBCs die at a constant
rate µ4, they can also be killed through phagocytosis by the macrophages at the rate η . The
parameter η therefore denotes the immunosensitivity of the IRBCs. At maturity, the IRBCs
burst open, releasing free merozoites into the blood system, causing secondary invasion
and disease progression. During malaria infection, the IRBCs may bind to the endothelial
lining of blood vessels in vital organs, such as brain, lung, and heart leading to disease
complications and sometimes death (Miller et al., 1994).
Merozoites (M): After 2-15 days, the infected hepatocytes burst open and release merozoites
into the blood system. This is represented by the term Nµ2HX , where N is the average
number of merozoites released per bursting infected hepatocyte. An average of K merozoites
are released per each bursting blood schizont. These free parasites suffer a natural death
at a rate δm, and invade susceptible RBCs at a rate βr. Within the red blood cells, the
merozoites mature either into uninucleate gametocyte or into erythrocytic stage schizont
containing 10-36 merozoites (Crutcher and Hoffman, 1996). After about 48-72 hours, the
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erythrocytic stage schizont ruptures, releasing more merozoites into blood stream to cause
further invasion of healthy RBCs. We assume that a proportion ζ of the merozoites contribute
to secondary invasion of the susceptible RBCs. The rest of the merozoites (1−ζ ) transform
into gametocytes that are later picked up by female Anopheles mosquitoes during feeding.
Further depletion of merozoite numbers may arise from destruction by host immunity or
from ageing. These two are however not considered in the model presented in this chapter.
Macrophages (Z): The presence of malaria parasites in the human body elicits responses
from numerous immune cells: such as the natural killers cells (through contact dependent
manner) (Chen et al., 2014), the macrophages (Bate et al., 1988; De Back et al., 2014), the
CD4+ T and the CD8+T cells among others (White et al., 2013). Owing to their effectiveness
in elimination of infected red blood cells and infective malaria parasites, we have considered
the innate macrophage cells as the main part of the immune response in malaria infection.
Consequently, we have assumed that macrophage cells are recruited at a constant rate λz from
the bone marrow. Moreover, they proliferate at a rate ρ3 at the sites of infection in proportion
to the density of IRBCs. This is represented by the term ρ3RX/(κ3 +RX) = ψ3(RX), where
κ3 denotes the number/concentration of the infected red blood cells at which the recruitment
of the macrophages is a half of the maximum rate. Although macrophages play an important
role in promoting erythropoiesis (De Back et al., 2014), and phagocyte on the IRBCs at a
rate η , they can also die naturally at a constant rate δz.
The variables and parameters that describe the in-host malaria dynamics are presented in
Tables 3.1 and 3.2, respectively. The above transmission dynamics of P. falciparum malaria
are summarised in the compartmental diagram given in Figure 3.1.
Table 3.1: Symbols and definition of state variables considered in the model at time t
Variable Description
H(t) Population of susceptible hepatocytes
HX(t) Population of infected hepatocytes
R(t) Population of susceptible erythrocytes (red blood cells)
RX(t) Population of infected erythrocytes
Z(t) Population of macrophages in the human body
S(t) Population of sporozoites
M(t) Population of merozoites
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Table 3.2: Symbols and description of parameters used in the model
Parameter Description
λh Recruitment rate of susceptible hepatocytes from the bone marrow
Λ The total rate of injection of sporozoites into liver due to mosquito bites
δs Death rate of sporozoites
µ1 Natural death rate of susceptible hepatocytes
βs The invasion rate of hepatocytes by sporozoites
µ2 Death rate of infected hepatocytes
λr Recruitment rate of susceptible RBCs from the bone marrow.
µ3 Natural death rate of susceptible erythrocytes
βr The invasion rate of susceptible RBCs by merozoites
µ4 Death rate of infected erythrocytes
δm Death rate of merozoites
λz Recruitment rate of macrophages from the bone marrow
δz The death rate of a macrophage
η Elimination rate of IRBCs by macrophages
ρ1 Production rate of hepatocytes due to presence of infected hepatocytes
ρ2 Production rate of RBCs due to presence of IRBCs
ρ3 Immunogenesity of infected red blood cells
κ1 Number of HX at which the recruitment of H is a half of the maximum rate.
κ2 Number of RX at which the recruitment of R is a half of the maximum rate
κ3 Number of RX at which the recruitment of Z is a half of the maximum rate
ζ The proportion of the merozoites that cause secondary infections
K The average number of merozoites released per bursting IRBCs
N The average number of merozoites released per bursting infected hepatocytes
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Figure 3.1: Schematic diagram for hepatocytic-erythrocytic and malaria parasite dynamics.
The dotted lines without arrows indicate cell-parasite interactions and the solid lines show
progression from one compartment to another.
In extending the in-host malaria model by Chiyaka et al. (2008), following model assumptions
are made:
1. A total of seven interacting populations are assumed at any given time t. They include
susceptible hepatocytes, infected hepatocytes, susceptible red blood cells, infected red
blood cells, macrophages, sporozoites and merozoites.
2. Numerous immune cells are elicited during malaria infection. However, only the highly
effective macrophages are considered in this model.
3. The red blood cells are recruited at a constant rate from the bone marrow. It is assumed
that the background recruitment is accelerated due to the presence of infected red blood
cells.
4. Infected red blood cells are eliminated by macrophages
5. Merozoites are generated both from the bursting liver schizonts and blood schizonts.
6. Macrophages are assumed to be recruited at a constant rate from the bone marrow.
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7. All model parameters are assumed non-negative.
8. Generation of macrophages is stimulated by the presence of infected red blood cells
only.
From the above description of the in-host dynamics of malaria and the representation in






























= Nµ2HX +Kζ µ4RX −δmM−βrRM,

(3.1)
where H(0)> 0,HX(0)≥ 0,R(0)> 0,RX(0)≥ 0,Z(0)> 0,S(0)≥ 0,M(0)≥ 0. (3.2)
3.4 Model analysis
In this section, we study whether the formulated model (3.1) is biologically and mathe-
matically meaningful. We establish model equilibrium points and investigate their stability
properties.
3.4.1 Well-posedness of the model
For the in-host malaria model (3.1) to be mathematically and biologically meaningful, we
need to prove that all the solutions of model (3.1) with nonnegative initial conditions, would
remain nonnegative for all time t ≥ 0. Positivity in the model is shown by proving the
following theorem.
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Theorem 3.1. Let the parameters in model (3.1) be positive constants. A nonnegative
solution (H(t),HX(t),R(t),RX(t),Z(t),S(t),M(t)) exists for all the state variables with
nonnegative initial conditions {H(0) = H0 ≥ 0, HX(0) = HX0 > 0, R(0) = R0 > 0, RX(0) =
RX0 ≥ 0, Z(0) = Z0 > 0, S(0) = S0 ≥ 0, M(0) = M0 ≥ 0 } ∀t ≥ 0.
Proof: Considering the first equation in system (3.1), let ψ1(t) = ρ1HX/(κ1 +HX) so that
dH
dt













Again, from the second equation in system (3.1), we have
dHX
dt




Upon integrating and applying the initial and conditions in inequality (3.2), we obtain
HX(t)≥ HX(0)exp{−µ2t}> 0. (3.8)
In a similar fashion, this procedure can be applied to all the remaining five equations in




































Therefore, the state variables (H,HX ,R,RX ,Z,S,M) of system (3.1) are nonnegative for all
time t > 0.
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3.4.2 Invariant region
System (3.1) describes the dynamics of interaction between the malaria parasites, the hepato-
cytes, the erythrocytes and macrophages. It is therefore important that it is analysed within a
suitable feasible region of biological interest.
Consider the model equations describing hepatocyte dynamics in system (3.1). Let NH
represent the total hepatocyte population, so that NH(t) = H(t)+HX(t).
On substituting the derivatives in system (3.1) and simplifying, we have
dNH
dt
≤ λh +ψ1(t)−µ∗h NH , (3.10)
where ψ1(t) = ρ1HX/(κ1 +HX) and µ∗h = min{µ1,µ2}.













h τ dτ + c1e−µ
∗
h t , (3.11)
where c1 is a constant of integration. By applying the initial condition NH(0) = NH0 > 0 in
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There are two possible cases in analysing the behaviour of NH(t) in inequality (3.13). In
the first case, NH(0)> λh/µ∗h so that, at time t = 0, the right-hand side (RHS) of inequality
(3.13) experiences the largest possible value of NH(0). That is, NH(t)≤ NH(0) for all time
t > 0.
In the second case, we consider NH(0) < λh/µ∗h so that, the largest possible value of the
RHS of inequality (3.13) approaches λh/µ∗h as time t goes to infinity. Thus, NH(t)≤ λh/µ∗h ,







for all time t > 0. (3.14)
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Using the above approach, let the total red blood cells population be NR(t), so that
NR(t) = R(t)+RX(t). From the model equations in system (3.1), we have
dNR
dt
≤ λr +ψ2(t)−µ∗r NR(t), (3.15)








∀t > 0. (3.16)
For the macrophage compartment Z(t), we have
dZ
dt











ψ3(τ)eδzτ dτ + c2e−δzt . (3.18)




























∀t > 0. (3.21)
Finally, let NP(t) represent the total population of malaria parasites at any time t. That is,
NP(t) = S(t)+M(t) and, from system (3.1),
dNP
dt
= Λ−δsS−βsSH +Nµ2HX +Kζ µ4RX −δmM,
≤ Λ+Nµ2HX +Kζ µ4RX −δpNP, where δp = min{δs,δm}. (3.22)























for all time t > 0. (3.25)
Based on this discussion, we have shown the existence of a bounded positive invariant region
for system (3.1). Let us denote this region as Ω ∈ R7+, where
Ω =
{




























Moreover, any solution of our system (3.1) which commences in Ω, at any time t ≥ 0 will
always remain confined in that region. We therefore deduce that the region Ω is positively
invariant and attracting with respect to malaria model in system (3.1). The in-host malaria
model represented by system (3.1) is hence well posed mathematically and biologically.
3.4.3 Existence of disease-free equilibrium point
The disease-free equilibrium point, E0, is the state in which the human host is free of malaria
parasites (or infection). At E0, the sporozoite recruitment rate, Λ = 0, and the parasite and
host-infected compartments have zero values; that is, S∗ = M∗ = R∗X = H
∗
X = 0. Therefore,















3.4.4 In-host basic reproduction number
Epidemiologically, a basic reproduction number is a threshold quantity which represents on
average, the number of secondary infections that a single infectious case would generate in a
completely susceptible populations over its entire infectious period (Dietz, 1993). A malaria
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in-host basic reproduction number is described in Chiyaka et al. (2008) as the number of
secondary infected red blood cells produced per primary infected red blood cell in a host at
the onset of infection.
Although Molineaux and Dietz (1999) emphasise that basic reproduction number is most
meaningful in malaria models describing explicitly infected red blood cells and merozoites
populations, the inclusion of the pre-erythrocytic liver stage in the model extends the above
description of the in-host basic reproduction number to incorporate the sporozoites popula-
tions.
The in-host basic reproduction number, denoted by R0 is computed using the technique of
the next generation matrix approach described in Van den Driessche and Watmough (2002).
The analytical computations here are perfomed using Mathematica software (code available
in Appendix B). We consider HX , RX , S and M as the parasite infested compartments. The
subsequent sub-model of system (3.1), is thus given by,
dHX
dt
= βsSH −µ2HX ,
dRX
dt






= Nµ2HX +Kζ µ4RX −δmM−βrRM.

(3.28)
Adopting the notations in Van den Driessche and Watmough (2002), we generate two matrices
from system (3.28): a nonnegative matrix F of new infections, and a non-singular matrix V ,
























−Nµ2HX −Kζ µ4RX +δmM+βrRM
 . (3.29)
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At disease-free equilibrium point E0, the matrices F and V are respectively given by
F =

0 0 βsλh/µ1 0
0 0 0 βrλr/µ3
0 0 0 0





µ2 0 0 0
0 µ4 +ηλz/δz 0 0
0 0 δs +βsλh/µ1 0
−Nµ2 −Kζ µ4 0 δm +βrλr/µ3
 . (3.31)
































0 0 0 0
0 0 0 0
 . (3.33)
The in-host basic reproduction number R0 is the spectral radius of the next generation matrix
G. It can clearly be seen that three of the four eigenvalues of matrix G in (3.33) have zero
values; that is, λ1 = λ2 = λ3 = 0. The fourth and largest nonnegative eigenvalue λ4 becomes







The terms in R0 can be interpreted as follows:
(i) The term Kβrλr/(βrλr+δmµ3) represents the expected number of infectious merozoite
parasite resulting from bursting blood schizonts at the blood stage of malaria infection.
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(ii) The second term ζ δzµ4/(ηλz+δzµ4) represents the expected proportion of merozoites
that participate in the cycle of erythrocytic schizogony.
(iii) Observe that the terms (βrλr)/(βrλr + δmµ3) < 1 and (δzµ4)/(ηλz + δzµ4) < 1. So
our R0 ≤ Kζ . This implies that the number of secondary infections during malaria
infections is largely influenced by the average number of merozoites released K, from
a bursting blood schizonts, most of which are responsible for secondary infections at
the blood stage.
Despite the inclusion of the liver stage dynamics, it is interesting to observe that the above
in-host basic reproduction number and hence the disease progression is heavily driven by the
dynamics at the erythrocytic stage. This result is consistent with the current and past malaria
chemotherapy research and development, which is heavily inclined towards the symptomatic
blood stage of infection.
In the sections that follow, both the local stability and global stability of the disease-free
equilibrium point E0 of system (3.1) are established.
3.4.5 Local stability of the disease-free equilibrium point, E0
To bring malaria infection under control, there is a need to identify disease transmission pa-
rameters that will guarantee the existence of a stable disease-free equilibrium point (Chiyaka
et al., 2008). The disease-free equilibrium point E0 is said to be locally asymptotically stable
if the eigenvalues of the Jacobian matrix of system (3.1), evaluated at E0 have negative real
parts.




−µ1 0 0 0 0 −βsλhµ1 0
0 −µ2 0 0 0 βsλhµ1 0
0 0 −µ3 ρ2κ2 0 0 −
βrλr
µ3
0 0 0 −ηλz
δz
−µ4 0 0 βrλrµ3
0 0 0 ρ3/κ3 −δz 0 0
0 0 0 0 0 −βsλh
µ1
−δs 0




Clearly, the first eigenvalue of matrix (3.35), λ1 =−µ1 < 0. Upon deleting the first row and
first column, matrix (3.35) is reduced to the following 6×6 matrix:
J2(E0) =

−µ2 0 0 0 βsλhµ1 0





−µ4 0 0 βrλrµ3
0 0 ρ3/κ3 −δz 0 0
0 0 0 0 −βsλh
µ1
−δs 0
Nµ2 0 Kζ µ4 0 0 −βrλrµ3 −δm

. (3.36)
Again, it can easily be seen from matrix (3.36) that the second eigenvalue, λ2 =−µ3 < 0.
We further reduce matrix (3.36) by deleting row two and column two. So,
J3(E0) =

−µ2 0 0 βsλhµ1 0
0 −ηλz
δz
−µ4 0 0 βrλrµ3
0 ρ3/κ3 −δz 0 0
0 0 0 −βsλh
µ1
−δs 0
Nµ2 Kζ µ4 0 0 −βrλrµ3 −δm

. (3.37)
From column 3 in matrix (3.37), λ3 =−δz < 0. This process continues and the matrix (3.37)
is further reduced to J4 by deleting the elements in row three and column three.
J4(E0) =








Nµ2 Kζ µ4 0 −βrλrµ3 −δm
 . (3.38)
From the third row of matrix (3.38), it can easily be seen that λ4 =−(βsλh/µ1 +δs)< 0.
Finally, we reduce the matrix (3.38) to J5, by deleting row three and column three. So,
J5(E0) =
−µ2 0 00 −ηλzδz −µ4 βrλrµ3
Nµ2 Kζ µ4 −βrλrµ3 −δm
 . (3.39)
From row one of matrix (3.39), the fifth eigenvalue λ5 =−µ2 < 0.
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The remaining two eigenvalues of matrix (3.35) can be obtained by reducing matrix (3.39)






Kζ µ4 −βrλrµ3 −δm
)
. (3.40)
Using the variable λ , the characteristic polynomial associated with matrix (3.40) is
p(λ ) = λ 2 +B1λ +B0, (3.41)
where



















The characteristic polynomial (3.41) has negative roots (eigenvalues) if B1 > 0 and B0 > 0.
The coefficient B1 in equation (3.42) is clearly positive (B1 > 0). We now need to show that
B0 in equation (3.43) is strictly positive if R0 < 1. This is done by expressing the coefficient






















It can clearly be seen from equation (3.44) that the coefficient B0 is positive if and only if
R0 < 1. We have thus established the following result.
Theorem 3.2. The disease-free equilibrium point E0 is locally asymptotically stable in Ω if
R0 < 1. If R0 > 1, then E0 is unstable.
Biologically, Theorem 3.2 implies that malaria infection can be eliminated from the human
host when R0 < 1. To ensure that elimination of malaria is independent of the initial sizes
of the subpopulations, it is necessary to show that E0 is globally asymptotically stable in Ω,
where the model is mathematically and biologically sensible.
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3.4.6 Global asymptotic stability of the disease-free equilibrium point,
E0
Using the results obtained in Kamgang and Sallet (2005), we show that the malaria-free
equilibrium point E0 is globally asymptotically stable when the in-host basic reproduction
number is less than unity (R0 < 1). We begin by rewriting system (3.1) in pseudo-triangular
form as follows:
Ẋ1 = A1(X)(X1 −X∗1 )+A2(X)X2,
Ẋ2 = A3(X)X2,
where X1 is the vector representing the state of different compartment of liver and blood
cells that are not infected and do not transmit malaria infections. X2 represents the states of
malaria parasites and host’s cells that are responsible for disease transmission. Hence,












From the subsystem X1, we have
A1(X) =
−µ1 0 00 −µ3 0
0 0 −δz
















A direct computation indicates that the eigenvalues of matrix A1(X) are real and negative.
This shows that the system Ẋ1 = A1(X)(X1 −X∗1 ) +A2(X)X2 is globally asymptotically




−µ2 0 βs λhµ1 0
0 −(η λz
δz
+µ4) 0 βr λrµ3
0 0 −(βs λhµ1 +δs) 0
Nµ2 Kζ µ4 0 −(βr λrµ3 +δm)
 . (3.45)
It can clearly be seen that A3(X) is a Metzler matrix: all the off-diagonal elements of A3(X)
are nonnegative. In order to establish the global stability of the disease-free equilibrium
point, we need to show that the matrix A3(X) is Metzler stable by providing a proof for the
following lemma:
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where A and D are square matrices. The matrix M is Metzler stable if and only if A and
D−CA−1B are Metzler stable.



































where ω1 = δs + βs(λh/µ1), ω3 = δm + βrλr(ηλh + (1−Kζ )δzµ4)/µ3(ηλz + δzµ4) and
ω2 = Nβsλh/µ1.
For the matrix D−CA−1B to be Metzler stable, ω3 should be strictly nonnegative. Therefore,
the expression in the numerator
βrλr(ηλh +(1−Kζ )δzµ4)≥ 0. (3.49)
Upon simplification of inequality (3.49),

















It is clearly seen that the matrix A in system (3.47) is Metzler stable. However, the matrix
D−CA−1B is Metzler stable if and only if R0 < 1. From Lemma 3.1, the following theorem
is deduced:
Theorem 3.3. The malaria-free equilibrium point E0 of system (3.1) is globally asymptoti-
cally stable if the threshold quantity R0 < 1.
The above result is quite significant in malaria control. The global stability of the disease-free
status would be guaranteed if and only if the in-host basic reproduction number R0 is less
than one. Malaria intervention should therefore focus on eliminating infected erythrocytes
and/or malaria merozoites that are responsible for erythropoiesis cycle and invasions at the
blood stage.
3.4.7 Endemic equilibrium point analysis
When the in-host basic reproduction number R0 is greater than one R0 > 1, the stability of
the disease-free equilibrium point E0 is violated. A different equilibrium state termed the





−µ1H −βsSH = 0, (3.50)




−µ3R−βrRM = 0, (3.52)




−δzZ = 0, (3.54)
Λ−δsS−βsSH = 0, (3.55)
Nµ2HX +Kζ µ4RX −δmM−βrRM = 0. (3.56)
Solving for the state variables R, H, Z, S, M in terms of the infected states HX and RX ,















S∗ = fS(H∗X) =
µhµ2H∗X












































2 βs > 0,
α2 =µ2 (µh (−δs)−βs (λh −κ1µ2 +Λ+ρ1)) ,
α1 =βs (λh (Λ−κ1µ2)+Λ(ρ1 −κ1µ2))−κ1µhµ2δs, and
α0 =κ1Λλhβs > 0.
The number and nature of the roots of equation (3.62) are determined by the following
discriminant (Schmidt and Hess, 1988):
∆ = 18α3α2α1α0 −4α23α0 +α22α12 −4α3α13 −27α32α02. (3.63)
So
(i) ∆ = 0, then equation (3.62) has a multiple real roots and only one endemic equlibrium
would exist,
(ii) ∆ < 0, then equation (3.62) has 1 real root and a complex conjugate root hence only
one endemic equilibrium,
(iii) ∆ > 0, then equation (3.62) has 3 distinct real roots and so there are more than one
endemic equilibrium point when R0 > 1 for system (3.1).
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Analysis under equation (3.63) implies that, in the absence of external interventions in the
form of anti-malarial treatment, there will always be some infected hepatocytes during
malaria infection. We further proceed to evaluate the possible values of the state variable
RX at equilibrium point by substituting expressions in equations (3.59), (3.60) and (3.61)








X +θ0) = 0, (3.64)
where
θ3 =−µ4βr(µhµ4 +η(ρ3 +λz))< 0,
θ2 =ηρ3 (βr (−κ2µ4 +ρ2 +λr)−1)+(µhµ4 +ηλz)(βr (−(κ2 +κ3)µ4 +ρ2 +λr)−1) ,
θ1 =ηκ2ρ3 (βrλr −1)− (µhµ4 +ηλz)(κ3 +κ2 (βr (κ3µ4 −λr)+1)+κ3 (−βr)(ρ2 +λr)) ,
θ0 =κ2κ3 (βrλr −1)(µhµ4 +ηλz) .





X +θ0 = 0. (3.65)
The state R∗X = 0 corresponds to a scenario in which there are no parasite infected red blood
cells. This could signify the liver stage of parasite development so that an endemic state
(H∗,H∗X ,R
∗,0,0,S∗,0) exists. Alternatively, R∗X = 0 could correspond to the disease-free
equilibrium point E0 for system (3.1).












Θ = 4µ4βr(κ2βrλr −κ2)+(βrλr −κ2µ4βr +ρ2βr −1)2. (3.68)
The root R∗X1 < 0 should be ignored since all the model state variables are nonnegative for
all time t ≥ 0. This leaves R∗X2,3 as the only two possible roots of equation (3.65).
From the above discussion, system (3.1) could experience a single endemic state or multiple
states subject to the roots of equations (3.62) and (3.64). If R∗X2,3 are real and positive then
one or two endemic equilibrium points are possible for system (3.1). It is thus evident that
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the explicit form of the endemic equilibrium point for model (3.1) is cumbersome. We shall
therefore show its existence numerically based on certain choice of parameter values in
subsection 3.5.3. Note that case (iii) of equation (3.63) indicates the possibility of having
multiple endemic equilibrium points and hence the likelihood of experiencing a backward
bifurcation phenomenon.
3.5 Numerical simulation and discussions
In this section, we provide some numerical simulations to illustrate the behaviour of system
(3.1). We carry out model sensitivity analysis and investigate parameter influence on the
dynamics of erythrocytes, hepatocytes, macrophages and malaria parasites under different
conditions on the in-host basic reproduction number, R0.
3.5.1 Sensitivity analysis
In epidemic modelling, sensitivity analysis is performed to investigate model parameters
with significant influence on R0, and hence on the transmission and the spread of the disease
under study (Chitnis et al., 2008; Okosun and Makinde, 2012; Olaniyi and Obabiyi, 2014).
Following Arriola and Hyman (2005), the normalised forward-sensitivity index of a variable,









Using the formulation in equation (3.69), and the in-host basic reproduction number R0
in equation (3.34), we obtain the following expressions for normalised forward sensitivity




















































The numerical sensitivity indices (SI) are calculated using Mathematica software and the
results summarised in Table 3.3. Note that, due to limited data on in-host dynamics, all the
parameter values (see Table 3.4) used in evaluating the sensitivity indices are obtained from
literature.
Table 3.3: Sensitivity indices of R0 to the model parameters
Parameter SI Parameter SI
K +1.0000 ζ +1.0000
βr +0.920422 µ3 -0.920422
λr +0.920422 λz -0.998585
µ4 +0.998585 η -0.998585
δz +0.998585 δm -0.920422
Table 3.4: Parameter values used in the numerical simulations of system (3.1)
Parameter Value Unit Source
Λ 20 sporozoites/day (Selemani et al., 2016)
δz 0.05 day−1 (Selemani et al., 2016)
δs 1.2 ×10−11 day−1 (Selemani et al., 2016)
η 10−10 cells/µl/day (Hetzel and Anderson, 1996)
λh 3 ×103 cells/µl/day (Selemani et al., 2016)
ρ1 2.5×10−5 day−1 (Chiyaka et al., 2008)
µ1 0.029 day−1 (Selemani et al., 2016)
ρ2 2.5×10−5 day−1 (Chiyaka et al., 2008)
βs 1.0 ×10−6 sporozoites/day (Selemani et al., 2016)
ρ3 2.5×10−5 day−1 (Chiyaka et al., 2008)
µ2 0.02 day−1 (Selemani et al., 2016)
κ1 1 cells/µl (Selemani et al., 2017a)
λr 4 ×41500 cells/µl−1/day (Li et al., 2011)
ζ 0.726 unitless (Talman et al., 2004)
µ3 0.0083 day−1 (Li et al., 2011)
κ2 1 cells/µl−1 (Selemani et al., 2017a)
βr 2.0 ×10−6 /merozoites/day (Hetzel and Anderson, 1996)
N 10000 Unitless (Tumwiine et al., 2008)
µ4 0.025 day−1 (Chiyaka et al., 2008)
κ3 1 cells/µl−1 (Selemani et al., 2017a)
Continued on next page
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Table 3.4 – Continued from previous page
Parameter Value Unit Source
δm 48 day−1 (Hetzel and Anderson, 1996)
K 16 Unitless (Chiyaka et al., 2008)
λz 30 /µl−1/day (Chiyaka et al., 2008)
A positive sign (+) on the SI indicates that an increase (decrease) in the value of such
a parameter increases (decreases) the value of the in-host basic reproduction number R0
and hence the growth of malaria infection. On the other hand, a negative sign (-) on SI is
indicative of a parameter that negatively affects R0; that is, an increase (decrease) in such
a parameter decreases (increases) the value of R0. In order to eliminate in-host malaria
infection, the in-host basic reproduction number should be less that one, that is, R0 < 1.
From Table 3.3, it can clearly be seen that the average number of merozoites released
per bursting infected erythrocyte K and the proportion of merozoites that cause secondary
invasions at the blood phase ζ , are the two most sensitive parameters in determining model
outcomes. They have the highest sensitivity indices of +1.0000. For instance, a 10% increase
(decrease) in the value of ζ or K generates a proportional 10% increase (decrease) on in-host
basic reproduction number and hence malaria infection.
The parameters λz, η , µ4, δz occupy the second rank on influencing the model outcomes.
An increase ( or decrease) in the parameters µ4 and δz is likely to increase ( or decrease)
the disease R0. On the other hand, an increase in λz and η has a direct negative influence
on disease R0. Note that a 50% increase (decrease) in the rate of elimination of infected
red blood cells at the erythrocytic stage will result into a 49.92925% decrease (increase) in
the in-host basic reproduction number and hence the disease progression. Macrophages are
highly instrumental in malaria parasite clearance and should be preserved.
The rate of generation of macrophages from the bone marrow, λz, together with the rate of
phagocytosis of infected red blood cells, η , is likely to decrease proportionally the disease
progression when they are increased. With increased λz, there would be more macrophages to
phagocytose and clear the rapidly growing density of blood schizonts. This would negatively
affect the erythrocytic schizogony. Decreased clearance rate by macrophages would only
guarantee successful multiplication of the merozoites through the erythrocytic schizogonic
cycle. The subsequent result is increased density of merozoites in the host’s blood, leading to
disease progression to even deadly levels.
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The rate of invasion of susceptible erythrocytes by merozoites βr, and the rate of generation
of erythrocytes from the epithelial cells of the host’s bone marrow λr increased (or decreased)
disease R0 when they are increased (or decreased). Epidemiologically, an improved erythro-
cyte invasion rate, βr, is likely to generate even more new blood schizonts. This increases
parasitaemia in the human host. A 10% increase (decrease) in βr would increase (decrease)
the threshold parameter R0 by about +9.2%.
Any therapeutic effort that clears the blood schizonts and the infectious merozoites at the
blood stage would definitely guarantee immense reduction in disease R0. Therefore, an
increase in the death rate of infected erythrocytes and that of the merozoites is likely to
decrease significantly the in-host basic reproduction number R0. This can be achieved
through the use of effective antimalarials such as ACTs in malaria treatment. Moreover,
effective vaccines at the erythrocytic stage could greatly minimize erythrocyte infection rate
βr.
Since the local sensitivity indices are relatively close, we carry out further investigation
on parameter influence on disease progression by generating the partial rank correlation
coefficients (PRCCs) for each parameter value in disease R0 in the following section.
3.5.2 Global sensitivity analysis
A global sensitivity analysis (GSA) is performed to examine the response of an epidemic
model to parameter variation within a wider range of parameter space (Wu et al., 2013).
Applying the approach in Wu et al. (2013), the PRCCs between the in-host basic reproduction
number R0 and each of the parameters in R0 are derived. Using 1000 simulations per run
of the Latin Hypercube Sampling (LHS) scheme (Stein, 1987), the established PRCCs are
derived and presented in Figure 3.2.
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Figure 3.2: Tornado plots of partial rank correlation coefficients (PRCCs) of parameters
that influence model R0 generated using parameter values in Table 3.4. Parameters with
PRCC > 0 and PRCC < 0 increase and decrease disease R0, respectively.
Parameters with positive PRCC values will increase R0 when they are increased and vice
versa for those with negative PRCC. Unlike the results in Table 3.3, the model parameter with
the highest influence on R0 according to the PRCCs results shown in Figure 3.2 is the rate of
invasion of red blood cells by merozoites, βr. This is followed closely by the recruitment
rate of susceptible red blood cells λr from the borne marrrow. Both parameters increase R0
when they are increased. The second set of parameters that also increase (decrease) disease
R0 when they are increased (decreased) are the ζ , K, µ3 and δz, respectively.
The merozoites’ death rate δm, the death rate of infected red blood cells and the rate of
elimination of infected erythrocytes by the macrophages η are shown to have the highest
negative influence on disease progression. Although the increase in µ4 was shown to increase
disease progression in Table 3.3, the results from global sensitivity analysis are contradictory.
An increase in the death rate of parasitised red blood cells µ4 decreases parasitaemia and
hence disease progression within the human host.
In Figure 3.3, the effects of the two most sensitive parameters (K,ζ ) on R0 are displayed
using Monte Carlo simulations (Rubinstein and Kroese, 2016). The results in Figures 3.3 are
consistent with those obtained earlier under sensitivity analysis (see Table 3.3). An increase
in K, and/or ζ increases R0 and severity of malaria infection.
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(a) (b)
Figure 3.3: Graphs (a) and (b) show the Monte Carlo simulations for the two parameters
with the greatest sensitivity indices in the in-host malaria model (3.1). Parameter values in
Table 3.4 and 1,000 simulations per run were used.
Based on these results of sensitivity analysis, we make the following remarks: (1) results of
global sensitivity analysis are robust and a lot more realistic for implementation, (2) malaria
control should target elimination of merozoites and infected red blood cells, (3) an effective
and efficient malaria vaccine that deactivates infectious merozoites could be helpful in limit-
ing erythrocyte invasion rate, and (4) a vaccine that is protective of susceptible erythrocytes
could further ensure reduced density of second and future generation of merozoites that are
responsible for disease progression.
3.5.3 Numerical results
In this section, numerical simulation of system (3.1) under different values of the threshold
parameter R0 is carried out. The in-host malaria model is solved numerically using the
package scipy.integrate.odeint in Python language. A sample code is shown in Appendix B.
The simulations are performed to illustrate the possible dynamics of the erythrocytes, the
hepatocytes, the malaria parasite and the macrophages when R0 is less or greater than one. For
purposes of these simulations, the initial conditions of the variables are hereby conveniently
set. It is noted that different output may be achieved for different initial conditions.
When the in-host basic reproduction number is less than unity (R0 < 1), the dynamics of
the different compartments in system (3.1) are as presented in Figures 3.4 and 3.5. At the
pre-erythrocytic stage, the density of susceptible hepatocyte initially decline as the density of
infected hepatocytes rises due to invasion from malaria sporozoites (see Figure 3.4). The
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host’s immune system responds to sporozoite invasion by increasing hepatocyte density
that levels off at the disease-free equilibrium point E0 (see Figure 3.4a). As the sporozoites
decline to near zero value (see Figure 3.4b), infected hepatocytes decline and stabilise at E0
in equation (3.27).
At the blood stage, the rising density of infected erythrocytes declines in a similar fashion
to that of the infective merozoites when R0 < 1 (see Figure 3.5). The densities of the
infected erythrocytes and merozoites approach E0 asymptotically. On the other hand, it is
observed that the density of susceptible red blood cells decreases initially due to infection by
merozoites and later rises before it plateaus at E0 as shown in Figure 3.5.


























(a) Susceptible and infected hepatocytes

















Figure 3.4: Graphs showing the dynamics of susceptible and infected hepatocytes in the
presence of malaria sporozoites when disease R0 = 0.8066 < 1. The initial conditions
are: H0 = 300000, HX 0 = 20000, R0 = 500000, RX 0 = 50, Z0 = 300000, S0 = 2000 and
M0 = 70. Used parameter values are shown in Table 3.4.
59


















Figure 3.5: Graphs showing the simulation of system 3.1 at the erythrocytic stage when
disease R0 = 0.8066 < 1. The chosen initial conditions are H0 = 300000, HX 0 = 20000,
R0 = 500000, RX 0 = 50, Z0 = 300000, S0 = 2000, and M0 = 70. Model parameter values
are shown in Table 3.4.
When R0 > 1, a sharp fall in the density of susceptible hepatocytes in the liver is observed
(see Figure 3.6a). This is due to rapid invasion of hepatocytes by the sporozoites. An
invasion on susceptible hepatocyte generates a corresponding steady rise in the density of
infected hepatocytes (see Figure 3.6b). Owing to natural intervention by the immune cells,
the respective decline and rising levels of susceptible and infected hepatocytes level off
and remain relatively constant after the third month. More hepatocytes are generated to
replace infected ones. There is a steady decline in sporozoite density at the liver stage (see
Figure 3.6c). The invaded hepatocytes develop into liver schizonts that burst open to release
merozoites and hence the steady decline in sporozoite levels.
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(a) Susceptible hepatocytes (b) Infected hepatocytes
(c) Sporozoites
Figure 3.6: Graphs showing population dynamics at the liver stage when R0 = 1.58690 > 1.
Used parameter values are shown in Table 3.4. Chosen initial conditions are: H0 = 300000,
HX 0 = 10, R0 = 500000, RX 0 = 10, Z0 = 10, S0 = 2000 and M0 = 20.
The severity of malaria infection is most rapid in the first 2 weeks within the host liver as
illustrated in Figures 3.6a, 3.6b and 3.6c. This is similar to results in (Selemani et al., 2017a;
Tabo et al., 2017). In the absence of clinical intervention, some of the sporozoites remain
dormant in the human liver and could cause future malaria infections.
As the liver schizonts release merozoites into the blood stream of the host, a rapid decline in
the density of red blood cells is observed (see Figure 3.7a). Merozoites invade susceptible
erythrocytes resulting in a corresponding rise in the density of infected erythrocytes as shown
in Figure 3.7b.
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(a) Susceptible erythrocytes (b) Infected erythrocytes
Figure 3.7: Graphs showing population dynamics of susceptible erythrocytes and infected
erythrocytes in the presence of malaria merozoites when R0 = 1.58690 > 1. The values of
the mode parameters are shown in Table 3.4.
In Figure 3.8a, there is an early sharp rise in the density of merozoites in the first week of
the blood stage. The density remains high for several weeks and does not decline for the
entire infection period of one month. A second generation merozoite invades other sets of
healthy erythrocyte within minutes, leading to an exponential growth in the density of blood
schizonts and hence merozoites in the human blood stream. Without therapeutic intervention,
the density of merozoites stabilises several weeks after infection at the endemic equilibrium
point. This is consistent with the findings in Chiyaka et al. (2008); Li et al. (2011); Selemani
et al. (2016).
The invasion of healthy red blood cells prompts an immune response from host’s macrophages.
These macrophages phagocyte on the generated blood schizonts. At the onset of erythrocytic
infection, several macrophages are generated. The rise in the density of macrophages is
proportional to that of infected erythrocytes as shown in Figure 3.8b. This rising density
is shown to level off after about 16 days at the endemic equilibrium point. It remains high
throughout the infection period.
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(a) Merozoites (b) Macrophages
Figure 3.8: Graphs showing the population dynamics of (a) merozoites and (b) macrophages
during the erythrocytic cycle. R0 = 1.58690 > 1 and the parameter values used are given in
Table 3.4.
From these discussions, the following observations are made: (1) if R0 < 1, low level malaria
infection can easily be contained by the host’s defence mechanism and loss of life is less
likely; (2) therapeutically, R0 < 1 may be achieved through quick intervention targeting the
blood schizonts and the merozoites responsible for secondary infections during erythrocytic
cycle; (3) Figures 3.6, 3.7 and 3.8 shows the existence of in-host malaria endemic equilibrium
point.
Hematological parameters such as the density of healthy and infected erythrocytes in malaria
hosts have considerable influence on malaria infection and possible impacts (Erhart et al.,
2004). According to WHO (WHO, 1990), high hyperparasitaemia causes drastic reduction
in concentrations of erythrocytes leading to anaemia among malaria patients (Bashawri et al.,
2002; Ekvall, 2003). The impacts of increasing the model parameters δm and βr on healthy
and infected red blood cells are as shown in Figures 3.9 and 3.10, respectively.
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Figure 3.9: Graphs that show the behaviour of (a) susceptible red blood cells and (b) infected
red blood cells. They were obtained by varying the death rate of merozoites δm from 20 to
80 in steps of 20, while keeping the other parameters (in Table 3.4) constant.

















































Figure 3.10: Graphs that show the behaviour of (a) susceptible red blood cells and (b)
infected red blood cells. They were obtained by varying the merozoite invasion rate βr from
2× 10−8 to 2× 10−5 in steps of 10−1, while keeping the other parameters (in Table 3.4)
constant.
Observe that an increase in the death rate of malaria merozoites δm decreases and increases
the density of infected erythrocytes and healthy erythrocytes, respectively (see Figures 3.9a
and 3.9b). Malaria control should thus target the infectious merozoites at the blood stage.
Results in Figure 3.10a indicate that an improved invasion rate by merozoites on susceptible
erythrocytes causes more loss in healthy erythrocytes. The reverse effect is observed in
Figure 3.10b, where an increase in the rate of infection of healthy erythrocytes produces a
64
corresponding increase in the density of infected erythrocytes. A keen look at Figure 3.10b
reveals that the infected red blood cells (IRBCs) begin to appear after about 10-15 days
of initial infection. This is consistent with the incubation period of P. falciparum malaria
(Collins and Jeffery, 2007).
The severity of malaria infection can easily increase if the density or production of macrophages
is compromised (Chiyaka et al., 2008). Figure 3.11b shows a near direct relationship on the
density of infected erythrocytes RX and the death rate of the macrophages δz. An increase in
the death rate of macrophages would propel erythrocytic schizogony and hence increased
merozoite numbers in the blood stream of the human host. A high merozoite density in-
creases the severity of malaria infection. This result is quite vital in malaria intervention,
especially with respect to malaria patients who may be suffering from other infections that are
deleterious to immune cells. Diseases such as HIV/AIDS greatly weaken the immune system
of the patient as important immune cells such as macrophages are destroyed (Honeycutt et al.,
2016; Koppensteiner et al., 2012). Macrophages are an important target cells for HIV-1 virus
(Shiri et al., 2005a). During malaria infections, such patients often suffer severe malaria and
should seek immediate medical attention.














































Figure 3.11: Graphs that show the effect of varying the rate of phagocytosis of infected red
blood cells by macrophages, η (in (a)) and the effect of increased decay rate of macrophages
δz (in (b)), on the dynamics of infected erythrocytes RX . All parameter values are shown in
Table 3.4.
Like the senescent erythrocytes, aberrant infected erythrocytes formed during malaria infec-
tion are eliminated phagocytically by the host’s macrophage cells in the red pulp of the spleen
(Krücken et al., 2005). The phagocytic potential of the spleen is vital at the erythrocytic cycle.
The higher the phagocytic behaviour of the macrophage, the lower the density of parasitised
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erythrocytes (see Figure 3.11b). Moreover, the severity of malaria infection increases with
decreasing ability of the host’s phagocytic macrophages to clear infected erythrocytes from
circulation during the erythrocytic cycle.
3.6 Conclusion
In this chapter, a mathematical model of in-host malaria infection by Chiyaka et al. (2008) is
extended to include the liver stage of parasite development. Unlike the models in Li et al.
(2011) and Tumwiine et al. (2008), the macrophages are considered as the most effective
innate immune cells in eliminating malaria parasites from blood circulation. In addition, the
liver hepatocytes are assumed to be generated from the bone marrow and through a process
of self-regeneration from existing hepatocytes. The malaria-free equilibrium point is shown
to be locally asymptotically stable when the in-host basic reproduction number is less than
unity. The global stability of the malaria-free state is only guaranteed if the threshold quantity
R0 is less than unity.
Numerical simulation results indicate that intervention during malaria infection should focus
on minimising merozoite invasion rate on healthy erythrocytes and the density of merozoites
in circulation, which are responsible for secondary invasion at the blood stage. In the absence
of malaria treatment, the immune cells (macrophages) are shown to be vital in eliminating
infected erythrocytes at the blood stage. The higher the rate of phagocytosis of infected
erythrocytes by macrophages, the lower the density of infected erythrocytes and hence
malaria parasitaemia. Patients suffering from such infections as HIV/AIDS which have
deleterous effect on the protective immune cells should seek immediate medical treament
when infected with malaria. Their compromised immune system exposes them to severe
malaria attacks and possible untimely death.
For quick and timely reduction of parasitaemia, an increased merozoite death rate using
antimalarial drugs such as ACT would be necessary. This would further ensure reduced
density of infected red blood cells and hence future generation merozoites. By killing a
single blood schizont, the production of 16 merozoites at maturity is avoided. Moreover, an
appropriate malaria vaccine that targets erythrocyte invasion process may equally guarantee
minimal recrudescence.
The next Chapter 4 incorporate malaria vaccines to the model discussed in this chapter. The
impacts of efficacious malaria vaccines and vaccine combinations that target the parasites at
different stages of their life cycle are evaluated.
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Chapter 4
Mathematical model for the in-host
malaria dynamics subject to malaria
vaccines
4.1 Introduction
To date, the WHO considers effective vector control strategies such as long-lasting insecticidal
treated nets (ITNs) and indoor residual spraying (IRS) as the main ways to prevent and reduce
malaria transmission in communities with high malaria prevalence (Homan, 2016; WHO,
2017a). Chemoprophylaxis and antimalarial drugs such as chloroquine and artemisinin-
based combination therapy (ACT) are currently used to prevent and treat clinical malaria,
respectively, in different parts of the world (Bhatt et al., 2015; WHO, 2015d). These strategies
have contributed to the substantial global decline in malaria mortality and morbidity (Nega1
et al., 2016). However, despite the success of the existing malaria prevention and control
strategies, reported malaria cases globally are still quite high. In 2017, the WHO reported
about 219 million malaria cases (WHO, 2017b). The global decline in malaria cases in
the period 2015-2017 is however insignificant (WHO, 2018f). A lot more effort is hence
necessary to further reduce cases and mortality due to malaria.
Parasite resistance to current antimalarial drugs (Dondorp et al., 2010; Maude et al., 2009;
Sidhu et al., 2002; Wellems and Plowe, 2001) and vector insecticides (Alout et al., 2017a,b;
Soko et al., 2015) pose a serious threat to malaria control. To defeat the disease, many
more tools with the potential to save lives today and in the future are needed (Birkett, 2016;
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Greenwood and Targett, 2009; MVI, 2018). An efficacious, safe and affordable malaria
vaccine would help to bridge the control gap left by other intervention measures (MVI, 2018).
A malaria vaccination strategy is performed to either induce protective immune responses
prior to malaria infection or to provide protection in case of malaria attack (Arama and
Troye-Blomberg, 2014).
Current malaria vaccines have shown minimal efficacy (Birkett, 2016; Birkett et al., 2013;
Miura, 2016). RTS,S/AS01 is the only malaria vaccine that has received a positive scientific
opinion from the European Medicines Agency (EMA) (EMA, 2015). However, the WHO
recommends further evaluation of RTS,S/AS01 in a series of pilot implementations before it
can be introduced on a wide scale (WHO, 2018d).
This chapter reviews malaria vaccine development and explores, using mathematical mod-
elling, the impacts of efficacious malaria vaccines. It also presents analytically and numeri-
cally, the probable effects of vaccine combinations in reducing levels of parasitaemia within
the human host.
4.2 Malaria vaccines
Malaria parasite has a tendency to undergo morphological changes accompanied with anti-
genic variations during its transition from the pre-erythrocytic to erythrocytic stages (Hisaeda
et al., 2005; Nega1 et al., 2016). This has presented an enormous challenge in malaria vaccine
development. Although there is no licensed vaccine against malaria today, many experts
believe that a malaria vaccine is a necessary tool for successful malaria elimination (MVFG,
2018; Ouattara and Laurens, 2014). Vaccines against malaria infection can be categorised
into three groups based on the targeted stage of the parasite life cycle (Arumugam et al.,
2014). These include: pre-erythrocytic vaccines (PEV), blood stage vaccines (BSV) and
transmission blocking vaccines (TBV) as shown in Figure 4.1. The development progress
and action of some of the most advanced malaria vaccines is presented in the discussions in
the following subsections.
4.2.1 Pre-erythrocytic vaccines (PEV)
The most advanced pre-erythrocytic malaria vaccine candidate against P. falciparum is called
RTS,S/AS01 (Birkett, 2016; Birkett et al., 2013; Nunes et al., 2014). The RTS,S malaria
vaccine is both safe and immunogenic (Abdulla et al., 2008; Otieno et al., 2016). This
68
vaccine is commercially known as ‘Mosquirix’ and has been developed by the U.S. military
at the Walter Reed Army Institute of Research (WRAIR) through a partnership between
GlaxoSmithKline (GSK) Biologicals, the Programs for Appropriate Technologies in Health
(PATH) and Malaria Vaccine Initiative (MVI) (Nega1 et al., 2016).
The antigen of RTS,S is a recombinant of circumsporozoite protein (CSP), hepatitis B surface
antigen (HBsAg) and HBsAg alone (S) (Ballou, 2009). CSP which is highly expressed on the
surface of sporozoites is made up of asparagine-alanine-asparagine-proline (NANP) amino
acid repeat region (R) and T-cell epitope domain (T).
During the pre-erythrocytic phase, the administered RTS,S target the CSP which mediates
the entry of sporozoites into liver hepatocyte (Frevert, 2004; Singh et al., 2007). RTS,S
vaccine induces both humoral and cellular immunity, with high antibody titres that can block
sporozoite infection of the liver hepatocytes (Nega1 et al., 2016; Nudelman et al., 1989;
Plassmeyer et al., 2009). Since the CSP-specific antibodies alone are insufficient to achieve
sterile immunity (Edogan et al., 1987), RTS,S is also designed to have CSP T-cell epitopes in
addition to the prominent B-cell epitope (Ballou, 2009; Moorthy and Ballou, 2009).
Several clinical trials (Abdulla et al., 2008; Alonso et al., 2004; Bojang et al., 2001; Polhemus
et al., 2009) and (RCTP, 2011) have shown the potential of RTS,S to prevent malaria infection
and clinical disease in infants and young children living in sub-Saharan Africa. RTS,S showed
a 30-50% protection for human trials in Africa (Alonso et al., 2004; RCTP, 2012). However,
an efficient pre-erythrocytic vaccine must be effective enough to protect humans with and
without natural immunity. Moreover, the period of protection offered by RTS,S is relatively
short. To improve its efficacy, more effort should focus on boosting immune responses at
the liver stage. RTS,S may also induce protection against clinical malaria at the blood stage
by temporarily reducing the density of merozoites that emerge from the bursting infected
hepatocytes (Guinovart et al., 2009). This could boost the naturally acquired erythrocytic
stage immunity (Arama and Troye-Blomberg, 2014).
A pilot implementation of RTS,S/AS01 is currently ongoing in selected areas in Kenya,
Ghana and Malawi to demonstrate feasibility of delivering the schedule to the target age
group and assess vaccine’s impact on mortality and potential adverse effects of the vaccine
(Galactionova et al., 2017).
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Figure 4.1: Malaria vaccines mapped on the parasite’s life cycle: pre-erythrocytic, blood-
stage and transmission-blocking vaccines. Source: Arumugam et al. (2014).
4.2.2 Blood stage vaccines (BSV)
BSVs elicit anti-invasion and anti-diseases responses at the blood stage (Moorthy et al., 2004).
They, therefore, lower merozoites density and prevent clinical manifestations and hence
severity of malaria infection in humans. Due to gene alteration and antigenic variation in
malaria merozoites, BSV may not provide complete immunity to the host (Pandey et al., 2013).
Nevertheless, BSV are capable of reducing mortality and morbidity due to malaria. At present,
merozoite surface protein 3 (MSP3) (Audran et al., 2005) and merozoite surface protein 1
(MSP1) (Ogutu et al., 2009) are the leading blood stage vaccine candidates for plasmodium
malaria (Plowe et al., 2009). MSP1 and MSP3 target merozoite to inhibit erythrocyte
invasion. Other BSV in clinical trials that have shown the allele-specific protection are:
apical membrane antigen 1 (AMA1) (Sagara et al., 2009), erythrocyte-binding antigen-175
(EBA-175) (El Sahly et al., 2010), glutamate-rich protein (GLURP) (Hermsen et al., 2007)
and serine repeat antigen 5 (SERA5) (Horii et al., 2010). AMA1 primarily targets the
merozoite’s invasion apparatus to prevent the infection of the red blood cells.
4.2.3 Transmission blocking vaccines (TBV)
The aim of TBV is to stop subsequent generation of infectious malaria sporozoites from the
mosquito vector. While, TBV does not directly protect the person who is vaccinated, it has
the potential to stop continued spread of malaria infection in a population. TBVs induce
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antibodies against antigens on gametes, zygotes and ookinetes, blocking ookinete to oocyst
transition and hence stopping parasite development within the mosquito midgut (Carter et al.,
2000). Currently, P. falciparum ookinete surface antigens (Pfs25) is the leading malaria
vaccine candidate in this category (Arevalo-Herrera et al., 2005; Hisaeda et al., 2000).
To improve its immunogenicity, Pfs25 is chemically cross linked to an Expo-protein A
(Pfs25-EPA) and delivered as a nanoparticle. Pfs25-EPA is currently under trials by the US
National Institute of Allergy and Infectious Diseases (Shimp Jr et al., 2013). The rest of
the TBVs are presently at the preclinical trial and includes: P. falciparum surface protein
28, P. falciparum surface protein 48, P. falciparum surface protein 45 and P. falciparum
surface protein 230 (Ouattara and Laurens, 2014; WHO, 2018c). Pfs25 and Pfs28 antigens
are expressed only after fertilization in the mosquito midgut and are not present in the
gametocyte as they circulate in the blood. A key aspect of TBVs is in their potential to reduce
the emergence and spread of parasite resistance to other malaria vaccine components and
even to antimalarial drugs (Carter et al., 2000). However, the absence of natural boosting
following immunisation with TBV might limit their efficacy and hence utilisation (Dinglasan
et al., 2013; Vannice et al., 2012).
4.2.4 The role of CD8+ T cells during malaria infection
Malaria parasites are susceptible to immune mediated control by CD8+ T-cells, which
target intracellular pathogens (Villarino and W Schmidt, 2013). The CD8+ T-cells have
both direct and indirect effector pathways for parasite elimination at the liver stage. The
indirect mechanism include the production of IFN-γ and TNF, whereas the direct mechanism
involves the release of perforin and granzymes (Nganou-Makamdop et al., 2012). IFN-γ
suppresses parasite development through direct impairment of parasite differentiation in
hepatocytes (Mellouk et al., 1987). Moreover, IFN-γ increases the expression of nitric oxide
synthase which leads to subsequent increase in nitric oxide that confers protection against
P. falciparum (Seguin et al., 1994). Although CD8+ T-cells are sufficiently primed during
blood stage malaria, they offer minimal contribution to protective immunity. It is thought that
vascular endothelial cells that acquire antigen from IRBCs stimulate CD8+ T-cells to release
perforin and granzyme B during blood stage malaria (Villarino and W Schmidt, 2013). The
capacity of CD8+ T-cells to eradicate malaria parasites and infected cells both at the liver
and blood stages is therefore considered in this study.
Several research studies on clinical malaria control have been carried out (Austin et al.,
1998b; Hellriegel, 1992; Kamangira et al., 2014; Li et al., 2011). Some of these models
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(Malaguarnera and Musumeci, 2002) have focussed on the role of the host’s immune cells in
in-host malaria control. Others (Kamangira et al., 2014; Magombedze et al., 2011a) have
targeted the use of antimalaria drugs in controlling clinical malaria. Chiyaka et al. (2008)
considered both the immune cells and malaria chemotherapy in malaria control in humans.
In (Rouzine and McKenzie, 2003), the role of innate immunity in mediating synchronization
between the replication cycles of parasites in different erythrocytes is explored. Kamangira
et al. (2014) investigated erythrocytes-malaria parasite dynamics in the presence of immune
response and or drug intervention at the erythrocytic stage. Tabo et al. (2017) incorporated
the liver stage in their model and investigated treatment as a control strategy for blood stage
malaria.
These research studies have been very insightful in understanding in-host malaria dynamics
and control, however, none of these investigations has attempted to evaluate the possible
impact of malaria vaccines in controlling clinical P. falciparum malaria. In this study,
therefore, an in-host malaria model that considers parasite-cell interactions at the liver and
blood stages, subject to malaria vaccines is formulated and analysed mathematically. The
goal of this chapter is to study the cell-parasite dynamics using a mathematical model and
to numerically investigate the impact of malaria vaccines and vaccine combinations in the
control of P. falciparum malaria infection within the human host.
4.3 Model formulation
A mathematical model of in-host P. falciparum malaria dynamics in the presence of malaria
vaccines is presented. The compartmental model is an extension of the in-host malaria
model in Chapter 3 of this thesis. Two more compartments of gametocytes G(t) and CD8+
T cells W (t) are incorporated into the model to capture the effects of the transmission
blocking vaccines and the general effects of CD8+ T cells on the density of the infected
erythrocytes and hence malaria infection dynamics. Based on their stage of infection,
the infected erythrocytes are classified into blood trophozoites (early stage of infection)
and blood schizonts (late stage of infection). Therefore, the rest of the populations include
susceptible hepatocytes H(t), infected hepatocytes X(t), malaria sporozoites S(t), susceptible
erythrocytes R(t), blood trophozoites T (t), blood schizonts C(t) and malaria merozoites
M(t).
Susceptible erythrocytes are recruited at a constant rate λr from the bone marrow and their
density decreases through natural death at the rate µr or due to invasion by the merozoites
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at the rate βr. Following merozoite invasion, susceptible erythrocytes move to the class of
infected erythrocytes T . The generated blood trophozoites decay naturally at a rate µt or
progress into blood schizonts C class at the rate γ . Mature blood schizonts burst open to
release more merozoites into blood stream. This is represented by the term PµcC/(1+dW ),
where P denotes the number of merozoites released per bursting blood schizont, µc is the
decay rate of the blood schizonts and d is the rate of inhibition of immune response.
At the pre-erythrocytic stage, the malaria sporozoites are debilitated by vaccine-induced
anti-CSP antibodies (PEV) as they molt through the tissues (Mellouk et al., 1990; Schwenk
et al., 2003). The reduced invasion by sporozoites is represented by the term βs(1−ν)SH,
where 0 < ν < 1 is the efficacy of the pre-erythrocytic vaccine. Sporozoites that successfully
invade the hepatocytes are however, targeted by vaccine-induced CSP-specific CD8+ T cells
(PEV). The CD8+ T cells kill the resulting infected hepatocyte (Renia et al., 1991; Sun
et al., 2003; White et al., 2013). This reduces the burst size N of the infected hepatocytes
to (1−b)N, where 0 < b < 1 is the probability with which the vaccine inhibits merozoite
emergence from infected hepatocyte.
An unbounded bilinear function rEI is considered by Anderson et al. (1989), Niger and
Gumel (2011) and Hetzel and Anderson (1996) to model the killing of infected cells I by
the CD8+T cells E. The simple mass-action term rEI depends solely on the product of
the density of the immune cells E and the density of the infected cells I. However, if the
fact that cell proliferation can saturate is taken into account, then the nonlinear bounded
Michaelis-Menten-Monod function, presented in equation (4.1) is most reasonable (Agur





where B is the concentration of substrate, ∇ is the growth rate of the microorganisms B, ∇max
is the maximum specific growth rate of B and Kb is the half-velocity constant, ∇/∇max.
In Pilyugin and Antia (2000), the nonlinear bounded Michaelis-Menten-Monod function
(4.1) is used to model the handling time in immune response and their targets and how it
affects the infection. In this study, the nonlinear bounded function p1IE/(1+β I), used in
Chiyaka et al. (2008), to describe the killing of infected erythrocytes I by the immune cells
E (CD8+ T cells, in our case) is adopted. This formulation has also been used by Cai et al.
(2017) and Selemani et al. (2017a). The parameter p1 describes the rate of removal of I by E
and 1/β is the saturation constant that stimulates the proliferation of the CD8+ T cells to
grow at half their maximum rate.
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The effects of the BSV on merozoite invasion of the erythrocytes are represented by the term
(1− ϱ)βrRM/(1+dW ), where 0 <ϱ< 1 is the efficacy of the BSV and 1/d is a saturation
constant that stimulates CD8+ T cells to grow at half their maximum rate. Further, BSV
reduces the density of merozoites that are released per bursting blood schizont, so that the
burst size P becomes (1−a)P, where 0 < a < 1 accounts for the vaccine-induced reduction
of merozoites released per bursting infected erythrocyte. BSV is further assumed to enhance
the production of CD8+T cells at a rate τ , where τ > 1. For purposes of simulation, it is
assumed that 1 < τ < 2. Administered TBV reduces the sporozoite recruitment rate from Λ
to (1−χ)Λ, where 0 < χ < 1 is the efficacy of the TBV. Inoculated sporozoites are assumed
to die naturally at the rate µs.
The immune cells (CD8+ T cells) are recruited at a constant rate λw from the thymus. Fur-
thermore, the presence of infected cells such as infected hepatocytes, blood trophozoites and
blood schizonts stimulates the production of CD8+ T cells. The increased production of W (t)
due to X(t), T (t) and C(t) is also modelled using the nonlinear bounded Michaelis-Menten-
Monod function (4.1) and is represented by the terms δxWX/(1+ε0X), δtWT/(1+ε1T ) and
δcWC/(1+ ε2C), respectively. The parameters δi|i = x, t,c represents the immunogenecity
of infected hepatocytes, blood trophozoites and blood schizonts, respectively. On the other
hand, the phagocytotic effects of CD8+ T cells on infected cells X , T and C are represented
by the terms kx(1−ν)WX/(1+ ε0X), kt(1− ϱ)WT/(1+ ε1T ) and kc(1− ϱ)WC/(1+ ε2C),
where, k j| j = x, t,c is the immunosensitivity of X ,T and C, respectively.
The density of blood schizonts C decreases when they burst open to release merozoites into
the blood stream or when they die naturally at the rate µc. A proportion π of the released
merozoites develops into gametocytes G(t) whose natural decay rate is denoted by µg. Just
like the susceptible hepatocytes whose natural mortality is at the rate µh, a constant decay
rates µt and µw are assumed for blood trophozoites and the CD8+ T cells, respectively. The
descriptions of state variables and parameters used in the model are summarised in Tables 4.1
and 4.2, respectively. The in-host malaria dynamics subject to malaria vaccines is represented
in the compartmental flow diagram in Figure 4.2.
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Table 4.1: Symbols and definition of state variables considered in the model at time t
Variable Description
H(t) Population of susceptible hepatocytes
X(t) Population of infected hepatocytes
R(t) Population of susceptible erythrocytes (red blood cells)
T (t) Population of blood trophozoites
C(t) Density of blood schizonts
S(t) Density of sporozoites
M(t) Density of merozoites in blood
G(t) Density of gametocytes in blood
W (t) Concentration of CD8+ T cells
Table 4.2: Description of parameters
Parameter Description
χ Efficacy of transmission blocking vaccine
ϱ Efficacy of blood stage vaccine
ν Efficacy of pre-erythrocytic stage vaccine
Λ The rate of injection of sporozoites into liver due to mosquito bites
µs, µw Decay rate of sporozoites and CD8+ T cells, respectively
λr,λh Rate of production of susceptible RBCs and
susceptible hepatocytes from the bone marrow, respectively
µh, µr, µx Death rate of susceptible hepatocyte, erythrocyte and infected hepatocyte,
respectively
π Proportion of parasites that become gametocytes per dying
blood schizont
kx,kt ,kc Immunosensitivity of infected hepatocytes, blood trophozoites
and blood schizonts, respectively
δx,δt ,δc Immunogenecity of infected hepatocytes, blood trophozoites
and blood schizonts, respectively
βs,βr Infection rate of hepatocytes and erythrocytes, respectively
µt , µc The rate of decay of blood trophozoites and blood schizonts, respectively
µm, µg Decay rate of merozoites and gametocytes, respectively
d The rate of inhibition of immune response
τ A parameter that accounts for vaccine-induced enhanced production
of CD8+T cells
Continued on next page
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Table 4.2 – Continued from previous page
Parameter Description
γ Rate of progression from blood trophozoite stage
to blood schizont stage
λw The rate of production of CD8+ T cells from thymus
1/ε0,1/ε1,1/ε2 half saturation constants for infected hepatocytes, blood
trophozoites and blood schizonts, respectively
b A parameter that accounts for PEV-induced reduction of merozoites
released per bursting liver schizont
a A parameter that accounts for BSV-induced reduction of merozoites
released per bursting blood schizont
P The average number of merozoites released per bursting
blood schizont
N Number of merozoites released per bursting hepatocyte
Figure 4.2: Schematic diagram for in-host malaria with vaccine therapy. The dotted lines
without arrows indicate cell-parasite interaction and the solid lines show progression from
one compartment to another.
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The incorporation of malaria vaccine control measures to the in-host malaria model in
Chapter 3 lead to the following additional model assumptions:
1. There are nine interacting populations of susceptible hepatocytes, infected hepato-
cytes, susceptible red blood cells, blood trophozoites, blood schizonts, sporozoites,
merozoites, gametocytes and CD8+ T cells, at any given time t.
2. It is assumed that malaria vaccines accelerate the rate of generation of CD8+ T cells.
3. CD8+ T cells are recruited at a constant rate from the thymus.
4. The blood stage vaccine reduces the rate of invasion of the susceptible red blood cells.
5. The pre-erythrocytic vaccine reduces the rate of invasion of the susceptible hepatocytes
at the liver stage.
6. The transmission blocking vaccine reduces the recruitment rate of sporozoites into the
liver.
7. Infected hepatocytes, blood schizonts and blood trophozoites are eliminated by CD8+
T cells.
8. Merozoites are generated both from the bursting liver schizonts and blood schizonts
only.
9. All model parameters are assumed non-negative.
10. Generation of CD8+ T cells is stimulated by the presence of infected hepatocytes,
blood schizonts and blood trophozoites.
Based on the above model description and assumptions, the in-host malaria model subject to
malaria vaccines is formulated using a system of nonlinear ordinary differential equations
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= λh −µhH −βs(1−ν)HS,
dX
dt


















































It is assumed that all the parameters used in the model are positive and the initial conditions
for system (4.2) are: H(0)> 0, X(0)≥ 0, S(0)≥ 0, R(0)> 0, T (0)≥ 0, C(0)≥ 0, M(0)≥ 0,
G(0)≥ 0, W (0)> 0.
4.4 Model analysis
We aim is to evaluate the effects of the different vaccines on the density of infected hepato-
cytes and infected erythrocytes. Therefore, the model should be biologically coherent. That
is, all the state variables and their solutions must be nonnegative and bounded, respectively,
in the region Φ, where
Φ =
{





























and Nr(t) = R(t)+T (t)+C(t), Nh(t) = H(t)+X(t), Np(t) = S(t)+M(t)+G(t),
µ∗1 = min{µr,µt ,µc}, µ∗2 = min{µh,µx} and µ∗3 = min{µs,µm,µg}.
For system (4.2) to be biologically meaningful, the following theorem is proved:
Theorem 4.1. The region Φ is positively invariant with respect to the in-host malaria model
(4.2) and a nonnegative solution (H(t),X(t),R(t),T (t),C(t),S(t),M(t),G(t),W (t)) exists
∀t ≥ 0.
Proof: From the sporozoite compartment S(t) in system (4.2), it is clear that
dS
dt
= (1−χ)Λ−µsS−βsHS ≥−(µs +βsH)S. (4.4)





This shows that in the absence of malaria interventions, S(t)≥ 0 for all time t ≥ 0.





This process can be repeated for all the state variables so that S(t),H(t), X(t), R(t), T (t),
C(t), M(t), G(t), W (t) are all positive for all t ≥ 0. Thus, the solutions of the in-host malaria
model remain positive in Φ, ∀t ≥ 0.
To show that the solutions of system (4.2) are bounded, let Nr be the total population of the
red blood cells in the human host, that is Nr(t) = R(t)+T (t)+C(t) and
dNr
dt









≤ λr −µ∗1 Nr where µ∗1 = min{µr,µt ,µc}. (4.7)













This implies that at any time t, Nr(t) ≤ max{Nr(0),λr/µ∗1}. This approach can similarly
be applied to the population of hepatocytes Nh(t) = H(t)+X(t), population of parasites
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The above analysis shows that the region Φ is positively invariant and attracting for system
(4.2) and the model is hence well posed for study.
4.4.1 Parasite-free equilibrium point and vaccination reproduction num-
ber
The parasite-free equilibrium (PFE), Ev, depicts the absence of malaria parasites from the
human host. The PFE of the in-host malaria model depicted in system (4.2) exists and is
given by












The vaccination reproduction number (denoted by Rv), on the other hand, is a threshold
quantity which governs the spread of the infection. It represents on average the number
of new infected erythrocytes (or hepatocytes) generated by a single infectious merozoite
(or sporozoites) at the blood (or liver) stage in the presence of malaria vaccines. Using the
next generation matrix approach (Diekmann et al., 1990; Van den Driessche and Watmough,
2002), the matrix F1 which represents the rate of appearance of new infections and the




























Taking partial derivatives of the terms in F1 and V1 and evaluating at the parasite-free






0 0 0 0
0 0 0 0 0 0
0 0 0 0 (1−ϱ)βrλrµw
µr(dτλw+µw)
0
0 0 0 0 0 0
0 0 0 0 0 0






Va 0 0 0 0 0
0 βsλh
µh
+µs 0 0 0 0
0 0 Vb 0 0 0
0 0 −γ (1−ϱ)τkcλw
µw
+µc 0 0





0 0 0 −πµc 0 µg

, (4.13)
where Va = ((1− ϱ)τkxλw/µw)+µx and Vb = γ +µt +((1− ϱ)τktλw)/µw.




















In the absence of malaria vaccines (χ =ϱ= ν = a = b = 0,τ = 1), the in-host malaria model






















Comparing equations (4.14) and (4.15), gives





































It is observed from equation (4.16) that in the absence of vaccination, Rv = Rm. However,
the introduction of malaria vaccines reduces the basic reproduction number by a factor of
0 < Θ∗∗ < 1. The use of efficacious malaria vaccines therefore has a great potential in
reducing mortality due to P. falciparum malaria disease.
4.4.2 Local stability of parasite-free equilibrium point
The local stability of Ev is investigated as follows. Linearising model system (4.2) around Ev
gives the following Jacobian matrix G1.
G1 =

−µh 0 −A0 0 0 0 0 0 0
0 −A1 A2 0 0 0 0 0 0
0 0 −A3 0 0 0 0 0 0
0 0 0 −µr 0 0 −A4 0 0
0 0 0 0 −A5 0 A6 0 0
0 0 0 0 γ −A7 0 0 0
0 A11 0 0 0 A8 −A9 0 0
0 0 0 0 0 πµt 0 −µg 0
0 τδxλw
µw
















































and A11 = (1−b)Nµx.
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It is clear from matrix G1, that the first eigenvalue, λ1 =−µh < 0. Upon deleting row one
and column one from matrix (4.17), a new sub-matrix G2 is produced.
G2 =

−A1 A2 0 0 0 0 0 0
0 −A3 0 0 0 0 0 0
0 0 −µr 0 0 A4 0 0
0 0 0 −A5 0 A6 0 0
0 0 0 γ −A7 0 0 0
A11 0 0 0 A8 −A9 0 0
0 0 0 0 πµt 0 −µg 0
τδxλw
µw
0 0 A10 τδcλwµw 0 0 −µw

. (4.18)
Applying the above procedure to columns 3,7 and 8 and their corresponding rows in matrix
(4.18), the next three eigenvalues: λ2 = −µr < 0, λ3 = −µg < 0 and λ4 = −µw < 0 are
obtained. The resultant matrix G3 is given by
G3 =

−A1 A2 0 0 0
0 −A3 0 0 0
0 0 −A5 0 A6
0 0 γ −A7 0
A11 0 0 A8 −A9
 . (4.19)





2 +β4λ +β5 = 0, (4.20)
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where
β1 = A1 +A3 +A5 +A7 +A9 > 0, (4.21)
β2 = A1A3 +A1A5 +A3A5 +A1A7 +A3A7 +A5A7 +A1A9 +A3A9
+A5A9 +A7A9 > 0, (4.22)
β3 = A1A3A5 +A1A3A7 +A1A5A7 +A3A5A7 +A1A3A9 +A1A5A9

















Equation (4.20) has negative roots (eigenvalues) if all its coefficients terms are positive. That
is, β1 > 0, β2 > 0, β3 > 0, β4 > 0 and β5 > 0. It is clear from equations (4.21) and (4.22) that
β1 and β2 are positive terms. However, the coefficients β3, β4 and β5 can only be positive if
the vaccine reproduction number Rv is less than unity, Rv < 1.
Thus, using Theorem 2 in Van den Driessche and Watmough (2002), the following lemma is
established.
Lemma 4.1. The parasite-free equilibrium Ev is locally asymptotically stable if Rv < 1 and
unstable if Rv > 1.
Lemma 4.1 shows that if the malaria parasite is eliminated following malaria infection,
then a vaccine or combinations of vaccines that would guarantee the existence of a stable
parasite-free equilibrium should be administered. Epidemiologically, when Rv < 1, it is
expected that the parasites will decay off so that the severity of malaria infection is reduced
to near zero or totally eliminated. On the other hand, if Rv > 1, the malaria infection persists
within the human host; that is, more red blood cells and susceptible hepatocytes are infected.
This implies that the vaccines may not be efficacious; their use does not eradicate malaria
parasites among infected individuals. The malaria parasites are therefore likely to persist at
the erythrocytic stage in an infected individual and subsequently, can be transmitted to other
persons in close contact via the mosquito vector.
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4.5 Critical efficacy of blood stage vaccine
Definition 4.1. Vaccine efficacy is interpreted as the proportionate reduction in malaria
disease attack rate within a vaccinated person compared to an unvaccinated person (Small
et al., 2010).





where ARU is the parasite attack rate of unvaccinated individual and ARV is the attack rate
for vaccinated people. A critical vaccine efficacy therefore refers to the minimum efficacy
value beyond which the vaccine is capable of eradicating the infection from the human host.
To establish a critical malaria vaccine efficacy from the vaccine reproduction number (4.14),
it is assumed that only the blood stage vaccine is administered to the individual. That is,

















By simplification, equation (4.27) reduces to
(1− ϱ)µ2w



























B0 =−∆∗∗µc(γ +µt)µ2w, B1 =−µw(∆∗∗τkcλw(γ +µc +µt)−µw), and (4.31)
B2 =−∆∗∗(τkcλw)2. (4.32)
85







where Bi, i = {0,1,2} are as defined in equation (4.30). Equation (4.33) implies that for
any blood stage vaccine to effectively control clinical malaria, its efficacy must be higher
than the stated critical vaccine efficacy.

























































where Ψ3 = ((((1− ϱ)τktλw)/µw)+ γ +µt).
The right-hand side of equation (4.34) is simplified by making the following representations:


















where Π∗ = (1/((1− ϱ)τλwkckt)). It is observed that (∂Rv/∂ ϱ)< 0 when µcµw2(γ +µt)>
τkcktλw
2(1− ϱ). Rv is therefore a decreasing function of the blood stage vaccine ϱ. This
means that an efficacious BSV reduces the density of infected erythrocytes within the human
host. Figure 4.4 shows the profiles of the density of blood trophozoites and blood schizonts
as a function of the efficacy of the BSV, ϱ. The density of infected erythrocytes decreases




The main concern in the control of infectious diseases is the capacity of the infection to invade
the population. The threshold quantity called the vaccine reproduction number, provides a
reasonable measure of the ability of the infective malaria parasites to invade the susceptible
cell populations (Heesterbeek and Dietz, 1996). When Rv < 1, the infective parasites produce
less than one new infection per infection period and the disease subsequently dies out.
However, when Rv > 1, an infective parasite generates several infections leading to disease
severity. In light of this, the sensitivity analysis of disease Rv in (4.14) is carried out so as to
determine important parameters in the dynamics of P. falciparum malaria in the presence of
vaccine controls. The normalised forward sensitivity index technique as presented by Arriola
and Hyman (2007) is adopted. Using Mathematica software, the sensitivity results for the 17
parameters in Rv are as shown in Table 4.3.
Table 4.3: The sensitivity indices of Rv with respect to model parameters
Parameter Sensitivity index Parameter Sensitivity index
P +1.0000 π -0.2500
a -0.2500 ϱ -0.770486
γ +0.293702 βr +0.0000663956
λr +0.0000664 µc +0.0000247494
µr -0.000066396 d -0.0222497
τ -0.080544 λw -0.080544
µw +0.080 µm -0.00006639
kc -0.0000247494 kt -0.0582696
µt -0.235433
The rate of merozoite invasion βr, the rate of progression of infected red blood cells from
the trophozoite state to blood schizonts γ and the average number of merozoites released per
bursting blood schizont P increase (or decrease) the vaccine reproduction number when they
are increased (or decreased) as shown in Table 4.3. Malaria vaccine development should
target these parameters to reduce malaria disease progression in humans. On the other
hand, the higher the efficacy of blood stage vaccine e, the lower the value of Rv. A highly
efficient erythrocytic vaccine has the potential to eradicate clinical malaria. The proportion
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of merozoites that develop into gametocytes π is also shown to decrease the value of Rv
when they are increased. The higher the density of gametocytes, the lower the density of
merozoites in the host’s blood. Although this would minimise secondary and subsequent
erythrocytic invasions and hence malaria severity, it has the potential to enhance parasite
transmission to the mosquito vector. This is due to increased density of gametocytes per
blood sample per mosquito bite.
The number of merozoites released per bursting infected red blood cells and the efficacy of
the blood stage vaccine are shown to be the most sensitive parameters in influencing in-host
malaria progression. For example, a 10% increase (or decrease) on P, will cause a 10%
increase (or decrease) in Rv. These two parameters should hence be carefully estimated
(Mikucki, 2012) and clinical malaria control using antimalarial drugs and malaria vaccines
should target the two parameters.
4.6.2 Vaccine efficacy
Lemma 4.2. The vaccination threshold Rv < 1 whenever ϱ>ϱc






















Figure 4.3: Graphs showing the density of (a) blood trophozoites T (t) and (b) blood schizonts
C(t) when the blood stage vaccine efficacy, ϱ= 0.94 >ϱc= 0.86 and Rv = 0.58 < 1. Used
parameter values are shown in Table 4.4.
When the efficacy of the BSV (ϱc) is higher than the critical vaccine efficacy ϱc, the mero-
zoites are eradicated from the blood stream. Under this setting, the capacity of the blood stage
vaccine to eradicate malaria parasites in the host’s blood stream is guaranteed by Lemma
4.2. The results of Lemma 4.2 are shown graphically in Figures 4.3a and 4.3b using different
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values of ϱ. In Figure 4.3, a blood stage vaccine with a minimum efficacy of 94% is needed
to control the blood stage parasites. Using the provided parameter values and expression
(4.14), it is observed that under this condition, Rv is less that unity. That is Rv = 0.58 < 1.
Lemma 4.3. The vaccination threshold Rv > 1 whenever ϱ<ϱc





















Figure 4.4: Graphs showing the density of (a) blood trophozoites T (t) and (b) blood schizonts
C(t) when the efficacy of blood stage vaccine, ϱ= 0.5 <ϱc= 0.86 and Rv = 1.27 > 1. Used
parameters values are shown in Table 4.4.
When the efficacy of the blood stage vaccine is lower than the critical efficacy (ϱ<ϱc), the
rate of infection of susceptible red blood cells is higher. This leads to increased density of
blood trophozoites and blood schizonts as shown in Figure 4.4. Using the parameter values
in Table 4.4 and the expression for the vaccine reproduction number, it is observed that the
above condition is only guaranteed when Rv is greater than unity. That is, Rv = 1.27 > 1.
It is clear, therefore, that only a highly efficacious blood stage vaccine, (ϱ> 90%) would
guarantee the achievement of a parasite-free equilibrium point shown in Figure 4.5. A blood
stage vaccine with lower efficacy (ϱ< 50%) is likely to be less effective in clearing the
malaria parasites. A malaria persistent steady state is hence probable (see Figure 4.5).
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Figure 4.5: Simulations showing the effect of varying the efficacy of blood stage vaccine (ϱ)
on the density of infected red blood cells. All other parameter values are shown in Table 4.4.

















Figure 4.6: Simulations showing the effect of varying the efficacy of blood stage vaccine (ϱ)
on the density of gametocytes in blood. All other parameter values are shown in Table 4.4.
The density of gametocytes in the blood stream is indirectly influenced by the blood stage
vaccine. Higher vaccine efficacy minimises the density of gametocytes that are later sucked
up by feeding anopheles mosquitoes. As the efficacy of blood stage vaccine diminishes,
higher density of gametocytes is observed in the blood stream as shown is Figure 4.6.
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The effect of BSV-induced reduction of merozoites released per bursting blood schizont is


















where Ψ3 = ((((1− ϱ)τktλw)/µw)+ γ +µt).
The following observations are made: the vaccine reproduction number Rv decreases with
increasing value of a. As less blood schizonts burst, less merozoites are released and hence
less secondary infections that increases the severity of the disease as displayed in Figure
4.7. This leads to the reduction in the vaccine reproduction number and hence the density of
infected red blood cells in the blood stream.










































Figure 4.7: Simulations showing the effect of varying the parameter a on the density of (a)
blood trophozoites T (t) and (b) blood schizonts C(t). All other parameter values are shown
in Table 4.4.
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The effect of the BSV-induced enhanced production of CD8+ T cells is monitored by the




























































where, Ψ3 = ((((1− ϱ)τktλw)/µw)+ γ +µt).






















∗ = (1−π)(1−a)γP(1− ϱ)2dkckt µcβrλrλw.
It is evident from equation (4.38) that Rv decreases with increasing τ . As more CD8+ T cells
are activated, more trophozoites and blood schizonts are killed through phagocytosis, leading
to reduction in the severity of malaria infection as shown in Figure 4.8.













































Figure 4.8: Simulation showing the the density of (a) blood trophozoites T (t) and (b)
blood schizonts C(t) for varying values of blood stage vaccine-induced enhanced production
parameter τ . All other parameter values are shown in Table 4.4.
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The effect of the BSV-induced reduction in the burst size P of infected red blood cells is























where Ψ3 = ((((1− ϱ)τktλw)/µw)+ γ +µt).
Note that (∂Rv/∂P)> 0 and Rv decreases (increases) with decreasing (increasing) value
of P. The higher the density of released merozoites from bursting blood schizonts, the higher
the rate of secondary invasions at the blood stage. The density of infected red blood cells
in blood is observed to increase with increasing value of P as shown in Figure 4.9. An
efficacious malaria vaccine would be necessary in minimising secondary and future invasions
that occur at the blood stage of malaria infection.










































Figure 4.9: Simulations showing how the infected red blood cell burst size P affects the
density of (a) blood trophozoites T (t) and (b) blood schizonts C(t). All other parameter
values are shown in Table 4.4.
4.6.3 Threshold analysis and vaccine impact
The Malaria Vaccine Technology Road map updated in November 2013 has two key strategic
goals targeting P. falciparum and P. vivax malaria by the year 2030: (1) to develop vaccines
with over 75% protective efficacy against clinical malaria and (2) to develop transmission
blocking vaccines thereby reducing new cases of human malaria infections (MVFG, 2018).
A combination of malaria vaccines (pre-erythrocytic, blood stage and transmission blocking
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vaccines) could help in achieving the over 75% strategic goal (Miura, 2016).
A highly efficacious blood stage vaccine has a potential to significantly reduce the number of
gametocytes in the blood stream, thereby minimising parasite transmission to mosquitoes
and subsequently to other human beings. In the following section, the possible impact of
different malaria vaccine combinations with varying degrees of efficacy is highlighted.
In the absence of malaria vaccines, ϱ= χ = ν = 0, it is observed from Figure 4.13, that the
density of infected red blood cells increases rapidly and settles at the parasite persistent
equilibrium point. This trend is also observed with the infected hepatocytes (see Figure
4.10b). The density of infected hepatocytes rises due to invasion by sporozoites for about a
week. This is followed by a slight decline in density and subsequent persistent concentration
at the liver stage.




































Figure 4.10: Time profile of the density of (a) infected red blood cells and (b) infected
hepatocytes in the absence of malaria vaccines (ϱ= χ = ν = 0). All parameter values are
shown in Table 4.4.
A malaria vaccine with an efficacy of 45% may not be adequate in eliciting sufficient immune
response to reduce and clear infection as shown in Figure 4.11. More Plasmodium parasites
are likely to persist in the blood stream, raising the severity of infections. A combination
of blood stage vaccine (efficiency ≥ 90%) and transmission blocking vaccine (efficiency ≥
90%) is likely to result in rapid eradication of the infected red blood cells from the human
host as displayed in Figure 4.12. Observe that the parasite-free equilibrium is highly probable
irrespective of the efficacy of the pre-erythrocytic vaccine in this context.
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Figure 4.11: Time profile of the density of (a) blood trophozoites and (b) blood schizonts for
ϱ= χ = 0.45 with varying efficacy of pre-erythrocytic vaccine ν . Used arameter values are
shown in Table 4.4.













































Figure 4.12: Time profile of the density of (a) blood trophozoites and (b) blood schizonts for
ϱ= χ = 0.9 with varying efficacy of pre-erythrocytic vaccine ν . The set of parameter values
is shown in Table 4.4.
Similarly, the density of gametocytes in the blood stream is observed to diminish quickly in
the presence of efficacious malaria vaccine combinations (see Figure 4.13).
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Figure 4.13: Simulation showing the profile of infected hepatocytes in the presence of
perfect malaria vaccines (ϱ= χ = 0.9). The efficacy of the pre-erythrocytic vaccine ν is
varied from 0 to 1. The set of parameter values is shown in Table 4.4.
Table 4.4: Parameter values used in the numerical simulations and sensitivity analysis
Parameter Value Range Units Source
P 16 (15-20) Unitless (Diebner et al., 2000)
kx 0.01 (0.001-0.9) /day (Chiyaka et al., 2008)
kt 0.01 (0.001-0.9) /day (Chiyaka et al., 2008)
kc 10−6 (10−7 −0.9) /day (Chiyaka et al., 2008)
µr 0.083 (0.05-0.1) /day (Anderson et al., 1989)
βr 2×10−1 (0.07-0.3) /mm3/day (Dondorp et al., 2000)
βs 10−3 (0.001-0.2) /mm3/day (Selemani et al., 2016)
π 0.2 (0.1-0.9) unitless (Talman et al., 2004)
µh 0.029 (0.01-0.5) /day Estimated
µx 0.02 (0.01-1) /day (Selemani et al., 2016)
λr 3×103 (3E+3–3E+8) cells/ml/day (Li et al., 2011)
λh 3×105 (3E+3–3E+8) cells/ml/day (Tumwiine et al., 2008)
λw 30 (10-40) /µl−1/day (Chiyaka, 2010)
µm 48 (46-50) /day (Li et al., 2011)
Λ 30 (18-35) sporozoites/day (Selemani et al., 2016)
µs 1.2 (1.0-2.4) /day (Selemani et al., 2016)
µt 0.5 (0.01-0.8) /day (Magombedze et al., 2011a)
µc 0.5 (0.01-0.9) /day (Magombedze et al., 2011a)
µg 6.25×10−5 (6E-5–7E-8) /day (Selemani et al., 2016)
Continued on next page
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Table 4.4 – Continued from previous page
Parameter Value Range Units Source
µw 2 (0.05-3) /day (Chiyaka, 2010)
δx 10−5 (10−4 −10−7) mm−3/day (Chiyaka, 2010)
δt 0.05 (0.01-0.08) mm−3/day (Chiyaka, 2010)
δc 0.05 (0.01-0.08) mm−3/day (Chiyaka, 2010)
γ 1.5 (0.1-2) /day (Selemani et al., 2016)
χ 0.2 (0-1) unitless Assumed
ν 0.3 (0-1) unitless Assumed
τ 1.5 (1-2) unitless (Niger and Gumel, 2011)
b 0.2 (0-1) unitless (Niger and Gumel, 2011)
a 0.2 (0-1) unitless (Niger and Gumel, 2011)
d 5×10−4 (5E-5–1E-2) unitless (Magombedze et al., 2011a)
N 104 (103 −105) Unitless (Tumwiine et al., 2008)
ϱ 0.45 (0-1) unitless (Birkett, 2016)
4.7 Discussion
Using numerical simulation, it is observed that the activated CD8+T cells and malaria
vaccines have a considerable effects on malaria control. Vaccination reduces the basic
reproduction number by a constant factor. A blood stage vaccine, with an efficacy of at least
90% is shown to be effective in controlling in-host P. falciparum malaria.
It is further observed that malaria vaccines that minimise the total number of merozoites re-
leased per bursting hepatocyte, reduces the density of blood trophozoites and blood schizonts.
Similarly, a highly efficacious vaccine greatly reduces the burst size of the blood schizonts,
so that less merozoites are released from the infected red blood cells. This has the potential
to reduce malaria severity and hence malaria transmission to the mosquito vector.
An efficacious blood stage vaccine should maximise the rate of activation of CD8+T cells.
It is noted that the higher the vaccine potential to activate these immune cells, the lower
the density of infected red blood cells in the human host. Moreover, different vaccine
combinations yield different results. In the absence of vaccine therapy, the density of infected
red blood cells (blood trophozoites and blood schizonts) is shown to increase and stabilise at
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the parasite persistent equilibrium point. A pre-erythrocytic vaccine with an efficacy of at
least 90% is also shown to guarantee the attainment of a parasite-free equilibrium.
Like many other epidemic models, the presented in-host malaria model is formulated based
on several model assumptions. The parameter values used in the study are also obtained
from past literature. The results of our study should therefore be approached with some
discretion. The presented model ignores the biology of CD8+ T activation and assumes
constant parameter values. It would therefore be difficult to predict with higher accuracy,
the optimal malaria vaccine efficacy. In spite of the stated shortcomings, the presented
in-host malaria model provides useful insights on the need to improve the efficacy of current
malaria vaccines in development and the need to try vaccine combinations in controlling P.
falciparum malaria infection.
4.8 Conclusion
In this chapter, a mathematical model for in-host malaria dynamics subject to malaria vaccines
has been presented. The analysis of the model provides useful insights into individual and
combined vaccine impacts in reducing the severity of clinical P. falciparum malaria. The
notion of critical vaccine efficacy is key in the development of malaria vaccines with the
potential to eliminate P. falciparum malaria in individuals that would get infected with the
disease.
In order to achieve a substantial reduction in malaria mortality and morbidity, the efficacy
of the malaria vaccine should be higher than the corresponding critical vaccine efficacy.
For instance, when the efficacy of the blood stage vaccine is lower than the critical efficacy
(ϱ<ϱc), the rate of infection of susceptible red blood cells is higher and clinical malaria
persists. However, the density of blood trophozoites and blood schizonts decreases drastically
if the efficacy of the blood stage vaccine is higher than the critical blood stage vaccine
efficacy. The combined administration of malaria vaccines (Miura, 2016) and antimalarial
drugs is likely to provide the much needed therapeutic control against P. falciparum malaria.
In the next Chapter 5, uncertainty and sensitivity analysis is performed to establish critical
model parameters for therapeutic target and interventions during clinical malaria infections.
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Chapter 5
Uncertainty and sensitivity analysis
applied to an in-host malaria model
subject to vaccines
5.1 Introduction
During disease model formulation, simplifications and assumptions on the model itself and
on the parameters that represent the different transitions and interactions in the model are
made. Owing to uncertainty in parameter values, it is important to correctly understand the
possible effects of such parameter values to the anticipated model outcome (Gomero, 2012;
Pereira and Broed, 2006). Uncertainty in the set of parameter values generates variability
in the model’s predictive capabilities. The lower the number of uncertain parameters in a
model, the lower the significance of variability introduced into a model. On the other hand, a
higher number of parameters with uncertain values result into a higher variability in model
outcome (Gomero, 2012).
In-host malaria transmission models have become very complex. Unlike simple models,
complex models may best be understood by numerical analysis (Blower and Dowlatabadi,
1994). Uncertainty and sensitivity analysis are instrumental in analysing the dynamics of
such structurally complex models that experiences high levels of uncertainty in the estimation
of their input parameter values. The concept of uncertainty analysis enables us to evaluate
the variability in the output (Iman and Helton, 1988). Conversely, a sensitivity analysis helps
us to discern important parameters in the dynamics of infection under study.
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There are three techniques of uncertainty and sensitivity analysis (Iman and Helton, 1988).
These include: (i) latin hypercube sampling / partial rank correlation coefficient (LHS/PRCC),
(ii) response surface methodology; and (3) differential analysis. The more sophisticated and
efficient approach of LHS/PRCC (Blower et al., 1991; Iman and Helton, 1988) that permits
synchronous variation of all input variables is considered in this study. LHS/PRCC sensitivity
analysis is a synergy of Latin Hypercube Sampling (McKay et al., 1979) and the Partial Rank
Correlation Coefficient (Hamby, 1994). It aims to identify and rank pivotal model parameters
whose uncertainties contribute to prediction imprecision (Gomero, 2012).
Several research studies (Anderson et al., 1989; Diebner et al., 2000; Diekmann et al., 1990;
Gravenor and Kwiatkowski, 1998; Gurarie and McKenzie, 2006; Hetzel and Anderson, 1996;
Hoshen et al., 2000; McQueen and McKenzie, 2004; Molineaux et al., 2001; Molineaux
and Dietz, 1999; Saul, 1998) have focussed on understanding the dynamics and control
of P. falciparum infections. Although most of these models have investigated parameter
importance in driving malaria infection, this is mainly based on the basic reproduction
number of the disease, which often do not have all the model parameters. Sensitivity analysis
for the entire parameter space provides the right rigour for parameter evaluation in driving
malaria disease progression.
Previous studies (Neilan et al., 2010; Zhong, 2011), used parameter-driven LHS/PRCC
procedure to ascertain important parameters and their relative importance in the disease
model output. In (Gomero, 2012), LHS/PRCC procedure is coupled with the optimal
control numerical procedure to simultaneously examine the effects of all LHS parameters on
the objective functional value. In this chapter, the LHS/PRCC uncertainty and sensitivity
analysis technique is applied to an in-host P. falciparum malaria model with vaccine controls
(pre-erythrocytic vaccines, blood stage vaccines and transmission blocking vaccines). Multi-
component and multi-stage vaccine combinations are evaluated to establish optimal vaccine
combinations.
5.2 Model formulation
The compartmental model in this chapter is an extension of in-most malaria model in
Chapter 3. The model is composed of nine compartments: the malaria sporozoites S(t), the
susceptible hepatocytes H(t), the infected hepatocytes X(t), the susceptible erythrocytes
R(t), the infected erythrocytes T (t), the gametocytes G(t), the merozoites M(t), unactivated
CD8+ T cells Wn(t) and activated CD8+ T cells Wa(t). The activation of CD8+ T cells
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caused by the presence of infected hepatocytes and infected erythrocytes only. This activation
is further assumed to occur at a constant rate λw for both infected hepatocytes X and infected
erythrocytes T . Unactivated CD8+ T cells are produced at a fixed rate Ω from the thymus.
A proportion q and ρ of infected erythrocytes and infected hepatocytes get eradicated by the
CD8+ T cells before they develop to the schizont stages, respectively. The rest of infected
hepatocytes develop asexually and burst open to release blood stage merozoites. It is assumed
that some of the newly generated merozoites develop into gametocytes. This proportion is
denoted by the parameter π . The commitment to gametocytogenesis is presumably made
during the immediately preceding cycle of blood schizogy (Diebner et al., 2000). These
blood floating gametocytes are transmitted to the mosquito vector during feeding, marking
the onset of sporogonic cycle (not considered in this study).
During blood meal, an infected female mosquito injects sporozoites into the blood stream
of the human host at a rate Λ. The sporozoites traverse the blood stream and enter the liver
where they invade the liver hepatocytes H at the rate βs to generate infected hepatocytes X at
the liver stage. A natural death rate of µs for malaria sporozoites is assumed. Susceptible
hepatocytes are recruited at a constant rate λh from the bone marrow. Both the infected and
uninfected hepatocytes experience natural death at the rates µx and µh, respectively.
Three malaria vaccines are considered in this model to reduce the severity of P. falciparum
malaria infection. These are: pre-erythrocytic vaccine (PEV) (see, (Birkett, 2016; Birkett
et al., 2013; Nunes et al., 2014)), blood stage vaccine (BSV) (see (Audran et al., 2005;
Moorthy et al., 2004; Ogutu et al., 2009)), and transmission blocking vaccines (TBV)(see
(Arevalo-Herrera et al., 2005; Hisaeda et al., 2000)). The leading PEV, BSV and TBV
considered in this study are RTS,S/AS01, merozoite surface protein 3 (MSP3), P. falciparum
ookinete surface antigens (Pfs25), respectively. The PEV, BSV and TBV vaccines are
assumed to possess efficacies denoted by ν , ϱ and χ , respectively. Note that 0 < ν < 1,
0 <ϱ< 1 and 0 < χ < 1.
A summary of the descriptions of model parameters and the state variables is presented in
Tables 5.1 and 5.2, respectively. The compartmental flow diagram for the in-host malaria
model is provided in Figure 5.1. The structural complexity of the in-host malaria model is
the motivation to apply LHS/PRCC technique for uncertainty and sensitivity analysis.
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Table 5.1: Table showing model parameters and their descriptions
Parameter Description
P Number of merozoites released per bursting erythrocyte
Λ Injection rate of sporozoites
µs Death rate of sporozoites
βr Rate of infection of erythrocytes by merozoites
µt Mortality rate of infected erythrocytes
λh The recruitment rate of hepatocytes
λr The recruitment rate of erythrocytes from the bone marrow
µh, µx Death rate of susceptible hepatocyte and
infected hepatocyte, respectively
π Proportion of merozoites that develop into gametocytes per dying
infected erythrocyte
ρ,q Immunosensitivity of infected hepatocyte and erythrocyte, respectively
χ Efficacy of transmisssion blocking vaccine
µr Natural mortality rate of susceptible erythrocytes
d Inhibition rate of CD8+T cells response
ϱ Efficacy of blood stage vaccine
λw Immunogenicity of IRBCs and infected hepatocytes
1/ε0,1/ε1 A saturation (half) constants for infected hepatocytes and
infected erythrocytes, respectively
µm, µg Death rate of merozoites and gametocytes, respectively
τ A modification parameter that accounts for vaccine-induced
increased generation of activated CD8+T cells
ν Efficacy of pre-erythrocytic stage vaccine
µn, µa Death rates of unactivated and activated CD8+ T cells, respectively
βs Infection rate of hepatocytes by sporozoites
Ω Recruitment rate of unactivated CD8+ T cells from the thymus
b A modification parameter accounting for PEV-induced reduction of merozoites
released per bursting infected hepatocyte,
a A modification parameter accounting for BSV-induced reduction of merozoites
released per bursting erythrocyte
N The average number of merozoites released per bursting
infected-hepatocytes
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Table 5.2: Description of the state variables
Variable Description
Wn(t) Concentration of unactivated CD8+T cells
Wa(t) Concentration of activated CD8+T cells
H(t) Population of susceptible liver hepatocytes
X(t) Population of infected hepatocytes
S(t) Population of malaria sporozoites
R(t) Population of susceptible erythrocytes
T (t) Population of infected erythrocytes
M(t) Population of merozoites
G(t) Density of gametocytes in blood
Figure 5.1: A compartmental representation of the dynamics of in-host malaria infection
with vaccine control measures.
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Based on the dynamics described in Figure 5.1, the following deterministic model describes
















































= Ω− τλw(X +T )Wn −µnWn,
dWa
dt
= τλw(X +T )Wn −µaWa,

(5.1)
subject to the following initial conditions:
S(0)≥ 0, H(0)> 0, X(0)≥ 0, R(0)> 0, T (0)≥ 0, M(0)≥ 0, G(0)≥ 0, Wn(0)> 0, Wa(0)≥
0.
Positivity of solutions
The long term behaviour of any dynamical system is instrumental in the understanding
of the system. System (5.1) monitors changes in the density of erythrocytes, hepatocytes,
malaria parasite and CD8+ T cells. To warrant biological sense, the state variables of system
(5.1) should be nonnegative. Specifically, we show that all solutions of system (5.1) with
nonnegative initial conditions will remain nonnegative ∀t ≥ 0.
Theorem 5.1. Given nonnegative initial conditions (S(0)≥ 0,H(0)> 0,X(0)≥ 0,R(0)>
0,T (0)≥ 0,M(0)≥ 0,G(0)≥ 0,Wn(0)> 0,Wa(0)≥ 0), the system (5.1) has a nonnegative
solution (S(t),H(t),X(t),R(t),T (t),M(t),G(t),Wn(t),Wa(t)), for all time t ≥ 0.
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Proof:













Therefore, S(t)≥ 0 ∀t ≥ 0.




Integrating the separable inequality (5.4) gives
Wa(t) =Wa(0)exp(−µat)≥ 0. (5.5)
Using the same argument, the rest of the state variables can similarly be shown to be
nonnegative for all time t ≥ 0. That is, H(t) > 0, X(t) ≥ 0, R(t) > 0, T (t) ≥ 0, M(t) ≥ 0,
G(t)≥ 0 and Wn(t)≥ 0 ∀t ≥ 0. This completes the proof.
Boundedness of solutions
The nonnegative solutions to system (5.1) must be well posed in regions of biological sense.
The proof that the solutions are bounded is as follows:
Let Nr be the total population of susceptible and infected erythrocytes in the host. This gives
Nr(t) = R(t)+T (t). Therefore,
dNr
dt
= λr −µrR−µtT −qTWa,
≤ λr − µ̄1Nr where µ̄1 = min{µr,µt}. (5.6)
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This implies that at any time t, Nr(t)≤ max{Nr(0),λr/µ̄1}.
Again, let Np(t) = S(t)+M(t)+G(t), be the sum of malaria parasites at any time t during

























e−µ̄2tΨ1(t)dt +C1e−µ̄2t , (5.9)















. The above procedure can similarly be
applied to the total concentrations of the liver hepatocytes Nl(t) = H(t)+X(t) and that of
CD8+ T cells Nw(t) =Wa(t)+Wn(t) so that
dNl
dt
≤ λh − µ̄3Nl and
dNw
dt
≤ Ω− µ̄wNw, (5.11)
where µ̄3 = min{µh,µx} and µ̄w = min{µa,µn}.













for all time t > 0.
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Therefore, all feasible solutions of system (5.1) enter the region:
D =
{



























which is a positively invariant set of system (5.1). This implies that all solutions in D remain
in D ∀t ≥ 0. It thus suffices to study the dynamics of system (5.1) in D .
5.3 Model analysis
5.3.1 Stability analysis of disease-free equilibrium point, E0
At E0, Λ = 0 and there are no activated CD8+ T cells; that is, Wa = 0. Setting the right-hand-
side of system (5.1) to zero, gives the following disease-free equilibrium:
















The disease-free steady state is very crucial in the understanding of in-host malaria infection
dynamics. In order to eradicate in-host malaria, it is important to identify and establish
necessary conditions for the disease-free equilibrium to be stable. This stability could be
achieved through the use of effective antimalarial drugs such as ACT or by using highly
efficacious P. falciparum malaria vaccines.
The next generation matrix (NGM) approach (see (Diekmann et al., 1990; Van den Driessche
and Watmough, 2002) for detailed explanation of the technique) is employed to compute
effective reproduction number Re f f of system (5.1). The NGM method presumes the local
stability of E0 for Re f f < 1 and instability for Re f f > 1. Re f f is the spectral radius of the
next generation matrix (F2V−12 ) of system (5.1); that is, Re f f = ρ(F2V
−1
2 ). Adopting the
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0 µx 0 0 0 0 0
0 0 µt 0 0 0 0
0 −V02 V03 βrλrµr +µm 0 0 0
















+µs, V02 = (1−ρ)(1−b)Nµx and V03 = (1−a)P(1−π)(1−q)µt . Thus,
the effective reproduction number Re f f is given by









Observe that R01 is the contribution of new cell invasions at the liver stage due to mortile
sporozoites and R02 is the contributions of new cell invasions at the blood stage due to
merozoite parasites. From equations (5.16) and (5.17), it is evident that new cell invasions
occur both at the liver stage (as depicted by R01) and at the blood stage (as depicted by R02).
This implies that clinical control of P. falciparum malaria should target the parasite at both
stages of its life cycle within the human host. An antimalarial drug or drug combinations
with the capacity to eradicate the sporozoites at the pre-erythrocytic stage and merozoites
at the erythrocytic stage is most recommended. Furthermore, malaria vaccine development
should equally focus on both stages of parasite development. A novel malaria vaccine should
108
begin parasite eradication from the pre-erythrocytic stage and this should continue to the
blood stage. This result is very important to the ongoing research and development of malaria
vaccines.
Theorem 5.2. The disease-free equilibrium E0 of system (5.1) is locally asymptotically stable
if Re f f < 1 and unstable otherwise.
Proof: The qualitative matrix stability approach (Abdulrahman et al., 2013) to determine the
local stability of the disease-free equilibrium E0 for system (5.1) is used. Linearisation of the
system (5.1) along E0 gives the following Jacobian matrix
J2(E0) =

−A2 0 0 0 0 0 0 0 0
−A3 −µh 0 0 0 0 0 0 0
A3 0 −µx 0 0 0 0 0 0
0 0 0 −µr 0 −A4 0 0 0
0 0 0 0 −µt A4 0 0 0
0 0 0 0 A0 −A5 0 0 0
0 0 0 0 A1 0 −µg 0 0









0 0 0 −µa

, (5.18)
where A0 = (1−a)P(1−π)(1−q)µt , A1 = (1−a)Pπ(1−q)µt , A2 = ((βsλh)/µh +µs),
A3 = (((1−ν)βsλh)/µh), A4 = (((1− ϱ)βrλr)/µr) and A5 = (βrλr/µr +µm).
To obtain the eigenvalues of matrix (5.18), first transform it into an upper triangular matrix.




× row 1+ row 2 → row 2 (7) A1A4−Y0µt




× row 1+ row 3 → row 3 (8) τΩλw−µt µn




× row 5+ row 6 → row 6 (9) τΩλw
µt µn




× row 5+ row 7 → row 7 (10) τΩλw−µgµn




× row 3+ row 8 → row 8 (11) τΩλw
µgµn




× row 3+ row 9 → row 9
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The resultant upper triangular matrix J∗2 is presented as follows:
J∗2 =

−A2 0 0 0 0 0 0 0 0
0 −µh 0 0 0 0 0 0 0
0 0 −µx 0 0 0 0 0 0
0 0 0 −µr 0 −A4 0 0 0
0 0 0 0 −µt A4 0 0 0
0 0 0 0 0 Y0 0 0 0
0 0 0 0 0 0 −µg 0 0
0 0 0 0 0 0 0 −µn 0





















< 0, λ2 =−µh < 0, λ3 =−µx < 0, λ4 =−µr < 0,
λ5 =−µt < 0, λ6 = Y0, λ7 =−µg < 0, λ8 =−µn < 0, λ9 =−µa < 0.
It can clearly be seen that λ1,λ2,λ3,λ4,λ5,λ7,λ8 and λ9 are all strictly negative. The
disease-free equilibrium is locally asymptotically stable if all the eigenvalues of the Jacobian
matrix (5.18) are negative. The conditions necessary for λ6 = Y0 to be strictly negative are
established as shown below:


























where Re f f = R02 as defined in equation (5.17).
Equation (5.23), implies that Y0 < 0 if and only if Re f f < 1. Hence, E0 is locally asymptoti-
cally stable if Re f f < 1. This completes the proof.
The global stability of the disease-free equilibrium is established using a suitable Lyapunov
candidate function (Li and Shu, 2010; Omondi et al., 2018). Consider the following theorem.
Theorem 5.3. The disease-free equilibrium E0 is globally asymptotically stable in R9+ if
Re f f ≤ 1.
Proof: Let V (X ,T,S,M,G) = ψ1X +ψ2T +ψ3S+ψ4M +ψ5G be a candidate Lyapunov
function for some nonnegative coefficients ψ1, ψ2, ψ3, ψ4 and ψ5. The derivative of V with
































































Evaluating the coefficients of the suitable Lyapunov function such that the coefficients of X ,
T , S, M and G are equal to zero gives
ψ1 =
































Using these coefficients, the time derivatives of the Lyapunov function is given as
dV
dt






T − µg(1− ϱ)λrµmµr
πβr(1−a)(1−q)
G(1−Re f f ).
(5.28)
If Re f f < 1 in equation (5.28) then [µg(1− ϱ)λrµmµr]/[πβr(1− a)(1− q)](1−Re f f ) > 0.
This gives (dV/dt)≤ 0. Furthermore, (dV/dt) = 0 if and only if T = X = G = 0. Therefore,
V is a Lyapunov function in D . Given that D is positively invariant and attracting, it follows
that the maximum invariant set in {(S,H,X ,R,T,M,G,Wn,Wa) ∈D : V̇ = 0} is the singleton
E0. By LaSalle’s invariant principle (LaSalle, 1976), E0 is globally asymptotically stable in
D provided that Re f f ≤ 1.
5.3.2 The malaria-persistent steady state
The malaria-persistent equilibrium Ep for system (5.1) in the presence of CD8+ T cells is
established by equating the right-hand side of system (5.1) to zero. Using Mathematica
software, system (5.1), exhibits a malaria-persistent equilibrium point
























(1+dW ∗a )[(1−b)2(1− ϱ)NX∗βrµmµx − (1+dW ∗a )µr]±
√
∆
2(1− ϱ)(1+dW ∗a )βr
, where (5.32)
∆m = (1+dW ∗a ){(−(e−1)βr(−4(1−π)(1−a)P(1−q)T ∗µt
+(1−b)2NX∗(1+dW ∗a )βrµx(4(1+dW ∗a )λr +(1−b)2(1− e)NX∗µ2mµx))









∆2s +4((1−ν)βsµs)((1−χ)Λ(1+dW ∗a )µh)
}
, (5.33)
where ∆s = βs(Λ(1−χ)(1−ν)− (1+dW ∗a )λh)− (1+dW ∗a )µhµs,
T ∗ =
1
















∆2x +4ε0((1−ν)βsS∗+(1+dW ∗a )µh)µx)(1−ν)βsλhS∗
2ε0((1−ν)βsS∗+(1+dW ∗a )µh)µx
, where (5.35)
∆x = (1−ν)(ε0λh −µx)βsS∗−dρW ∗2a µh −µhµx −W ∗a ((1−ν)ρβsS∗+µh(ρ +dµx)).
Based on the formulated model in system (5.1), the activated CD8+ T cells only exist due to
the presence of infected red blood cells and infected hepatocytes. Hence, in the absence of
malaria infection (X = T = 0), Wa = 0. Moreover, none of the malaria parasites exists; that
is S∗ = M∗ = G∗ = 0. It is further observed that when S∗ = M∗ = X∗ = T ∗ =W ∗a = 0, the
susceptible erythrocytes, susceptible hepatocytes and the unactivated CD8+ T cells become
H∗ = (λh/µh), R∗ = (λr/µr) and W ∗n = (Ω/µn), respectively. This gives an equilibrium point
called the disease-free equilibrium point of system (5.1) illustrated in equation (5.13). From
the above computations, it is evident that the analytical expressions of Ep is too complex.
The numerical simulation of the equilibrium points is provided in Section 5.6.
Theorem 5.4. The malaria persistent steady state Ep is locally asymptotically stable if
Re f f > 1 in the interior of the biologically feasible region D .
Proof: The stability of the malaria persistent equilibrium Ep (when Re f f > 1 but close to 1)
is proved using the center manifold theory (CMT) presented by Castillo-Chavez and Song
(2004). The notations used therein Castillo-Chavez and Song (2004) and without re-stating
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the theorem are adopted to calculate the values of arguments a and b. The signs (+ or -) of a
and b determine the local dynamics of system (5.1) around Ep (White and Comiskey, 2007).











The CMT is applied by first transforming the state variables
(S,H,X ,R,T,M,G,Wn,Wa) into (x1,x2,x3,x4,x5,x6,x7,x8,x9), respectively. The model in
system (5.1), is hence represented as (dg/dt)= g(x), where x=(x1,x2,x3,x4,x5,x6,x7,x8,x9).
The model (5.1) thus becomes
ẋ1 = (1−χ)Λ−µsx1 −βsx1x2,






























ẋ8 = Ω− τλw(x3 + x5)x8 −µnx8,




x1(0) ≥ 0, x2(0) ≥ 0, x3(0) ≥ 0, x4(0) ≥ 0, x5(0) ≥ 0, x6(0) ≥ 0, x7(0) ≥ 0, x8(0) ≥ 0,
x9(0)≥ 0.
The new system (5.37) with the bifurcation point β∗ has a simple zero eigenvalue. This
attribute enables the use of CMT to analyse the stability of system (5.37) near β∗ =
max{β ∗s ,β ∗r }= max{βs,βr}.
Therefore, a right eigenvector w = [w1,w2,w3,w4,w5,w6,w7,w8,w9]T associated with the
simple zero eigenvalue is obtained from the linearisation matrix corresponding to the zero
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eigenvector as follows:
−A2 0 0 0 0 0 0 0 0
−A3 −µh 0 0 0 0 0 0 0
A3 0 −µx 0 0 0 0 0 0
0 0 0 −µr 0 −A4 0 0 0
0 0 0 0 −µt A4 0 0 0
0 0 0 0 A0 −A5 0 0 0
0 0 0 0 A1 0 −µg 0 0



































where A0, · · · ,A5 are as presented in the Jacobian matrix (5.18).








































,w6 = 1, w1 = w2 = w3 = 0. (5.39)
Similarly, upon solving for the left eigenvector v = [v1,v2,v3,v4,v5,v6,v7,v8,v9]T associated
with the zero eigenvalue in system (5.37) gives
v1 = v2 = v3 = v4 = 0, v5 = P(1−a)(1−π)(1−q),v6 = 1,v7,v8,v9 = 0.






































































































The above procedure in computing the values of b is repeated. The non-zero partial derivatives















































(P(1−a)(1−π)(1−q)(1− ϱ)+1)> 0. (5.44)
Thus, a is positive (a > 0) and b is negative (b < 0). Based on item (iv) of theorem
2 in (Castillo-Chavez and Song, 2004), the malaria persistent equilibrium Ep is locally
asymptotically stable for Re f f > 1, but close to 1.
5.4 Uncertainty and sensitivity analysis
5.4.1 Sensitivity analysis of infected and infective states of the in-host
malaria model
The in-host malaria model in this chapter has numerous unknown parameters, coupled with
limited data. Therefore, there is a considerable uncertainty (Blower et al., 1991) in estimating
the values of the 30 transmission parameters in system (5.1). The uncertainty in the input
values allows significant variability in the model predictions of the future malaria parasite
density within the human host and the concentrations of the infected red blood cells and hence
the severity of clinical P. falciparum malaria. Consequently, LHS/PRCC sensitivity analysis
is performed to evaluate variability in model predictions. With LHS/PRCC technique, it
is possible to explore the entire parameter space of system (5.1), with minimal computer
simulation.
The effects of the LHS parameters on the two infected state variables are simultaneously
examined: the infected liver hepatocytes X(t) and the infected red blood cells T (t) and the
three infective parasite states: the sporozoite S(t), the merozoites M(t) and the gametocytes
G(t) in model (5.1). The PRCCs are used to identify the key parameters contributing to the
imprecision in predicting the future density of infected liver hepatocytes and infected red
blood cells (Blower et al., 1991).
117
5.4.2 Sampling the Latin hypercube sampling (LHS) parameters
The process of performing Latin Hypercube Sampling on disease models consists of the
following steps: (1) identifying model of interest, (2) listing all the model parameters together
with their estimated or exact values, (3) extracting uncertain parameters from the list of
model parameter values; provide baseline values and range values for known and unknown
parameters, respectively, (4) for U simulations, the inequality U > (4/3)Q, must be true
for Q uncertain parameters (McKay et al., 1979). The parameter space is hence defined
by Q dimensions. The appropriate sample size U is established from the desired level of
significance attached to the PRCC values (Blower and Dowlatabadi, 1994), (5) a probability
density function (pdf) for each uncertain parameter is then specified. This may include (i)
uniform distribution, (ii) triangular distribution, (iii) multi-modal Weibull distribution and
(iv) skewed distribution. Finally, each pdf is then divided into U overlapping equiprobable
intervals, which are then randomly sampled once.
Next, define the probability distribution function of parameter p to be f (p), the interval of
f (p) to be F(p) and the inverse of F(p) to be F−1(p). If the function is normalized then:
[F(p)]pmaxpmin = 1. (5.45)




f (p)dp = F(pimax)−F(pimin). (5.46)
At the end of step (5), each of the Q uncertain parameters will have U values. This is stored
in an U ×Q matrix.
5.4.3 Partial rank correlation coefficient (PRCC) methodology
To perform PRCC, begin by ranking the LHS parameters in the LHS matrix together with
the outcome measures. In our case, the outcome measures are the states T (t), X(t), M(t),
G(t) and S(t). Two linear regression models are generated in response to each parameter
and outcome measure. A Pearson rank correlation coefficient for the residuals from the
two regression models gives the PRCC values for that specific parameter. The underlying
parameter distributions can be established through expert judgment or based on empirical
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evidence (Pereira and Broed, 2006). Due to lack of data on the distribution function, a
uniform distribution for all model parameters in Table 5.9 is considered.
The PRCC for each input variable is established as follows: Begin by adding an additional
column Q+1 (called the outcome vector), to the matrix containing the input parameter values.
Secondly, the ranks 1,2, · · ·U corresponding to each column is represented by the set of
ordinal numbers ξ1i,ξ2i, · · · ,ξki, where the index i denotes the run number. The average rank
η is given as η = (1+U)/2. In the event that two or more parameters have the same ranking
based on a particular run, then only one of the parameters is considered in the calculation of





i=1(ξit −η)(ξ jt −η)√
∑
U
t=1(ξit −η)2 ∑Us=1(ξ js −η)2
, i, j = 1,2,3, · · · ,Q. (5.47)
Next, let the matrix D = [di j] be the inverse of matrix C and ρiz be the PRCC corresponding












The above procedure is repeated for a second outcome variable and so on until the PRCCs
are obtained for all the input parameters and their corresponding outcome variables.
5.5 Results of analysing the LHS/PRCC for the in-host malaria
model
Using 1000 runs of Latin hypercube sampling, the PRCC and p values of the 30 parameters
in system (5.1) are computed based on the regression coefficient for outcome measures T (t),
X(t), M(t), G(t) and S(t) and summarised in Tables 5.3, 5.4, 5.5, 5.6 and 5.7. The size of
PRCC shows the importance of the uncertainty in estimating the value of the specific variable
in contributing to the prediction imprecision (Blower et al., 1991). The PRCC sign (+ or
-), however, shows the qualitative relationship between the input parameter and the output
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variables. Parameters with large PRCC values coupled with a corresponding small p value
(p value < 0.05) are considered as the most influential (Gomero, 2012).
A slight change in a highly influential parameter is likely to produce a significant change in
the outcome variable. The symbol (∗) indicates less influential parameters with p values <
0.05 and PRCC values in the range (-0.1 to -0.49 or 0.1 to 0.49 ). Further, the symbol (∗∗) is
used to indicate moderately critical parameters in prediction imprecision, and have p value <
0.05 and PRCC values in the range (-0.5 to -0.79 or 0.5 to 0.79 ) . Lastly, the symbol (∗∗∗)
indicates the most critical and likely contributors to uncertainty, with PRCC values in the
range (-0.8 to -0.99 or +0.8 to +0.99).
Results displayed in Tables 5.3, 5.4, 5.5, 5.6 and 5.7 indicate that the rate of invasion by
merozoites βr, the rate of invasion of liver hepatocytes by sporozoites βs, malaria vaccine
efficacies (ϱ, ν , and χ) and the recruitment rates for hepatocytes and erythrocytes, λh and
λr, respectively, are statistically significant in determining the variation of concentrations of
infected erythrocytes, infected hepatocytes and the density of malaria parasites (sporozoites,
merozoites and gametocytes). The number of merozoites P released per bursting infected
erythrocytes and the number of merozoites N released per bursting infected hepatocytes are
shown to significantly increase the density of the merozoites and the density of infected
erythrocytes T . Clinical malaria controls should thus target these infected cells for eradication
before they mature to schizont stages.
Moreover, from Tables 5.3 and 5.6, the proportion of merozoites that develop into game-
tocytes per dying infected erythrocyte π and immunosensitivity of infected erythrocytes
q are shown to have significant influence in determining the density of gametocytes and
merozoites, respectively, during clinical P. falciparum infection. An efficacious blood stage
vaccine coupled with a transmission blocking vaccine antigens has the potential of reducing
the density of gametocytes during clinical malaria. This reduces parasite transmission to
mosquito vector.
It is evident that a highly efficacious pre-erythrocytic vaccine such as RTS,S/SA01 (with
efficacy ν) and blood stage vaccine such as MSP3 (with efficacy ε) could effectively help in
reducing parasitaemia and malaria severity during clinical P. falciparum infections. Sporo-
zoite invasion rate βs and the merozoite invasion parameter βr are also shown to increase the
disease Re f f and hence the severity of the disease within the human host.
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Table 5.3: Partial rank correlation coefficients (PRCC) between infected red blood cells T
and model parameters. The results are significant at the 0.05 level
Parameter PRCC p value Parameter PRCC p value
Λ 0.040124 0.69185 ν ∗-0.35423 0.0001255
µs 0.092654 0.35921 d -0.021968 0.82825
λh 0.16815 0.094459 λw 0.02639 0.79438
λr
∗∗∗0.99993 1.2467E-191 τ 0.028815 0.77596
βr
∗∗ 0.60394 0.0030343 a -0.033076 0.7439
βs -0.072861 0.47128 b -0.037844 0.70854
µh 0.045043 0.65633 P ∗ 0.28652 0.0038515
µx 0.022164 0.82674 N ∗∗ 0.50348 0.0003056
π 0.24376 0.14528 ε0 -0.050167 0.62012
µr
∗∗ -0.54174 5.8708E-9 ε1 0.0092028 0.92759
µt -0.043585 0.66677 ρ 0.087162 0.38852
µm -0.08574 0.39634 q ∗-0.261905 0.00154063
µg -0.13006 0.19715 µn -0.093091 0.35694
χ -0.13607 0.17706 µa -0.054864 0.58771
ϱ -0.30701 0.0018909 Ω 0.041721 0.68024
Table 5.4: Partial rank correlation coefficients (PRCC) between infected hepatocytes X and
model parameters. The results are significant at the 0.05 level
Parameter PRCC p value Parameter PRCC p value
Λ -0.034437 0.73375 ν ∗ -0.307831 0.00093836
µs 0.071002 0.48269 d -0.1442 0.15231
λh
∗∗∗ 0.9749 9.5419E-66 λw -0.094174 0.35135
λr 0.06407 0.52654 τ ∗ -0.20137 0.000044531
βr -0.080809 0.42415 a -0.075135 0.45751
βs
∗∗ 0.53926 0.00016701 b 0.061933 0.54045
µh
∗∗∗-0.87273 2.7908E-23 P 0.076347 0.45026
µx 0.14762 0.14273 N 0.10516 0.29776
π -0.045846 0.6506 ε0 0.21125 0.034877
µr 0.094998 0.34713 ε1 -0.16583 0.09918
µt 0.12588 0.21205 ρ 0.033235 0.74272
µm 0.13493 0.18073 q 0.095106 0.34658
µg 0.033064 0.74399 µn 0.039223 0.69843
χ -0.28902 0.0035417 µa -0.052237 0.60575
ϱ -0.061742 0.5417 Ω 0.10411 0.30264
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Table 5.5: Partial rank correlation coefficients (PRCC) between merozoites M and model
parameters. The results are significant at the 0.05 level
Parameter PRCC p value Parameter PRCC p value
Λ 0.013086 0.89718 ν ∗∗ -0.61866 6.9194E-12
µs 0.12012 0.23389 d 0.12239 0.22509
λh - 0.005884 0.95367 λw -0.30208 0.0022545
λr
∗∗-0.78852 2.0731E-22 τ -0.11155 0.26918
βr
∗∗0.77199 5.3565E-21 a 0.14416 0.15243
βs 0.10834 0.28328 b -0.18907 0.059575
µh 0.080773 0.42436 P ∗ 0.28652 0.0038515
µx
∗ 0.46617 1.0183E-06 N ∗∗ 0.50348 0.0003056
π -0.29849 0.0025577 ε0 -0.23892 0.01667
µr 0.060227 0.55168 ε1 -0.057548 0.56955
µt -0.05975 0.55485 ρ -0.25708 0.0098207
µm -0.090522 0.37042 q -0.047855 0.63635
µg 0.18256 0.069072 µn -0.0015737 0.9876
χ ∗∗-0.67251 1.8298E-14 µa 0.1363 0.17632
ϱ -0.024582 0.80818 Ω -0.12172 0.22769
Table 5.6: Partial rank correlation coefficients (PRCC) between gametocytes G and model
parameters. The results are significant at the 0.05 level
Parameter PRCC p value Parameter PRCC p value
Λ 0.09861 0.32902 ν ∗∗ -0.54919 3.2858E-09
µs -0.18356 0.067537 d -0.33627 0.00062476
λh 0.16929 0.092216 λw -0.14215 0.15831
λr
∗∗∗-0.79454 5.8878E-23 τ -0.080527 0.42578
βr
∗∗-0.76958 8.4228E-21 a -0.16499 0.10092
βs -0.021251 0.83378 b -0.31287 0.0015279
µh 0.060337 0.55095 P 0.059063 0.55941
µx
∗ 0.40198 3.3899E-05 N 0.24601 0.013619
π ∗∗ 0.698883 0.0032768 ε0 -0.28727 0.0037563
µr -0.022582 0.82353 ε1 0.075806 0.45349
µt 0.075502 0.45531 ρ -0.047433 0.63933
µm 0.067991 0.50149 q 0.12264 0.22416
µg -0.084857 0.40124 µn -0.12368 0.22021
χ ∗∗-0.55186 2.6601E-09 µa 0.17443 0.082611
ϱ ∗∗ -0.55799 1.6273E-09 Ω 0.15261 0.12956
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Table 5.7: Partial rank correlation coefficients (PRCC) between sporozoites S and each
parameter. The results are significant at the 0.05 level
Parameter PRCC p value Parameter PRCC p value
Λ ∗ 0.31314 0.00097533 ν 0.0067811 0.94661
µs
∗∗ -0.68707 0.0094591 d 0.010905 0.91425
λh -0.012635 0.90071 λw 0.0043436 0.96579
λr 0.03593 0.72266 τ 0.023508 0.81642
βr 0.025432 0.80168 a 0.0065303 0.94859
βs -0.0091069 0.92835 b -0.017604 0.86199
µh 0.022838 0.82156 P -0.019561 0.84683
µx 0.0056574 0.95545 N -0.015923 0.87505
π -0.0047473 0.96261 ε0 -0.00027845 0.99781
µr 0.00025243 0.99801 ε1 -0.0003386 0.99733
µt -0.011016 0.91338 ρ -0.031317 0.75709
µm 0.0096995 0.9237 q -0.0037326 0.9706
µg -0.023075 0.81974 µn 0.030253 0.7651
χ ∗-0.699368 0.0001184 µa -0.0042258 0.96672
ϱ 0.01863 0.85403 Ω -0.0052564 0.95861
Figures 5.2 and 5.3 illustrates Monte Carlo simulations for some of the parameters with the
greatest PRCC values against model Re f f .
(a) (b)
Figure 5.2: The Monte Carlo simulations for some of the parameters with the greatest
partial rank correlation coefficient (PRCC) magnitudes, using values in Table 5.9 and 1000
simulations per run. The parameters are: (a) sporozoite invasion rate βs and (b) efficacy of




Figure 5.3: The Monte Carlo simulations for some of the parameters with the greatest
partial rank correlation coefficients (PRCC) magnitudes, using values in Table 5.9 and 1000
simulations per run. They are: (a) proportion of parasites that become gametocytes π , (b)
merozoite invasion rate βr, (c) efficacy of blood stage vaccine ϱ and (d) the number of
merozoites produced per bursting blood schizont P.
It is evident that a highly efficacious pre-erythrocytic vaccine such as RTS,S/SA01 and
blood stage vaccine such as MSP3 could effectively help in reducing parasitaemia and
malaria severity during clinical P. falciparum infections. Sporozoite invasion rate βs and the
merozoite invasion parameter βr are also shown to increase the model Re f f and hence the
severity of the disease within the human host.
Although the LHS/PRCC technique is useful in identifying significant parameters in the in-
host malaria model, it fails to rank the parameters in order of their contribution to variations
and disease progression. This ranking is very crucial in the design of clinical interventions
and in the development of malaria vaccines. The normalised forward sensitivity index of
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the effective reproduction number in equations (5.16) and (5.17) against LHS parameters in
Table 5.9 are considered in the next section.
5.5.1 Sensitivity analysis based on effective reproduction number, Re f f
The normalised forward sensitivity (NFS) index technique described by Arriola and Hyman
(2005) is adopted to compute the sensitivity indices of the model Re f f with respect to input
parameters P,βr,βs,λh,λr,µh,µr,µx, µm,ϱ,a,π,ν . The sensitivity indices are evaluated in
Mathematica software based on the baseline parameter values given in Table 5.9 and results
presented in Table 5.8.
Table 5.8: Table of sensitivity results
Parameter SI Parameter SI
P +1.00000 a -0.785714
βs +1.00000 π -0.785714
λh +1.00000 βr +0.62402
µh -1.00000 λr +0.62402
µx -1.00000 µm -0.62406
ϱ -0.785714 µr -0.62406
ν -0.785714 q -0.428571
From Table 5.8, it is observed that the density of merozoites released per bursting blood
schizont P, the rate of invasion of healthy hepatocytes βs and erythrocytes βr, the rate
of recruitment of susceptible hepatocytes λh and erythrocytes λr have a direct effect on
severity of clinical malaria. A 10% increase (or decrease) in the magnitude of P increases
(or decreases) model Re f f by 10%. Clinical malaria control should aim at reducing these
parameters. On the other hand, malaria vaccines (ϱ and ν) are shown to reduce Re f f when
their efficacies are improved.
An increase (or decrease) in the immunosensitivity of infected red blood cells q is similarly
shown to reduce (or increase) the model Re f f . The proportion of merozoites that develop
into gametocytes π is also shown to decrease the value of Re f f when they are increased.
By rank, the parameters P,βs,λh are the most influential in model (5.1), followed by the
vaccine efficacies ϱ and ν . Clinical considerations should thus favour these parameters in the
development of malaria vaccines.
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Table 5.9: Parameter values used in the sensitivity analysis and numerical simulations
Paremeter Value Min Max Unit Source
Λ 30 20 35 sporozoites/day (Selemani et al., 2016)
µs 1.2 0.8 1.5 /day (Selemani et al., 2016)
λr 3E5 3E3 3E6 cells/ml/day (Li et al., 2011)
λh 3E5 3E3 3E6 cells/µl−1/day (Tumwiine et al., 2008)
βr 8E-5 8E-7 8E-3 /mm3/day (Dondorp et al., 2000)
βs 5E-4 5E-5 5E-3 /mm3/day (Selemani et al., 2016)
µh 0.029 0.01 0.03 /day (Selemani et al., 2017b)
µx 0.02 0.01 0.05 /day (Selemani et al., 2016)
π 0.2 0.1 0.9 Unitless (Talman et al., 2004)
µr 8.3E-5 8.3E-6 0.0001 /day (Anderson et al., 1989)
µm 48 46 49 /day (Li et al., 2011)
µt 0.7 0.5 0.8 /day (Magombedze et al., 2011a)
µg 0.0625 0.5 0.78 /day (Selemani et al., 2016)
χ,ϱ,ν 0.6 0 1 Unitless Assumed
d 5E-4 1E-4 0.001 Unitless Assumed
τ 1.5 1.2 1.9 Unitless (Niger and Gumel, 2011)
λw 30 25 35 cells/day (Niger and Gumel, 2011)
a,b 0.17 0.2 0.5 Unitless (Niger and Gumel, 2011)
P 16 13 20 Unitless (Diebner et al., 2000)
N 10000 8000 11000 Unitless (Tumwiine et al., 2008)
ε0,ε1 1E-5 1E-6 1E-4 /day (Tumwiine et al., 2008)
q 0.01 0.001 0.02 Unitless (Niger and Gumel, 2011)
ρ 0.3 0.2 0.45 Unitless (Niger and Gumel, 2011)
µn,µa 0.4 0.3 0.72 /day (Li et al., 2011)
Ω 30 24 33 /day (Magombedze et al., 2011a)
In conclusion, the LHS/PRCC technique is robust and considers the entire parameter space
in determining significant parameters in the disease model. However, it fails the ranking
test. On the other hand, although the NFS index approach is beneficial in discerning and
ranking significant parameters in a model, it fails to explain the considerable uncertainties
in estimating parameter values. It therefore fails to uncover parameter effects on particular
variables or populations in the model. Due to the importance attached to the significance and
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rank of each parameter in the model, it is advisable that both approaches be used in future
analysis of parameter uncertainty and sensitivity analysis in disease models.
5.6 Numerical simulation
In this section, the dynamics of the in-host malaria in system (5.1) is numerically illustrated
using Python software. When the effective reproduction number Re f f is less than unity,
clinical P. falciparum malaria is observed to die out (see Figures 5.4 and 5.5).






























































Figure 5.4: Population dynamics of the liver hepatocytes and the sporozoites when the
effective reproduction number Re f f = 0.8881 < 1. The parameter values are shown in Table
5.9.
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Figure 5.5: The dynamics of system (5.1) when the effective reproduction number Re f f =
0.8881 < 1.
The disease-free equilibrium E0 is globally asymptotically stable. Note that even if Re f f is
less than unity, some activated CD8+T cells Wa(t) still exist (see Figure 5.5e). This shows
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that individual-level acquired immunity against malaria is maintained for some period of
time even if all malaria parasites are eradicated from the host. All simulations are performed
using parameter values given in Table 5.9.
Similarly, the density of sporozoites declines rapidly when Re f f = R01 < 1, leading to
a corresponding decrease in the density of infected hepatocytes as shown in Figure 5.4.
The malaria-persistent steady state, Ep = (S∗,H∗,X∗,R∗,T ∗,M∗,G∗,W ∗n ,W
∗
a ) = (10
3,3×
105,3×103,5×106,5×103,103,5×102,5×103,5×103) is shown to be stable when Re f f
is greater than unity, Re f f = 1.3364 > 1 (see Figures 5.7 and 5.6). It is observed that
the densities of sporozoites, merozoites, gametocytes, infected hepatocytes and infected
erythrocytes grow and persists both at the pre-erythrocytic and blood stages of parasite
development.






























































Figure 5.6: When the effective reproduction number Re f f = 1.3364 > 1, the malaria-
persistent equilibrium Ep is stable.
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Figure 5.7: When the effective reproduction number Re f f = 1.3364 > 1, the malaria-
persistent equilibrium point Ep is stable for the chosen set of parameter values. The model
parameter values are shown in Table 5.9 and R(0) = 5×106.
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5.7 Multi-component and multi-stage vaccine cocktail
The need to develop a multi-component and multi-stage P. falciparum malaria vaccine with
sufficient prospect to minimise the severity of malaria infection from human host is illustrated.
Several strategies have been considered in the development of efficient multi-component
and multi-stage P. falciparum vaccine formulations (Doolan and Hoffman, 2001; Pan et al.,
2004; Rampling et al., 2016; Stoute et al., 1997; Stowers et al., 2002; White and Smith,
2013). A synthetic peptide (SPf66) that combines antigens from the blood stages of malaria
linked together with an antigen from the sporozoite stage reduced the number of first attacks
with P. falciparum by 28% in South America (Graves and Gelband, 2006). High level of
sterile efficacy and safety of combining pre-erythrocytic vaccine RTS,S/AS01B with vectored
vaccines were reported by Rampling et al. (2016).
P. falciparum chimeric protein 2.9 which is a combination of the C-terminal regions of
domain III of AMA-1 and 19-kDa of MSP1 induced both anti-MSP1–19 and anti-AMA-
1(III) Abs at levels 11- and 18-fold higher, respectively, than individual components did (Pan
et al., 2004). Studies in Faber et al. (2013) have also shown that a combination of multiple
vaccine candidates in fusion proteins may lead to improved characteristics of the vaccine.
Synergism from combination of transmission blocking vaccines is shown in (White and
Smith, 2013) to confer protection by simultaneously inducing multiple, independent immune
responses directed towards P. falciparum sporozoites. This ensures high levels of vaccine
efficacy against the parasite. The need for multi-stage malaria vaccine is also emphasised
in (Doolan and Hoffman, 2001) where DNA vaccines are shown to have high capacity to
induce CD8+ cytotoxic T lymphocytes and interferon-gamma responses in humans during P.
falciparum infection (Tuteja, 2002).
From these studies, it is evident that a multi-stage specific vaccine cocktail has the potential
to prevent initial malaria infection at the pre-erythrocytic stage, reduce or eradicate clinical
manifestation and prevent the transmission of gametocytes from infected human hosts to
susceptible feeding female Anopheles mosquitos (Boes et al., 2015). Therefore, effects of
malaria vaccine combinations on the severity of P. falciparum malaria infection are evaluated
numerically. The vaccines are broadly categorised as: pre-erythrocytic vaccines, blood
stage vaccines and transmission blocking vaccines. The vaccines are assumed to have an
optimal efficacy of 75%. This figure chosen is in consistency with the WHO strategic goal of
developing a P. falciparum vaccine with atleast 75% efficacy (MVFG, 2018).
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Results in Figure 5.8, show the effects of all the three vaccines combined with a constant
optimal efficacy of 75%. The simulations here were performed in Matlab software. A
sample code is presented in Appendix B. The density of infected erythrocytes T and infected
hepatocytes X is shown to fall significantly. The severity of malaria infection is therefore
highly reduced when the three efficacious vaccine antigens are combined.




























T(t) with e = v =  = 75%
(a)




















X(t) with e = v =  = 75%
X(t) without vaccines
(b)
Figure 5.8: Impact of a 75% efficacious combined malaria vaccines (pre-erythrocytic vaccine,
blood stage vaccine and transmission blocking vaccine) on the dynamics of infected erythro-
cytes T and infected hepatocytes X . The simulations are performed when R01 = 2.564 > 1,
and R02 = 5.564 > 1.
The use of only one vaccine is shown in Figures 5.9, 5.10 and 5.11 to have minimal effects
on the severity of malaria infection.
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T(t) with e = v = 0% and  = 75%
T(t) with e = v =  = 75%
(a)






























X(t) with e = v = 0% and  = 75%
X(t) with e = v =  = 75%
(b)
Figure 5.9: Impact of a 75% efficacious transmission blocking vaccine (TBV) on the dynam-
ics of infected erythrocytes and infected hepatocytes. The simulations are performed when
R01 = 2.564 > 1, and R02 = 5.564 > 1.




























T(t) with  = e = 0% and v = 75%
T(t) with e = v =  = 75%
(a)






























X(t) with  v = 75% and e=  = 0%
X(t) with e = v =  = 75%
(b)
Figure 5.10: Impact of a 75% efficacious pre-erythrocytic vaccine (PEV) on the dynamics
of infected erythrocytes and infected hepatocytes. The simulations are performed when
R01 = 2.564 > 1, and R02 = 5.564 > 1.
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T(t) with  = v = 0% and e = 75%
T(t) with e = v =  = 75%
(a)






























X(t) with  = v = 0% and e = 75%
X(t) with e = v =  = 75%
(b)
Figure 5.11: Impact of a 75% efficacious blood stage vaccine (BSV) on the dynamics
of infected erythrocytes and infected hepatocytes. The simulations are performed when
R01 = 2.564 > 1, and R02 = 5.564 > 1.
Finally, a combination of any two vaccines (with different antigens) is likely to moderately
reduce the severity of malaria infection. The effects of paired - vaccine combinations are as
shown in Figures 5.12, 5.13 and 5.14. Unlike infected hepatocytes, transmission blocking
vaccines are shown to have minimal effects on the density of infected red blood cells (see
Figure 5.10).




























T(t) with  = v = 75% and e = 0%
T(t) with e = v =  = 75%
(a)































X(t) with  = v = 75% and e = 0%
X(t) with e = v =  = 75%
(b)
Figure 5.12: The effect of combining a pre-erythrocytic vaccine (PEV) and a trasmission
blocking vaccine (TBV) that are both 75% efficacious on the dynamics of infected erythro-
cytes and infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and
R02 = 5.564 > 1.
134




























T(t) with e =  = 75% and v = 0%
T(t) with e = v =  = 75%
(a)































X(t) with e =  = 75% and v = 0%
X(t) with e = v =  = 75%
(b)
Figure 5.13: The effect of combining a trasmission blocking vaccine (TBV) and a blood
stage vaccine (BSV) that are both 75% efficacious on the dynamics of infected erythrocytes
and infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and
R02 = 5.564 > 1.




























T(t) with  v = e = 75% and  = 0%
T(t) with e = v =  = 75%
(a)































X(t) with  v = e = 75% and  = 0%
X(t) with e = v =  = 75%
(b)
Figure 5.14: The effect of combining a blood stage vaccine (BSV) and a pre-erythrocytic
vaccine (PEV) that are both 75% efficacious on the dynamics of infected erythrocytes
and infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and
R02 = 5.564 > 1.
A combination of an efficacious pre-erythrocytic vaccine and an effective blood stage vaccine
antigens has the potential to significantly reduce malaria severity as shown in Figure 5.14.
Moreover, a combination of antigens from transmission blocking vaccine and those of
pre-erythrocytic vaccine at the liver stage, as shown in Figure 5.12b, are very effective in
suppressing the density of infected hepatocytes in the liver.
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5.8 Conclusion
Results of uncertainty and sensitivity analysis have significant epidemiological importance
in malaria control. The in-host malaria model presented in system (5.1) is shown to be
sensitive to variations in vaccine efficacies χ,ϱ and ν . Only efficacious malaria vaccines
have a chance to eradicate P. falciparum malaria or to reduce its severity significantly during
clinical infection. Sensitivity indices based on the effective reproduction number indicate
that the rate of invasion of susceptible erythrocytes by merozoites βr and the rate of invasion
of liver hepatocytes by sporozoites βs are highly sensitive to malaria disease progression.
Malaria vaccines must therefore target and eradicate the infective parasites and infected cells.
Other parameters such as the proportion of merozoites that become gametocytes per dying
infected erythrocyte π and the average number of merozoites released per bursting erythrocyte
P are also shown to have a considerable impact on Re f f and hence the severity of infection.
A highly efficacious blood stage vaccine has a potential to greatly reduce the density of
malaria gametocytes in blood. This reduces malaria transmission from the human host to the
mosquito vector. Given the protective capacity of liver stage- specific CD8+ T cells (Villarino
and W Schmidt, 2013), a lot more research that focuses on developing an efficacious blood
stage vaccine that would prime blood trophozoite-specific CD8+ T cells is called for. The
parameter τ which accounts for vaccine-induced production of CD8+ T cells is shown to
have significant negative effects on the density of infected hepatocytes. The more efficient
the pre-erythrocytic vaccine is, the lower the density of released merozoites into the host’s
blood.
Moreover, a rapid eradication of parasitised liver hepatocytes is likely to result into less
infected erythrocytes at the blood stage. An efficacious pre-erythrocytic vaccines has a
potential to eradicate infected liver hepatocytes. Such liver stage vaccines may also reduce
the overall burst size of an infected hepatocyte, leading to reduced erythrocytic schizogony
and hence the severity of clinical P. falciparum malaria.
Multiple combination of malaria vaccine antigen has a great potential of reducing the severity
of malaria infections due to P. falciparum. The synergy of combining pre-erythrocytic
vaccines, blood stage vaccines and transmission blocking vaccines antigens induces multiple
immune responses with the potential to prevent or eradicate malaria infection. As highlighted
in Kumar (2007), this study shows that a highly effective vaccine combination is critical for
P. falciparum malaria disease elimination goal.
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Although efficacious malaria vaccines are shown to be very effective in reducing severity
of clinical malaria, the results from this study further confirm the need to combine vaccine
with existing antimalarial therapy to achieve a complete eradication of the parasites from
the host. Moreover, the LHS/PRCC analysis revealed that the prediction imprecision was
mainly due to certain key parameters. Long term precise predictions of the density of infected
liver hepatocytes and infected erythrocytes would be difficult until these key parameters are
correctly determined. A great understanding of parameter uncertainty and sensitivity analysis
of in-host malaria in humans is therefore necessary in order to develop effective vaccines
against P. falciparum pathogens.
In the next Chapter 6, the impact of multiple-strains of P. falciparum infections on the severity




Multiple-strain infection and resistance
to antimalarial therapy: A mathematical
modelling perspective
6.1 Introduction
The emergence of parasite resistance (Dondorp et al., 2010; Maude et al., 2009; Sidhu et al.,
2002; Wellems and Plowe, 2001) to antimalarial drugs has contributed significantly to human
mortality and morbidity due to malaria infection, worldwide (Smith et al., 2010; Snow et al.,
2001; White, 1999). A global malaria control strategy of 1992 (WHO, 1993) that advocated
for early diagnosis and prompt treatment has been heavily compromised by the emergence
of parasite resistance to antimalarial drugs. The evolution of parasite resistance has been
described in Kim and Schneider (2013) as an example of a Darwinian evolution. Parasites
undergo mutations in their genome in response to drug-treated human host. These mutations
reduce the rate of parasite elimination from the host and increases their survival chances
(Kim and Schneider, 2013).
The most extensively used antimalarial drugs against the deadly P. falciparum malaria are
Chloroquine (CQ) and Sulfadoxine-pyrimethamine (SP) (Talisuna et al., 2004; White and
Pongtavornpinyo, 2003). These drugs are cheap, easily available and slowly eliminated
from the human body (White and Pongtavornpinyo, 2003). However, the extensive use of
CQ and SP resulted into P. falciparum resistance. This led to global increase in malaria
cases and mortality (Trape et al., 1998). In 2006, the World Health organization (WHO)
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recommended the use of artemisinin-based combination therapies (ACTs) as a first-line
treatment for uncomplicated P. falciparum malaria (WHO, 2015c).
Resistance to ACTs which are currently the standard treatment for uncomplicated P. falci-
parum is likely to cause global health crisis especially in African region where P. falciparum
malaria is endemic (Ashley et al., 2014; Ouji et al., 2018). The Global Technical Strategy for
Malaria 2016-2030 calls on countries and global malaria partners to monitor the efficacy of
antimalarial medicines so that the most appropriate treatments can be selected for national
policies (WHO, 2018f).
In this chapter, the effects of parasite resistance to antimalarial drugs are investigated by
extending the in-host malaria model by Anderson et al. (1989). The malaria parasites are
categorised into drug-sensitive strain and drug-resistant strain. The impact of multi-strain
infection on severity of the disease is investigated in the context of parasite resistance.
6.1.1 Parasite resistance to antimalarial drugs
The emergence of parasite resistance to malaria therapy dates back to the 19th century.
Quinine (introduced in 1820) was the first-line antimalarial drug against P. falciparum
(Dobson, 2001). High mortality cases coupled with high parasite resistance led to the
introduction of a second drug, chloroquine (CQ) in 1934 (Thompson and Leslie, 1972). A
decade later, CQ was considered the first-line antimalarial drug by several countries until
1957, when the first foci of P. falciparum resistance was detected along Thai-Cambodia
border (Harinasuta et al., 1965). In Africa, CQ resistance to P. falciparum was first discovered
among travelers from Kenya to Tanzania (Fogh et al., 1979). By 1983, CQ resistance had
spread to Sudan, Uganda (Onori, 1984), Zambia (Ekue et al., 1983) and Malawi (David et al.,
1984).
CQ was replaced for the first time with Sulfadoxine-pyrimethamine (SP) as a first line
antimalarial drug in Thailand in 1967. Several other countries in Asia and South America
followed thereafter (Talisuna et al., 2004). Resistance to SP was however reported the same
year (Wernsdorfer and Payne, 1991) in the region. In 1988, CQ was replaced for the first time
in Africa. South Africa replaced CQ with SP (Bredenkamp et al., 2001). In 1993, Malawian
government changed the treatment policy from CQ to SP. Other African countries followed
thereafter: Kenya, South Africa and Botswana (in 1998); Cameroon, Tanzania (in 2001) and
Zimbabwe (in 2000) (Bloland et al., 1993). The effectiveness of SP was equally undermined
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by resistance. Unlike CQ, P. falciparum resistance to SP was mainly attributed to the long
half-life of the drug (Foote and Cowman, 1994).
Confirmed resistance to the artemisinin derivatives was first reported in Cambodia and
Mekong regions (CMR) in 2008 (WHO, 2016a). The number of ACTs with high failure
rates in CMR is presented in Figure 6.1. Artemisinin resistance is characterised by slow
parasite clearance (WHO, 2018f). To leverage on parasite resistance, cost of treatment and
burden of malaria infection to communities and governments, the WHO recommends the
use of artemisinin-based combination therapy (ACTs) as the first and second-line treatment
drugs for uncomplicated P. falciparum malaria (WHO, 2016a). ACT is a combination of
artemisinin derivative and a partner monotherapy drug. Artemisinin derivatives include
artemether, artesunate and dehydroartemisinin. These derivatives reduce the parasite biomass
within the first three days of therapy while the partner drug, with longer half-life, eliminates
the remaining parasites (WHO, 2018e).
Figure 6.1: Number of artemisinin-based combination therapies (ACTs) with high failure
rates in the treatment of P. falciparum infections. Source: WHO (2018f).
Currently, WHO recommends five different ACTs: (1) Artesunate-amodiaquine (AS+AQ),
(2) artesunate-mefloquine (AS+MQ), (3) artesunate+sulfadoxine-pyrimethamine (AS+SP),
(4) artemether-lumefantrine (AM-LM) and (5) dihydroartemisinin-piperaquine (DHA+PPQ).
Additionally, artesunate-pyronaridine (AS+PY) which has received a positive scientific
opinion from the European Medicines Agency (EMA) maybe used in regions where ACT
treatment response is low (WHO, 2018e). Access to ACT has been tremendous in the
last 8 years; with recorded increases of 122 million procured treatment courses for the
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period 2010-2016. However, resistance to currently used ACTs have important public health
consequences, especially in the African region, where resistant P. falciparum is predominant.
Numerous cross-sectional studies (Bushman et al., 2016; Harrington et al., 2009) have
revealed the possible impact of multiple-strains of P. falciparum in the development of
resistance to ACTs. In Bushman et al. (2018) and citations therein, drug-sensitive parasites
are shown to strongly suppress the growth and transmission of drug-resistant P. falciparum
parasites. Although high transmission settings such as sub-Saharan Africa account for about
90% of all global malaria deaths, resistance to antimalarial drugs have been shown to emerge
from low transmission settings, such as Southeast Asia and South America (Bushman et al.,
2018).
Causes of parasite resistance to ACTs are diverse. Historical studies (Mita et al., 2009;
Vinayak et al., 2010) indicate that antimalarial-resistant parasites could emerge from a
handful of lineages. It is argued elsewhere (Hastings and Watkins, 2005; Talisuna et al., 2003)
that recombination during sexual reproduction in the mosquito vector could be responsible
for the delayed appearance of multi-locus resistance in high-transmission regions. Moreover,
owing to repeated exposure for many years, individuals in high-transmission settings are
likely to develop clinical immunity to malaria, leading to stronger selection for resistance
(Klein et al., 2008). Studies in Bushman et al. (2018) also support the hypothesis that in-host
competition between drug-sensitive and drug-resistant parasites could inhibit the spread of
resistance in high transmission settings. Owing to their integral role in the recent success of
global malaria control, the protection of efficacy of ACTs should be a global health priority
(WHO, 2017b).
Mathematical models of in-host malaria epidemiology and control constitute important
tools in guiding strategies for malaria control (McKenzie, 2000; McKenzie and Samba,
2004) and the associated financial planning (Coleman et al., 2004). While some researchers
have focussed on probabilistic models (Hastings, 1997; Mackinnon, 2005), others have
investigated the effects of drug treatment and resistance development using deterministic
models (Aneke, 2002; Koella and Antia, 2003). A deterministic model by Esteva et al. (2009)
monitored the impact of drug resistance on the transmission dynamics of malaria in a human
population. In Bushman et al. (2018), the impacts of within-host parasite competition is
shown to inhibit the spread of resistance (Klein et al., 2012; Legros and Bonhoeffer, 2016).
On the contrary, some models (Hastings, 1997; Wargo et al., 2007) have suggested that
within-host competition is likely to speed up the spread of resistance in high-transmission
settings due to a phenomenon called ‘competitive release’. In this chapter, theoretical insights
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using mathematical modelling of the impact of multiple-strain infections on resistance,
dynamics and antimalarial control of P. falciparum malaria are provided.
6.2 Model formulation
To investigate the effects of parasite resistance to antimalarial drugs and the impact of
multiple-strain infection on severity of the disease, the deterministic blood stage malaria
model by Anderson et al. (1989) is extended. This model considers the co-infection and
competition between the drug-sensitive (dss) and the drug-resistant (drs) P. falciparum strains
in the presence of antimalarial therapy. The drs arise presumably from the dss. The rare
mechanism here could possibly be due to single point mutation (zur Wiesch et al., 2011).
Both drs and dss initiate immune responses that follow density-dependent kinetics.
The model is composed of eight compartments: susceptible/healthy/unparasitised erythro-
cytes X(t), parasitised/infected erythrocytes (Yr(t) and Ys(t)), merozoites (Ms(t) and Mr(t)),
gametocytes (Gs(t) and Gr(t)) and immune cells W (t). The healthy red blood cells (RBCs)
make up the resource for competition between the drug-resistant strain and the drug-sensitive
strain. The infected red blood cells (IRBCs) and the different erythrocytic parasite life
cycles are categorised based on the strain of infecting parasite. The merozoites are there-
fore categorised into drug-sensitive strain and drug-resistant strain, denoted by Ms(t) and
Mr(t), respectively. The merozoites invade the healthy erythrocytes during erythrocytic
stage leading to formation of infected erythrocytes. The variable Ys(t) denotes the red blood
cells (RBCs) infected with drug-sensitive merozoites, whereas, Yr(t) refers to the RBCs
infected with drug-resistant merozoites. Similarly, the variables Gs(t) and Gr(t) represent
drug-sensitive and drug-resistant gametocytes, respectively. Owing to saturation in cell and
parasite growth, the nonlinear Michaelis-Mented-Monod function described in Agur et al.
(1989); Antia et al. (1994) and used in Cai et al. (2017); Chiyaka et al. (2008); Pilyugin and
Antia (2000); Selemani et al. (2017a), is considered to model the reductive effects of the
immune cells on the parasite and infected-cell populations.
The density of the healthy RBCs is increased at the rate λx per healthy RBC from the host’s
bone marrow and die naturally at a rate µx. Following parasite invasion by free floating
merozoites, the healthy erythrocytes get infected by both drug-sensitive and drug-resistant
merozoite strains at the rates β and δrβ , respectively. The parameter δr (with 0 < δr < 1)
accounts for the reduced fitness (infectiousness) of the resistant parasite strains in relation to
the drug-sensitive strain. The destruction of the healthy red blood cells is however limited
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by the adaptive immune cells W . This is represented by the term 1/(1+ γW ), where γ is a
measure of the efficacy of the immune cells. The equation that governs the evolution of the
healthy RBCs is hence given by
dX
dt




The infected red blood cells are generated through mass action contact (invasion) between
the healthy erythrocytes X and the blood floating merozoites (Mr and Ms). The merozoites
subdivide mitotically, within the infected erythrocytes, into thousands of other merozoites
leading to cell-burst and emergence of malaria characteristic symptoms. Additionally, a
single infected erythrocyte undergoes hemolysis at the rate µys to produce P secondary
merozoites, sustaining the erythrocytic cycle. The drug-sensitive IRBCs (Ys) burst open to
generate more drug-sensitive merozoites or drug-sensitive gametocytes at the rate σs.
Similar dynamics are observed with the drug-resistant IRBCs, where the drug-resistant
gametocytes are generated at the rate σr from IRBCs. Treatment with ACT is assumed
to inhibit the development of the merozoite within the infected erythrocyte. The drug-
infested erythrocytes are hence likely to die faster. This is represented by the term (1−
ωs)
−1, where 0 < ωs < 1 represents the antimalarial-specific treatment efficacy. In this
chapter and for purposes of illustration and simulations, ωs, corresponds to the efficacy
of artemether-lumefantrine (AL), which is the recommended first-line antimalarial ACT
drug for P. falciparum infection in Kenya. It is assumed that no treatment is available for




















The drug-resistant merozoites Mr and the drug-resistant gametocytes Gr die naturally at the
rates µmr and µgr, respectively. It is further assumed that drug sensitive merozoites Ms and
gametocytes Gs may develop into drug-resistant merozoites Mr and gametocytes Gr at the
rates Ψ1 and Ψ2, respectively. The cost of resistance associated with AL is represented
by the parameter αs. Parasite resistance to antimalarial drugs exacerbates the erythrocytic
cycle and increases the cost of treatment (De Roode et al., 2004; Hayward et al., 2005). The
higher the resistance to antimalarial therapy, the higher the density of malaria parasites in
blood. Therefore, this decline in drug effectiveness is modelled by re-scaling the density of
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merozoites released per bursting infected erythrocyte P by the factor (1−αs), where αs = 1
implies no resistance, that is, the ACT is highly effective in eradicating the parasites. αs = 0
corresponds to maximum resistance; and the used ACT drug is least effective in treating
the infection. The converse of these descriptions applies to the drug-resistant P. falciparum
parasite strain. The equations that govern the rate of change of the infected red blood cells








− (Ψ1 +µms +ζ )Ms, (6.4)
dMr
dt











− (Ψ2 +µgs +η)Gs, (6.6)
dGr
dt




Antimalarial therapy increases the rate of elimination of drug-sensitive merozoites and
gametocytes. This is represented by the nonnegative enhancement parameters ζ and η ,
respectively. Although the innate immunity is faster, it is often limited by the on and off rates
in its response to invading pathogens (Doolan et al., 2009; Liehl et al., 2015). The adaptive
immunity on the contrary, is very slower at the beginning but lasts long enough to ensure
no parasite growth in subsequent infections (Bushman et al., 2016). It is assumed that the
immune cells are independent of the invading parasite strain. For simplicity, we consider
the adaptive immune system, which is mainly composed of the CD8+T cells (Villarino and
W Schmidt, 2013).
The assumption that the background recruitment of immune cells is constant (at the rate λw)
is adopted. Additionally, the production of the immune cells is assumed to be boosted by
the infective and infected cells (Gr,Gs), (Mr,Ms) and (Yr,Ys) at constant rates hg, hm and hy,
respectively. Circulating gametocytes, infective merozoites and infected erythrocytes are thus
removed phagocytotically by the immune cells at the rates kgW , kmW and kyW , respectively.
The immune cells also get depleted through natural death at the rate µw. The equation for the






Gs +Gr + eg
+
hy(Ys +Yr)
Ys +Yr + ey
+
hm(Ms +Mr)
Ms +Mr + em
}
W −µwW. (6.8)
Following invasion by the merozoites, the IRBCs either produce merozoites or differentiate
into gametocytes upon bursting. The total erythrocyte population at any time t, denoted by
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C(t) is therefore given by
C(t) = X(t)+Ys(t)+Yr(t). (6.9)
Similarly, the sum total of P. falciparum parasites, denoted by L(t) within the host at any
time t is described by the following equation:
L(t) = Ms(t)+Mr(t)+Gs(t)+Gr(t). (6.10)
The above dynamics can be represented by the schematic diagram shown in Figure 6.2. The
list of model variables and parameters are provided in Tables 6.1 and 6.3, respectively.
Figure 6.2: A model flow diagram. Drug-sensitive variables are shown in green colours while
the drug-resistant variables are indicated in orange colours. Non-strain specific variables like
susceptible red blood cells (RBCs) and immune cells are shown in blue colour. Solid lines
indicate the movement of populations from one compartment to another. Dotted lines show
possible interactions between the different populations.
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Table 6.1: Description of the state variables of model (6.11).
Variable Description
X Population of uninfected/unparasitised red blood cells (erythrocytes)
Ys Population of red blood cells infected by drug-sensitive merozoites
Yr Population of red blood cells infected by drug-resistant merozoites
Ms Population of drug-sensitive merozoites
Mr Population of drug-resistant merozoites
Gs Population of drug-sensitive gametocytes
Gr Population of drug-resistant gametocytes
W Population of strain-independent immune cell
Table 6.2: Description of model parameters
Parameter Description
λx The rate of recruitment of red blood cells
ωs Antimalarial treatment efficacy
αs Fitness cost associated with drug-sensitive merozoites Ms
αr Fitness cost associated with drug-resistant merozoites Mr
λw Background recruitment rate of immune cells
eg,em,ey Hill parameters in Gi, Mi and Yi dynamics (i = s,r)
µx Per capita natural mortality rate of unparasitised erythrocytes
µys Natural mortality rate of drug-sensitive IRBCs
µyr Natural death rate of drug-resistant IRBCs
ζ Rate of eradication of drug-sensitive merozoites by antimalarial drugs
η Rate of eradication of drug-sensitive gametocytes by antimalarial drugs
µms Death rate of drug-sensitive merozoites
µmr Mortality rate of drug-resistant merozoites
µgs Per capita mortality rate of drug-sensitive gametocytes
µgr Mortality rate of drug-resistant gametocytes
µw Natural mortality rate of immune cells (CD8+T cells)
β The rate of infection of susceptible RBCs by blood floating merozoites
σr, σs Rate of formation of gametocytes from the infected RBCs
P Number of merozoites produced per dying infected RBC
hy Immune cells proliferation rate due to IRBCs
hm Immune cells proliferation rate due to asexual merozoites
hg Immune cells proliferation rate due to gametocytes
Continued on next page
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Table 6.2 – Continued from previous page
Parameter Description
ky Phagocytosis rate of IRBCs by immune cells
km Phagocytosis rate of merozoites by immune cells
kg Phagocytosis rate of gametocytes by immune cells
Ψ1 Rate of development of resistance by drug-sensitive merozoites
Ψ2 Rate of development of resistance by drug-sensitive gametocytes
δr Accounts for the reduced fitness of the resistant parasite strain
γ Efficiency of immune effector to inhibit merozoite infection
1/a Half-saturation constant for Y (t), M(t) and G(t)
In extending the deterministic blood stage malaria model by Anderson et al. (1989), following
model assumptions are made:
1. There are eight interacting populations of susceptible red blood cells, drug-sensitive
merozoites, drug-resistant merozoites, red blood cells infected with drug-sensitive
merozoites, red blood cells infected with drug-resistant merozoites, drug-sensitive
gametocytes, drug-resistant gametocytes and immune cells, at any given time t.
2. The drug-resistant strains of merozoites and gametocytes are assumed to arise presum-
ably from the drug-sensitive strains of merozoites and gametocytes, respectively.
3. Red blood cell infection is merozoite-strain dependent. The infected red blood cells
are hence categorised based on the infecting merozoite strain.
4. It is assumed that the drug-resistant merozoites have a lower rate of infection compared
to their drug-sensitive competitors.
5. The invasion of the red blood cells is limited by the adaptive immune cells.
6. Treatment using the ACT drug is assumed to inhibit merozoite development within
infected red blood cells.
7. Only drug-sensitive merozoites are targeted by antimalarial treatment.
8. The immune cells are assumed to be recruited at a constant rate from the bone marrow.
9. All model parameters are assumed non-negative.
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10. Generation of immune cells is stimulated by the presence of infected red blood cells,
merozoites and gametocytes.
Based on the above model descriptions, model assumptions and the schematic diagram

































− (Ψ1 +µms +ζ )Ms,
dMr
dt











− (Ψ2 +µgs +η)Gs,
dGr
dt









Gs +Gr + eg
+
hy(Ys +Yr)
Ys +Yr + ey
+
hm(Ms +Mr)





subject to the following initial conditions
X(0)> 0,Yi(0)≥ 0,Mi(0)≥ 0,Gi(0)≥ 0,W (0)> 0, for i = s,r.
6.3 Model analysis
6.3.1 Positivity and uniqueness of solutions
The consonance between a formulated epidemiological model and its biological reality is key
to its usefulness. Given that all the model parameters and variables are nonnegative, it is only
sound that the model solutions be positive at any future time t ≥ 0 within a given biological
space.
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Theorem 6.1. The region R8+ with solutions of system (6.11) is positively invariant under
the flow induced by system (6.11).
Proof: We need to show that every trajectory from the region R8+ will always remain within
it. By contradiction, assume ∃t∗ (where t∗ refers to time) in the interval [0,∞), such that
X(t∗) = 0, X ′(t∗) < 0 but for 0 < t < t∗, X(t) > 0, and Yi > 0, Mi > 0, Gi > 0, and Wi > 0
for i = {r,s}. Notice that at t = t∗, X(t) is declining from the original zero value. If such as







= λx > 0. (6.12)
This is a contradiction i.e. X ′(t∗)> 0. It shows the nonexistence of such t∗. This argument
can be extended to all the remaining seven variables (Ys,Yr,Ms,Mr,Gs,Gr,W ). The process of
verification is however simpler. The steps as presented in Chiyaka et al. (2009) are followed.
Let the total erythrocyte population C(t) evolve according to the following formulation:
dC
dt









≤ λx −µcC, (6.13)




≤ P{(1−αs)µysYs +(1−αr)µyrYr}+σsYs +σrYr −µpL, (6.14)
where µp = min{µms,µmr,µgs,µgr}.
The solution of the last equation in system (6.11) together with those of equations (6.13) and




















































Here, C(0) = X(0)+Ys(0)+Yr(0) and L(0) = Ms(0)+Mr(0)+Gs(0)+Gr(0) represents
the initial total populations of erythrocytes and malaria parasites, respectively. It is observed
that the solutions of W (in system (6.11)), C (in inequality (6.13)) and P (in inequality
(6.14)) remain nonnegative for all future time t ≥ 0. Moreover, the total populations are
bounded: 0 ≤C(t)≤ max{C(0),(λx/µc)}, 0 ≤W (t)≤ max{W (0),λw/µw)} and L(t)≤
max{L(0),(((σs +σr)µp)/((P(1−αs)µys +P(1−αr)µyr))}. Thus, all the state variables
of system (6.11) and all their corresponding solutions are nonnegative and bounded in the
phase space ϕ , where
ϕ =
{
(X ,Ys,Yr,Ms,Mr,Gs,Gr,W ) ∈ R8+ : C(t)≤ max{C(0),(λx/µc)},








It is obvious that ϕ is twice continuously differentiable function. That is, ϕi ∈ C2. This is
because its components ϕi,1 ≤ i ≤ 8 are rational functions of state variables that are also
continuously differentiable functions. In conclusion, the domain ϕ is positively invariant. It
is therefore feasible and biologically meaningful to study system (6.11).
Theorem 6.2. The system (6.11) has a unique solution
Proof: Let x = (X ,Ys,Yr,Ms,Mr,Gs,Gr,W )T ∈ R8+, so that x1 = X and x2 = Ys as presented
in system (6.11). Similarly, let g(x) = (gi(x), i = 1, · · · ,8)T be a vector defined in R8+. The
system (6.11) can hence be written as
dx
dt
= g(x), x(0) = x0, (6.18)
where x : [0,∞)→R8+ denotes a column vector of state variables and g : R8+ →R8+ represents
the right-hand side (RHS) of system (6.11). The result is as follows.
Lemma 6.1. The function g is continuously differentiable in x
Proof: All the terms in g are either linear polynomials or rational functions of nonvanishing
polynomials. Since the state variables (X ,Ys,Yr,Ms,Mr,Gs,Gr,W ) are all continuously
differentiable functions of t, it follows that all the elements of vector g are continuously
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differentiable. Moreover, let V (x,n,θ) = {x+ θ(n− x) : 0 ≤ θ ≤ 1}. By mean value
theorem,
||g(n)−g(x)||∞ = ||g′(m,n−x)||∞, (6.19)
where m ∈V (x,n,θ) denotes the mean value point and g′ the directional derivative of the










where ei is the ith coordinate unit in R8+. It is easy to see that all the partial derivatives of g
are bounded and that there exists a nonnegative M, such that∥∥∥∥∥ 8∑i=1(▽gi(m)
∥∥∥∥∥
∞
≤ M for all m ∈V. (6.21)
Therefore, there exists M > 0 such that
||g(n)−g(x)||∞ ≤ M||n−x||∞. (6.22)
This shows that the function g is Lipschitz continuous. Since g is Lipschitz continuous, it
follows that system (6.11) has a unique solution by uniqueness theorem of Picard (Hale,
1969).
6.3.2 Stability analysis of the parasite-free equilibrium point (PFE)
The in-host malaria dynamics are investigated by studying the behaviour of the model at
the different model equilibrium points. Knowledge of model equilibrium points is useful in
establishing parameters that drive the infection to different stability points. System (6.11)
has a parasite-free equilibrium point E0 given by









Using the next generation operator method by Van den Driessche and Watmough (2002) and
the matrix notations therein, a nonsingular matrix Q showing the terms of transitions from
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0 0 βλxµw(γλw+µw)µx 0 0 0
0 0 0 δrβλxµw(γλw+µw)µx 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0






v1 0 0 0 0 0
0 v2 0 0 0 0
−P(1−αs)µys 0 v3 0 0 0
0 −P(1−αr)µyr −Ψ1 v4 0 0
−σs 0 0 0 v5 0
0 −σr 0 0 −Ψ2 v6

, (6.25)
where v1 = ((kyλw/µw)+σs +µys/(1−ωs)), v2 = ((kyλw/µw)+σr +µyr),
v3 = (ζ + µms + Ψ1 + (kmλw/µw) + (βλxµw/(γλw + µw)µx)) v4 = (µmr + (kmλw/µw) +
(δrβλxµw/(γλw +µw)µx), v5 = (η +µgs +(kgλw/µw)+Ψ2) and v6 = (µgr +(kgλw/µw)).
The effective reproduction number RE associated with the parasite-free equilibrium is the





0 0 0 0 0
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From equation (6.27), it is evident that in a multiple-strain P. falciparum malaria infection,
the progression of the disease depends on the effective reproduction numbers of the different
parasite strain. If the threshold quantity Rs > Rr, the drug-sensitive parasite strain will
dominate the drug-resistant strain. To manage the infection in this case, the patient should be
given antimalarials that can eradicate the drug-sensitive parasites. Conversely, if Rr > Rs,
the infection is mainly driven by the drug-resistant parasite strain. In this scenario, the
used antimalarial drugs should be highly efficacious and effective enough to kill both the
drug-resistant strain and the drug-sensitive parasite strain in the blood of the human host. This
result is quite instrumental in improving antimalarial therapy for P. falciparum infections.
The best antimalarials should be sufficient enough to eradicate both drug-sensitive and
drug-resistant parasite strain within the human host.
The following lemma is based on Theorem 2 in Vannice et al. (2012).
Lemma 6.2. The parasite-free equilibrium point E0 is locally asymptotically stable if RE < 1
(Rs < 1 and Rr < 1) and unstable otherwise.
The Jacobian matrix associated with system (6.11) at E0 is given by
JE0 =





0 −v1 0 βλxµw(γλw+µw)µx 0 0 0 0
0 0 −v2 0 βλxµw(γλw+µw)µx 0 0 0
0 P(1−αs)µys 0 −v3 0 0 0 0
0 0 P(1−αr)µyr Ψ1 −v4 0 0 0
0 σs 0 0 0 −v5 0 0
















where the terms v1, · · ·v6 are as defined in matrix (6.25). It is clear from matrix (6.30) that the
first four eigenvalues are −µx (from column 1), −µw (from column 8), −(µgr + kgλwµw ) =−v6
(from column 7), −(η + µgs + kgλwµw ) = −v5 (from column 6). They are all negative. The
remaining four eigenvalues are obtained from the roots of the following quartic equation:
P(λ ) = λ 4 + p1λ 3 + p2λ 2 + p3λ + p4, (6.31)
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where
p1 =(v1 + v2 + v3 + v4)> 0, (6.32)




















Due to complexity in the coefficients of the characteristic (6.31), the Routh-Hurwitz stability
criterion (Allen, 2007) provides sufficient condition for the existence of the roots of the given
polynomial on the left half of the plane.
Definition 6.1. The solutions of the characteristic equation (6.31) are negative or have
negative real parts provided that the determinants of all Hurwitz matrices are positive (Allen,
2007).
Based on the Routh-Hurwitz criterion, the system of inequalities that describe stability region
E0 is presented as follows:
(i) p1 > 0, (ii) p3 > 0, (iii) p4 > 0, and (iv) p1 p2 p3 > p23 + p
2
1 p4.
From equation (6.32), it is clear that p1 > 0. Upon simplifying p2 in equation (6.33), then













where B1 =−P(1−αs)µys and B2 =−P(1−αr)µyr.Thus,











= (v1 + v3)(v2 + v4)+ v1v3[1−Rs]+ v2v4[1−Rr]> 0 if and only if Rs,Rr < 1.
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= v1v3[1−Rs]v2v4[1−Rr]> 0 if and only if Rs,Rr < 1. (6.38)
Simplifying equation (6.34) gives

















































= v1v3(v2 + v4)[1−Rs]+ v2v4(v1 + v3)[1−Rr]> 0, if and only if Rs,Rr < 1. (6.39)
Since all the coefficients of the characteristic equation (6.31) are nonnegative, all its roots
are therefore negative or have negative real parts. Hence, the Jacobian matrix (6.30) has
negative eigenvalues or eigenvalues with negative real parts if and only if the effective
reproduction number RE is less than unity. The equilibrium point E0 is therefore locally
asymptotically stable when RE < 1 (when both Rs < 1 and Rr < 1). This implies that an
effective antimalarial drug would cure the co-strain infected human host, provided that the
drug reduces the effective reproduction number to less than 1.
Lemma 6.2 shows that P. falciparum malaria can be eradicated/controlled within the human
host if the initial parasite and cell populations are within the basin of attraction of the trivial
equilibrium point E0. To be certain to eliminate the infection irrespective of the initial
parasite and cell populations, it is necessary to prove the global stability of the parasite-free
equilibrium point. This is presented in the following subsection.
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6.3.3 Global asymptotic stability analysis of the PFE point
Following the work by Kamgang and Sallet (2005), the system (6.11) is rewritten in pseudo-
triangular form:




where X1 is a vector representing the densities of noninfective population groups (unpara-
sitised erythrocytes and immune cells) and X2 represents the densities of infected/infective
groups (infective P. falciparum parasites and/or infected host cells) that are responsible for
disease transmission. For purposes of clarity, (X1,0) is represented with X1 and (0,X2) with
X2 in R8+×R8+. Assume the existence of a parasite-free equilibrium in ϕ : X∗ = (X∗1 ,0).
Thus,










System (6.40) is analysed based on the assumption that it is positively invariant and dissipative
in ϕ . Moreover, the subsystem X1 is globally asymptotically stable at X∗1 on the projection
of ϕ on R8+. This implies that whenever there are no infective malaria parasites, all cell
populations will settle at the parasite-free equilibrium point E0. Finally, D2 in system (6.40)
is a Metzler matrix that is irreducible for any X ∈ ϕ . It is assumed that adequate interactions
between and among different parasites and cell compartments exist in the model.




























It is easily seen that the eigenvalues of matrix D1 are both real and negative (−µx < 0,
−µw < 0). This shows that the subsystem Ẋ1 = D1(X)(X −X∗1 ) +D2(X)X2 is globally
asymptotically stable at the trivial equilibrium X∗1 . Additionally, from subsystem Ẋ2 =
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D3(X)X2, the following matrix is obtained.
D3(X) =

−v1 0 βλxµw(γλw+µw)µx 0 0 0
0 −v2 0 βλxµw(γλw+µw)µx 0 0
P(1−αs)µys 0 −v3 0 0 0
0 P(1−αr)µyr Ψ1 −v4 0 0
σs 0 0 0 −v5 0
0 σr 0 0 Ψ2 −v6

. (6.45)
Notice that all the off-diagonal entries of D3(X) are nonnegative (equal to or greater than
zero), showing that D3(X) is a Metzler matrix. To show the global stability of the parasite-
free equilibrium E0, it is necessary to show that the square matrix D3(X) in (6.45) is a
Metzler stable. We therefore need to prove the following lemma.







where K11 and K22 are square matrices. The matrix K is Metzler stable if and only if K11
and K22 −K21K−111 K12 are Metzler stable.
Proof:







 , K12 =




 0 P(1−αr)µyr Ψ1σs 0 0
0 σr 0
 , K22 =
 −v4 0 00 −v5 0
0 Ψ2 −v6
 . (6.48)




(γλw+µw)µxv1v3+Pβ (αs−1)λxµwµys 0 −
βλxµw
v1v3(γλw+µw)µx+Pβ (αs−1)λxµwµys









K22 −K21K−111 K12 =
 −v4 0 00 −v5 0
0 Ψ2 −v6
 , (6.50)
where v4 = (µmr+(kmλw/µw)+(δrβλxµw/(γλw+µw)µx)), v5 = (η+µgs+kgλw/µw+Ψ2)
and v6 = (µgr + kgλw/µw).
From equation (6.50), it is evident that all the diagonal elements of matrix K22 −K21K−111 K12
are negative and the rest of the elements in the matrix are nonnegative. This shows that matrix
K22 −K21K−111 K12 is Metzler stable, and the parasite-free equilibrium point E0 is globally
asymptotically stable in the biologically feasible region ϕ of system (6.11). Epidemiolog-
ically, the above result implies that when there is no malaria infection, the different cell
populations under consideration will stabilise at the parasite-free equilibrium. However,
if there exists a P. falciparum infection, then an appropriate control in form of effective
antimalarial drugs would be necessary to clear the parasites from the human blood and restore
the system to the stable parasite-free equilibrium state.
6.3.4 Coexistence parasite-persistant equilibrium point
The existence of a nontrivial equilibrium point represents a scenario in which the P. falciparum
parasites are present within the host and the following conditions hold: X∗ > 0,Y ∗s ≥ 0,Y ∗r ≥
0,M∗s ≥ 0,M∗r ≥ 0,G∗s ≥ 0,G∗r ≥ 0,W ∗ > 0. Equating the right-hand side of system (6.11)
to zero and solving for the state variables gives the parasite-persistent equilibrium point
E1 = (X∗,Y ∗s ,Y ∗r ,M∗s ,M∗r ,G∗s ,G∗r ,W ∗), where
X∗ =
(1+ γW ∗)λx
β (M∗s +δrM∗r )+(1+ γW ∗)µx





















−a(1−ωs)λx −ωsσs +σs +µys
)





(−(βM∗r δr +(γW ∗+1)µx)) , (6.53)




















µx +µx) , (6.56)
















< 0, b1 = aσ1Y ∗s −W ∗kg −η −µg1 −Ψ2
and c1 = σ1Y ∗s > 0. (6.59)
a2 =−aµg2 < 0, b2 = aG1Ψ2 +aσ2Y ∗r −W ∗kg −µg2












a3 =− (aβM∗r δr (ζ +µms +Ψ1)+aγW ∗µmsµx +aµmsµx +aβP(1−αs)µysY ∗s
+Ψ1 (a(γW ∗+1)µx +β )+aγζW ∗µx +aβλx +aζ µx +βζ
+βW ∗km +β µms)< 0, (6.62)
b3 =−βM∗r δr
(
a(αs −1)PY ∗s µys +ζ +W ∗km +µms +Ψ1
)
− (αs −1)βPY ∗s µys
−βλx − (γW ∗+1)µx
(




c3 =P(1−αs)Y ∗s µys (βM∗r δr +(γW ∗+1)µx)> 0, (6.64)
a4 =− (aβM∗s (Ψ1δr +µmr)+µmr (a(γW ∗+1)µx +βδr)+a(1−αr)βPY2δrµy2
+βW ∗kmδr)< 0, (6.65)
b4 =M∗s
(
−β (aδrλx +µmr)+a(1−αr)βPY2µy2 +Ψ1 (a(γW ∗+1)µx +βδr)
)
+(1−αr)PY2µy2 (a(γW ∗+1)µx +βδr)−W ∗km (βM∗s +(γW ∗+1)µx)





(1−αr)βPY2µy2 +βδrλx +Ψ1(γW ∗+1)µx
)




µw△0 − (hg(G∗s +G∗r )+hm(M∗s +M∗r )+hy(Y ∗s +Y ∗r ))
(6.68)
where △0 = (eg +G∗s +G∗r )(em +M∗s +M∗r )(ey +Y ∗s +Y ∗r ).
Using Descartes’ “Rule of Signs” (Wang, 2004), it is evident that irrespective of the sign
of b̄ in (6.53), b in (6.56), b1 in (6.59), b2 in (6.60), b3 in (6.63) and b4 in (6.66), the state










r can only have one real positive root. This shows that
the model (6.11) has a unique parasite-persistent equilibrium point E1.
6.3.5 Stability of the coexistence parasite-persistent equilibrium point
Here, we shall prove that the coexistence parasite-persistent equilibrium E1 is local asymp-
totically stable when RE > 1(or whenRs > 1andRr > 1). The methodology followed is by
Esteva and Vargas (2000) and is based on Krasnoselskii technique (Krasnoselskii, 1964). This
methodology requires to prove that the linearisation of system (6.11) about the coexistence
parasite-persistent equilibrium, does not have a solution of the form
S̄(t) = S̄0eξ t , (6.69)
where S̄0 = (S1,S2, · · · ,S7), (Si,ξ ) ∈ C and the real part of ξ is nonnegative, (Re(ξ ) ≥ 0).
Note that C is the set of complex numbers.
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Substituting a solution of the form of equation (6.69) into the linearised system (6.11) about


























































































ξ S7 =λ +
(
hg(Gs +Gr)
Gs +Gr + eg
+
hy(Ys +Yr)
Ys +Yr + ey
+
hm(Ms +Mr)





where (C∗−Ys −Yr) = X , k1 = (Ψ1 +µms +ζ ) and k2 = (Ψ2 +µgs +η).






































































































Gs +Gr + eg
+
hy(S1 +S2)
Ys +Yr + ey
+
hm(S3 +S4)





∆1 =βMs(1+aYs)(1−ωs)+ kyW (1−ωs)(1+ γW )+µys(1+aYs)(1+ γW )
+σs(1+aYs)(1−ωs)(1+ γW ), ∆6 = (1+ γW )(1+aYr),
∆2 =δrβMr(1+aYr)+ kyW (1+ γW )+(µyr +σr)(1+aYr)(1+ γW ),
∆3 =(1+aMs)(β (C∗−Ys −Yr))+ kmW (1+ γW )+ k1(1+aMs)(1+ γW ),
∆4 =(1+aMr)(δrβ (C∗−Ys −Yr))+ kmW (1+ γW )+µmr(1+aMr)(1+ γW ),
∆5 =(1+ γW )(1+aYs)(1−ωs), ∆7 = (1+ γW )(1+aMs),
∆8 =(1+ γW )(1+aMr). (6.72)
Separating the negative terms gives the following system:





ξ , F2(ξ ) =






ξ , F4(ξ ) =






ξ , F6(ξ ) =
(1+aGr)
kgW +µgr









0 0 β C
∗
1+γw 0 0 0 0
0 0 0 δrβC
∗
1+γW 0 0 0
P(1−αs)µys 0 βC
∗
1+γW + k1 0 0 0 0
0 P(1−αr)µyr Ψ1 0 0 0 0
σs 0 0 0 0 0 0
0 σr 0 0 0 0 0
0 0 λw 0 0 0 0

. (6.75)
Note that X∗ = C∗ −Y ∗s −Y ∗r and all the elements in the square matrix H are nonneg-
ative. The coordinates of E1 are all positive and the jth coordinate of the vector H (S̄)












∗) satisfies E1 = H E1. Assume, for example that system (6.73)
has a solution of the form S̄, then there exists a small positive real number ε , such that
162
|S̄| ≤ εE1, where |S̄| = (|S1|, |S2|, · · · , |S7|). Note also that |.| is a norm in the field of
complex numbers.
Next, it is important to show that Re(ξ )< 0. To do so, proof by contradiction is applied. Let
ξ = 0 and ξ ̸= 0. For the case when ξ = 0, the determinant (∇) of system(6.70) is given by
∇ =
v5v6µw{v2v4∇∗µx +Pβ (1−αr)λxµwµyr}{v1v3∇∗µx +Pβ (1−αs)λxµwµys}
(γλx +µw)2µ2x
, (6.76)
where the positive terms v1, · · · ,v6 are as defined in matrix (6.25).
It is clear that the above determinant is nonnegative (∇ > 0). Consequently, the system
(6.70) can only have the trivial solution S̄ = (0,0,0,0,0,0, λw
µw
). On the contrary, for ξ ̸= 0,
it is assumed that Re(ξ ) ≥ 0. Defining F(ξ ) = min |1 + Fj(ξ )|, j = 1,2, · · · ,7 implies
that F(ξ ) > 1 and ε/F(ξ ) < ε . The minimality of ε means that |S̄| > ε/F(ξ )E1. While
considering the non-negativity property of H , if the norms on the two sides of system (6.73)
are assumed, then
F(ξ )|S̄| ≤ H |S̄| ≤ εH E1 = εE1. (6.77)
This implies that |S̄| ≤ ε/F(ξ )E1 ≤ εE1, which is a contradiction. Therefore, Re(ξ ) < 0
and E1 is locally asymptotically stable when RE > 1.
6.4 Numerical simulations
6.4.1 Boundary equilibrium points
In this subsection, it is shown by means of numerical simulation, the existence and stability
of a positive parasite-persistent equilibrium point that involves only one of the parasite strains
under study.
Drug-sensitive-only persistent-equilibrium point Es
This is an equilibrium point where only the drug-sensitive parasite strain is present in the
infected human host. That is, the drug-resistant populations Yr = Mr = Gr = 0. This steady
state is only feasible if no resistant parasites emerge from infected red blood cells and the
use of antimalarial treatment does not lead to resistance development; that is Ψ1 = Ψ2 = 0.
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The previous system (6.11) is thus reduced to:
dX
dt












































Numerically, this equilibrium point is illustrated as shown in Figure 6.3.

















drug-sensitive infected erythrocytes, Ys
 drug-resistant infected erythrocytes, Yr
 Gametocytes, Gs
(a)















 drug-resistant infected erythrocytes, Yr
healthy/unparasitized erythrocytes, X
(b)
Figure 6.3: Simulations of system (6.11) showing the existence of drug-sensitive-only
equilibrium point. All other parameter values are shown in Table 6.3.
Drug-resistant-only persistent-equilibrium point Er
In this case, the population of the drug-sensitive parasite strain declines to zero as the density
of the resistant strain grows and stabilises at an optimal population size. This is also illustrated
numerically as shown in Figure 6.4.
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Figure 6.4: Simulations of system (6.11) showing the existence of drug-resistant-only equi-
librium point. Used parameter values are shown in Table 6.3.
Table 6.3: Baseline values and range for parameters of model (6.11)
Parameter Value Range Units Source
λw 30 (10-40) Cells/µl/day (Chiyaka, 2010)
ωs 0.5 (0-1) Unitless Assumed
αs 0.4 (0.1-1) Unitless Assumed
αr 0.2 (0.01-1) Unitless Assumed
eg,em,ey 104 (103 −105) Unitless (Colijn and Cohen, 2015)
λx 3×103 (3E+2-3E+8) cells/µl/day (Li et al., 2011)
µx 1/120 (0.05-0.1) day−1 (Chiyaka, 2010)
µys 0.5 (0.3-0.8) day−1 (Mohammed et al., 2013)
µyr 0.3 (0.3-0.8) day−1 Assumed
µms,µmr 48 (46-50) day−1 (Li et al., 2011)
µgs,µgr 0.0625 (0.05-0.1) day−1 (Ofosu-Okyere et al., 2001)
µw 0.05 (0.02-0.08) day−1 (Ofosu-Okyere et al., 2001)
δr 0.7 (0.01-0.99) Unitless Assumed
ζ ,η 0.5 (0-1) /day (Mohammed et al., 2013)
P 16 (15-20) Unitless (Klein et al., 2008)
β 6.5×10−7 (4.8-6.8)E-7 Merozoites/day (Hellriegel, 1992)
σr, σs 0.02 (0.01-0.03) day−1 (Hellriegel, 1992)
hy,hm,hg 0.05 (0.01-0.08) mm−3/day (Chiyaka, 2010)
ky,km,kg 0.000001 (0.001-0.9) day−1 (Chiyaka et al., 2008)
Ψ1 0.2 (0.01-2.2) day−1 Assumed
Continued on next page
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Table 6.3 – Continued from previous page
Parameter Value Range Units Source
Ψ2 0.01 (0.001-0.1) day−1 Assumed
δr 0.3 (0-1) Unitless Assumed
γ 0.5 (0-1) Immune cells/µl Assumed
1/a 0.2 (0-1) Unitless (Niger and Gumel, 2011)
6.4.2 Within-host competition between parasite strains
























 infected erythrocytes, Yr
(a)































 infected erythrocytes, Yr
(b)




























drug-sensitive infected erythrocytes, Ys
 drug-resistant infected erythrocytes, Yr
(c)
Figure 6.5: Simulations of system (6.11). The figures show the dynamics of drug-sensitive
and drug-resistant infected red blood cells under different conditions of the threshold values
Rs and Rr. In Figure 6.5a, Rs > Rr. In Figure 6.5b, Rr > Rs, Ψ1 = 0. All other parameter
values are shown in Table 6.3.
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The competitive exclusion principle is investigated by simulating the system (6.11) under
different values of the threshold quantities Rs and Rr in equation (6.27). System (6.11) is
simulated so that Rs = 4.022 and Rr = 0.3131, and a convergence to the drug-sensitive-
only endemic equilibrium point Es, as shown in Figure 6.5a is achieved. Again, using the
parameter values in Table 6.3 with Ψ1 = 0.9 and (Rs = 0.022 ; Rr = 3.0098), the solutions
of Ys and Yr converge to the drug-resistant-only endemic equilibrium point Er (Figure 6.5b).
Provided that both Rs and Rr are greater than 1 (as shown in Figure 6.5c), the parasite-
infected erythrocytes persist in the human host. This implies that the merozoites (both
drug-sensitive and drug-resistant) continue to multiply in the absence of antimalarial therapy,
ωs = 0, or in the presence of ineffective antimalarial drugs. Similar results are observed in
the dynamics of merozoites (Ms and Mr) as shown in Figure 6.6. It should be noted that
the dominant merozoite strain is likely to drive the infection under these conditions. As
the density of one strain increases, the population of the other strain is likely to decrease
due to a phenomenon known as competitive exclusion principle (Hardin, 1960). The most
fit parasite strain survives as the weaker competitor dies out, as shown in Figure 6.5a.
Both drug-sensitive and drug-resistant merozoite would remain persistent if poor-quality
antimalarial drugs are administered to P. falciparum malaria patients. Thus, in the absence of
efficacious antimalarial drugs like ACTs with the potential to eradicate resistant merozoites,
an exponential growth in the density of drug-resistant merozoites as shown in Figure 6.5b is
most likely. This may lead to severe malaria and eventual death of the patient.



















































Figure 6.6: Simulations of system (6.11). The figures show the dynamics of the merozoites
under different conditions of the threshold values Rs and Rr. Competitive exclusion among
the parasite strains is shown in Figure 6.6a. In Figure 6.6b, both parasite strains coexist and
Rr > Rs, Ψ1 = 0. Other parameter values are shown in Table 6.3.
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The bifurcation analysis of both scenarios is presented in Figure 6.7 (with and without
competition between the parasite strains). When there is competition between the parasite
strains as shown in Figure 6.7(a), it is observed that the strain with a higher threshold quantity
RE would exclude the other strain. A decrease in the population of the drug-sensitive strain
would pave way for a surge in the population of the drug-resistant strain and vice versa. This
is despite the fact that drug-resistant strain emerge from the drug-sensitive strain as a result
of mutation (Ashley et al., 2014). In Figure 6.7(b), coexistence of the strains is observed.
Like the resistance strain, the sensitive strain is only present when their threshold quantity, Rs
is greater than unity. Both strains are however present when Rr > 1 and Rs > 1. Additionally,
when Rr < 1 and Rs < 1, the parasite-free equilibrium (PFE) point as shown in Figures 6.7(a)
and 6.7(b) is achieved.
Figure 6.7: Bifurcation diagrams showing competitive exclusion (a) and coexistence equilib-
rium (b) for the drug-sensitive strain and drug-resistant P. falciparum parasite strain under
different values of threshold quantities Rs and Rr. Both parasite strains coexist when Rs > 1
and Rr > 1 (see Figure 6.7(b) ).
6.4.3 Antimalarial drug effects and parasite clearance




















Thus, Rs is a decreasing function of ωs (the efficacy of antimalarial drug used). Therefore,
using a highly efficient antimalarial drug could lead to a scenario where Rs < 1 and Rr < 1
(disease-free state shown in Figure 6.8c). In Figure 6.8a, system (6.11) is simulated by
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varying the efficacy of the antimalarial drug ωs and other model parameters chosen such that
Rr = 3.221 and Rs = 2.221. The higher the efficacy of the used antimalarial, the lower the
density of infected erythrocytes. Thus, governments and ministry of health officers should
only roll out or permit the administration of antimalarials or ACTs that can eradicate (totally)
both the drug-resistant strain and the drug-sensitive strain of P. falciparum parasites.

















































































































Figure 6.8: The figures depict the effect of varying the efficacy of antimalarial drug used
ωs and the rate of development of resistance by the drug-sensitive merozoites Ψ1, on the
density of infected erythrocytes (Ys,Yr). The value of ωs ranges from 0 to 1. The rest of the
parameter values are shown in Table 6.3.
The rate of development of resistance by the drug-sensitive merozoites, Ψ1 is shown to
have minimal impact on the dynamics of infected red blood cells Yr as long as Rr > 1 and
Rr > 1 (see Figure 6.8b). Nevertheless, analytical results indicate that the higher the rate






















Further simulations based on contour plots (see (Lane, 2003) for the theory on contour
plots) are used to ascertain the relational effects of selected pairs of model parameters on
the disease threshold quantities Rs and Rr. In Figure 6.9a, both β and µw increases the
reproduction number due to drug-sensitive P. falciparum parasite strain. A direct relationship
exists between the two parameters: the higher the decay rate of the immune cells, the higher
the rate of infection of healthy erythrocytes.



























































































Figure 6.9: Contour plot of Rs as a function of (a) β and µw, (b) ωs and µys, (c) P and γ
In Figure 6.9b, the least increase in Rs with respect to an increase in ωs relative to µys is
observed. Antimalarial therapy is shown to be very effective in reducing the severity of
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P. falciparum infection. Conversely, the number of merozoites produced per dying blood
schizont, P, is shown in Figure 6.9c to have a very high positive impact on Rs and hence on
the severity of malaria infection due to drug-sensitive parasite strain. Clinical control should
target and eradicate infected red blood cells to diminish the erythrocytic cycles of infections.






































































































Figure 6.10: Contour plot of Rr as a function of (a) αr and µyr, (b) Ψ1 and σr, (c) P and β .
It is observed in Figure 6.10b that the rate at which merozoites develop resistance due to
treatment failure has no resultant effects on the rate of formation of gametocytes that undergo
sexual reproduction within the mosquito vector. The higher the value of Rr, the higher the
cost of resistance as shown in Figure 6.10a. The higher the density of drug-resistant parasite
strain, the higher the level of resistance and hence the cost of disease control. Unfortunately,
highly effective antimalarial drugs (such as ACTs) that can eradicate both parasite strains
are often slightly expensive in several P. falciparum malaria endemic regions (Gelband
et al., 2004). Like the parameter P, the parasite infection rate β is shown to have a direct
positive effect on the threshold quantity Rr (Figure 6.10c ) due to drug-resistant parasite strain.
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Effective antimalarials should hence target new cell infections and eliminate recrudescence
(by killing already infected erythrocytes).
6.5 Effects of multiple - strain infection and fitness cost on
parasite clearance
Numerous studies (Babiker et al., 2009; Bushman et al., 2016) have suggested the negative
impacts of drug-resistance on the fitness and ability of the parasite to dominate P. falciparum
infection. Resistance to antimalarial drugs imposes fitness cost on the drug-resistant parasite.
The drug-resistant parasite strain is thought to experience impaired growth within the human
host (Bushman et al., 2018). The cost of resistance is further exacerbated due to competition
between parasite strains within an infected human-host. In Figure 6.11a, the area under the
curve for the drug-resistant strain or the number of infected erythrocytes is lower than that
of the drug-sensitive strain. However, in a multiple-strain infection (Figure 6.11b), the area
difference is much bigger. This implies that competition between the parasite strains within
the human host could result in elimination of one of the parasite-strains provided that both
Rs and Rr are less than unity.














drug-sensitive infected erythrocytes, Ys
 drug-resistant infected erythrocytes, Yr
(a)














drug-sensitive infected erythrocytes, Ys
 drug-resistant infected erythrocytes, Yr
(b)
Figure 6.11: Dynamics of drug-sensitive (blue) and drug-resistant (orange) strains in a single
infection (a) and in a multiple-infection (b) in a naive human-host with no antimalarial drug
treatment (ωs = 0). The rest of the parameter values are shown in Table 6.3.
The presence of multiple-strains of P. falciparum parasites is likely to complicate and
worsen the severity of malaria disease infection in humans. Figures 6.12 and 6.13 show
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the simulated model (6.11) for single and multiple-strain infections, in the absence of pre-
existing immunity and antimalarial drugs. The persistence of gametocytes in Figures 6.12c
and 6.13c is consistent with the actual observations of human malaria infection in the absence
of antimalarial therapy (see Teun et al. (2010)). Acquired immunity is shown in Figure 6.12c
to increase and eventually level-off at higher levels to contain future infections.




















































































Figure 6.12: Dynamics of infected red blood cells, gametocytes and the immune cells with a
single strain P. falciparum infection. Here, there is no pre-existing immunity. The rest of the
parameter values are shown in Table 6.3.
Although the aspect of timing is key in these multiple-strain infections, it is assumed here
that the two strains are introduced at the same time. In the long run, it is evident in Figures
6.11b and 6.13c that the sensitive strain overtakes the resistant strain. This could be as a
result of strain-specific adaptive responses that symmetrically affects the sensitive parasites.
Unlike single-strain P. falciparum parasite infections, data on multiple-strain infections are
not readily available. Nevertheless, a multiple-strain infection (drug-sensitive and drug-
173
resistant) as presented in this chapter is biologically reasonable and consistent with that of P.
Chabaudi described by De Roode et al. (2005).































































































Figure 6.13: Within-human dynamics of single and multiple-strain dynamics of infected
red blood cells, gametocytes and the immune cells in the absence pre-existing immunity and
with no antimalarial treatment (ωs = 0). Other parameter values are shown in Table 6.3.
6.5.1 Sensitivity analysis
In this subsection, the primary model output of interest for the sensitivity analysis are the
infected erythrocytes (Ys,Yr). However, the effective reproduction number RE is a threshold
quantity which represents on overage the number of secondary infected erythrocytes due
to merozoite invasions. This therefore measure the sensitivity indices of the effective
reproduction number relative to model parameters. Using the normalised forward sensitivity
index technique (Arriola and Hyman, 2007) and parameter values in Table 6.3, the sensitivity
indices of all the parameters in RE are as presented in Table 6.4. Observe that the rate of
infection of healthy erythrocytes by the merozoites β , the density of merozoites generated per
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bursting blood schizonts P, the efficacy of antimalarial drug used ωs, and the rate at which
drug-sensitive merozoites develop resistance Ψ1 are the four most influential parameters, in
determining the disease dynamics as presented in system (6.11).
Table 6.4: Sensitivity indices of RE relative to the model parameters
Parameter SI Parameter SI
β +0.9988 Ψ1 -0.77534
P +1.0000 µys -0.492
ωs -0.87513 λw -0.3471
λx +0.7199 ζ -0.0041
µx -0.0016 δr +0.0023
ky -0.02701 km -0.0020
σs -0.7619 σr -0.541872
γ -0.3333 αr -0.1111
µmr -0.433 αs -0.09891
µms -0.52123 µw 0.3716
µyr -0.232
Results from sensitivity analysis emphasise the use of highly efficacious antimalarial drugs
such as ACTs in malaria endemic regions. This would mitigate the many cases of malaria
in the region and further help to reduce emerging cases of parasite resistance to existing
therapies. Drugs with a higher parasite clearance rate would greatly reduce resistance, which
is associated with longer parasite exposure to antimalarial drugs. It is imperative therefore,
that government and ministry of health personnel in malaria endemic countries enforce
the use of efficient antimalarial drugs that not only cure infected malaria patients but also
eliminate the chance of P. falciparum parasites to develop resistance to existing therapy.
6.6 Conclusion
In this chapter, a deterministic model of multiple-strain P. falciparum malaria infection has
been formulated and analysed. The parasite strains are categorised as either drug-sensitive or
drug-resistant. The infected erythrocytes and the malaria gametocytes are similarly grouped
according to the strain of the parasite responsible for their existence. The immune cells are
incorporated to reduce the invasive characteristic of the malaria merozoites. Antimalarial
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therapy is applied to the model but only targets red blood cells infected with drug-sensitive
merozoites. Based on the computed effective reproduction number RE , it is evident that
the success of P. falciparum infection in the presence of multiple parasite strains is directly
dependent on the ability of the individual parasite strains to drive the infection. The parasite
strain with a higher threshold value, RE is likely to dominate the infection. Prescribed
antimalarial drugs should therefore be effective enough to eradicate both drug-sensitive and
drug-resistant parasite strains within the human host.
The use of antimalarial treatment may eradicate one parasite strain so that either a drug-
sensitive-only persistent equilibrium point or a drug-resistant-only persistent equilibrium
point is attained. To assess the impacts of the different parasite strains to disease dynamics,
the model is simulated for different values of the threshold quantities Rs and Rr. It is observed
that when Rr > 1 and Rs > 1, both parasite strains are persistent and the infection becomes
severe. If Rr > 1 and Rs < 1, then the drug-sensitive parasites would decline to zero as the
drug-resistant strain continue to multiply and remain persistent, increasing the severity of
infections. On the other hand, if Rs > 1 and Rr < 1, then the drug-resistant parasite strain
would be eradicated. Moreover, provided that the threshold quantities Rs and Rr are less
than unity, the use of an efficacious antimalarial drug would help eradicate P. falciparum
infection.
The efficacy of antimalarial drug is shown to have direct negative impact on the density of
infected red blood cells. This result is consistent with that in Filipe et al. (2007). The efficacy
of antimalarial drug is however shown to have least effect on the population of drug-resistant
infected erythrocytes. The rate of development of resistance by drug-sensitive parasites is
also shown to drive the infection due to resistant parasite strain. Using contour plots and
results from sensitivity analysis, it is observed that the efficacy of antimalarial drug used
ωs, the density of blood floating merozoites produced per infected erythrocyte P, the rate
of development of resistance Ψ1, and the rate of infection by merozoites β are the most
important parameters in the disease dynamics and control. Although the drug-resistant strain
is shown to be less fit, the presence of both strains in the human host has a huge impact on the
cost and success of antimalarial treatment. To reduce the emergence of resistant strain, it is
vital that only effective antimalarial drugs are administered to patients in hospitals, especially
in malaria endemic regions. The results from this study call for regular and strict surveillance
on antimalarial drugs in clinics and hospitals in malaria-endemic countries.
In the next Chapter 7, optimal control theory is applied to establish an appropriate combina-
tion therapy against clinical P. falciparum malaria.
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Chapter 7
Application of optimal control theory to
hepatocytic-erythrocytic dynamics of P.
falciparum malaria
7.1 Introduction
In this chapter, optimal control theory is applied to an in-host malarial model that is charac-
terised by a combination of antimalarial drugs and different vaccine antigens. The analysis
of the model with constant vaccine therapy is available in Chapter 4 of this thesis. Time-
dependent vaccine and antimalarial drug control therapies are incorporated into the model.
The objective of this study is to establish an appropriate combination therapy for clinical P.
falciparum malaria.
7.2 Antimalarial drugs and drug combinations
Currently, artemisinin-based combination therapy (ACTs) is the standard of care for uncom-
plicated P. falciparum malaria. The five WHO recommended ACTs include: (i) artemether
+ lumefantrine, (ii) artesunate + amodiaquine, (iii) artesunate + mefloquine and (iv) dihy-
droartemisinin + piperaquine, (v) artesunate + sulfadoxine–pyrimethamine (SP) (WHO,
2015c). Drug resistance against 4-aminoquinolines and sulpha compounds has remained
one of the greatest challenge to malaria chemotherapy development (Visser et al., 2014). P.
falciparum resistance to artesunate in Western Cambodia was characterised by slow parasite
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clearance as shown in Figure 7.1. Further evidence of resistance to artemisinins (Don-
dorp et al., 2009; Noedl et al., 2008) highlights the need for continuous investment in the
development of alternative anti-malarial drugs and vaccines.
The combination of anti-malarial drugs have achieved tremendous success in malaria treat-
ment and transmission reduction (NIH, 2019; Visser et al., 2014). Administration of two or
more antimalarials with different targets and modes of action has been shown to be highly
effective compared to monotherapy drugs (WHO, 2015c). A rapidly acting artemisinin drug
in ACTs exhibit an extremely short half-life. It is hence combined with a longer-acting
monotherapy (partner drug) to limit recrudescence and achieve higher clinical response. The
artemisinin component reduces parasite numbers by a factor of about 104 in each 48-hour
asexual cycle (Hodel et al., 2016). Further, it is active against gametocytes that mediate
onward transmission to mosquito vector. The longer-acting monotherapy drug, eradicates
the remaining parasites. This further reduces the possible occurrence of resistance due to
mutations during treatment. Additionally, the long-acting drug may provide a period of
post-treatment prophylaxis (WHO, 2015c).
According to Okell et al. (2008), a combination of an ACT partner drug and a nonartemisinin
regimen with longer prophylactic times is destined to achieve a greater impact in higher-
transmission settings. The addition of artesunate to amodiaquine reduced gametocyte carriage
and did not adversely affect tolerability in P. falciparum patients (Osorio et al., 2007). Else-
where (Smithuis et al., 2010), artesunate-mefloquine provided the greatest post-treatment
suppression of malaria in Myanmar and the addition of a single dose of primaquine substan-
tially reduced transmission potential.
Although antimalaria drugs and insecticides have helped reduce malaria cases and deaths
globally, these two interventions are vulnerable to development of resistance (Chitnis et al.,
2015). The availability of effective malaria vaccines is a critical tool for sustainable control
and elimination (Abdulla et al., 2011). Unfortunately, malaria vaccine development has been
hindered by the extreme complexity of malaria parasite biology. The parasites have a diverse
genome which enables them to evade immune system and complete their intricate infection
cycle (Mahmoudi and Keshavarz, 2018).
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Figure 7.1: Normalised P. falciparum parasite clearance curves showing the fraction of
initial parasitaemia versus time in patients treated with artesunate in Western Cambodia and
Western Thailand. Parasite clearance was significantly slower in Western Cambodia. Source:
Dondorp et al. (2009).
7.2.1 The need to combine different vaccine antigens
Several clinical and pre-clinical studies (Bauza et al., 2016; Mahmoudi and Keshavarz, 2018;
Sherrard-Smith et al., 2018) have demonstrated the significant benefit of combining two or
more malaria vaccine antigens. Recombinant PfMSP-142 formulated with AS02A elicited
high antibody titres among young children in Western Kenya (Ogutu et al., 2009). JAIVAC-1
formulated with Montanide ISA720 elicited balanced antibody responses against both PfF2
and PfMSP-119 and exhibited significant growth inhibitory activity against P. falciparum
(Chitnis et al., 2015). Adenovirus-CSP prime combined with a protein-CSP boost regime
provided 100% protection in C57BL/6 mice (Bauza et al., 2016). Moreover, a combined
efficacy of 90.8% (86.7-94.2%) was observed in the pre-erythrocytic vaccines (PEV) +
transmission-blocking vaccine (TBV) antibody group; 7.8% higher than the estimated efficacy
if the two antibodies acted independently (Sherrard-Smith et al., 2018). These studies have
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shown that a combination of two or more malaria vaccine antigens is synergistic and is likely
to achieve better results in the control of in-host malaria infections.
7.2.2 Optimal control theory applied to malaria models
Optimal control theory (Lenhart and Workman, 2007) has been very helpful in identifying
optimal control measures against particular diseases. In malaria epidemiology, the application
of optimal control theory has for a long time been limited to population level models (Agusto
et al., 2012; Makinde and Okosun, 2011; Mwanga et al., 2015; Okosun et al., 2011). In most
of these models, the main objective has been to minimise the population of humans infected
with malaria while keeping the costs of control, such as purchase of insecticide-treated
bed nets (ITNs), indoor residual spraying (IRS) and antimalarial drugs, as low as possible
(Mwanga et al., 2015). In all these dynamical models, optimal control therapy strategies
were explored using Pontryagin’s maximum principle (Pontryagin, 1987).
A combination of different vaccine antigens are shown by Orwa et al. (2018) to be highly
effective in reducing parasitaemia and severity of clinical P. falciparum malaria. In addition,
a combination of two malaria drugs, fosmidomycin and piperaquine was also established
to have higher efficacy, safety and well tolerated (Mombo-Ngoma et al., 2017). Elsewhere
(Pukrittayakamee et al., 2004), a combination of artesunate and primaquine (PQ) resulted in
significantly shorter gametocyte clearance times. In Pukrittayakamee et al. (2004), artesunate
is shown to inhibit gametocyte development whereas primaquine accelerates gametocyte
clearance in P. falciparum malaria (see Figure 7.3). It is argued that a combination of efficient
antimalarial drugs and efficacious malaria vaccines present the best therapeutic strategy to
achieving malaria elimination.
7.3 The optimal control model
The model presented in this study is an extension of the in-host malaria model subject to
vaccine interventions in Chapter 4 of this thesis. The model describes the interactions of (i)
sporozoites (S), (ii) uninfected hepatocytes (H), (iii) infected hepatocytes (X), (iv) uninfected
red blood cells (R), (v) early stage infected red blood cells (Blood trophozoites, T ), (vi)
mature infected red blood cells (blood schizonts, C), (vii) merozoites (M), (viii) gemetocytes
(G) and (ix) CD8+ T cells (Z). The only two vaccines considered in this chapter are: pre-
erythrocytic vaccine (PEV) and blood stage vaccine (BSV), which offer direct protection
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to the recipient human host. The specific vaccines are: RTS,S/AS01 (Birkett, 2016) and
merozoite surface protein 3 (Miura, 2016), respectively. The model is extended by adding
antimalarial drug therapy: artemether-lumefantrine (a blood schizontocide)(Ogutu, 2013)
and primaquine (a gametocytocide) (WHO, 2012b). The combined chemotherapy not only
target rapid parasite clearance but also reduced parasite transmissibility to mosquito vector.
It is clear that the four interventions considered here, target different sites within the complex
malaria dynamics.
The gametocytocide considered in this study is a single dose 0.25 mg base/kg of primaquine.
This WHO recommended drug, mainly targets the blood stage gametocytes. It kills the
gametocytes irrespective of their stages of development (Recht et al., 2014). This reduces
the probability of parasite transmission to the mosquito vector and hence disease morbidity.
The lower dose of 0.25mg base/kg of primaquine is considered by WHO as safer and as
effective as higher doses (see Figure 7.2) in reducing transmissibility (Eziefula et al., 2014;
White et al., 2012; WHO, 2012b). In Figure 7.3, a combination of quinine and the lower dose
of 0.25mg base/kg of primaquine is shown to be highly effective in timely eradication of
parasitaemia. However, pregnant women and infants aged 6 months or below are exempted
from this additinal dose in endemic regions. Moreover, higher doses of PQ could be harmful
to those with glucose-6-phosphate dehydrogenase (G6PD) deficiency (Graves et al., 2014).
Figure 7.2: Mean duration of female gametocyte carriage in children with P. falciparum
malaria treated with artemether-lumefantrine (AL) and different doses of primaquine. The
dashed line indicates the set threshold for non-inferiority compared with the 0·75 mg/kg
reference group. Source: Eziefula et al. (2014).
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Figure 7.3: The comparison of durations of P. falciparum gametocytaemia following quinine
alone compared with quinine plus 0.25 mg base/kg of primaquine. Source: Pukrittayakamee
et al. (2004).
The Pontryagin’s maximum principle is used to minimise the population of infected hepato-
cytes X , infected erythrocytes T , infective blood stage merozoites M and the gametocytes
G. RTS,S/AS01 and MSP3 reduces the rates of invasion of healthy hepatocytes and healthy
erythrocytes, respectively. The hepatocyte invasion rate βs and the erythrocyte invasion rates
βr are hence, reduced to (1−u1(t))βs and (1−u2(t))βr, respectively. The time dependent
controls u1 and u2, therefore represent the efficacies of the pre-erythrocytic vaccine and the
blood stage vaccine, respectively. The use of primaquine reduces the burst size N of liver
schizonts to (1− u3(t))N, where u3(t) is the normalised primaquine dosage efficacy as a
function of time. Similarly, the administration of AL, reduces the burst size P of infected
erythrocytes to (1−u4(t))P, where u4(t) is the normalised AL dosage efficacy as a function
of time. The in-host model of P. falciparum malaria subject to antimalarial drugs and malaria
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= λh −µhH − (1−u1(t))βsSH,
dX
dt


















































subject to the following initial conditions:
S(0)≥ 0,H(0)> 0,X(0)≥ 0,R(0)> 0,T (0)≥ 0,C(0)≥ 0,M(0)≥ 0,G(0)≥ 0,Z(0)> 0.
(7.2)
A brief description of model parameters are as presented in Table 7.1.
Table 7.1: Description of model parameters
Parameter Description
Λ The rate of injection of sporozoites into liver due to mosquito bites
µs Death rate of sporozoites
βs Rate of invasion of hepatocytes by sporozoites
λh Rate of supply of hepatocytes from the bone marrow
λr Rate of supply of erythrocytes from the bone marrow
µh, µx Death rate of susceptible hepatocyte and infected hepatocyte,
respectively
π Proportion of parasites that become gametocytes per bursting
blood schizont C
kx,kt ,kc Immunosensitivity of X , T and C, respectively
Continued on next page
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Table 7.1 – Continued from previous page
Parameter Description
δx,δt ,δc Immunogenecity of X , T and C, respectively
µr Natural mortality rate of healthy RBC
βr Rate of infection of RBCs by merozoites
µt , µc Rate of decay of blood trophozoites and blood schizonts, respectively
µm, µg Rate of decay of merozoites and gametocytes, respectively
P Average number of merozoites released per bursting
blood schizont
N The average number of merozoites released per bursting infected
hepatocytes
γ Rate of progression from blood trophozoite to schizont stages
α Rate of inhibition of immune response
λz Rate of production of CD8+ T-cells
1/ε0,1/ε1,1/ε2 Half saturation constants for X , T and C, respectively
µz Rate of decay of CD8+ T-cells
7.4 Formulation of optimal control problem
We endeavor to reduce malaria disease severity within the human host by reducing parasite
invasion of the healthy hepatocytes and erythrocytes. To curtail further transmission, we
also aim to reduce the density of sexual gametocytes within the host’s blood stream. To
achieve these two, we set out to establish the most effective control strategy drawn from
a combination of malaria vaccine antigens and antimalarial drugs regimens. The policies
under consideration are u1(t), u2(t), u3(t) and u4(t) described in Section 7.3. Therefore, the
objective function J defined over a feasible set of controls (u1,u2,u3,u4) over a finite time














subject to system (7.1).
In system (7.3), A1,A2,A3 and A4 are the costs associated with minimising the infected hepa-
tocyte, infected erythrocytes, the merozoites and gametocytes, respectively. The parameter
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t f denotes the time period of intervention. The quantities B1,B2,B3 and B4 represent the
weight constants for pre-erythrocytic vaccine, blood stage vaccine, blood schizontocide and
gametocytocide, respectively. The weight constants accounts for the relative importance
pre-assigned by the modeller to the contributing terms in the objective function (Lee et al.,
2010). Additionally, we endeavour to minimise the social costs related to resources needed
for pre-erythrocytic vaccines 12B1u
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As in other epidemic models (Joshi et al., 2006; Okosun et al., 2011), the costs associated with
using antimalarial drugs and malaria vaccines are directly proportional to the rates at which
these controls are implemented. Therefore, the coefficients A1X ,A2T,A3M and A4G are
















4 are proportional to the square of the corresponding control
function. They are hence nonlinear and take quadratic forms.






4) which minimises the objective function J









where U = {(u1,u2,u3,u4)such that{u1,u2,u3,u4} is a Lebeque measurable control set with
0 ≤ ui(t)≤ 1, i = 1, · · · ,4, for t ∈ [0, t f ]}.
7.4.1 Existence of optimal solutions to the control problem







4) = min(u1,u2,u3,u4)∈U J(u1,u2,u3,u4) of problem in system (7.1)
are satisfied. The resulting optimality problem is solved based on Pontryagin’s Maximum
Principle (Pontryagin, 1987).
Theorem 7.1. Consider an optimal problem N (t,Y (t),ui(t)) of system (7.1), subject to
initial conditions of state variable Y (t) ∈ R9+ and boundary condition of control vari-







4) = min(u1,u2,u3,u4)∈U J(u1,u2,u3,u4) if the following necessary conditions
are satisfied (Chuma et al., 2019):
(i) Control set U and the corresponding state variables are nonempty,
(ii) Control set U is convex and closed,
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(iii) The right hand side of the state system is bounded by the linear function in the state
and control variables,
(iv) The integrand of the objective function is convex,
(v) There exist constant numbers q1, q2 > 0 and ξ > 1 such that the integrand of the
objective function is bounded below by q1(|u1|+ |u2|+ |u3|+ |u4|)ξ/2 −q2.
Proof: The existence of an optimal control is verified by conditions stated by Fleming and
Rishel (1975). From the optimal problem N (t,Y (t),ui(t)) of system (7.1), the set of all
state variables Y (t) ∈ R9+ and the control variables {ui(t) ∈U |0 ≤ ui(t)≤ 1}, t ∈ [0, t f ] are
non-negative. The first condition is hence satisfied. By definition, the optimal solution ui(t)
is convex and bounded in U . Hence, the second condition is satisfied (Mlay et al., 2015;
Mpeshe et al., 2014).
The optimal system (7.1) is bounded which determines the compactness needed for the
existence of the optimal control (Athithan and Ghosh, 2015). The third condition therefore
holds. Moreover, the integrand in the objective function in equation (7.3) is clearly convex
on the control set U . This proves the fourth condition. It is clear that the state variables are
bounded in system (7.1). Following the work by Mlay et al. (2015), the integrand in (7.3) is


















for i = 1, · · · ,4. This proves condition five. The above five conditions are hence satisfied.















7.4.2 Characterisation of the optimal control
The Pontryagin’s Maximum Principle (Pontryagin, 1987) is used in solving the stated optimal
control problem. This principle converts the optimality system (7.1), (7.3) and (7.4) into a
problem of minimising a pointwise Hamiltonian Ha, with respect to controls u1, u2, u3 and
u4. The Lagrangian of the optimal control problem is given by











Clearly, the second derivative of L in equation (7.7) with respect to ui, i = 1, · · · ,4, are





u∗4. The aim is to obtain the Lagrangian minimum value. This is accomplished by defining a
Hamiltonian function Ha for the control problem as follows:
Ha = L(X ,T,M,G,u1,u2,u3,u4)
+ϒ1Ṡ+ϒ2Ḣ +ϒ3Ẋ +ϒ4Ṙ+ϒ5Ṫ +ϒ6Ċ+ϒ7Ṁ+ϒ8Ġ+ϒ9Ż































































where ϒi, for i = 1,2,3, · · · ,9, are the adjoints or co-state variables.
Theorem 7.2. Let S∗,H∗,X∗,R∗,T ∗,C∗,M∗,G∗ and Z∗ be the solutions of the correspond-








4). Then there exists adjoint variables ϒi, i = 1,2, · · · ,9 satisfying
dϒ1
dt
= (ϒ2 −ϒ3)(1−u1)βsH +ϒ1(µs +βsH),
dϒ2
dt














































































with transversality conditions (or boundary conditions)




0 if ui ≤ 0,
ui if 0 < ui < 1,
1 if ui ≥ 1.
(7.11)
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Proof: The form of the adjoint system and the transversality conditions therein are stan-
dard results from the Pontryagin’s Maximum Principle (Pontryagin, 1987). To obtain the
differential equations governing the adjoint or co-state variables, we first set S = S∗, H = H∗,
X = X∗, R = R∗, T = T ∗, C =C∗, M = M∗, G = G∗ and Z = Z∗, and differentiate (partially)
the Hamiltonian function Ha in equation (7.8) with respect to each of the state variables
















; ϒ9(t f ) = 0. (7.18)
To obtain the optimality equations (7.12)-(7.15), first carry out partial derivative of the
Hamiltonian Ha with respect to the controls (u1,u2,u3,u4) and then solve for u∗i (optimal





= βs(ϒ2 −ϒ3)S∗H∗+B1u∗1 = 0. (7.19)

















































































Utilising the characteristic functions (7.12)-(7.15), the following optimality system (7.27)-





























































































































































































































































































































































where ϒi(t f ) = 0, for i = 1,2,3, · · · ,9 and S(0)≥ 0,H(0)> 0,X(0)≥ 0,R(0)> 0,T (0)≥
0,C(0)≥ 0,M(0)≥ 0,G(0)≥ 0,Z(0)> 0.
7.4.3 Uniqueness of the optimality system
Given that the state variables and the adjoint functions are bounded and satisfy Lipschitz
conditions, the uniqueness of the optimal controls can easily be derived using the technique
explained by Kim et al. (2012). Thus, the following theorem is stated.
Theorem 7.3. The bounded solutions to the optimality system are unique.
Proof: Suppose (S,H,X ,R,T,C,M,G,Z,ϒ1,ϒ2,ϒ3,ϒ4,ϒ5,ϒ6,ϒ7,ϒ8,ϒ9) and
(X̄ , H̄, S̄, R̄, T̄ ,C̄,M̄, Ḡ, Z̄, ϒ̄1, ϒ̄2, ϒ̄3, ϒ̄4, ϒ̄5, ϒ̄6, ϒ̄7, ϒ̄8, ϒ̄9) are two different solutions of our
optimality system. Let S = eϒtv1, H = eϒtv2, X = eϒtv3, R = eϒtv4, T = eϒtv5, C = eϒtv6,
M = eϒtv7, G = eϒtv8, Z = eϒtv9, ϒ1 = e−ϒtw1, ϒ2 = e−ϒtw2, ϒ3 = e−ϒtw3, ϒ4 = e−ϒtw4,
ϒ5 = e−ϒtw5, ϒ6 = e−ϒtw6, ϒ7 = e−ϒtw7, ϒ8 = e−ϒtw8 and ϒ9 = e−ϒtw9 . Similarly, let
S̄ = eϒt v̄1, H̄ = eϒt v̄2, X̄ = eϒt v̄3, R̄ = eϒt v̄4, T̄ = eϒt v̄5, C̄ = eϒt v̄6, M̄ = eϒt v̄7, Ḡ = eϒt v̄8,
Z̄ = eϒt v̄9, ϒ̄1 = e−ϒtw̄1, ϒ̄2 = e−ϒtw̄2, ϒ̄3 = e−ϒtw̄3, ϒ̄4 = e−ϒtw̄4, ϒ̄5 = e−ϒtw̄5, ϒ̄6 =












































































































∣∣∣∣∣w7v6(1+αeϒt v̄9)− w̄7v̄6(1+αeϒtv9)(1+αeϒtv9)(1+αeϒt v̄9)
∣∣∣∣∣. (7.32)
Substituting S = eϒtv1 into the first equation of system (7.1), (dS/dt), the state equation
becomes
eϒt(v̇1 +ϒv1) = ϒ−µsv1eϒt −βsv2v1e2λ t . (7.33)
Similarly, substituting ϒ1 = e−ϒtw1 into the first equation of system (7.9), (dϒ1/dt), the
adjoint equation becomes
e−ϒt(ẇ1 −ϒw1) = (w2 −w3)(1−u∗1(t))βsv2 +µsw1e−ϒt +βsw1v2. (7.34)
Now, subtracting the equations for S and S̄ in equation (7.33), ϒ1 and ϒ̄1 in equation (7.34)
gives
ϒ(v1 − v̄1)+(v̇1 − ¯̇v1) =−µs(v1 − v̄1)−βseϒt(v1v2 − v̄1v̄2) and (7.35)
ϒ(w1 − w̄1)+(ẇ1 − ¯̇w1) = (1−u∗1)βseϒt {v2(w2 −w3)− v̄2(w̄2 − w̄3)}+µs(w1 −w1)
+βseϒt(w1v2 − w̄1v̄2). (7.36)
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Then multiply each equation by the appropriate difference of functions ((v1 − v̄1) and (w1 −
w̄1), respectively) and integrate from 0 to t f . This gives (for case of equation (7.35))
1
2







(v1 − v̄1)2dt −βseϒt
∫ t f
0
(v1v2 − v̄1v̄2)(v1 − v̄1)dt. (7.37)
Following the same procedure for the remaining state variables and adjoint variables (for H











(v2 − v̄2)2dt −βs
∫ t f
0
(1−u∗1)(v1v2 − v̄1v̄2)(v2 − v̄2)eϒtdt, (7.38)
1
2







(v3 − v̄3)2dt +βs
∫ t f
0










(v3 − v̄3)eϒtdt, (7.39)
1
2
(v4 − v̄4)2 +ϒ
∫ t f
0















(v4 − v̄4)2 dt, (7.40)
1
2
























(v5 − v̄5)eϒt dt
− (µt + γ)
∫ t f
0











(v5 − v̄5)(v6 − v̄6)dt −µc
∫ t f
0










(v6 − v̄6)eϒt dt, (7.42)
1
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(v7 − v̄7)dt −βr
∫ t f
0
(v4v7 − v̄4v̄7)(v7 − v̄7)dt, (7.43)
1
2







(v6 − v̄6)(v8 − v̄8)dt −
∫ t f
0
(u∗3 −µg)(v8 − v̄8)2 dt, (7.44)
1
2























































(1+ ε0eϒtv3)(1+ ε0eϒt v̄3
)






(1+ ε0eϒtv3)(1+ ε0eϒt v̄3
)
(v3 − v̄3)e2ϒt dt
≤ (C1eϒt f +C2e2ϒt f )
∫ t f
0









[(v1 − v̄1)2 +(v2 − v̄2)2 +(v3 − v̄3)2]dt. (7.47)
Upon combining the integrals in equations (7.37)-(7.45) gives
1
2
(v1 − v̄1)2(t f )+
1
2
(v2 − v̄2)2(t f )+
1
2
(v3 − v̄3)2(t f )+
1
2
(v4 − v̄4)2(t f )+
1
2




(v6 − v̄6)2(t f )+
1
2
(v7 − v̄7)2(t f )+
1
2
(v8 − v̄8)2(t f )+
1
2

































[(v1 − v1)2 +(v2 − v2)2 +(v3 − v3)2 +(v4 − v4)2
+(v5 − v5)2 +(v6 − v6)2 +(v7 − v7)2 +(v8 − v8)2 +(v9 − v9)2 +(w1 −w1)2
+(w2 −w2)2 +(w3 −w3)2 +(w4 −w4)2 +(w5 −w5)2 +(w6 −w6)2
+(w7 −w7)2 +(w8 −w8)2 +(w9 −w9)2]dt (7.48)




[(v1 − v1)2 +(v2 − v2)2 +(v3 − v3)2 +(v4 − v4)2 +(v5 − v5)2 +(v6 − v6)2
+(v7 − v7)2 +(v8 − v8)2 +(v9 − v9)2]+
∫ t f
0
[(w1 −w1)2 +(w2 −w2)2
+(w3 −w3)2 +(w4 −w4)2 +(w5 −w5)2 +(w6 −w6)2 +(w7 −w7)2




where D̄1 and D̄2 depend on the coefficients and the bounds of vi and wi, i = 1, · · · ,9. If ϒ
is chosen such that ϒ > (D̄1 + D̄2) and t f < (1/3ϒ) ln((ϒ− D̄1)/D̄2), then v1 = v̄1, v2 = v̄2,
v3 = v̄3, v4 = v̄4, v5 = v̄5, v6 = v̄6, v7 = v̄7, v8 = v̄8, v9 = v̄9, w1 = w̄1, w2 = w̄2, w3 = w̄3,
w4 = w̄4, w5 = w̄5, w6 = w̄6, w7 = w̄7, w8 = w̄8, w9 = w̄9. Hence, the solution is unique for
small time t f .
The non-linear optimal controls are obtained by solving the optimality system (7.27)-(7.28),
which combines the state system (7.1), the adjoint system (7.9), the initial conditions (7.2),
boundary conditions (7.10) and the characteristics of the optimal functions (7.12)-(7.15).
In order to solve the optimality system, the initial and transversality conditions are used
alongside the characterisation of the optimal control (u1,u2,u3,u4) given in equations (7.12)-
(7.15). We therefore obtain optimal control measures through numerical simulations, in the
next section. The optimal control set u∗i , i = 1, · · · ,4 gives an optimal control strategy against
in-host P. falciparum malaria infection.
7.5 Numerical simulations
In this section, we study the numerical results obtained from the optimal control model
(7.1). The backward-forward sweep (BFS) algorithm (Lenhart and Workman, 2007) and the
fourth-order Runge-kutta scheme in Matlab (Ince, 1943) are applied to solve the optimality
system. The BFS algorithm has been implemented in several research studies (Joshi et al.,
2006; Nakakawa et al., 2017; Namawejje et al., 2014; Okosun et al., 2011; Omondi et al.,
2018). The optimal control code presented by Lenhart and Workman (2007) is modified
to solve the optimality system (7.27). The initial conditions S0, H0, X0, R0, T0, C0, M0, G0,
Z0, and ūi are used to solve for the state variables x̄ = (S,H,X ,R,T,C,M,G,Z) forward in
time using Runge-kutta fourth-order scheme in Matlab. The adjoint system ϒ̄i, i = 1, · · · ,9 is
solved backward in time using the transversality condition ϒi(t f ) = 0 and the values of x̄ and
ū. The control variables ū are then updated in the second iteration by entering the new values
of the state and adjoint variables. This process is repeated until convergence is achieved.
The parameter values used in the simulations are obtained from existing literature on in-host
malaria modelling and control. These are as presented in Table 7.2. Other parameter values
are however assumed. The retail price of ACTs in sub-Saharan Africa is roughly 5-7 US
dollars ($) (Palafox et al., 2015). The median price of AL (the blood schizontocide) is $5.26
in Uganda, $6.03 in Benin, $4.58 in DRC, $5.36 in Nigeria and $5.36 in Zambia (Palafox
et al., 2015). A cross-sectional study on the availability and retail prices of antimalarial drugs
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in rural Western Kenya (Kioko et al., 2016), revealed that the mean price (range) of an adult
treatment course for AL was $4.5 ($0.35–5) while DHA-PPQ was $4.39 ($0.71–7.06). Penny
et al. (2016), estimated the cost per dose of RTS,S/AS01 to be $6.52 ($2.69 –$12.9). In this
study, the average retail price of $5 for AL and PQ per dose are assumed. Additionally, the
pre-erythrocytic vaccine (RTS,S/AS01) is considered highly cost-effective and is estimated
to assume a mid-range cost of $5 per dose under a four-dose schedule (Winskill et al., 2017b).
This implies a unit cost of $39.25 is incurred per fully vaccinated child (Penny et al., 2016;
Winskill et al., 2017b). It is further assumed that the blood-stage vaccine would bear a similar
cost of $5 (≈ Kshs. 500) per dose. Therefore, the costs A1 = A2 = $39.25(≈ Kshs.3925).
Similarly, A3 = A4 = $5(≈ Kshs.500).
Malaria treatment using ACTs have made a significant contribution to current success in
malaria control efforts. For the period 2014-2017, WHO spent about US $11.71, $13.70,
$12.53 and $14.18 per malaria cases averted, respectively. The 2015 World malaria report
showed that about 663 million malaria cases were averted for the period 2001-2015 (WHO,
2016b); of these cases, 21% (17%, 29%) were averted due to ACT use. Therefore, an average
of US $11.90 was spent per year on malaria cases averted by ACTs in the period 2014-2017.
Additionally, a report by the President’s Malaria Initiative (PMI), estimated that about US $94
(95% CI: $51, $166) was spent per disability adjusted life year (DALY) averted for the period
2005-2017 (Winskill et al., 2017a). This represents about US $7.80 per cases averted per
year. Unlike the efficacies of antimalarial drugs (95%), the vaccines considered in this study
have a moderate efficacy of 75%. The weight constants B1, B2, B3 and B4 are hence assigned
a slighly lower average value of US $7.5 (≈ Kshs. 750). That is, B1 = B2 = B3 = B4 = 750.
In Figures 7.4 - 7.15, the coefficients A1 = A2 = 3925, A3 = A4 = 500 and Bi = 750, i =
1, · · · ,4. The initial conditions S(0) = 3000, H(0) = 3×105, X(0) = 5×102, R(0) = 5×106,
T (0) = 5×103, C(0) = 5000, M(0) = 9000, G(0) = 5000, Z(0) = 3000 are used to illustrate
the effects of various control strategies against in-host P. falciparum malaria infections.
Arbitrary initial conditions were chosen because the presented model (with constant vaccine
control) exhibits global stability behaviour (see Chapter 4). Note that all the possible set of
control combinations were considered in this study. However, only those that gave substantial
decrease in the populations pre-defined in the objective function (7.4) are presented. To
simplify the analyses, the four controls are grouped into the following six categories:
• Strategy 1: A combination of two controls
– (1A) A combination of blood schizontocide and gametocytocide only: u1 =
0,u2 = 0,u3 ̸= 0,u4 ̸= 0.
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– (1B) A combination of pre-erythrocytic and blood stage vaccine antigens only:
u1 ̸= 0,u2 ̸= 0,u3 = 0,u4 = 0,.
– (1C) A combination of pre-erythrocytic vaccine and blood schizontocide drugs
only: u1 ̸= 0,u2 = 0,u3 ̸= 0,u4 = 0.
• Strategy 2: A combination of three controls
– (2A) Pre-erythrocytic vaccine antigen, blood stage vaccine antigen and blood
schizontocide only: u1 ̸= 0,u2 ̸= 0,u3 ̸= 0,u4 = 0.
– (2B) Pre-erythrocytic vaccine antigen, blood schizontocide and gametocytocide
only: u1 ̸= 0,u2 = 0,u3 ̸= 0,u4 ̸= 0.
• Strategy 3: A combination of all the four controls (pre-erythrocytic vaccine antigen,
blood stage vaccine antigen, blood schizontocide and gametocytocide) : u1 ̸= 0,u2 ̸=
0,u3 ̸= 0,u4 ̸= 0.
Table 7.2: Table showing parameter values used for model simulations
Parameter Value Range Units Source
P 16 (15-20) Unitless (Diebner et al., 2000)
kx 0.01 (0.001-0.9) /day (Chiyaka et al., 2008)
kt 0.02 (0.003-0.9) /day (Chiyaka et al., 2008)
kc 0.001 (0.001-0.9) /day (Chiyaka et al., 2008)
µr 0.083 (0.05-0.1) /day (Anderson et al., 1989)
βr 0.02 (0.01-0.3) /mm3/day (Dondorp et al., 2000)
βs 0.001 (0.0001-0.2) /mm3/day (Selemani et al., 2016)
π 0.2 (0.1-0.9) Unitless (Talman et al., 2004)
µh 0.029 (0.01-0.5) /day Estimated
µx 0.02 (0.01-1) /day (Selemani et al., 2016)
λr 3000 (300−3×105) cells/ml/day (Li et al., 2011)
λh 3000 (3×105 −3×108) cells/µl−1/day (Tumwiine et al., 2008)
λz 30 (10-40) /µl−1/day (Chiyaka, 2010)
µm 48 (46-50) /day (Li et al., 2011)
Λ 30 (18-35) sporozoites/day (Selemani et al., 2016)
µs 1.2 (1.0−2.4) /day (Selemani et al., 2016)
µt 0.27 (0.01-0.8) /day (Magombedze et al., 2011a)
µc 0.7 (0.1-0.9) /day (Magombedze et al., 2011a)
Continued on next page
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Table 7.2 – Continued from previous page
Parameter Value Range Units Source
µg 6.3×10−5 (6.0−7.0)×10−5 /day (Selemani et al., 2016)
µz 2 (0.5-3) /day (Chiyaka, 2010)
δx 10−5 (10−4-10−7) mm−3/day (Chiyaka, 2010)
δt 10−6 (10−5-10−7) mm−3/day (Chiyaka, 2010)
δc 10−4 (10−3-10−7) mm−3/day (Chiyaka, 2010)
γ 1.5 (0.1-2) /day (Selemani et al., 2016)
ε0 1E-5 (1E-6, 1E-4) /day (Tumwiine et al., 2008)
ε1 1E-4 (1E-6, 1E-4) /day (Tumwiine et al., 2008)
ε2 1E-6 (1E-7, 1E-4) /day (Tumwiine et al., 2008)
α 5E-4 (5E-5-2E-2) Unitless (Magombedze et al., 2011a)
N 104 (8E+3-2E+5) Unitless (Tumwiine et al., 2008)
7.5.1 Simulation results
The impact of employing strategy (1A) (a combination of blood schizontocide and gameto-
cytocide only) in the control of P. falciparum infection in humans is as presented in Figure
7.4. It is evident that an antimalarial drug with such a combination is highly effective in
eradicating the merozoites and infected red blood cells as shown in Figures 7.4b and 7.4c,
respectively. However, this combination strategy offers little effect on the population of
infected hepatocytes as shown in Figure 7.4d. This is because these drugs are not active
against the liver stage parasites or schizonts. Moreover, a moderate decrease in the population
of gametocytes is also observed (see Figure 7.4a). Besides effective antimalarial drugs, it is
clear that other therapeutic measures may be necessary to eradicate all parasites and infected
cells during P. falciparum malaria infections. The control profile of strategy (1A) is shown in
Figure 7.5.
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Figure 7.4: Simulations of system (7.1), showing the impact of a combination of blood
schizontocide u3 and a gametocitocide u4 only during clinical P. falciparum malaria infection.
Used parameter values are shown in Table 7.2.



























Figure 7.5: Profiles of blood schizontocide u3 and gametocytocide u4. Here, u1 = 0, u2 = 0.
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In Figure 7.6, a combination of malaria vaccine antigens is considered. This corresponds
to strategy (1B). The combination of pre-erythrocytic vaccine antigen u1 and blood-stage
vaccine antigen u2 is shown to be very effective in decreasing the populations of infected
erythrocytes (Figure 7.6c) and infected hepatocytes (Figure 7.6d). Although the merozoites
are eradicated, this takes a slightly longer time, due to low vaccine efficacies (see Figure 7.6b).
A 100% efficacy of PEV would, however, not require augmenting with BSV. Nevertheless,
the efficacies of PEV and BSV is still likely to drop over time as the antibodies decay
(Sherrard-Smith et al., 2018). The control profile under this strategy is presented in Figure
7.7. It is observed that the efficacies of the vaccines should be maintained high for the entire
period of intervention.











































































































Figure 7.6: Simulations of system (7.1), showing the impact of a combination of pre-
erythrocytic vaccine antigens u1 with blood stage vaccine antigens u2 only. Used parameter
values are shown in Table 7.2.
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Figure 7.7: Profiles of pre-erythrocytic vaccine antigen u1 and blood stage vaccine antigens
u2. Here, u3 = 0, u4 = 0.











































































































Figure 7.8: Simulations of system (7.1), showing the impact of a combining pre-erythrocytic
malaria vaccine u1 and blood schizontocides u3 only in the control of within-human P.
falciparum infection. Used parameter values are shown in Table 7.2.
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The combined use of pre-erythrocytic vaccine and blood schizontocide, strategy (1C), is
shown to greatly decrease the population of infected erythrocytes and infected hepatocytes in
Figures 7.8c and 7.8d, respectively. Unlike strategies (1A) and (1B), this third strategy (IC)
is slightly more effective; it eradicates the merozoites and gametocytes within 30 days of
infection (see Figures 7.8a and 7.8b). Additionally, this strategy has a maximum duration
of 11 days before it eradicates all infected erythrocytes from the host. To guarantee total
eradication of all infected cells and infective parasites, the used antimalarial drug should be
highly effective (efficacy > 95%). The moderate effect of this strategy on the gametocyte
population means that the treated malaria patients would facilitate parasite transmission to
the mosquito vector, increasing future malaria cases and mortality. Figure 7.9 shows the
profile of the control measures in this strategy. The efficacy of the pre-erythrocyte vaccine
(u1) should be maintained throughout the control period. Similarly, the effectiveness of blood
schizontocide (u3) should remain high for at least half of the intervention period.



























Figure 7.9: Profiles of pre-erythrocytic vaccine antigen u1 and blood schizontocide drug u3.
Here, u2 = 0, u4 = 0.
If two or more vaccines and antimalarial drugs are combined, then different outcomes are
observed as presented in Figures 7.10-7.15. In Figure 7.10, blood schizontocide u3 is used to
treat malaria patients who have received a combination of pre-erythrocytic vaccine antigens
u1 and blood stage vaccine antigens u2. This defines strategy (2A). The control profiles of
u1 ̸= 0, u2 ̸= 0 and u3 ̸= 0 are presented in Figure 7.11. Although there is a general decrease
in the populations of infected cells and infective parasite, the rate of decline is moderate
and the clearance of gametocytes lasts longer than 20 days. A better result is however,
presented in Figure 7.12. In this strategy (2B), a combination of blood schizontocide
u3 and gametocytocides u4 is administered to a malaria patient who is already on a pre-
erythrocytic vaccine u1. A rapid rate of decline in populations of infected erythrocytes,
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infected hepatocytes, merozoites and gametocytes is observed. The density of gametocytes
fall exponentially; within 15 days of blood stage malaria. It is also noted that total eradication
of merozoite parasites from the human host occurs within two weeks of infection. The
profiles of the three control measures are displayed in Figure 7.13.











































































































Figure 7.10: Simulations of system (7.1), showing the impact of a combination of pre-
erythrocytic vaccine antigens u1, blood stage vaccine antigens u2 and blood schizontocide u3
only. Used parameter values are shown in Table 7.2.
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Figure 7.11: Profiles of pre-erythrocytic vaccine antigen u1, blood stage vaccine antigen u2
and blood schizontocide u3. Here, u4 = 0.











































































































Figure 7.12: Simulations of system (7.1), showing the impact of a combination of pre-
erythrocytic vaccine u1, blood schizontocide u3 and gametocitocidal drug u4. Used parameter
values are shown in Table 7.2.
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Figure 7.13: Profiles of pre-erythrocytic vaccine antigen u1, blood schizontocide u3 and
gametocytocide u4. Here u2 = 0.
Finally, in Figure 7.14, all the four control efforts are employed (strategy 3). Here, anti-
malarial drugs consisting of blood schizontocides and gametocytocides are administered to
malaria patients who are equally on a combined pre-erythrocytic and blood stage vaccine
antigens. Just like in strategy (2B), tremendous decline is observed in the populations of
gametocytes, merozoites, infected hepatocytes and infected erythrocytes when all the control
measures are employed. It takes a much shorter time to eradicate the malaria parasites from
the blood of the human host. Both the merozoites and infected red blood cells get eradicated
within 12 days of infection. It is clear that both strategy (2B) and strategy 3 offer the best
control options in controlling in-host P. falciparum malaria. Moreover, the simulations
results in Figures 7.12 and 7.14 reveal that the emergence of clinical malaria would be least
likely if either of these control strategies is implemented correctly. Nevertheless, strategy
(2B) only needs one highly efficacious malaria vaccine to achieve the same result as that
in strategy 3. Additionally, strategy (2B) is likely to be less costly compared to strategy 3,
which incorporates all the four control measures. In conclusion, the optimal control strategy
against P. falciparum malaria is strategy (2B): a combination of efficacious pre-erythrocytic
vaccine, effective blood schizontocide and a gametocytocide.
In Figure 7.15, the control profiles for each of the four controls employed in strategy 3
are presented. It is observed that the control profiles of the pre-erythrocytic vaccine (u1)
and blood stage vaccines antigens (u2) are maintained at highest levels of efficacy (75% in
our case) to ensure maximum eradication of asexual sporozoites and infected erythrocytes,
respectively. Similarly, the concentrations of blood schizontocides (u3) and gametocytocides
(u4) should be maintained at the highest levels to maximise eradication of asexual merozoites
and infected erythrocytes, respectively. Like in other control strategies already discussed, the
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effectiveness of the antimalarial drugs is likely to fall after day 45 and this remains lowest till
the end of the intervention period.











































































































Figure 7.14: Simulations of system (7.1), showing the impact of combining antigens of pre-
erythrocytic vaccine and blood stage vaccine together with the administration of combined
blood schizontocide and gametocitocidal drugs. Used parameter values are shown in Table
7.2. Here, u1 ̸= 0, u2 ̸= 0, u3 ̸= 0, u4 ̸= 0.
The best control strategy of an in-host malaria infection should eradicate all infective mero-
zoites, infected hepatocytes and infected red blood cells within the shortest time possible at
a minimal cost. Epidemiologically, the best control strategy should ensure no gametocyte
parasites are available for transmission to the mosquito vector. Although strategy (2B) is the
optimal strategy in this study, it should be implemented alongside existing vector control
measures such as ITNs and IRS if malaria elimination goal is to be achieved (WHO, 2015b).
This result is crucial for malaria drug development and highlights the urgent need for a highly
efficacious pre-erythrocytic malaria vaccine to complement existing ACTs.
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(d) Optimal control, u4
Figure 7.15: Plots showing the profiles of pre-erythrocytic vaccine antigen u1, blood stage
vaccine antigen u2, blood schizontocide u3 and gametocytocide u4.
7.6 Conclusion
In this chapter, optimal control theory has been applied to a deterministic in-host malaria
model. The model incorporates antimalarial drugs and malaria vaccines as control strategies
during clinical P. falciparum malaria. The objective was to establish the best combination
strategy involving (1) a blood schizontocide (2) a gametocytocide (3), a pre-erythrocytic
vaccine antigen and (4) blood stage vaccine antigen against P. falciparum malaria. The drug
and vaccine combinations are categorised into: (i) strategy (1A): a combination of a blood
schizontocide and gametocytocide, (ii) strategy (1B): a combination of pre-erythrocytic
and blood stage vaccine antigens, (iii) strategy (1C): a combination of pre-erythrocytic
vaccine and blood schizontocide drug, (iv) strategy (2A): a combination of pre-erythrocytic
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vaccine antigen, blood stage vaccine antigen and blood schizontocide, (v) strategy (2B): a
combination of pre-erythrocytic vaccine antigen, blood schizontocide and gametocytocide
and (vi) strategy 3: a combination of all the four control options (pre-erythrocytic vaccine
antigen, blood stage vaccine, blood schizontocide and gametocytocide).
The Pontryagin’s Maximum Principle was used to characterise and discuss control strategies
that substantially reduced the populations of infected erythrocytes, infected hepatocytes and
malaria parasites. The necessary conditions were derived and analysed for the existence of
the optimal control of malaria infection. For sufficiently small values of intervention time,
we proved the uniqueness of the optimality system. From the analysis, it was found out
that eradication of in-host malaria will be possible if highly efficacious vaccines are used in
combination with antimalaria drug therapy. Numerical results showed that a combination of
pre-erythrocytic vaccine, blood schizontocide and gametocytocide drugs would offer the best
control strategy against clinical P. falciparum malaria. A combination of all the four control
measures equally gave a comparatively good results, however, it may be too expensive.
Nonetheless, the synergy of malaria vaccine antigens and antimalarial drug regimens is
crucial for future malaria chemotherapy control.
It is important to note that the parameter values and weights used in this analysis are estimated
for illustration purposes. More realistic results would be feasible if data on the costs of
implementation of the four controls are available. However, the results presented in this
chapter give insights on the need to combine effective antimalarial drugs and to use them
alongside efficacious malaria vaccine antigens to control P. falciparum malaria infections.
This study is concluded in the next Chapter 8. It summarises the results of the study and list




8.1 Conclusion and discussion
Despite the renewed optimism regarding the achievement of malaria elimination goal, the
current antimalarial measures offer little in the way of novel strategies (Sinha, 2014). Malaria
cases are strangely on the rise in the top ten high burden African countries (Nigeria, Burkina
Faso, Ghana, Niger, Mali, Guinea, Benin, Côte d’Ivoire, Togo and Sierra Leone). It is on
record that 3.5 million more cases were reported in 2017 in these countries (WHO, 2018f).
The appearance of parasite resistance to currently recommended antimalarial drugs (ACTs) in
Thailand and Cambodia and the possible risk of spreading to other malaria endemic regions
has generated global concern for future malaria control and elimination measures. Progress
in malaria control is currently hampered with inadequate investment (WHO, 2018f). With
minimal progress in malaria vaccine development and the absence of alternative drugs in
the pipeline, the need to discover and develop newer malaria therapeutic strategies cannot
be overemphasised (WHO, 2018f). This study was aimed at formulating and analysing
mathematical models of in-host malaria dynamics with the goal of improving malaria vaccine
and therapeutic strategies.
In this study, the dynamics and interactions of malaria parasites, the erythrocytes (red blood
cells), the liver hepatocytes and the immune cells are represented using a system of nonlinear
ordinary differential equations. The extended models are subject to therapeutic conditions of
antimalarial drugs and malaria vaccines. The specific control efforts of the immune cells is
highlighted in all the formulated models. Parasite resistance and the effects of competition
between different parasite strains are also discussed. Based on the next generation matrix
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method, the basic/effective reproduction numbers are computed. Optimal control theory is
also applied to establish the best therapeutic combination strategy against in-host falciparum
malaria infection.
The first model in this study is a deterministic model of in-host malaria infection without
therapeutic interventions The model incorporates parasite and cell dynamics at the liver and
blood stages within the human host. Innate immune cells called macrophages are deployed
to eliminate infected red blood cells and malaria parasites from blood circulation. In addition,
the liver hepatocytes are assumed to be generated from the bone marrow and through a
process of self-regeneration from existing hepatocytes. The malaria-free equilibrium point
is shown to be locally asymptotically stable when the in-host reproduction number is less
than unity. The global stability of the malaria-free state is only guaranteed if the basic
reproduction number R0 is less than unity.
Results based on numerical simulation show that intervention during malaria infection should
target the merozoite invasion rate on healthy erythrocytes and the density of merozoites in
circulation that are responsible for secondary invasion at the blood stage. In the absence
of malaria treatment, the macrophages are shown to be vital in eliminating infected ery-
throcytes at the blood stage. The higher the rate of phagocytosis of infected erythrocytes
by macrophages, the lower the density of infected red blood cells and hence malaria par-
asitaemia. For quick and timely reduction of parasitaemia, an increased merozoite death
rate using antimalarial drugs such as ACT would be necessary. This would further ensure
reduced density of infected red blood cells and hence decreased recrudescence. Moreover,
erythrocyte invasion-avoidance vaccine would minimise the density of infected erythrocytes
and hence malaria disease severity. This intervention could help terminate the erythrocytic
schizony, leading to minimal parasite transmission to mosquito vector.
The potential role of efficacious malaria vaccines in in-host malaria control and eradication
is presented in the second model in this study. The in-host malaria model incorporates pre-
erythrocytic vaccine (PEV), blood stage vaccine (BSV) and transmission blocking vaccine
(TBV). The model is mathematically analysed to provide useful insights on individual and
combined vaccine impacts in reducing the severity of P. falciparum malaria. It was established
that a highly efficacious malaria vaccine (efficacy > 90%) is likely to offer the much needed
protection against P. falciparum malaria. This estimate should however be treated with
some discretion due to ‘not so accurate’ parameter values. Additionally,the critical vaccine
efficacy necessary in the development of future malaria vaccines was established. To achieve
a substantial reduction in mortality and morbidity due to malaria infections, the efficacy of
the malaria vaccines should be higher than the corresponding critical vaccine efficacies. For
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instance, when the efficacy of the blood stage vaccine is lower than the critical efficacy, the
rate of infection of susceptible erythrocytes is higher and clinical malaria persists. However,
the concentration of blood trophozoites and blood schizonts decreases drastically if the
efficacy of the blood stage vaccine is higher than the critical blood stage vaccine efficacy. A
combination of different malaria vaccine antigens yields better therapeutic results compared
to individual vaccine antigens. Vaccine combinations induce multiple immune responses
with the potential to prevent or eradicate malaria infection. Analysis of the model here shows
that a highly effective vaccine combination is critical for P. falciparum malaria elimination
goal.
Due to uncertainties that may accompany choices for parameter values, it is important to
correctly understand the possible effects of the parameter values to the model outcome. The
more sophisticated and efficient sensitivity analysis approach of LHS/PRCC is applied to the
third in-host malaria model subject to vaccine control measures. The model is shown to be
highly sensitive to variations in malaria vaccine efficacies. Only efficacious malaria vaccines
have a chance to eliminate P. falciparum malaria or to reduce its severity during infection.
Sensitivity indices based on the basic reproduction number indicates that the parasite invasion
rates are highly sensitive to disease progression. Licensed malaria vaccines must therefore be
efficacious enough for quick and rapid eradication of all infective parasites. Other parameters
such as the proportion of merozoites that become gametocytes per dying blood schizont and
the average number of merozoites released per bursting blood schizonts are also shown to
have a considerable impact on the severity of malaria infection.
A highly effectious blood stage vaccine is also effective in reducing the density of malaria
gametocytes. This is likely to reduce malaria transmission from the human host to the
mosquito vector. The protective capacity of liver stage- specific CD8+ T cells is a motivation
for developing a blood stage vaccine that would boost the production of blood trophozoite-
specific CD8+ T cells. It is observed that the more efficient the pre-erythrocytic vaccine is,
the lower the density of released merozoites into the host’s blood stream. Moreover, a rapid
clearance of infected hepatocytes is likely to result into less infected erythrocytes at the blood
stage. An efficacious pre-erythrocytic vaccine has a potential to eliminate all infected liver
hepatocytes. Such vaccines may also reduce the overall burst size of an infected hepatocyte,
leading to reduced erythrocytic schizonogy.
The synergy of combining pre-erythrocytic vaccines, blood stage vaccines and transmission
blocking vaccines antigens induces multiple immune responses with the potential to prevent
malaria infection. Although efficacious malaria vaccines are shown to be effective in reducing
severity of clinical malaria, the results further confirm the need to combine malaria vaccines
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with existing antimalarial therapy to achieve a complete clearance of the parasites from the
human host. Moreover, from the LHS/PRCC analysis, it is observed that long term precise
predictions of the density of infected liver hepatocytes and infected erythrocytes would be
difficult until certain sensitive parameters are correctly determined.
The effects of parasite resistance under single and multiple-strain parasite infection is also
investigated in this study. The parasites are categorised as either drug-sensitive strain (dss)
or drug-resistant strain (drs). The immune cells are incorporated to reduce the invasive
characteristic of the malaria merozoites. The dynamics here are strictly limited to the blood
stage of malaria infection. Antimalarial therapy is applied to the model but only targets
erythrocytes infected with drug-sensitive merozoites. The results show that the success of
P. falciparum infection in the presence of multiple parasite strain is directly dependent on
the ability of the individual parasite strains to dominate the infection. The parasite strain
with a higher threshold value, RE is likely to dominate the infection. Prescribed antimalarial
drugs should therefore be effective enough to eradicate both drug-sensitive and drug-resistant
parasite strains.
To assess the impacts of the different parasite strains to disease dynamics, the model is
simulated for different values of the threshold quantities Rs and Rr. It is observed that
when Rr > 1 and Rs > 1, then both parasite strains are persistent and the infection becomes
severe. If Rr > 1 and Rs < 1, then the drug-sensitive parasites would decline to zero as the
drug-resistant strain continue to multiply and remain persistent, increasing the severity of
infections. On the other hand, if Rs > 1 and Rr < 1, then the drug-resistant parasite strains
would be eradicated. Moreover, provided that the threshold quantities Rs and Rr are less than
unity, the use of an efficacious antimalarial drug would help clear P. falciparum infection
from the human host.
The efficacy of antimalarial drug is shown to have direct negative impact on the density of
infected erythrocytes. The higher the efficacy of administered antimalarial drug, the lower
the population of infective merozoites and the smaller the density of infected erythrocytes.
This ensures prompt recovery from malaria infection. The efficacy of antimalarial drug is
however shown to have least effect on the population of drug-resistant infected erythrocytes.
Using contour plots and results from sensitivity analysis, it is observed that the efficacy
of antimalarial drug used, the density of blood floating merozoites produced per infected
erythrocyte, the rate of development of resistance and the rate of infection by merozoites are
the most important parameters in blood-stage P. falciparum malaria infection and control
efforts.
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Although the drug-resistant strain is shown to be less fit, the presence of both strains in
the human host has a huge impact on the cost and success of antimalarial treatment. To
reduce the emergence of resistant strains, it is vital that only effective antimalarial drugs
are administered to patients in hospitals, especially in malaria endemic regions. Similarly,
to improve malaria therapy and reduce cases of parasite resistance to existing therapy, our
results call for regular and strict surveillance on antimalarial drug use in clinics and hospitals
in malaria-endemic countries.
The theory of optimal control is applied to the in-host malaria model in this study. The model
incorporates antimalarial drug regimens and malaria vaccine antigens as control strategies
against clinical P. falciparum malaria. The goal of using this model is to establish the best
combination strategy involving a pre-erythrocytic vaccine antigen, a blood stage vaccine
antigen, a blood schizontocide and a gametocytocide against in-host P. falciparum malaria
infection. The drug and vaccine combinations are categorised into: (i) a combination of blood
schizontocide and gametocytocide only (strategy 1A), (ii) a combination of pre-erythrocytic
and blood stage vaccine antigens only (strategy 1B), (iii) a combination of pre-erythrocytic
vaccine antigen and blood schizontocide drug only (strategy 1C), (iv) a combination of
pre-erythrocytic vaccine antigen, blood stage vaccine antigen and blood schizontocide only
(strategy 2A), (v) a combination of pre-erythrocytic vaccine antigen, blood schizontocide
and gametocytocide only (strategy 2B) and (vi) a combination of all the four control options
(pre-erythrocytic vaccine antigen, blood stage vaccine antigen, blood schizontocide and
gametocytocide), (strategy 3).
The Pontryagin’s Maximum Principle was used to characterise and discuss control strategies
that substantially reduced the populations of infected erythrocytes, infected hepatocytes and
malaria parasites. The necessary conditions were derived and analysed for the existence of
the optimal control therapy for malaria infection. For sufficiently small values of intervention
time, the uniqueness of the optimality system was proved. Numerical results showed that a
combination of pre-erythrocytic vaccine antigen, blood schizontocide and gametocytocide
drugs offers the best control strategy against P. falciparum malaria infection.
8.2 Policy recommendations based on this study
Despite global and regional success in reducing morbidity and mortality due to malaria,
malaria still remains a major public health problem in Kenya. About 4 million malaria cases
are reported annually, with about 5.1% mortality rate among patients admitted with severe
215
malaria. Over 99% of all reported cases are due to the deadly P. falciparum malaria. Research
findings from this study could be useful to malaria research organisations such as the Kenya
Medical Research Institute (KEMRI), Centers for Disease Control and Prevention (CDC-
Kenya) and the Ministry of Health in their effort to prevent and control malaria infections in
the country. Specific policy recommendations include the following:
1. For quick and timely treatment of uncomplicated P. falciparum malaria, treatment
using efficacious ACTs such as artemether-lumefantrine (AL) is necessary.
2. Malaria vaccine minimises the density of infected erythrocytes and hence malaria
disease severity. Vaccines such as RTS,S/AS01, should be used alongside existing
antimalarial drugs to control P. falciparum malaria infections in the country.
3. Threats caused by parasite resistance offer a unique opportunity to closely monitor
use and misuse of antimalarial drugs. Regular and strict surveillance on quality and
standards of antimalarial drugs in medical facilities in the country is therefore very
critical.
4. To reduce mortality and morbidity, only qualified medical officers should be permitted
to diagnose and administer antimalarial treatment to malaria patients in the country.
5. Patients suffering from such infections as HIV/AIDS or tuberculosis which have
deleterous effect on the protective immune cells should seek immediate medical
treament when infected with malaria. Their compromised immune system exposes
them to severe malaria attacks and possible untimely death.
6. Individuals presenting malaria symptoms should also be tested for other infections
such as HIV/AIDS and tuberculosis.
8.3 Limitations and future work
This study uses mathematical modelling and analyses to provide useful and rich insights
necessary for understanding in-host malaria dynamics and for improving vaccine and thera-
peutic control measures against P. falciparum malaria. Like many other epidemic models,
the in-host malaria models presented here have numerous model assumptions. These assump-
tions help to minimise model complexities and maintain systems with manageable analytical
sizes. However, the malaria parasite life cycle is extremely complex with several biological
functions that are largely unknown. Some of the assumptions in this study could be dropped
to improve model outcome. For example, the presented model ignores the biology of CD8+
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T activation and assumes constant rate of production of the immune cells during malaria
parasite invasion. Secondly, the formation of gametocytes is another mystery in the malaria
parasite life cycle. The actual rate of commitment of merozoites to form gametocytes is
largely unknown and highly speculated. This process has been highlighted in some studies
(Bechtsi and Waters, 2017) as a random process that would best be captured using a stochastic
model. Nevertheless, the actual process is still unclear with only a small proportion of the
parasites per erythrocytic cycle committing to gametocytogenesis (Josling and Llinas, 2015).
It is important to note that the values of the parameters used in this study were either obtained
from existing literature or simply assumed. This is partly occasioned by lack of data and also
due to some unknown dynamics within the complex malaria parasite life cycle. Availability
of clinical data on P. falciparum malaria dynamics with and without vaccine and antimalarial
drugs could be very helpful in estimating model parameter values for even better results.
It would therefore be difficult to predict with higher accuracy, the optimal malaria vaccine
efficacy. Time delay from invasion to schizont rupture is not captured in this study. This
is another key area that could improve the results presented here. A time-dependent delay
parameter would be a plausible addition to future in-host malaria models. In addition,
this study acknowledges that the parasite invasion rates may not necessarily be constant
throughout the infection period.
Finally, model validation is a very powerful step in disease modelling. Another possible
extension of the models considered in this study can be implemented by carrying out model
validation based on valid data on in-host P. falciparum malaria dynamics and therapeutic
control. Note that the weights used in the optimal control analysis are estimated for illustration
purposes. More realistic results would be feasible if data on the costs of implementation of
the four controls are available.
In spite of the stated shortcomings, the presented models and analyses performed in this
study provide useful insights on in-host malaria dynamics and therapeutic control measures
against P. falciparum malaria. The results from this study call for continued investment in
malaria drug development and urgent drive to improve the efficacy of malaria vaccines such
as RTS,S/AS01. The administration of effective antimalarial drugs alongside malaria vaccine
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Definition A.1. Linearisation. In mathematics, linearisation refers to the process of finding
a linear approximation to a function at a given point.
The concept of linearisation is very important in the study of dynamical systems. It enables
us to assess the local stability of the equilibrium point(s) of a non-linear dynamical system.
The process of linearing such a system is presented as follows:
Consider a compartmental model of n state variables (populations): y1(t),y2(t), · · · ,yn(t).
The argument t is the independent time variable. This system can be modelled using
autonomous n first order differential equations as follows.
y′1 = G1(y1,y2, · · · ,yn),
y′2 = G2(y1,y2, · · · ,yn),
...
y′n = Gn(y1,y2, · · · ,yn).

(A.1)
Definition A.2. Equilibrium point. We define the equilibrium point (or critical or stationary
or rest point) of the system (A.1) as a solution (y∗1,y
∗
2, · · · ,y∗n) such that
G1(y∗1,y
∗
2, · · · ,y∗n) = 0,
G2(y∗1,y
∗








A small perturbation ε on the steady state (y∗1,y
∗
2, · · · ,y∗n) gives
y1(t) = y∗1 + ε ȳ1(t),
y2(t) = y∗2 + ε ȳ2(t),
...
yn(t) = y∗n + ε ȳn(t).

(A.3)
Substituting (A.3) into (A.1), the differential equations become
y′1 = G1(y
∗
1 + ε ȳ1,y
∗
2 + ε ȳ2, · · · ,y∗n + ε ȳn),
y′2 = G2(y
∗
1 + ε ȳ1,y
∗




1 + ε ȳ1,y
∗
2 + ε ȳ2, · · · ,y∗n + ε ȳn).

(A.4)




















































































ȳn +O(||ȳ1, ȳ2, · · · , ȳn||),

(A.5)




2, · · · ,y∗n) is a steady state, then
G1(y∗1,y
∗
2, · · · ,y∗n) = G2(y∗1,y∗2, · · · ,y∗n) = · · ·= Gn(y∗1,y∗2, · · · ,y∗n) = 0. (A.6)
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· · · ∂Gn
∂yn
 (A.9)
is the Jacobian matrix of system (A.1), evaluated at the steady state (y∗1,y
∗
2, · · · ,y∗n).
The equilibrium point y∗ = (y∗1,y
∗
2, · · · ,y∗n) is said to be stable if all the eigenvalues of the
Jacobian matrix (A.9) evaluated at y∗, have negative real parts. The equilibrium point is
unstable if at least one of the eigenvalues has a positive real part.
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Appendix B
Samples of used simulation codes
B.1 (Python Code): Numerical simulations, model 3.1, section 3.6
''' Required packages'''
import scipy
import numpy as np
import scipy.integrate
from pylab import * # for plotting commands
import pylab as pl
''' Declaring the fixed parameters '''
betar=2.0*10**(-5); betas=1.6*10**(-6); mu1=0.029





kappa1=1; kappa2=1; kappa3=1; Lambda=20; N=10000







H0 = 3*10**5; HX0 = 2*10**4; R0 = 5*10**5; RX0 = 50;
Z0 = 3*10**5; S0 = 2000; M0 = 70
''' Numerical solution of the model'''









''' Time span over which the integration is done '''
time = scipy.linspace(0, 200, 150) # 1000 plotting points
X0 = scipy.array([H0, HX0, R0, RX0, Z0, S0, M0])
''' The integration of the ODEs '''
Xs = scipy.integrate.odeint(odesystem,X0,time)
'''Plotting'''
p1=pl.plot(time,Xs[:,0],'b',lw = 2) #H





#''' The plot legend'''
pl.legend(('H', 'H_X'), loc="top left")
pl.show()
252
B.2 (Matlab Code): Vaccine combinations, model 5.1, section 5.7
% Part A:
function y2dot=y2combineddot(t3,y2) %defining the function
% Parameter values
Lambda=2500000; mus=0.002; lambdah=3*10^5; lambdar=3*10^5;
betar=2.0*10^(-4); betas=3.0*10^(-5); muh=0.2; mux=0.2;
pi=0.2; kx=0.01; kt=0.01; kc=0.0000001; dx= 0.00001;
dt= 0.00001; dc= 0.00001; mur=0.000083; mut=0.27; muc=0.7;
mum=48; mug=0.0000625; gamma=1.5; chi=0;e=0.75; v=0; d=0.0005;
lambdaw=30; tau=1.5; muw=2; b=0.2; a=0.2; P=16; N=10000;
% Basic reproduction number
% z(1)=H, z(2)=X, z(3)=S, z(4)=R, z(5)=T, z(6)=C, z(7)=M, z(8)=G,
z(9)=W
RO1 = ((1-v)* betas* lambdah)/(muh*mur)
%Model R01 due to pre-erythrocytic infection
RO2 = (P*(1-pi)* (1-a)*(1-e)*betar* lambdar)/(betar* lambdar+mum*mur)
%Model R01 due to erythrocytic infection
%Model system of equations
y2dot(1)=lambdah - muh * y2(1)-betas * (1-v) * y2(3) *
y2(1);
y2dot(2)=betas * (1-v) * y2(3) * y2(1)-mux * y2(2)-kx * (1-v)
* y2(9)* y2(2);
y2dot(3)=Lambda * (1-chi)-mus * y2(3)-betas * y2(3) * y2(1);
y2dot(4)=lambdar-((1-e) * betar * y2(4) * y2(7)) - mur * y2(4);
y2dot(5)=((1-e) * betar * y2(4) * y2(7)) - mut * y2(5)-gamma * y2(5)
-(kt * (1-e) * y2(9) * y2(5));
y2dot(6)=gamma * y2(5)-muc * y2(6)-(kc * (1-e) * y2(9) * y2(6));
y2dot(7)=(1-b) * N * mux * y2(2)+(P * (1-pi) * (1-a) * muc * y2(6))
-mum* y2(7)
-betar * y2(4) * y2(7);
y2dot(8)=pi * muc * y2(6)- mug * y2(8);
y2dot(9)=tau * lambdaw + y2(9)*(dx * y2(2) + dt * y2(5) + dc * y2(6))
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-muw * y2(9);
y2dot=[y2dot(1) y2dot(2) y2dot(3) y2dot(4)
y2dot(5) y2dot(6) y2dot(7) y2dot(8) y2dot(9)]';
% PART B
clear;
to = 0; %Initial time in years.
tf =80; %Final time in years.
%Initial conditions
yo = [3*10^5 4*10^3 1000 5*10^4 4*10^1 50000 1000 5000 20000];
% yo = [H0, X0, SO, R0, T0, C0, M0, G0, W0];
[t1 y]= ode45('ycombineddot',[to tf],yo); %
[t5 z4]= ode45('z4combineddot',[to tf],yo); %
[t2 z]= ode45('zcombineddot',[to tf],yo); %
figure(1)
hold on
plot(t1,y(:,2),'--r','LineWidth',2.2) % No vaccine at all
plot(t5,z4(:,2),':b','LineWidth',2.2) % 75% for v, v=chi=0
plot(t2,z(:,2),'g','LineWidth',2.2) % perfect vaccine 75% efficacious
legend('X(t) without vaccines','X(t) with v = e = 75% and
\chi = 0%','X(t) with e = v = \chi = 75%','Location','East')
xlabel('Time (Days)')
ylabel('Infected Hepatocytes, X(t)')














D[v1,HX ]/.{H->λh/µh,HX ->0,R->λr/µr,RX ->0,Z->λz/δz,S->0,M->0}
µ2
v2 = µ4RX +ηRX Z
RX µ4 +RX Zη






v4 =−Nµ2HX −Kζ µ4RX +δmM+βrRM




mat = {{µ2,0,0,0} ,{0,µ4 +(ηλz/δz),0,0} ,{0,0,δs +(βsλs/µ1),0} ,
{−Nµ2,−Kζ µ4,0,δm +(βrλr/µ3),0}}
v = MatrixForm[mat]
µ2 0 0 0
0 µ4 +(ηλz/δz) 0 0
0 0 δs +(βsλh/µ1) 0







































0 0 0 βrλr
µ3
0 0 0 0
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Human malaria remains a major killer disease worldwide, with nearly half (3.2 billion) of the world’s population at risk of malaria
infection.The infectious protozoan disease is endemic in tropical and subtropical regions, with an estimated 212 million new cases
and 429,000 malaria-related deaths in 2015. An in-host mathematical model of Plasmodium falciparummalaria that describes the
dynamics and interactions of malaria parasites with the host’s liver cells (hepatocytic stage), the red blood cells (erythrocytic stage),
and macrophages is reformulated. By a theoretical analysis, an in-host basic reproduction number 𝑅0 is derived. The disease-free
equilibrium is shown to be locally and globally asymptotically stable. Sensitivity analysis reveals that the erythrocyte invasion
rate 𝛽𝑟, the average number of merozoites released per bursting infected erythrocyte 𝐾, and the proportion of merozoites that
cause secondary invasions at the blood phase 𝜁 are the most influential parameters in determining the malaria infection outcomes.
Numerical results show that macrophages have a considerable impact in clearing infected red blood cells through phagocytosis.
Moreover, the density of infected erythrocytes and hence the severity of malaria are shown to increase with increasing density
of merozoites in the blood. Concurrent use of antimalarial drugs and a potential erythrocyte invasion-avoidance vaccine would
minimize the density of infected erythrocytes and hence malaria disease severity.
1. Introduction
Human malaria remains a major killer disease worldwide,
with nearly half (3.2 billion) of the world’s population at risk
of malaria infection [1]. The infectious disease is endemic
in tropical and subtropical regions, with an estimated 212
million new cases (uncertainty range: 148–304 million) and
429,000 malaria-related deaths (range: 235,000–639,000) in
2015 [2]. 92% of the deaths and 90% of the cases occurred
in sub-Saharan Africa. 70% of the reported deaths occurred
among children below the age of five. Despite existing vector
control measures and tremendous progress in the develop-
ment of antimalarial therapy accompanied with worldwide
decline in incidence rate (fell by 21% in 2015) and mortality
rate (fell by 29% in 2015), malaria remains one of the greatest
global health challenges to date [2].
The protozoan disease is caused by parasites of the genus
Plasmodium which are transmitted to humans by the bite of
female Anopheles mosquito. Plasmodium falciparum, which
is predominant in sub-Saharan Africa, New Guinea, and
Haiti [3], is the major cause of malaria infections. The other
Plasmodium species that cause malaria are P. vivax, P. ovale,
P. malariae, and P. knowlesi [4]. P. vivax and P. ovale can hide
in the liver for prolonged periods as hypnozoites, causing
relapsing malaria months or even years after the initial
infection [5]. P. vivax has the greatest geographical range of
the disease and hence is the main contributor to worldwide
malaria morbidity [3]. Our study focuses on the dynamics of
Plasmodium falciparum in the human host.
During their obligatory blood meals, infected female
Anopheles mosquitoes inject sporozoites belonging to Plas-
modium falciparum species into the human dermis [6]. The
motile sporozoites travel through the blood vessels and
enter the host’s liver. Hepatocyte invasion is accompanied
by the formation of parasitophorous vacuole (PV) around
the sporozoite [7]. They form preerythrocytic schizonts and
multiply by schizogony, culminating in the production of
8–24 first generation merozoites that are released into the
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blood when the liver schizonts burst open [8]. The released
merozoites invade susceptible erythrocytes and undergo
another phase of schizogony, which is relatively faster com-
pared to that at the exoerythrocytic stage [9].
Within a period of two days, the infected red blood
cells rupture to release about 16 daughter merozoites [10].
Most of the released merozoites quickly invade susceptible
erythrocytes, leading to another cycle of infections. The
waves of bursting erythrocytes and the invasion of fresh
erythrocytes by the newly released merozoites increase par-
asitemia and produce malaria’s characteristic symptoms [11].
In the absence of adequate protective immune response
or antimalarial therapy, the host is likely to suffer severe
anaemia or even die [12]. The rest of the daughter merozoites
develop into sexual forms called gametocytes [10]. These
gametocytes are later taken up by other female Anopheles
mosquitoes during feeding [13]. This marks the beginning
of the sporogenic cycle that occurs within the mosquito
vector.
The presence of the malaria parasites in the human
body elicits response from numerous immune cells. The
innate immune system and the adaptive immune system form
the first and the second lines of defence, respectively [14].
Adaptive immune system further provides protection against
future exposures to malaria pathogens. Innate immune cells
such as the Plasmodium falciparum DNA, natural killer cells
(NK cells), dendritic cells (DCs), macrophages, natural killer
T (NKT) cells, and T cells are involved in the clearance
of circulating parasites, infected erythrocytes, and infected
hepatocytes [14]. Subject to parasite strain, the DCs and
NK cells may prompt or restrain inflammatory responses
[15]. The NKT cells also help regulate DCs and T cell
responses to Plasmodium [14]. Moreover, studies in [16] have
demonstrated that malaria infection induces activation of
Toll-like receptors (TLRs): TLR1, TLR2, TLR4 (which are
located on the cell surface), and TLR9 which is not expressed
on the cell surface. TLR2 and TLR9 are also activated
by malarial glycosylphosphatidylinositol (GPI) anchors and
parasite-derived DNA bound to hemozoin [16].
Unlike the NK cells, the macrophages have been shown
to effectively phagocytose malaria-infected red blood cells
during the erythrocytic phase [17]. A part from its ability
to wholly ingest infected red blood cells, the macrophages
can also selectively extract malaria parasites from recently
infected erythrocytes [18]. The parasite-extraction capability
of macrophage therefore leaves the surviving erythrocytes to
continue circulating like the other healthy red blood cells.
The rest of the paper is organized as follows: in Sec-
tion 2, we formulate the in-host malaria model and state
the invariant region in which the model is defined. In
Section 3, we compute and describe the model in-host
reproduction number. The results on model equilibrium
points (disease-free equilibrium and endemic equilibrium
points) and the stability of the disease-free equilibrium point
are also considered in Section 3. Section 4 is devoted to
numerical solution of the in-host model under different
conditions of the threshold parameter (in-host reproduction
number). Parameter sensitivity analysis and the effects of
parameter variation on different populations are investigated
in Section 4. A conclusion and discussion complete the paper
in Section 5.
2. In-Host Malaria Model
Several studies onmathematicalmodelling of in-hostmalaria
and its dynamics within the human host have been done.
Nearly all the earlier mathematical models (see, e.g., [25–27])
focused on improving Plasmodium falciparum control while
focusing on the blood stage of parasite development. These
models have been found to be useful in explaining in-host
observations by means of biologically plausible assumptions
such as parasite diversity, predicting the impact of interven-
tions or the use of antimalarials [28], and estimating hidden
parameter values [29]. Although the models in [19, 21, 23,
30] have considered the impact of immune response and
treatment, the modelling is only limited to the blood stage
of Plasmodium falciparum development. In [20, 22, 31], the
liver stage is incorporated in the malaria model. However,
the contribution of immune system is ignored in [20, 31].
Moreover, all the immune cells are assumed to play an active
role duringmalaria infection in [22].Thismay not be entirely
true. The specific impacts of immune responses to malaria
infection are well discussed in [32–36].
In the following sections, we extended the model in [21]
by incorporating the liver stage of parasite development. The
reformulated in-host malaria model focuses on the erythro-
cytic and hepatocytic stages and describes the dynamics of
interactions between the malaria parasites, the liver hepa-
tocytes, the red blood cells, and the macrophages (immune
system cells). Unlike the work in [20, 22], we ignored the
vector stage of parasite development and assumed a twofold
process in the generation of hepatocytes: from the bone
marrow and from self-replication of the existing hepatocytes.
Again, we have assumed that the generation of macrophages
and the susceptible red blood cells from the bone marrow
increase with increasing density of the infected erythrocytes.
However, whatever density of the infected erythrocytes, there
is a limit on the rate at which cells can be released from the
bone marrow.
2.1. Model Formulation. Thehepatocytic-erythrocyticmalar-
ia model describes the dynamics of Plasmodium falciparum
parasite during the hepatocytic and erythrocytic stages and
their interactions with the host’s red blood cells, liver hep-
atocytes, and the macrophages. The compartmental model
assumes seven interacting populations of sporozoites 𝑆(𝑡),
susceptible hepatocytes 𝐻(𝑡), infected hepatocytes 𝐻𝑋(𝑡),
susceptible red blood cells (RBCs) 𝑅(𝑡), infected red blood
cells (IRBCs) 𝑅𝑋(𝑡), merozoites𝑀(𝑡), and macrophages 𝑍(𝑡)
at any time 𝑡. The dynamics of malaria parasites and host-cell
populations in each compartment are described as follows.
Sporozoites (𝑆).The femaleAnophelesmosquito is assumed to
inject sporozoites into the human system during blood meal
at a constant rate Λ. The sporozoites molt through the blood
stream and reach the liver in about 2 hours, where they invade
the hepatocytes at the rate 𝛽𝑠. We assume that the sporozoites
can die naturally at a rate 𝛿𝑠.
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Susceptible Hepatocytes (𝐻). We consider the bone marrow
and self-replication as the main sources of the liver hepato-
cytes. The recruitment of hepatocytes from the bone marrow
is assumed to occur at a constant rate 𝜆ℎ. Just like during
liver transplant [37], we argue that, during severe malaria
infections, the rate of generation of healthy hepatocytes is
likely to increase tremendously and in proportion to the
concentrations of the infected liver cells [38]. This additional
increase is represented by the term 𝜌1𝐻𝑋/(𝜅1 + 𝐻𝑋) =𝜓1(𝐻𝑋), where𝐻𝑋 and 𝜌1, respectively, represent the concen-
tration of infected hepatocytes and their rates of generation.
The parameter 𝜅1 represents the number/concentration of
the infected hepatocytes at which the recruitment of the
healthy hepatocytes is a half of the maximum rate. Owing to
invasion by sporozoites at the rate 𝛽𝑠, susceptible hepatocytes
get infected and progress to subpopulation 𝐻𝑋. In addition,
hepatocytes in compartment𝐻 are assumed to have a natural
life expectancy and may hence die naturally at the rate 𝜇1.
Infected Hepatocytes (𝐻𝑋). Infected hepatocytes mature into
liver-stage schizonts. These schizonts burst open releasing
2000–40000 uninucleate merozoites into the blood stream
[39]. The term 𝑁𝜇2𝐻𝑋 represents the total population of
merozoites released upon bursting of infected hepatocytes.
The parameter 𝜇2 represents the death rate of the infected
hepatocytes.
Susceptible Red Blood Cells (𝑅). Similar to malaria models
in [21, 23, 30], we have assumed that the susceptible RBCs
get recruited at a constant rate 𝜆𝑟 from the bone marrow.
We further assume that, during infection, the erythrocyte
production is accelerated owing to the presence of IRBCs at
the rate 𝜌2. This increase is denoted by the term 𝜌2𝑅𝑋/(𝜅2 +𝑅𝑋) = 𝜓2(𝑅𝑋), where 𝜅2 represents number/concentration
of the infected red blood cells at which the recruitment of
susceptible red blood cells is a half of the maximum rate. The
particular mechanisms involved in this accelerated process
are, however, still poorly understood [40]. The susceptible
RBCs get infected by merozoites at a rate proportional to
the contact rate of their density, 𝛽𝑟𝑀𝑅. The positive constant𝛽𝑟 describes the rate of successful invasion by a malaria
merozoite. The susceptible RBCs die naturally at a rate 𝜇3.
Infected Red Blood Cells (𝑅𝑋). Upon invasion by merozoites,
the healthy RBCs get infected, leading to the formation of
infected red blood cells 𝑅𝑋. Although the RBCs die at a
constant rate 𝜇4, they can similarly be killed through phago-
cytosis by the macrophages at the rate 𝜂. At maturity, the
IRBCs burst open, releasing free merozoites into the blood
system, causing secondary invasion and disease progression.
Merozoites (𝑀). After 2–15 days, the infected hepatocytes
burst open and release merozoites into the blood system.
This is represented by the term 𝑁𝜇2𝐻𝑋, where 𝑁 is the
average number of merozoites released per bursting infected
hepatocytes. An average of 𝐾 merozoites is released per each
bursting IRBC.These free parasites suffer a natural death at a
rate 𝛿𝑚 and invade susceptible RBCs at a rate 𝛽𝑟. Within the
red blood cells, themerozoites mature either into uninucleate
Figure 1: Schematic diagram for hepatocytic-erythrocytic and
malaria parasite dynamics.The dotted lines without arrows indicate
cell-parasite interaction and the solid lines show progression from
one compartment to another.
gametocyte or into erythrocytic stage schizont containing
10–36 merozoites [39]. After about 48–72 hours, the erythro-
cytic stage schizont ruptures, releasing more merozoites into
blood stream to cause further invasion of healthy RBCs. We
assume that a proportion 𝜁 of the merozoites contribute to
secondary invasion of the susceptible RBCs. The rest of the
merozoites (1 − 𝜁) transform into gametocytes that are later
picked up by female Anophelesmosquitoes during feeding.
Macrophages (𝑍). Owing to their effectiveness in elimination
of infected erythrocytes and infective malaria parasites, we
have considered the innate macrophage cells as the main part
of the immune response in malaria infection. Consequently,
we have assumed that the macrophage cells are recruited
at a constant rate 𝜆𝑧 from the bone marrow. Moreover,
they proliferate at a rate 𝜌3 in the sites of infection in
proportion to the density of IRBCs. This is represented by
the term 𝜌3𝑅𝑋/(𝜅3 + 𝑅𝑋) = 𝜓3(𝑅𝑋), where 𝜅3 denotes the
number/concentration of the infected red blood cells atwhich
the recruitment of the macrophages is a half of the maximum
rate. We further assume that they can die naturally at a
constant rate 𝛿𝑧.
The variables and parameters that describe in-host
malaria dynamics are as in Tables 1 and 2, respectively.
The above transmission dynamics of malaria are sum-
marised in the compartmental diagram in Figure 1.
From the above description of the in-host dynamics of
malaria and the representation in Figure 1, we derive the
following system of ordinary differential equations:
d𝐻
d𝑡 = 𝜆ℎ + 𝜌1𝐻𝑋𝜅1 + 𝐻𝑋 − 𝜇1𝐻 − 𝛽𝑠𝑆𝐻,
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Table 1: Symbols and definition of state variables considered in the model.
Variable Description𝐻(𝑡) The population of susceptible hepatocytes at time 𝑡𝐻𝑋(𝑡) The population of infected hepatocytes at time 𝑡𝑅(𝑡) The population of susceptible red blood cells (erythrocytes) at time 𝑡𝑅𝑋(𝑡) The population of infected red blood cells at time 𝑡𝑍(𝑡) The density of macrophages in the human body at time 𝑡𝑆(𝑡) The population of sporozoites at time 𝑡𝑀(𝑡) The population of merozoites at time 𝑡
Table 2: Symbols and description of parameters used in the model.
Parameter DescriptionΛ The total rate of injection of sporozoites into liver due to mosquito bites𝛿𝑠 The death rate of sporozoites𝜆ℎ Recruitment rate of susceptible hepatocytes from the bone marrow𝜇1 Natural death rate of susceptible hepatocytes𝛽𝑠 The invasion rate of hepatocytes by sporozoites𝜇2 Death rate of infected hepatocytes𝜆𝑟 Recruitment rate of susceptible RBCs by the bone marrow𝜇3 The natural death rate of RBCs𝛽𝑟 The invasion rate of RBCs by merozoites𝜇4 Death rates of IRBCs𝛿𝑚 The death rate of merozoites𝜆𝑧 Recruitment rate of macrophages from the bone marrow𝛿𝑧 The death rate of a macrophage𝜂 Elimination rate of IRBCs by macrophages𝜌1 Production rate of hepatocytes due to presence of infected hepatocytes𝜌2 Production rate of RBCs due to presence of IRBCs𝜌3 Immunogenicity of IRBCs𝜅1 Number of 𝐻𝑋 at which the recruitment of 𝐻 is a half of the maximum rate𝜅2 Number of 𝑅𝑋 at which the recruitment of 𝑅 is a half of the maximum rate𝜅3 Number of 𝑅𝑋 at which the recruitment of 𝑍 is a half of the maximum rate𝜁 The proportion of the merozoites that cause secondary infections𝐾 The average number of merozoites released per bursting IRBCs𝑁 The average number of merozoites released per bursting infected hepatocytes
d𝐻𝑋
d𝑡 = 𝛽𝑠𝑆𝐻 − 𝜇2𝐻𝑋,
d𝑅
d𝑡 = 𝜆𝑟 + 𝜌2𝑅𝑋𝜅2 + 𝑅𝑋 − 𝜇3𝑅 − 𝛽𝑟𝑅𝑀,
d𝑅𝑋
d𝑡 = 𝛽𝑟𝑅𝑀 − 𝜇4𝑅𝑋 − 𝜂𝑅𝑋𝑍,
d𝑍
d𝑡 = 𝜆𝑧 + 𝜌3𝑅𝑋𝜅3 + 𝑅𝑋 − 𝛿𝑧𝑍,
d𝑆
d𝑡 = Λ − 𝛿𝑠𝑆 − 𝛽𝑠𝑆𝐻,
d𝑀
d𝑡 = 𝑁𝜇2𝐻𝑋 + 𝐾𝜁𝜇4𝑅𝑋 − 𝛿𝑚𝑀 − 𝛽𝑟𝑅𝑀,
(1)
where 𝐻(0) ≥ 0, 𝐻𝑋(0) ≥ 0, 𝑅(0) ≥ 0, 𝑅𝑋(0) ≥ 0, 𝑍(0) ≥ 0,𝑆(0) ≥ 0, and 𝑀(0) ≥ 0.
3. Model Analysis
3.1. Basic Properties. In this section, we study whether the
formulated model (1) is biologically and mathematically
meaningful. We establish model equilibrium points and
investigate their stability properties.
3.1.1. Well-Posedness of the Model. For the in-host malaria
model (1) to be mathematically and biologically meaningful,
we need to prove that all the solutions of model system (1)
with nonnegative initial conditions would remain nonnega-
tive for all time 𝑡 ≥ 0. Positivity in the model is shown by
proving the following theorem.
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Theorem 1. Let the parameters in model (1) be positive
constants. A nonnegative solution (𝐻(𝑡),𝐻𝑋(𝑡), 𝑅(𝑡), 𝑅𝑋(𝑡),𝑍(𝑡), 𝑆(𝑡),𝑀(𝑡)) exists for all the state variables with nonnega-
tive initial conditions {𝐻(0) = 𝐻0 ≥ 0, 𝐻𝑋(0) = 𝐻𝑋0 ≥ 0,𝑅(0) = 𝑅0 ≥ 0, 𝑅𝑋(0) = 𝑅𝑋0 ≥ 0, 𝑍(0) = 𝑍0 ≥ 0,𝑆(0) = 𝑆0 ≥ 0, 𝑀(0) = 𝑀0 ≥ 0}∀𝑡 ≥ 0.
Proof. Considering the first equation in system (1), let𝜓1(𝑡) =𝜌1𝐻𝑋/(𝜅1 + 𝐻𝑋), so that
d𝐻
d𝑡 = 𝜆ℎ + 𝜑 (𝑡) − 𝜇1𝐻 − 𝛽𝑠𝑆𝐻,
d𝐻
d𝑡 ≥ − (𝜇1 + 𝛽𝑠𝑆)𝐻, (2)
which yields𝐻(𝑡) ≥ 𝐻 (0) exp{−(∫𝑡
0
𝛽𝑠𝑆 (𝑠) 𝑑𝑠 + 𝜇1𝑡)} > 0. (3)
In a similar fashion, this procedure can be applied to all the
remaining six equations in model system (1), so that we have
the following solutions:𝐻𝑋 (𝑡) ≥ 𝐻𝑋 (0) exp {−𝜇2𝑡} > 0,𝑅 (𝑡) ≥ 𝑅 (0) exp{−(∫𝑡
0
𝛽𝑟𝑀(𝑠) 𝑑𝑠 + 𝜇3𝑡)} > 0,𝑅𝑋 (𝑡) ≥ 𝑅𝑋 (0) exp{−(∫𝑡
0
𝜂𝑍 (𝑠) 𝑑𝑠 + 𝜇4𝑡)} > 0,𝑍 (𝑡) ≥ 𝑍 (0) exp {−𝛿𝑧𝑡} > 0,𝑆 (𝑡) ≥ 𝑆 (0) exp{−(∫𝑡
0
𝛽𝑠𝐻(𝑠) 𝑑𝑠 + 𝛿𝑠𝑡)} > 0,𝑀 (𝑡) ≥ 𝑀 (0) exp{−(∫𝑡
0
𝛽𝑟𝑅 (𝑠) 𝑑𝑠 + 𝛿𝑚𝑡)} > 0.
(4)
Therefore, state variables (𝐻,𝐻𝑋, 𝑅, 𝑅𝑋, 𝑍, 𝑆,𝑀) of model
system (1) are nonnegative for all time 𝑡 > 0.
3.1.2. Invariant Region. Let𝑁𝐻(𝑡) represent the total hepato-
cyte population, so that 𝑁𝐻(𝑡) = 𝐻(𝑡) + 𝐻𝑋(𝑡).
On substituting the derivatives in system (1) and simpli-
fying, we have 𝑑𝑁𝐻𝑑𝑡 ≤ 𝜆ℎ + 𝜓1 (𝑡) − 𝜇ℎ𝑁𝐻, (5)
where 𝜓1(𝑡) = 𝜌1𝐻𝑋/(𝜅1 + 𝐻𝑋) and 𝜇ℎ = min{𝜇1, 𝜇2}.
Using integrating factor 𝑒𝜇ℎ𝑡,𝑁𝐻 (𝑡) ≤ 𝜆ℎ𝜇ℎ + 𝑒−𝜇ℎ𝑡 ∫𝑡0 𝜓1 (𝜏) 𝑒𝜇ℎ𝜏𝑑𝜏 + 𝑐1𝑒−𝜇ℎ𝑡, (6)
where 𝑐1 is a constant of integration. By applying the initial
condition 𝑁𝐻(0) = 𝑁𝐻0 > 0 in (6), we obtain𝑐1 = (𝑁𝐻 (0) − 𝜆ℎ𝜇ℎ ) − ∫𝑡0 𝜓1 (𝜏) 𝑒−𝜇ℎ𝜏𝑑𝜏. (7)
Substituting the value of 𝑐1 into𝑁𝐻(𝑡) in (6) and simplifying,
we get 𝑁𝐻 (𝑡) ≤ 𝜆ℎ𝜇ℎ + 𝑒−𝜇ℎ𝑡 (𝑁𝐻 (0) − 𝜆ℎ𝜇ℎ ) . (8)
There are two possible cases in analyzing the behaviour of𝑁𝐻(𝑡) in (8). In the first case, we consider 𝑁𝐻(0) > 𝜆ℎ/𝜇ℎ
so that, at time 𝑡 = 0, the right-hand side (RHS) of (8)
experiences the largest possible value of 𝑁𝐻(0). That is,𝑁𝐻(𝑡) ≤ 𝑁𝐻(0) for all time 𝑡 > 0.
In the second case, we consider 𝑁𝐻(0) < 𝜆ℎ/𝜇ℎ, so
that the largest possible value of the RHS of (8) approaches𝜆ℎ/𝜇ℎ as time 𝑡 goes to infinity. Thus, 𝑁𝐻(𝑡) ≤ 𝜆ℎ/𝜇ℎ,∀𝑡 > 0. From these two cases, we conclude that 𝑁𝐻(𝑡) ≤
max{𝑁𝐻(0), 𝜆ℎ/𝜇ℎ} for all time 𝑡 > 0.
Using the above approach, let the total red blood cells
population be 𝑁𝑅(𝑡), so that 𝑁𝑅(𝑡) = 𝑅(𝑡) + 𝑅𝑋(𝑡). From the
model equations in system (1), we have𝑑𝑁𝑅𝑑𝑡 ≤ 𝜆𝑟 + 𝜓2 (𝑡) − 𝜇𝑟𝑁𝑅 (𝑡) , (9)
where 𝜓2(𝑡) = 𝜌2𝑅𝑋/(𝜅2 + 𝑅𝑋) and 𝜇𝑟 = min{𝜇3, 𝜇4}. Upon
solving for 𝑁𝑅 in (9), we have 𝑁𝑅(𝑡) ≤ max{𝑁𝑅(0), 𝜆𝑟/𝜇𝑟},∀𝑡 > 0.
For the macrophage compartment 𝑍(𝑡), we have
d𝑍
d𝑡 = 𝜆𝑧 + 𝜓3 (𝑡) − 𝛿𝑧𝑍, for 𝜓3 (𝑡) = 𝜌3𝑅𝑋𝜅3 + 𝑅𝑋 . (10)
By integration, the solution of (10) is presented as𝑍 (𝑡) ≤ 𝜆𝑧𝛿𝑧 + 𝑒−𝛿𝑧𝑡 (𝑍 (0) − 𝜆𝑧𝛿𝑧 ) . (11)
By inspection, 𝑍(𝑡) ≤ max{𝑍(0), 𝜆𝑧/𝛿𝑧} for all time 𝑡 > 0.
Finally, let𝑁𝑃(𝑡) represent the total population ofmalaria
parasites at any time 𝑡. That is,𝑁𝑃(𝑡) = 𝑆(𝑡) +𝑀(𝑡) and, from
system (1),
d𝑁𝑃
d𝑡 = Λ − 𝛿𝑠𝑆 − 𝛽𝑠𝑆𝐻 + 𝑁𝜇2𝐻𝑋 + 𝐾𝜁𝜇4𝑅𝑋− 𝛿𝑚𝑀,≤ Λ + (𝐾𝜁𝜇4𝑅𝑋 + 𝑁𝜇2𝐻𝑋) − 𝛿𝑝𝑁𝑝,
where 𝛿𝑝 = min {𝛿𝑠, 𝛿𝑚} . (12)
Let (𝐾𝜁𝜇4𝑅𝑋 + 𝑁𝜇2𝐻𝑋) = 𝜓4(𝑡), so that on solving for𝑁𝑃(𝑡)
we get
𝑁𝑝 (𝑡) ≤ Λ𝛿𝑝 + 𝑒−𝛿𝑝𝑡 (𝑁𝑝 (0) − Λ𝛿𝑝) (13)
Clearly, the malaria parasite populations 𝑆(𝑡) and 𝑀(𝑡) are
bounded above. That is,𝑁𝑃(𝑡) ≤ max{𝑁𝑃(0), Λ/𝛿𝑝} for all time 𝑡 > 0.
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Based on this discussion, we have shown the existence of
a bounded positive invariant region for our model system (1).
Let us denote this region as Ω ∈ R7+, whereΩ = {(𝐻,𝐻𝑋, 𝑅, 𝑅𝑋, 𝑍, 𝑆,𝑀) ∈ R7+ : 𝑁𝑃 (𝑡)
≤ max{𝑁𝑃 (0) , Λ𝛿𝑝} ,𝑁𝐻 (𝑡)≤ max{𝑁𝐻 (0) , 𝜆ℎ𝜇ℎ } ,𝑁𝑅 (𝑡)≤ max{𝑁𝑅 (0) , 𝜆𝑟𝜇𝑟 } , 𝑍 (𝑡) ≤ max{𝑍 (0) , 𝜆𝑧𝛿𝑧 }} .
(14)
Moreover, any solution of our system (1)which commences inΩ at any time 𝑡 ≥ 0will always remain confined in that region.
We therefore deduce that the region Ω is positively invariant
and attracting with respect to malaria model (1). Our in-host
malaria model (1) is hence well posed mathematically and
biologically.
3.1.3. Disease-Free Equilibrium Point. The disease-free equi-
librium point,E0, is the state in which the human host is free
of malaria infection. At E0, the sporozoite recruitment rate,Λ = 0, and parasite and host-infected compartments have
zero values; that is, 𝑆∗ = 𝑀∗ = 𝑅∗𝑋 = 𝐻∗𝑋 = 0. Therefore,
E0 = (𝐻∗, 𝐻∗𝑋, 𝑅∗, 𝑅∗𝑋, 𝑍∗, 𝑆∗,𝑀∗)= (𝜆ℎ𝜇1 , 0, 𝜆𝑟𝜇3 , 0, 𝜆𝑧𝛿𝑧 , 0, 0) . (15)
3.1.4. In-Host Basic Reproduction Number. The in-host repro-
duction number of model (1) denoted by 𝑅0 is computed
using the technique of the next-generation matrix approach
described in [41]. We consider 𝐻𝑋, 𝑅𝑋, 𝑆, and 𝑀 as the par-
asite infested compartments. Adopting the notations in [41],
we generate a nonnegative matrix 𝐹 of new infections and a
nonsingularmatrix𝑉, showing the transfer of infections from
one compartment to the other as follows:
𝐹 = ((
(












The inverse of matrix 𝑉 is hence given by
𝑉−1 = (((((
(




The next-generation matrix 𝐺, which is the product of
matrices 𝐹 and 𝑉−1, works out to be
𝐺 = ((((
(
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The in-host basic reproduction number 𝑅0 is the spectral
radius of the next-generation matrix 𝐺. It can clearly be seen
that three of the four eigenvalues of matrix 𝐺 in (19) have
zero values; that is, 𝜆1 = 𝜆2 = 𝜆3 = 0. The fourth and
largest nonnegative eigenvalue 𝜆4 becomes the in-host model
reproduction number. We therefore have𝑅0 = 𝐾𝛽𝑟𝜆𝑟(𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3) ⋅ 𝜁𝛿𝑧𝜇4(𝜂𝜆𝑧 + 𝛿𝑧𝜇4) . (20)
The terms in model 𝑅0 can be interpreted as follows:
(1) The term 𝐾𝛽𝑟𝜆𝑟/(𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3) represents the
expected number of infectious merozoite parasites
resulting from bursting blood schizonts at the blood
stage of malaria infection.
(2) The second term 𝜁𝛿𝑧𝜇4/(𝜂𝜆𝑧 + 𝛿𝑧𝜇4) represents the
expected proportion of merozoites that participate in
the cycle of erythrocytic schizogony.
(3) Observe that the terms (𝛽𝑟𝜆𝑟)/(𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3) < 1
and (𝛿𝑧𝜇4)/(𝜂𝜆𝑧 + 𝛿𝑧𝜇4) < 1. So our 𝑅0 ≤ 𝐾𝜁.
This implies that the number of secondary infections
during malaria infections is largely influenced by the
average number of merozoites released 𝐾, from a
bursting blood schizont, most of which are respon-
sible for secondary infections at the blood stage.
Despite the inclusion of the liver stage dynamics, it is
interesting to observe that the above in-host reproduction
number and hence the disease progression are heavily driven
by the dynamics at the erythrocytic stage.
In the sections that follow, we shall establish both the local
stability and global stability of disease-free equilibrium point
(15) of model system (1).
3.1.5. Local Stability of the Disease-Free Equilibrium Point,E0.
The Jacobian matrix of model system (1) evaluated at the








It is clear from the first, third, and fifth columns of matrix
(21) that the Jacobian matrix has negative eigenvalues 𝜆1 =−𝜇1, 𝜆2 = −𝜇3, and 𝜆3 = −𝛿𝑧. Upon deleting the first, third,
and fifth rows and columns, matrix (21) is reduced to the








From row three in (22),𝜆4 = −𝛽𝑠𝜆ℎ/𝜇1−𝛿𝑠.We further reduce
matrix (22) by deleting row three and column three. So,
𝐽3 (E0) = (−𝜇2 0 00 −𝜂𝜆𝑧𝛿𝑧 − 𝜇4 𝛽𝑟𝜆𝑟𝜇3𝑁𝜇2 𝐾𝜁𝜇4 −𝛽𝑟𝜆𝑟𝜇3 − 𝛿𝑚). (23)
Note from rowone of (23) that the fifth eigenvalue𝜆5 = −𝜇2 <0.
The remaining two eigenvalues can be obtained by reduc-
ing matrix (23) into the following 2 × 2 matrix:
𝐽6 (E0) = (−𝜂𝜆𝑧𝛿𝑧 − 𝜇4 𝛽𝑟𝜆𝑟𝜇3𝐾𝜁𝜇4 −𝛽𝑟𝜆𝑟𝜇3 − 𝛿𝑚). (24)
Using the variable 𝜆, the characteristic polynomial associated
with matrix (24) is 𝑝 (𝜆) = 𝜆2 + 𝐴𝜆 + 𝐵, (25)
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where 𝐴 = 𝛿𝑚 + 𝜂𝜆𝑧𝛿𝑧 + 𝛽𝑟𝜆𝑟𝜇3 + 𝜇4 and (26)𝐵 = 𝜂𝛿𝑚𝜆𝑧𝛿𝑧 + 𝜂𝛽𝑟𝜆𝑟𝜆𝑧𝛿𝑧𝜇3 + 𝛿𝑚𝜇4 + 𝛽𝑟𝜆𝑟𝜇4𝜇3− 𝐾𝜁𝛽𝑟𝜆𝑟𝜇4𝜇3 . (27)
The characteristic polynomial (25) has negative roots (eigen-
values) if 𝐴 > 0 and 𝐵 > 0. The coefficient 𝐴 in (26) is
clearly positive. We now need to show that 𝐵 in (27) is strictly
positive if 𝑅0 < 1. This is done by expressing the coefficient
term 𝐵 in terms of model 𝑅0 as follows:𝐵 = 1𝛿𝑧𝜇3 [(𝜇4𝛿𝑧 + 𝜂𝜆𝑧) (𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3)− 𝐾𝜁𝛽𝑟𝛿𝑧𝜆𝑟𝜇4] ,= 1𝛿𝑧𝜇3 [(𝜇4𝛿𝑧 + 𝜂𝜆𝑧) (𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3)⋅ [1 − 𝐾𝜁𝛽𝑟𝛿𝑧𝜆𝑟𝜇4(𝜇4𝛿𝑧 + 𝜂𝜆𝑧) (𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3)]] ,= (𝜇4𝛿𝑧 + 𝜂𝜆𝑧) (𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3)𝛿𝑧𝜇3 [1 − 𝑅0] .
(28)
It can clearly be seen from (28) that the coefficient𝐵 is positive
if and only if 𝑅0 < 1. We have thus established the following
result.
Theorem 2. The disease-free equilibrium E0 is locally asymp-
totically stable in Ω if 𝑅0 < 1. If 𝑅0 > 1, then E0 is unstable.
Biologically, Theorem 2 implies that malaria infection
can be eliminated from the human host when 𝑅0 < 1.
To ensure that elimination of malaria is independent of the
initial sizes of the subpopulations, it is necessary to show that
E0 is globally asymptotically stable in Ω, where the model is
mathematically and biologically sensible.
3.1.6. Global Asymptotic Stability of the Disease-Free Equilib-
rium. Using the results obtained in [42], we show that the
malaria-free equilibrium state E0 is globally asymptotically
stable when 𝑅0 < 1. We begin by rewriting the model system
(1) in pseudotriangular form as follows:?̇?1 = 𝐴1 (𝑋) (𝑋1 − 𝑋∗1 ) + 𝐴2 (𝑋)𝑋2,?̇?2 = 𝐴3 (𝑋)𝑋2, (29)
where 𝑋1 is the vector representing the state of different
compartment of liver and blood cells that are not infected and
do not transmit malaria infections. 𝑋2 represents the states
of malaria parasites and host’s cells that are responsible for
disease transmission. Hence,𝑋 = (𝑋1, 𝑋2) ,𝑋1 = (𝐻, 𝑅, 𝑍) ,𝑋2 = (𝐻𝑋, 𝑅𝑋, 𝑆,𝑀) and𝑋∗1 = (𝜆ℎ𝜇1 , 𝜆𝑟𝜇3 , 𝜆𝑧𝛿𝑧 ) .
(30)
From the subsystem 𝑋1, we have
𝐴1 (𝑋) = (−𝜇1 0 00 −𝜇3 00 0 −𝛿𝑧) and
𝐴2 (𝑋) = (
𝜌1𝜅1 0 −𝜆ℎ𝜇1 𝛽𝑠 00 𝜌2𝜅2 0 −𝜆𝑟𝜇3 𝛽𝑟0 𝜌3𝜅3 0 0 ).
(31)
A direct computation indicates that the eigenvalue of matrix𝐴1(𝑋) is real and negative. This shows that the system ?̇?1 =𝐴1(𝑋)(𝑋1 −𝑋∗1 ) + 𝐴2(𝑋)𝑋2 is globally asymptotically stable
at the disease-free equilibrium, E0. Similarly, the subsystem𝑋2 gives rise to the following matrix 𝐴3(𝑋):
𝐴3 (𝑋) = (((((((
(




It can clearly be seen that 𝐴3(𝑋) is a Metzler matrix:
all the off-diagonal elements of 𝐴3(𝑋) are nonnegative. In order to establish the global stability of the disease-free equilibrium, we need to show that the matrix 𝐴3(𝑋)
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is Metzler stable by providing a proof of the following
lemma.
Lemma 3. Let 𝑀 be a square Metzler matrix that is block
decomposed: 𝑀 = (𝐴 𝐵𝐶 𝐷) , (33)
where 𝐴 and 𝐷 are square matrices. The matrix 𝑀 is Metzler
stable if and only if 𝐴 and 𝐷 − 𝐶𝐴−1𝐵 are Metzler stable.
In our case, matrix𝑀 is represented bymatrix𝐴3 in (32),
so that𝐴 = (−𝜇2 00 −(𝜂𝜆𝑧𝛿𝑧 + 𝜇4)) ,
𝐵 = (𝛽𝑠 𝜆ℎ𝜇1 00 𝛽𝑟 𝜆𝑟𝜇3),𝐶 = ( 0 0𝑁𝜇2 𝐾𝜁𝜇4 ) and
𝐷 = (−(𝛽𝑠 𝜆ℎ𝜇1 + 𝛿𝑠) 00 −(𝛽𝑟 𝜆𝑟𝜇3 + 𝛿𝑚) ) .
(34)
Upon computation in Mathematica software, we obtain𝐷 − 𝐶𝐴−1𝐵 = (−𝜔1 0𝜔2 −𝜔3) , (35)
where 𝜔1 = 𝛿𝑠 + 𝛽𝑠(𝜆ℎ/𝜇1), 𝜔2 = 𝑁𝛽𝑠𝜆ℎ/𝜇1, and 𝜔3 = 𝛿𝑚 +𝛽𝑟𝜆𝑟(𝜂𝜆ℎ + (1 − 𝐾𝜁)𝛿𝑧𝜇4)/𝜇3(𝜂𝜆𝑧 + 𝛿𝑧𝜇4).
For the matrix 𝐷 − 𝐶𝐴−1𝐵 to be Metzler stable, 𝜔3
should be strictly nonnegative. Therefore, the expression in
the numerator𝛽𝑟𝜆𝑟 (𝜂𝜆ℎ + (1 − 𝐾𝜁) 𝛿𝑧𝜇4) ≥ 0. (36)
Upon simplification of (36),𝐾𝜁𝛽𝑟𝜆𝑟𝛿𝑧𝜇4 ≤ 𝛽𝑟𝜆𝑟 (𝜂𝜆ℎ + 𝛿𝑧𝜇4) , (37)(𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3𝛽𝑟𝜆𝑟 )( 𝐾𝜁𝛽𝑟𝜆𝑟𝛿𝑧𝜇4(𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3) (𝜂𝜆𝑧 + 𝛿𝑧𝜇4))≤ 1, (38)(𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3𝛽𝑟𝜆𝑟 )𝑅0 ≤ 1 (39)𝑅0 ≤ 𝛽𝑟𝜆𝑟𝛽𝑟𝜆𝑟 + 𝛿𝑚𝜇3 < 1. (40)
Clearly, matrix 𝐴 in (34) is Metzler stable. However, the
matrix 𝐷 − 𝐶𝐴−1𝐵 is Metzler stable if and only if 𝑅0 < 1.
From Lemma 3, we deduce the following theorem.
Theorem 4. Themalaria-free equilibriumE0 of model system
(1) is globally asymptotically stable if the threshold quantity𝑅0 < 1.
The above result is quite significant in malaria control.
The global stability of the disease-free statuswould be guaran-
teed if and only if the in-host basic reproduction number𝑅0 is
less than one. Malaria intervention should therefore focus on
eliminating infected erythrocytes and/or malaria merozoites
that are responsible for erythropoiesis cycle and invasions at
the blood stage.
3.2. The Endemic Equilibrium Analysis. When 𝑅0 > 1, the
stability of the disease-free equilibrium (15) is violated. A
different equilibrium state termed the endemic equilibrium is
achieved. Equating to zero the RHS of system (1) and solving
for the state variables 𝑅, 𝐻, 𝑍, 𝑆, and 𝑀 in terms of the
infected states𝐻𝑋 and 𝑅𝑋, we obtain the endemic stateE1 =(𝐻∗, 𝐻∗𝑋, 𝑅∗, 𝑅∗𝑋, 𝑍∗, 𝑆∗,M∗), where𝐻∗ = 1𝜇1 {𝜆ℎ + 𝜌1𝐻∗𝑋𝜅1 + 𝐻∗𝑋 − 𝜇2𝐻∗𝑋} ,𝑆∗ = 𝜇1𝜇2𝐻∗𝑋𝛽𝑠 (𝜆ℎ + 𝜌1𝐻∗𝑋/ (𝜅1 + 𝐻∗𝑋) − 𝜇2𝐻∗𝑋) , (41)𝑅∗ = 1𝜇3 {𝜆𝑟 + 𝜌2𝑅∗𝑋𝜅2 + 𝑅∗𝑋 − 𝜇4𝑅∗𝑋} ,𝑀∗ = 𝜇3 (𝑅∗𝑋𝜇4 + 𝜂𝑅∗𝑋 (𝜌3𝑅∗𝑋/ (𝜅3 + 𝑅∗𝑋) + 𝜆𝑧)𝜇1 ) (42)𝑍∗ = 1𝛿𝑧 {𝜆𝑧 + 𝜌3𝑅∗𝑋𝜅3 + 𝑅∗𝑋} (43)
Substituting (41) into the 2𝑛𝑑 equation in (1) and simplifying,
we obtain the following cubic equation:𝛼3𝐻∗3𝑋 + 𝛼2𝐻∗2𝑋 + 𝛼1𝐻∗𝑋 + 𝛼0 = 0, (44)
where𝛼3 = 𝜇22𝛽𝑠 > 0,𝛼2 = 𝜇2 (𝜇1 (−𝛿𝑠) − 𝛽𝑠 (𝜆ℎ − 𝜅1𝜇2 + Λ + 𝜌1)) ,𝛼1 = 𝛽𝑠 (𝜆ℎ (Λ − 𝜅1𝜇2) + Λ (𝜌1 − 𝜅1𝜇2))− 𝜅1𝜇1𝜇2𝛿𝑠, and𝛼0 = 𝜅1Λ𝜆ℎ𝛽𝑠 > 0.
(45)
The number and nature of the roots of (44) are determined
by the following discriminant:Δ = 18𝛼3𝛼2𝛼1𝛼0 − 4𝛼23𝛼0 + 𝛼22𝛼12 − 4𝛼3𝛼13− 27𝛼32𝛼02. (46)
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So
(i) if Δ = 0, then (44) has multiple real roots and only
one endemic equilibrium would exist,
(ii) if Δ < 0, then (44) has 1 real root and a complex con-
jugate root and hence only one endemic equilibrium,
(iii) ifΔ > 0, then (44) has 3 distinct real roots and so there
is more than one endemic equilibrium when 𝑅0 > 1
for model system (1).
Analysis under (46) implies that, in the absence of external
interventions in the form of antimalarial treatment, there
will always be some infected hepatocytes during malaria
infection. We then evaluate the possible values of the state
variable 𝑅𝑋 at equilibrium by substituting expressions in (42)
and (43) into the 4𝑡ℎ equation in (1). After simplification
in Mathematica software, we obtain the following cubic
equation: 𝑅∗𝑋 (𝜃3𝑅∗3𝑋 + 𝜃2𝑅∗2𝑋 + 𝜃1𝑅∗𝑋 + 𝜃0) = 0, (47)
where𝜃3 = −𝜇4𝛽𝑟 (𝜇1𝜇4 + 𝜂 (𝜌3 + 𝜆𝑧)) < 0,𝜃2 = 𝜂𝜌3 (𝛽𝑟 (−𝜅2𝜇4 + 𝜌2 + 𝜆𝑟) − 1) + (𝜇1𝜇4 + 𝜂𝜆𝑧)⋅ (𝛽𝑟 (− (𝜅2 + 𝜅3) 𝜇4 + 𝜌2 + 𝜆𝑟) − 1) ,𝜃1 = 𝜂𝜅2𝜌3 (𝛽𝑟𝜆𝑟 − 1) − (𝜇1𝜇4 + 𝜂𝜆𝑧) (𝜅3+ 𝜅2 (𝛽𝑟 (𝜅3𝜇4 − 𝜆𝑟) + 1) + 𝜅3 (−𝛽𝑟) (𝜌2 + 𝜆𝑟)) ,𝜃0 = 𝜅2𝜅3 (𝛽𝑟𝜆𝑟 − 1) (𝜇1𝜇4 + 𝜂𝜆𝑧) .
(48)
Clearly, 𝑅∗𝑋 = 0 or𝜃3𝑅∗3𝑋 + 𝜃2𝑅∗2𝑋 + 𝜃1𝑅∗𝑋 + 𝜃0 = 0. (49)
The state 𝑅∗𝑋 = 0 corresponds to a scenario in which there
are no parasite-infected red blood cells. This could signify
the liver stage of parasite development so that an endemic
state (𝐻∗∗, 𝐻∗∗𝑋 , 𝑅∗∗, 0, 0, 𝑆∗∗, 0) exists. Alternatively, 𝑅∗𝑋 = 0
could correspond to the disease-free equilibrium point (15)
for system (1).
The roots of the cubic equation (49) are given as𝑅∗𝑋1 = − 𝜅3 (𝜇1𝜇4 + 𝜂𝜆𝑧)𝜂𝜌3 + 𝜇1𝜇4 + 𝜂𝜆𝑧 < 0,𝑅∗𝑋2,3 = (𝛽𝑟𝜆𝑟 − 𝜅2𝜇4𝛽𝑟 + 𝜌2𝛽𝑟 − 1) ± √Θ2𝜇4𝛽𝑟 , (50)
where Θ = 4𝜇4𝛽𝑟 (𝜅2𝛽𝑟𝜆𝑟 − 𝜅2)+ (𝛽𝑟𝜆𝑟 − 𝜅2𝜇4𝛽𝑟 + 𝜌2𝛽𝑟 − 1)2 . (51)
The root 𝑅∗𝑋1 < 0 should be ignored, since all the model state
variables are nonnegative for all time 𝑡 ≥ 0. This leaves 𝑅∗𝑋2,3
as the only two possible roots of (49).
From the above discussion, model (1) could experience
a single endemic state or multiple endemic states subject to
the roots of (44) and (47). If 𝑅∗𝑋2,3 are real and positive,
then one or two endemic equilibrium points are possible
for model (1). It is thus evident that the explicit form of
the endemic equilibrium state for model (1) is cumbersome.
We shall therefore show its existence numerically based on
a certain choice of parameter values in Section 4. Note that
case (iii) of (46) indicates the possibility of having multiple
endemic equilibria and hence the likelihood of experiencing a
backward bifurcation phenomenon. This will be investigated
in another research paper.
4. Numerical Simulations and Discussions
In this section, we provide some numerical simulations to
illustrate the behaviour of model system (1). We carry out
model sensitivity analysis and investigate parameter influence
on the dynamics of red blood cells, macrophages, and
malaria parasites under different conditions on the in-host
reproduction number, 𝑅0.
4.1. Sensitivity Analysis. In epidemic modelling, sensitivity
analysis is performed to investigate model parameters with
significant influence on𝑅0 andhence on the transmission and
the spread of the disease under study [43]. Following [44], the
normalised forward-sensitivity index of a variable, △, which
depends differentially on a parameter, 𝛼, is defined asΥ△𝛼 = 𝜕△𝜕𝛼 × 𝛼△. (52)
Using the formulation in (52) and the parameter values in
Table 3, the local sensitivity indices (SI) of 𝑅0 (see (20)) rel-
ative to the model parameters are calculated in Mathematica
software and the results summarised inTable 4.Note that, due
to limited data on in-host dynamics, all the parameter values
used in evaluating the sensitivity indices are obtained from
indicated past literature.
A positive sign on the SI indicates that an increase
(decrease) in the value of such a parameter increases
(decreases) the value of 𝑅0 and hence the growth of malaria
infection. On the other hand, a negative sign is indicative of
a parameter that negatively affects 𝑅0. In order to eliminate
in-host malaria infection, the in-host reproduction number
should be less than one, that is, 𝑅0 < 1.
The average number of merozoites released per bursting
infected erythrocyte𝐾 and the proportion of merozoites that
cause secondary invasions at the blood phase 𝜁 are the most
sensitive parameters in determining the disease outcomes.
They have the highest sensitivity indices of +1.0000. For
instance, a 10% increase (decrease) 𝜁 or 𝐾 generates a
10% increase (decrease) on 𝑅0 and hence malaria infection
severity.
The parameters 𝜆𝑧, 𝜂, 𝜇4, and 𝛿𝑧 occupy the second
rank in influencing the model outcomes. An increase in
the parameters 𝜇4 and 𝛿𝑧 is likely to increase the model𝑅0. On the other hand, an increase in 𝜆𝑧 and 𝜂 has a
direct negative influence on 𝑅0. Macrophages are highly
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Table 3: Parameter values used in the numerical simulation and demonstration of the existence of endemic equilibrium point. See Table 2
for detailed parameter descriptions.
Symbol Interpretation Value Source𝛿𝑧 Death rate of macrophages 0.05/day [19]𝛿𝑠 Death rate of sporozoites 1.2 × 10−11 /day [20]𝜂 Elimination rate of IRBCs by macrophages 10−10𝑐𝑒𝑙𝑙𝑠𝜇𝑙−1//𝑑𝑎𝑦 [19]𝜆ℎ Recruitment rate of 𝐻 2.5 × 108𝑐𝑒𝑙𝑙𝑠/𝜇𝑙−1/𝑑𝑎𝑦 [21]𝜌1 Production rate of 𝐻 due to 𝐻𝑋 2.5 × 10−5/𝑑𝑎𝑦 [19]𝜇1 Death rate of 𝐻 0.029 /day [20]Λ Rate of injection of sporozoites 20 sporozoites/day [20]𝜌2 Production rate of RBCs due to IRBCs 2.5 × 10−5/𝑑𝑎𝑦 [19]𝛽𝑠 Hepatocyte invasion rate 1.0 × 10−6/𝑠𝑝𝑜𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠/𝑑𝑎𝑦 [20]𝜌3 Immunogenicity of IRBCs 2.5 × 10−5/𝑑𝑎𝑦 [19]𝜇2 Death rate of infected hepatocytes 0.02/day [20]𝜅1 Inhibition rate 1 𝑐𝑒𝑙𝑙𝑠/𝜇𝑙−1 [22]𝜆𝑟 Recruitment rate of RBCs 2.5 × 108𝑐𝑒𝑙𝑙𝑠/𝜇𝑙−1/𝑑𝑎𝑦 [23]𝜁 Merozoites that cause secondary infections 0.726 (unitless) [24]𝜇3 Death rate of healthy RBCs 0.0083/day [23]𝜅2 Inhibition rate 1 𝑐𝑒𝑙𝑙𝑠/𝜇𝑙−1 [22]𝛽𝑟 Invasion rate of RBCs 2.0 × 10−9/𝑚𝑒𝑟𝑜𝑧𝑜𝑖𝑡𝑒𝑠/𝑑𝑎𝑦 [23]𝑁 Merozoites per liver schizont 10000/day [21]𝜇4 Death rate of infected RBCs 0.025/day [19]𝜅3 Inhibition rate 1 𝑐𝑒𝑙𝑙𝑠/𝜇𝑙−1 [22]𝛿𝑚 Death rate of merozoites 48/day [23]𝐾 Merozoites per blood schizont 16 [21]𝜆𝑧 Recruitment rate of macrophages 30/𝜇𝑙−1/𝑑𝑎𝑦 [19]
Table 4: Sensitivity indices of 𝑅0 relative to the model parameters.
Parameter SI Parameter SI
K +1.0000 𝜁 +1.0000𝛽𝑟 +0.920422 𝜇3 -0.920422𝜆𝑟 +0.920422 𝜆𝑧 -0.998585𝜇4 +0.998585 𝜂 -0.998585𝛿𝑧 +0.998585 𝛿𝑚 -0.920422
instrumental in malaria parasite clearance and should be
preserved.
The rate of generation of macrophages from the bone
marrow, 𝜆𝑧, together with the rate of phagocytosis of infected
red blood cells, 𝜂, is likely to decrease, proportionally, the
disease progression when they are increased. With increased𝜆𝑧, there would be more macrophages to phagocytose
and clear the rapidly growing density of blood schizonts.
This would negatively affect the erythrocytic schizogony.
Decreased clearance rate by macrophages would only guar-
antee successful multiplication of the merozoites through
the erythrocytic schizogonic cycle. The subsequent result is
increased concentration of merozoites in the host blood and
disease progression to even deadly levels.
The parameters 𝛽𝑟 and 𝜆𝑟 increase (or decrease) 𝑅0
when they are increased (or decreased). Epidemiologically, an
improved erythrocyte invasion rate, 𝛽𝑟, is likely to generate
even more new blood schizonts. This increases parasitemia
in the host. A 10% increase (decrease) in 𝛽𝑟 would increase
(decrease) the threshold parameter 𝑅0 by about +9.2%.
Any therapeutic effort that clears the blood schizonts and
the infectious merozoites at the blood stage would definitely
guarantee immense reduction in model 𝑅0. Therefore, an
increase in the death rate of the infected red blood cells
and that of the merozoites is likely to decrease significantly
the in-host reproduction number 𝑅0. This can be achieved
through the use of effective antimalarials such as the use
of artemisinin based combination therapy (ACT) in malaria
treatment. Moreover, effective vaccines at the erythrocytic
stage could greatly help minimize erythrocyte infection rate𝛽𝑟.
Since the local sensitivity indices are relatively close, we
carry out further investigation on parameter influence on
disease progression by generating the partial rank correlation
coefficients (PRCCs) for each parameter value inmodel𝑅0 in
the following section.
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4.1.1. Global Sensitivity Analysis. A global sensitivity analysis
(GSA) is performed to examine the response of an epi-
demic model to parameter variation within a wider range
of parameter space [45]. Applying the approach in [45], the
PRCCs between the in-host basic reproduction number 𝑅0
and each of the parameters in Table 2 are derived. Using
1000 simulations per run of the Latin Hypercube Sampling
(LHS) scheme [46], the established PRCCs are derived and
presented in Figure 2.
Unlike the results in Table 4, the model parameter with
the highest influence on 𝑅0 according to the PRCCs results
shown in Figure 2 is the rate of invasion of red blood cells by
merozoites,𝛽𝑟.This is followed closely by the recruitment rate
of susceptible red blood cells 𝜆𝑟 from the bone marrow. The
second set of parameters that also increase (decrease) model𝑅0 when they are increased (decreased) are 𝜁, 𝐾, 𝜇3, and 𝛿𝑧,
respectively.
The merozoites’ death rate 𝛿𝑚, the death rate of IRBCs𝜇4, and the rate of elimination of IRBCs by macrophages𝜂 are shown to have the highest negative influence on
disease progression. Although an increase in 𝜇4 was shown
to decrease disease progression in Table 4, the results from
global sensitivity analysis are contradictory. An increase
in the death rate of parasitized erythrocytes 𝜇4 decreases
parasitemia and hence disease progression.
Based on these results of sensitivity analysis, we make
the following remarks: (1) results of global sensitivity analysis
are robust and a lot more realistic for implementation,
(2) malaria control should target elimination of merozoites
and infected red blood cells, (3) an effective and efficient
malaria vaccine that deactivates infectious merozoites could
be helpful in limiting erythrocyte invasion rate, and (4) a
vaccine that is protective of susceptible erythrocytes could
further ensure reduced density of second and future gener-
ation of merozoites that are responsible for disease progres-
sion.
4.2. Numerical Results. Model system (1) is solved numer-
ically using the package scipy.integrate.odeint in Python
language. The simulations are performed to illustrate the
possible dynamics of the red blood cells, the malaria parasite,
and macrophages. For purposes of these simulations, the
initial conditions of the variables are hereby assumed. We
note that different dynamics could be achieved for a different
set of initial conditions.
For 𝑅0 < 1 (see Figure 3), the density of suscepti-
ble hepatocyte initially declines as the density of infected
hepatocytes rises due to invasion from sporozoites. The
host’s immune system responds to sporozoite invasion by
increasing hepatocyte density that levels off at the disease-
free equilibriumpointE0 (see Figure 3(a)). As the sporozoites
decline to near zero (see Figure 3(b)), infected hepatocytes
decline and stabilize at E0 in (15).
At the blood stage, the rising density of infected erythro-
cytes declines in a similar fashion to that of the infective
merozoites when 𝑅0 < 1 (see Figure 3(c)). The densities
of the infected erythrocytes and merozoites approach E0
asymptotically. On the other hand, we observe that the












Figure 2: Tornado plots of PRCCs of parameters that influence
model 𝑅0 generated using parameter values in Table 3. Parameters
with 𝑃𝑅𝐶𝐶 > 0 and 𝑃𝑅𝐶𝐶 < 0 increase and decrease model 𝑅0,
respectively.
to infection by merozoites and later rises before it plateaus as
shown in Figure 3(c).
When 𝑅0 > 1, a sharp fall in the density of susceptible
hepatocytes in the liver is observed (see Figure 4(a)). This
is due to rapid invasion of hepatocytes by the sporozoites.
An invasion on susceptible hepatocyte generates a corre-
sponding steady rise in the density of infected hepatocytes
(see Figure 4(b)). Owing to natural intervention by the
immune system cells, the respective decline and rising levels
of susceptible and infected hepatocytes level off and remain
relatively constant after the third month. More liver cells are
generated to replace infected ones. Figure 4(c) indicates a
steady decline in sporozoite density at the liver stage during
infections. Invaded hepatocytes burst open to produce mero-
zoites instead of sporozoites and hence the steady decline in
sporozoite levels.
Malaria infection dynamics are most rapid in the first 2
weeks within the host liver as illustrated in Figures 4(a), 4(b),
and 4(c). This is similar to results in [22, 31]. In the absence
of clinical intervention, some of the sporozoites may remain
dormant in the human liver and could cause future malaria
infections. As the liver schizonts releasemerozoites into host’s
blood stream, a rapid decline in the density of red blood cells
is observed (see Figure 5(a)). However, the density of infected
erythrocytes is noted to rise with equal proportion as shown
in Figure 5(b).
An early sharp rise in the density of merozoites in the
first one week of the blood stage is noted in Figure 5(c). The
density remains high for several weeks and does not decline
for the entire infection period of one month. A second-
generation merozoite invades other sets of healthy erythro-
cytes within minutes, leading to an exponential growth in
the density of blood schizonts and hence merozoites in
the human blood. Without therapeutic intervention, the
density of merozoites stabilizes several weeks after infection
at the endemic equilibrium point. This is consistent with the
findings in [19, 20, 23].




























































(c) Blood stage dynamics
Figure 3: Graphs showing the simulation of in-host malaria model (1) when the model 𝑅0 = 0.22866 < 1. Figures (a) and (b) show model
dynamics at the liver stage. The chosen initial conditions are 𝐻0 = 300000, 𝐻𝑋0 = 20000, 𝑅0 = 500000, 𝑅𝑋0 = 50, 𝑍0 = 300000, 𝑆0 = 2000,
and 𝑀 = 70. Used parameter values are given in Table 3.
The invasion of healthy erythrocytes prompts an immune
response from host’s macrophages. These macrophages
phagocyte on the generated blood schizonts. At the onset
of erythrocytic infection, several macrophages are generated.
The rise in the density of macrophages is proportional to that
of infected erythrocytes as shown in Figure 5(d). This rising
density is shown to level off after about 16 days at the endemic
equilibrium point. It remains high throughout the infection
period.
From these discussions, we make the following observa-
tions: (1) if 𝑅0 < 1, low level malaria infection can easily be
contained by the host’s defence mechanism and loss of life
is less likely; (2) therapeutically, 𝑅0 < 1 may be achieved
through quick interventions targeting the blood schizonts
and the merozoites responsible for secondary infections
during the erythrocytic cycle; (3) Figures 4 and 5 prove the
existence of malaria endemic equilibrium point.
Hematological parameters such as the density of healthy
and infected erythrocytes in malaria hosts have considerable
influence on malaria infection and possible impacts [47].
According to WHO [48], hyperparasitemia causes dras-
tic reduction in concentrations of erythrocytes, leading to
anaemia among malaria patients. The impacts of increasing
the model parameters 𝛿𝑚 and 𝛽𝑟 on healthy and infected
red blood cells are as shown in Figures 6 and 7, respec-
tively.
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(a) Susceptible hepatocytes (b) Infected hepatocytes
(c) Sporozoites
Figure 4: Graphs showing population dynamics of the liver hepatocytes and malaria sporozoites when 𝑅0 = 1.58690 > 1. Used parameter
values can be found in Table 3 with the chosen initial conditions described by 𝐻0 = 300000, 𝐻𝑋0 = 10, 𝑅0 = 500000, 𝑅𝑋0 = 10, 𝑍0 = 10,𝑆0 = 2000, and 𝑀 = 20.
Observe that increased death rate of malaria merozoites𝛿𝑚 decreases and increases the concentration of parasitized
red blood cells and healthy red blood cells, respectively (see
Figures 6(a) and 6(b)). Malaria control should thus target the
infectious merozoites at the blood stage.
Results in Figure 7(a) indicate that an improved invasion
rate by merozoites on susceptible red blood cells causes more
loss in healthy erythrocytes. The reverse effect is observed
in Figure 7(b), where an increase in the rate of infection of
healthy erythrocytes produces a corresponding increase in
the density of IRBCs. A keen look at Figure 7(b) reveals that
the infected red blood cells begin to appear after about 10–15
days of initial infection.This is consistent with the incubation
period of Plasmodium falciparummalaria [49].
The severity of malaria infection can easily increase if the
density or production of macrophages is compromised [19].
Figure 8(b) shows a near direct relationship on the density
of infected red blood cells 𝑅𝑋 and the death rate of the
macrophages 𝛿𝑧. An increase in the death of macrophages
would propel erythrocytic schizogony and hence increased
merozoite numbers in the human blood. A high merozoite
density increases the severity of malaria infection. This
result is quite vital in malaria intervention, especially with
respect to malaria patients who may be suffering from other
infections that are deleterious to immune cells. Diseases
such as HIV/AIDS greatly weaken the immune system of
the patient as crucial immune cells such as macrophages
are destroyed. Macrophages are important target cells for
HIV-1 virus [50]. During malaria infections, such patients
often suffer from severe malaria and should seek immediate
medical attention.
Like the senescent red blood cells, aberrant infected
erythrocytes formed during malaria infection are eliminated
phagocytically by the host’s macrophage cells in the red pulp
of the spleen [51]. The phagocytic potential of the spleen
is vital at the erythrocytic cycle. The higher the phagocytic
behaviour of the macrophage, the lower the density of
parasitized erythrocytes (see Figure 8(a)). The severity of
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(a) Susceptible erythrocytes (b) Infected erythrocytes
(c) Merozoites (d) Macrophages
Figure 5: Graphs showing population dynamics of red blood cells, macrophages, andmalaria merozoites when𝑅0 = 1.58690 > 1. Simulation
parameter values are available in Table 3.
malaria infection increases with decreasing ability of the
host’s phagocytic merozoites to clear infected red blood cells
from circulation during the erythrocytic cycle.
5. Conclusion and Discussion
In this paper, a mathematical model of in-host malaria infec-
tion in [21] is extended to include the liver stage of parasite
development. Unlike themodels in [19, 23, 30], we considered
the macrophages as the most effective innate immune cells
in eliminating malaria parasites from the human blood
circulation. In addition, the liver hepatocytes are assumed to
be generated from the bonemarrow and through a process of
self-regeneration from existing hepatocytes.
We proved that the formulated model is biologically and
mathematically well posed in an invariant region Ω. The
malaria-free equilibrium is shown to be locally asymptotically
stable when the in-host reproduction number is less than
unity. The global stability of the malaria-free state is only
guaranteed if the threshold quantity 𝑅0 is less than unity.
Our numerical results show that intervention during
malaria infection should focus on minimizing merozoite
invasion rate on healthy erythrocytes and the density of
merozoites in circulation, which are responsible for sec-
ondary invasion at the blood stage. In the absence of malaria
treatment, the immune cells (macrophages) are shown to be
vital in eliminating infected red blood cells at the blood stage.
The higher the rate of phagocytosis of infected erythrocytes
by macrophages, the lower the density of infected red blood
cells and hence malaria parasitemia. Patients suffering from
such infections as HIV/AIDS and TB that have deleterious
effect on the protective immune cells should seek immediate
medical treatment when infected with malaria. Their com-
promised immune system exposes them to severe malaria
attacks and possible untimely death.
For quick and timely reduction of parasitemia, an
increased merozoite death rate using antimalarial drugs such
as ACT would be necessary. This would further ensure
reduced density of infected red blood cells and hence future
generation merozoites. By killing a single blood schizont,
















































(b) Effect of 𝛿𝑚 on 𝑅𝑋
Figure 6: Graphs showing the behaviour of (a) susceptible RBCs and (b) infected RBCs. They were obtained by varying the death rate of


















r = 2e − 08
r = 2e − 07
r = 2e − 06
r = 2e − 05

















r = 2e − 08
r = 2e − 07
r = 2e − 06
r = 2e − 05
(b) Effect of 𝛽𝑟 on 𝑅𝑋
Figure 7: Graphs showing the behaviour of (a) susceptible RBCs and (b) infectedRBCs.Theywere obtained by varying themerozoite invasion
rate 𝛽𝑟 from 2 × 10−8 to 2 × 10−5 in steps of 10−1, while keeping the other parameters in Table 3 constant.
we are likely to avoid the production of sixteen merozoites
at maturity. Moreover, an appropriate vaccine that targets
erythrocyte invasion process may equally guarantee minimal
erythropoiesis. The erythrocyte invasion-avoidance vaccine
would minimize the density of infected erythrocytes and
hence malaria disease severity. This intervention could help
terminate the erythrocytic schizont, leading tominimal para-
site transmission to mosquito vector for further development
and sexual reproduction.
In this study, drug resistance was not analyzed; this
can be considered as a potential area for future investiga-
tion.
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(b) Effect of 𝛿𝑧 on 𝑅𝑋
Figure 8: Graphs showing the effect of varying the rate of phagocytosis of IRBCs by macrophages, 𝜂 (in (a)), and the effect of increased decay
rate of macrophages, 𝛿𝑧 (in (b)), on the behaviour of infected erythrocytes 𝑅𝑋. All parameter values are in Table 3.
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ABSTRACT
Despite the success of the existing malaria control strategies,
reportedmalaria cases are still quite high. In 2016, theWHO reported
about 216 million malaria cases; 90% of which occurred in the WHO
African Region. In this paper, a mathematical model for the in-host
Plasmodium falciparummalaria subject to malaria vaccines is formu-
lated and analysed. An efficacious pre-erythrocytic vaccine is shown
to greatly reduce the severity of clinical malaria. Based on the nor-
malized forward sensitivity index technique, the average number
of merozoites released per bursting blood schizont is shown to be
the most sensitive parameter in the model. Numerical simulation
results further suggest that an efficacious blood stage vaccine has
the potential to reduce the burst size of the blood schizonts and
maximize the rate of activation of CD8+ T cells during malaria infec-
tion. Moreover, vaccine combinations that are efficaciousmight help
in achieving a malaria free population by the year 2030. This paper
provides useful insights in malaria vaccine control and a unique
opportunity to intensify support and funding for malaria vaccine
development.
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1. Introduction
To date, the World Health Organization (WHO) considers effective vector control strate-
gies such as long-lasting insecticidal nets (ITNs) and indoor residual spraying (IRS) as
the main ways to prevent and reduce malaria transmission in communities with high
malaria prevalence (Homan, 2016;WHO, 2017a). In addition, chemoprophylaxis and anti-
malarial drugs such as chloroquine and artemisinin-based combination therapy (ACT)
are currently used to prevent and treat clinical malaria, respectively, in different parts of
the world (Bhatt et al., 2015; WHO, 2015). These strategies have contributed to the sub-
stantial global decline in malaria mortality and morbidity (Negal, Alemu, & Tasew, 2016).
However, despite the success of the existing malaria prevention and control strategies,
reported malaria cases are still quite high. In 2016, the WHO reported about 216 million
malaria cases; 90% of which occurred in the WHO African Region (WHO, 2017b). This
represented an increase of 5 million malaria cases from the year 2015.
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Malaria is a mosquito-borne infectious disease caused by an intracellular protozoan
parasite of the genus Plasmodium (Liehl et al., 2015; Risco-Castillo et al., 2015). Plas-
modium falciparum is the deadliest (Derbyshire, Mota, & Clardy, 2011) and predominant
malaria parasite in sub-Saharan African and was responsible for 99% of all malaria
cases in 2016 (WHO, 2017b). While probing for blood, female Anopheles mosquito
inoculates sporozoites into the human dermis. The deposited parasites rapidly migrate
to the liver, where they invade the hepatocytes with the formation of protective para-
sitophorous vacuole (Bertolino & Bowen, 2015; Ishino, Yano, Chinzei, & Yuda, 2004;
Mota et al., 2001). During this pre-erythrocytic stage, the sporozoites undergo rapid
asexual reproduction (White et al., 2014; White, 2017), develop and differentiate asymp-
tomatically into thousands of erythrocytic forms called merozoites (Sturm et al., 2006).
The cyclical erythrocytic stage begins when infected hepatocytes burst open, releasing
infective-merozoites into the blood stream (Haldar, Murphy, Milner, & Taylor, 2007).
The released merozoites quickly invade susceptible red blood cells leading to the for-
mation of infected red blood cells (IRB) cells. The waves of bursting erythrocytes and
invasions of fresh erythrocytes by secondary merozoites produce malaria characteristic
symptoms such as chills and headache (Derbyshire et al., 2011). Some merozoites develop
into sexual forms called gametocytes that are later sucked up by feeding mosquitoes
for sexual reproduction and development within the mosquito gut (sporogonic stage).
If left untreated, malaria patients may develop severe symptoms and progress to coma
or death.
Parasite resistance to current antimalarial drugs (Dondorp et al., 2010; Maude
et al., 2009; Sidhu, Verdier-Pinard, & Fidock, 2002; Wellems & Plowe, 2001) and
vector insecticides (Alout, Labbé, Chandre, & Cohuet, 2017a; Alout, Roche, Dabiré,
& Cohuet, 2017b; Soko, Chimbari, &Mukaratirwa, 2015) poses a serious threat to malaria
control. To defeat the disease, many more tools with the potential to save lives today and
in the future are needed (Birkett, 2016; Greenwood & Targett, 2009; MVI, 2018). An effi-
cacious, safe and affordable malaria vaccine would help to bridge the control gap left by
other intervention measures (MVI, 2018).
A malaria vaccination strategy is performed to either induce protective immune
responses prior to malaria infection or to provide protection in case of malaria attack
(Arama & Troye-Blomberg, 2014). Current malaria vaccines have shown minimal effi-
cacy (Birkett, 2016; Birkett, Moorthy, Loucq, Chitnis, & Kaslow, 2013; Miura, 2016). In
the completed phase III clinical testing, RTS,S/AS01 (which is the most advanced malaria
vaccine to date) showed 36.3% vaccine efficacy in children and 25.9% in infants (Bir-
kett, 2016; Miura, 2016). Although the results of phase 3 trials are promising, a more
efficacious malaria vaccine is crucial if the 2030 goal of malaria eradication by WHO is
to be accomplished (malERA Consultative Group on Vaccines et al., 2011).
Although there is no licensed vaccine against malaria today, many experts believe that
a malaria vaccine is a necessary tool for successful malaria elimination (MVFG, 2018;
Ouattara & Laurens, 2014). There are three categories of malaria vaccine candidates:
pre-erythrocytic vaccines (PEV), blood stage vaccines (BSV) and transmission blocking
vaccines (TBV) that target the parasite at different stages of its life cycle (see Figure 1). PEV
are designed to prevent malaria infections in humans by inducing antibodies that block
invasion of hepatocytes by sporozoites and/or cell-mediated immune responses that target
infected hepatocytes (Duffy, Sahu,Akue,Milman,&Anderson, 2012). In this respect, PEVs
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Figure 1. Target sites in themalaria life cycle that could be interrupted by pre-erythrocytic, blood-stage
and transmission-blocking vaccines. Source: Arama and Troye-Blomberg (2014).
target malaria sporozoites thereby interrupting the life cycle of malaria parasite at an early
stage (March et al., 2013). Several clinical trials (Abdulla et al., 2008; Alonso et al., 2004;
Bojang et al., 2001; Polhemus et al., 2009) and (RTS, S. C. T. P., 2011) have shown the
potential of RTS,S to prevent malaria infection and clinical disease in infants and young
children living in sub-Saharan Africa (Birkett, 2016; Miura, 2016; RTS, S. C. T. P., 2012).
PEV may also induce protection against clinical malaria at the blood stage by temporar-
ily reducing the number of merozoites that emerge from the bursting infected liver cells
(Alonso et al., 2004).
BSV on the other hand elicits anti-invasion and anti-disease responses at the blood
stage (Moorthy, Good, & Hill, 2004). They, therefore, lower merozoites density and pre-
vent clinical manifestations and hence severity of malaria infection in humans. Due to
gene alteration and antigenic variation in malaria merozoites, BSV may not provide com-
plete immunity to the host (Pandey et al., 2013). At present, merozoite surface protein 3
(MSP3) (Audran et al., 2005) and merozoite surface protein 1 (MSP1) (Ogutu et al., 2009)
are the leading blood stage vaccine candidates for plasmodium malaria (Plowe, Alonso,
& Hoffman, 2009).
The aim of TBV is to stop subsequent generation of infectious malaria sporozoites
from the female anopheles mosquito vector. TBV induces antibodies against antigens on
gametes, zygote and ookinetes, blocking ookinete to oocyst transition and hence stopping
parasite development within the mosquito midgut (Carter, Mendis, Miller, Molineaux,
& Saul, 2000). Consequently, the density of malaria sporozoites in the mosquito salivary
glands is decreased. The leading malaria vaccine candidate in this category is the Plasmod-
ium falciparum ookinete surface antigens (Pfs25) (Arevalo-Herrera et al., 2005; Hisaeda
et al., 2000).
Due to intracellular infections, P. falciparum parasites are susceptible to immune-
mediated control by CD8+ T cells, which target intracellular pathogens (Villarino, 2013).
The CD8+ T cells have both direct and indirect effector pathways for parasite elimination
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at the liver stage. The indirect mechanism includes the production of IFN-γ and TNF,
whereas the direct mechanism involves the release of perforin and granzymes (Nganou-
Makamdop, van Gemert, Arens, Hermsen, & Sauerwein, 2012). IFN-γ suppresses par-
asite development through direct impairment of parasite differentiation in hepatocytes
(Mellouk et al., 1987). Moreover, IFN-γ increases the expression of nitric oxide syn-
thase which leads to subsequent increase in nitric oxide that confers protection against
P. falciparum (Seguin et al., 1994). Although CD8+ T cells are sufficiently primed
during blood stage malaria, they offer very minimal contribution to protective immu-
nity. It is thought in Villarino (2013) that vascular endothelial cells that acquire anti-
gen from IRBCs stimulate CD8+ T cells to release perforin and granzyme B during
blood stage malaria. The capacity of CD8+ T cells to eradicate malaria parasites and
infected cells both at the liver stage and at the blood stage is therefore considered in
this paper.
A lot of research has been carried on clinical malaria control (Austin, White, & Ander-
son, 1998; Hellriegel, 1992; Kamangira, Nyamugure, & Magombedze, 2014; Li, Ruan,
& Xiao, 2011; Tumwiine, Hove-Musekwa, & Nyabadza, 2014). Some of these models
have focussed on the role of the host’s immune cells (Malaguarnera & Musumeci, 2002;
Tumwiine et al., 2014) while others are based on the use of antimalarial drugs (Kamangira
et al., 2014; Magombedze, Chiyaka, & Mukandavire, 2011) in controlling clinical malaria.
In Chiyaka, Garira, and Dube (2008), both the immune cells and malaria chemotherapy
controls are considered. In Rouzine and McKenzie (2003), the role of innate immunity
in mediating synchronization between the replication cycles of parasites in different ery-
throcytes is explored. Kamangira et al. (2014) investigated erythrocytes–malaria parasite
dynamics in the presence of immune response and/or drug intervention at the erythro-
cytic stage. Results in Nannyonga, Mwanga, Haario, Mbalawata, and Heilio (2014) showed
that malaria merozoites can be absorbed in already IRB cells, leading to faster rapture
of IRB cells and hence causing anaemia. Tabo, Luboobi, and Ssebuliba (2017) incorpo-
rated the liver stage in their model and investigated treatment as a control strategy for
blood stagemalaria. Results from their study showed that a treatment strategy using highly
effective drugs targeting specific parameters can reduce malaria progression and control
the disease in humans. The above research activities have been very insightful in under-
standing in-host malaria dynamics and control, however, none of these investigations has
attempted to evaluate the possible impacts of malaria vaccines in controlling clinical P.
falciparum malaria both at the liver stage and at the blood stage. In this study, we for-
mulate a more detailed in-host malaria model that considers parasite–cell interactions at
the liver stage and the blood stage subject to malaria vaccines. Our goals are to study the
interacting cell-parasite populations through a mathematical model and to numerically
investigate the possible impacts of malaria vaccines on the severity of P. falciparummalaria
infection.
The rest of the paper is organized as follows. In the following section, we incorporate
vaccination control to a formulated in-host malaria model and describe the corresponding
model parameters and variables. The vaccine model is analysed and its vaccine repro-
ductive number together with parameter sensitivity analysis is computed in Section 3. In
Section 4, we investigate the effects of malaria vaccines and vaccine efficacy on malaria
dynamics and malaria severity. A discussion and conclusion complete the paper in Sec-
tions 5 and 6, respectively.
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2. Model formulation
We present a mathematical model of in-host P. falciparum malaria dynamics in the
presence of malaria vaccines. The compartmental model is an extension of the hep-
atocytic–erythrocytic in-host malaria model in Orwa, Mbogo, and Luboobi (2018) in
which two compartments of gametocytes G(t) and CD8+ T cells W(t) are added to cap-
ture the effects of the transmission blocking vaccines and the general effects of CD8+
T cells on the density of the IRB cells and hence malaria infection dynamics. The rest
of the populations include susceptible liver hepatocytes H(t), infected liver hepatocytes
X(t), malaria sporozoites S(t), susceptible red blood cells R(t), infected red blood cells
(blood trophozoites) T(t), infected red blood cells (blood schizonts) C(t) and malaria
merozoitesM(t).
During feeding, infected mosquito injects  sporozoites into the human skin. These
sporozoites traverse Kupffer and endothelial cells and enter the liver hepatocytes. Suscep-
tible liver hepatocytes are recruited by self-replication at a rate λh. Following invasion
by sporozoites at the rate βs, infected hepatocytes X progress to hepatic-schizont which
eventual burst open at the rate μx to release merozoites into the blood stream. The ini-
tial recruitment of the merozoites is hence represented by the term NμxX, where N is
the number of merozoites released per bursting infected hepatocyte. The released mero-
zoites invade and infect the host’s red blood cells at a rate βr and die naturally at the
rate μm.
Based on their stage of infection, we classify IRB cells as either blood trophozoites
(early stage of infection) or blood schizonts (late stage of infection). Susceptible RBCs are
recruited at a constant rate λr from the bone marrow and their concentration decreases
through natural death at the rate μr or due to invasion by the merozoites at the rate
βr. Following merozoite invasion, susceptible RBCs move to the class of infected red
blood cells (blood trophozoites) T. The generated blood trophozoites decay naturally at
a rate μt or progress into blood schozonts C class at the rate γ . Mature blood schizonts
burst open to release more merozoites into blood stream. This is represented by the term
(PμcC/1 + dW), where P denotes the number of merozoites released per bursting blood
schizont and μc is the decay rate of the blood schizonts.
At the pre-erythrocytic stage, themalaria sporozoites are debilitated by vaccine-induced
anti-CSP antibodies (PEV) as they molt through the tissues (Mellouk et al., 1990; Schwenk
et al., 2003). This reduced invasion of hepatocytes by themalaria sporozoites is represented
by the term βs(1 − ν)SH, where 0 < ν < 1 is the efficacy of the pre-erythrocytic vaccine.
Sporozoites that successfully invade the hepatocytes are, however, targeted by vaccine-
induced CSP-specific CD8+ T cells (PEV). The CD8+ T cells kill the resulting infected
hepatocyte (Renia et al., 1991; Sun et al., 2003; White et al., 2013). The killing of infected
hepatocytes reduces the burst sizeN of the infected hepatocytes. This is represented by the
term (1 − b)N, where 0<b<1 is the probability withwhich the vaccine inhibitsmerozoite
emergence from infected hepatocyte.
An unbounded bilinear function rEI is considered inAnderson,May, andGupta (1989),
Niger and Gumel (2011) and Hetzel and Anderson (1996) to model the killing of infected
cells I by the CD8+ T cells E. The simple mass-action term depends solely on the product
of the concentration of the immune cells and the density of the infected cells. However, if
we take into account the fact that cell proliferation can saturate then the nonlinear bounded
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Michaelis–Menten–Monod function, presented in Equation (1) is most reasonable (Agur,
Abiri, & Van der Ploeg, 1989; Antia, Levin, & May, 1994).
∇ = ∇max BKb + B
, (1)
where B is the concentration of substrate, ∇ is the growth rate of the microorganisms
B, ∇max is the maximum specific growth rate of B and Kb is the half-velocity constant,
∇/∇max.
In Pilyugin and Antia (2000), the nonlinear boundedMichaelis–Menten–Monod func-
tion (1) is used to model the handling time in immune response and their targets and
how it affects the infection. In this paper, we adopt such a nonlinear bounded function
(p1IE/(1 + βI)) in Chiyaka et al. (2008), where it is used to describe the killing of infected
erythrocytes I by the immune cells E (CD8+T cells, in our case). This formulation has also
been used in Cai, Tuncer, and Martcheva (2017) and Selemani, Luboobi, and Nkansah-
Gyekye (2017). The parameter p1 describes the rate of removal of I by E and 1/β is the
saturation constant that stimulates the proliferation of the CD8+ T cells to grow at half
their maximum rate.
The effects of the BSV on merozoite invasion of the red blood cells are represented
by the term (((1 − )βrRM)/1 + dW), where 0 <  < 1 is the efficacy of the BSV and
1/d is a saturation constant that stimulates CD8+ T cells to grow at half their maximum
rate. In addition, BSV reduces the density of merozoites that are released per bursting
blood schizont, so that the burst size P becomes (1 − a)P, where 0<a<1 accounts for
the vaccine-induced reduction of merozoites released per bursting IRB cell. BSV is fur-
ther assumed to enhance the production of CD8+ T cells at a rate τ , where τ > 1. For
purposes of simulation, we assume 1 < τ < 2. Administered TBV is assumed to reduce
the recruitment rate of the sporozoites  to (1 − χ), where 0 < χ < 1 is the efficacy
of the TBV. Moreover, the inoculated sporozoites are assumed to die naturally at the
rate μs.
The immune cells (CD8+ T cells) are recruitment at a constant rate λw from
the thymus. Furthermore, the presence of infected cells such as infected hepatocytes,
blood trophozoites and blood schizonts stimulates the production of CD8+ T cells.
The increased production of W(t) due to X(t), T(t) and C(t) is also modelled using
the nonlinear bounded Michaelis–Menten–Monod function (1) and is represented by
the terms (δxWX/1 + ε0X), (δtWT/1 + ε1T) and (δcWC/1 + ε2C), respectively. The
parameter δi|i = {x, t, c} represents the immunogenecity of infected hepatocytes, blood
trophozoites and blood schizonts respectively. On the other hand, the phagocytotic
effects of CD8+ T cells on infected cells (X, T and C) are represented by the terms
(kx(1 − ν)WX/1 + ε0X), (kt(1 − )WT/1 + ε1T) and (kc(1 − )WC/1 + ε2C), where
kj|j = {x, t, c} is the immunosensitivity of X,T and C, respectively.
The density of blood schizonts C decreases when they burst open to release merozoites
into blood stream or when they die naturally at the rate μc. A proportion π of the released
merozoites develops into gametocytesG(t)whose natural decay rate is denoted byμg . Just
like the susceptible hepatocytes whose natural mortality is at the rate μh, we assume a
constant decay rates μt and μw for blood trophozoites and the CD8+ T cells respectively.
The descriptions of the variables and parameters used in the model are summarized in
Tables 1 and 2 respectively.
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Table 1. Description of variables.
Variable Description
H(t) Concentration of uninfected hepatocytes
X(t) Concentration of infected hepatocytes
R(t) Concentration of susceptible red blood cells
T(t) Concentration of blood trophozoites
C(t) Concentration of blood schizonts
S(t) Concentration of sporozoites
M(t) Concentration of merozoites in blood
G(t) Concentration of gametocytes in blood
W(t) Concentration of CD8+ T cells
Table 2. Description of parameters.
Parameter Description
 The rate of injection of sporozoites into liver due to mosquito bites
μs The decay rate of sporozoites
λh Rate of production of susceptible hepatocytes from the bone marrow
λr Rate of production of susceptible RBC by the bone marrow
μh ,μx Death rate of susceptible hepatocyte and infected hepatocyte
respectively
π Proportion of parasites that become gametocytes per dying
blood schizont
kx , kt , kc Immunosensitivity of infected hepatocytes, blood trophozoites
and blood schizonts respectively
δx , δt , δc Immunogenecity of infected hepatocytes, blood trophozoites
and blood schizonts respectively
βs Infection rate of hepatocytes by sporozoites
μr The natural mortality rate of RBC
βr Rate of infection of RBCs by merozoites
μt ,μc The rate of decay of blood trophozoites and blood schizonts respectively
μm ,μg Decay rate of merozoites and gametocytes respectively
γ Progression rate of IRB cells from trophozoite
to schizont stage
χ Efficacy of transmission blocking vaccine
 Efficacy of blood stage vaccine.
d The rate of inhibition of immune response
λw The rate of production of CD8+ T cells
1/ε0, 1/ε1, 1/ε2 half saturation constants for infected hepatocytes, blood
trophozoites and blood schizonts respectively
τ A parameter that accounts for vaccine-induced enhanced production
of CD8+ T cells
ν Efficacy of pre-erythrocytic stage vaccine
μw Decay rate of CD8+ T cells
b A parameter that accounts for PEV-induced reduction of merozoites
released per bursting infected hepatocyte
a A parameter that accounts for BSV-induced reduction of merozoites
released per bursting blood schizont
P The average number of merozoites released per bursting
blood schizont
N The average number of merozoites released per bursting infected
hepatocytes
The in-host malaria dynamics subject to vaccination is represented in the compartmen-
tal flow diagram in Figure 2. Based on the above model description and assumptions, the
in-host malaria model that takes vaccines into account is formulated using a system of
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Figure 2. Schematic diagram for in-host malaria with vaccine therapy. The dotted lines without arrows
indicate cell–parasite interactionand the solid lines showprogression fromonecompartment to another.
nonlinear ordinary differential equations and presented as follows:
dS
dt
= (1 − χ) − μsS − βsHS,
dH
dt
= λh − μhH − βs(1 − ν)HS,
dX
dt
= βs(1 − ν)SH − μxX − kx(1 − ν)WX1 + ε0X ,
dR
dt
= λr − (1 − )βrRM1 + dW − μrR,
dT
dt
= (1 − )βrRM
1 + dW − μtT − γT −
kt(1 − )WT
1 + ε1T ,
dC
dt
= γT − μcC − kc(1 − )WC1 + ε2C ,
dM
dt
= (1 − b)NμxX + P(1 − π)(1 − a)μcC1 + dW − μmM − βrRM,
dG
dt
= πμcC − μgG,
dW
dt
= τλw + W
(
δxX
1 + ε0X +
δtT
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We assume that all the parameters used in the model are positive and the initial conditions
for system (2) are:H(0) ≥ 0,X(0) ≥ 0, S(0) ≥ 0,R(0) ≥ 0,T(0) ≥ 0,C(0) ≥ 0,M(0) ≥ 0,
G(0) ≥ 0,W(0) ≥ 0.
3. Model analysis
3.1. Well-posedness of themodel
Weaim to evaluate the effects of the different vaccines on the concentration of infected hep-
atocytes and infected red blood cells. Therefore, themodel should be biologically coherent.
That is, all the state variables and their solutions must be non-negative and bounded,
respectively, in the region , where
 =
{




























and Nr(t) = R(t) + T(t) + C(t), Nh(t) = H(t) + X(t), Np(t) = S(t) + M(t) + G(t), μ1
= min{μr,μt ,μc}, μ2 = min{μh,μx} and μ3 = min{μs,μm,μg}.
For the in-host malaria model (2) to be biologically meaningful, we prove the following
theorem.
Theorem 3.1: The region is positively invariant with respect to the in-host malaria model
(2), and a non-negative solution (H(t),X(t),R(t),T(t),C(t), S(t),M(t),G(t),W(t)) exists
∀t ≥ 0.
Proof: From the sporozoite compartment S(t) in system (2), we have
dS
dt
= (1 − χ) − μsS − βsHS ≥ −(μs + βsH)S. (4)
Integrating (4) yields




This shows that in the absence of malaria interventions, S(t) ≥ 0 for all time t ≥ 0.
Using the same argument above, it is easy to see that




This process can be repeated for all the state variables so that S(t),H(t), X(t), R(t), T(t),
C(t), M(t), G(t), W(t) are all positive for all t ≥ 0. Thus the solutions of in-host malaria
model (2) remain positive in for all time t ≥ 0. A quick guide on proof for positivity and
LETTERS IN BIOMATHEMATICS 231
boundedness is available in Nyabadza, Njagarah, and Smith (2013) and Traoré, Sangaré,
and Traoré (2017).
To show that the solutions of model system (2) are bounded, we let Nr be the total con-




= λr − μrR − μtT − μcC −
(
kt(1 − )WT





≤ λr − μ1Nr where μ1 = min{μr,μt ,μc}. (8)









This implies that at any time t, Nr(t) ≤ max{Nr(0), λrμ1 }. This approach can similarly be
applied to the population of hepatocytes Nh = H(t) + X(t), population of parasites Np =






















The above analysis shows that the region  is positively invariant and attracting for
system (2) and the model is hence well posed for study. 
3.2. Parasite free equilibrium and vaccination reproduction number
The parasite free equilibrium (PFE), Ev , depicts the absence of malaria parasites from the
human host. The PFE of the in-host malaria model system (2) exists and is given by












The vaccination reproduction number (denoted by Rv), on the other hand, is a threshold
quantity which governs the spread of the infection. It represents on average the number of
new infected cells (RBCs or liver hepatocytes) generated by a single infectious merozoite
(or sporozoites) at the blood (or liver) stage in the presence of malaria vaccines. Using
the next generation matrix approach (Diekmann, Heesterbeek, & Metz, 1990; Van den
Driessche &Watmough, 2002), thematrixF1 that represents the rate of appearance of new
infections and the matrix V1 that denotes the transfer of infections from one compartment
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μxX + kx(1 − ν)WX1 + ε0X−(1 − χ) + μsS + βsSH
μtT + γT + kt(1 − )WT1 + ε1T
−γT + μcC + kc(1 − )WC1 + ε2C





Upon taking the partial derivatives of the terms inF1 andV1 and evaluating at the parasite








0 0 0 0
0 0 0 0 0 0
0 0 0 0
(1 − e)βrλrμw
μr (dτλw + μw) 0
0 0 0 0 0 0
0 0 0 0 0 0












+ μs 0 0 0 0
0 0 Vb 0 0 0
0 0 −γ (1 − )τkcλw
μw
+ μc 0 0











where Va = (((1 − )τkxλw)/μw) + μx and Vb = γ + μt + (((1 − )τktλw)/μw).
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The vaccination reproduction number is the spectral radius of (F1V−11 ). That is,














+ γ + μt
) . (13)
In the absence of malaria vaccines (χ =  = ν = a = b = 0, τ = 1), model (2) has a basic
reproduction number Rm given by


















On comparing Equations (13) and (14), we deduce the following:
Rm = Rv × ∗∗, (15)
where
∗∗ =
































We observe from Equation (15) that in the absence of vaccination, Rv = Rm. However,
the introduction of malaria vaccines reduces the basic reproduction number by a factor
of 0 < ∗∗ < 1. The use of efficacious malaria vaccines therefore has a great potential in
reducing mortality due to P. falciparummalaria disease.
3.3. Sensitivity analysis
The main concern in the control of infectious diseases is the capacity of the infection to
invade the population. The threshold quantity called the vaccine reproduction number
provides a reasonable measure of the ability of the infective malaria parasites to invade
the susceptible cell populations (Heesterbeek & Dietz, 1996). When Rv < 1, the infective
parasites produce less than one new infection per infection period and the disease subse-
quently dies out. However, when Rv > 1, an infective parasite generates several infections
leading to disease severity. In light of this, we carry out sensitivity analysis of model Rv
in (13) so as to determine important parameters in the dynamics of P. falciparummalaria
in the presence of vaccine controls. Following Arriola and Hyman (2007), the normal-







Based on the model Rv and the parameter values in Table 4, we derive the following ana-
lytical expressions for sensitivity indices of Rv with respect to parameters , P,π and τ . A
part from the parameter P, whose sensitivity index does not depend on other parameter
values, the rest of the expressions for the sensitivity indices are complex (see for instance
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(18)–(20)).We therefore evaluate the sensitivity indices of Rv using the baseline parameter
values in Table 4.






( − 1)τkcλw − μcμw −
kt






π = − 1 −  (19)
τ = τλw
(
− ( − 1)kc
( − 1)τkcλw − μcμw −
2d
dτλw + μw −
( − 1)kt




Using Mathematica software, the sensitivity results for the 17 parameters in Rv are as
shown in Table 3. The rate of merozoite invasion βr, the rate of progression of infected
red blood cells from the trophozoite state to blood schizonts γ and the average number
of merozoites released per bursting blood schizont P increase (or decrease) the vaccine
reproduction number when they are increased (or decreased) as shown in Table 3. Malaria
vaccine development should target these parameters to reducemalaria disease progression
in humans. On the other hand, the higher the efficacy of blood stage vaccine , the lower
the value of Rv . A highly efficient erythrocytic vaccine has the potential to eradicate clin-
ical malaria. The proportions of merozoites that development into gametocytes π is also
shown to decrease the value ofRv when they are increased. The higher the concentration of
gametocytes, the lower the density of merozoites in the host’s blood. Although this would
minimize secondary and subsequent erythrocytic invasions and hence malaria severity, it
has the potential to enhance parasite transmission to the mosquito vector. This is due to
increased concentration of gametocytes per blood sample per mosquito bite.
The density of merozoites released per bursting infected red blood cells and the efficacy
of the blood stage vaccine are shown to be the most sensitive parameters in influencing in-
host malaria progression. For example, a 10% increase (or decrease) on P will cause a 10%
increase (or decrease) in Rv . These two parameters should hence be carefully estimated
(Mikucki, 2012) and clinical malaria control using antimalarial drugs andmalaria vaccines
should target the two parameters. This is because a small variation in such a parameter will
lead to large quantitative changes in Rv and hence on malaria disease progression.
Table 3. The sensitivity indices of Rv with respect model parameters.
Parameter Sensitivity index Parameter Sensitivity index
P +1 π −0.25
a −0.25  −0.770486
γ +0.293702 βr +0.0000663956
λr +0.0000664 μc +0.0000247494
μr −0.000066396 d −0.0222497
τ −0.080544 λw −0.080544
μw +0.080 μm −0.00006639
kc −0.0000247494 kt −0.0582696
μt −0.235433
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3.4. Local stability of parasite free equilibrium
The local stability of Ev is investigated as follows. We begin by linearizing model system




−μh 0 −A0 0 0 0 0 0 0
0 −A1 A2 0 0 0 0 0 0
0 0 −A3 0 0 0 0 0 0
0 0 0 −μr 0 0 −A4 0 0
0 0 0 0 −A5 0 A6 0 0
0 0 0 0 γ −A7 0 0 0
0 A11 0 0 0 A8 −A9 0 0












A0 = (1 − ν)βsλh
μh
,A1 = (1 − ν)τkxλw
μw










,A5 = γ + μt + (1 − )τktλw
μw
,






) ,A7 = (1 − )τkcλw
μw






+ μm,A10 = τδtλw
μw
and A11 = (1 − b)Nμx.
It is easy to see frommatrix J1 that the first eigenvalue, λ1 = −μh < 0. Upon deleting row




−A1 A2 0 0 0 0 0 0
0 −A3 0 0 0 0 0 0
0 0 −μr 0 0 A4 0 0
0 0 0 −A5 0 A6 0 0
0 0 0 γ −A7 0 0 0
A11 0 0 0 A8 −A9 0 0










On applying the above procedure to columns 3, 7 and 8 and their corresponding rows
in matrix (22), we obtain the next three eigenvalues: λ2 = −μr < 0, λ3 = −μg < 0 and




−A1 A2 0 0 0
0 −A3 0 0 0
0 0 −A5 0 A6
0 0 γ −A7 0
A11 0 0 A8 −A9
⎞
⎟⎟⎟⎟⎠ . (23)
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The rest of the eigenvalues are obtained by solving the characteristic equation of matrix J3:
λ5 + β1λ4 + β2λ3 + β3λ2 + β4λ + β5 = 0, (24)
where
β1 = A1 + A3 + A5 + A7 + A9 > 0, (25)
β2 = A1A3 + A1A5 + A3A5 + A1A7 + A3A7 + A5A7
+ A1A9 + A3A9 + A5A9 + A7A9 > 0, (26)
β3 = A1A3A5 + A1A3A7 + A1A5A7 + A3A5A7 + A1A3A9 + A1A5A9 + A3A5A9 (27)
















Equation (24) has negative roots (eigenvalues) if all its coefficients terms are positive. That
is, β1 > 0, β2 > 0, β3 > 0, β4 > 0 and β5 > 0. We can clearly see from Equations (25)
and (26) that β1 and β2 are positive terms. However, the coefficients β3, β4 and β5 can only
be positive if the vaccine reproduction number Rv is less than unity, Rv < 1.
Thus, using Theorem 2 in Van den Driessche and Watmough (2002), the following
lemma is established.
Lemma 3.1: The disease free equilibrium Ev is locally asymptotically stable if Rv < 1 and
unstable if Rv > 1.
Lemma 3.1 shows that if we are to eliminate the malaria parasite following malaria
infection, then we have to administer a vaccine or combinations of vaccines that would
guarantee the existence of a stable disease free equilibrium. Epidemiologically, when Rv <
1, we expect the parasites to decay off so that the severity of malaria infection is reduced
to near zero or totally eliminated. On the other hand, if Rv > 1, the malaria infection
persists within the human host; that is, more red blood cells and susceptible hepatocytes
are infected. This implies that the vaccines may not be efficacious; their use do not erad-
icate malaria infection among infected individuals. The malaria parasites are therefore
likely to persist at the erythrocytic stage in an infected individual and subsequently can
be transmitted to other persons in close contact via the mosquito vector.
3.5. Critical efficacy of blood stage vaccine
Definition 1: Vaccine efficacy is interpreted as the proportionate reduction inmalaria dis-
ease attack rate within a vaccinated person compared to an unvaccinated person (Small,
Cheng, & Ten, 2010).
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Generally, the vaccine efficacy VE is expressed as follows (Orenstein, Wassilak, Strebel,
Bernier, & Blackwelder, 1990):
VE = ARU − ARVARU × 100, (31)
whereARU is the parasite attack rate of unvaccinated individual andARV is the attack rate
for vaccinated people. A critical vaccine efficacy therefore refers to the minimum efficacy
value beyond which the vaccine is capable of eradicating the infection from the human
host. To establish a critical malaria vaccine efficacy from the vaccine reproduction num-
ber (13), we assume that only the blood stage vaccine is administered to the individual.
That is, ν = 0, b=0, χ = 0. We then solve for  from the equation Rv = 1 as follows:

















By simplification, Equation (32) reduces to
(1 − )μ2w













(1 − π)(1 − a)γPμcβrλrμw . (34)
Upon solving for (1 − ) in (33) using the quadratic formula, we obtain






B0 = −μc(γ + μt)μ2w, B1 = −μw(τkcλw(γ + μc + μt) − μw), and
B2 = −(τkcλw)2.
From Equation (35), the critical efficacy of the blood stage vaccine, 0 < c < 1, is








where Bi, i = {0, 1, 2}, are as defined in Equation (35).
Equation (36) implies that for any blood stage vaccine to effectively control clinical
malaria, then its efficacy must be higher than the stated critical vaccine efficacy.
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Differentiating Rv with respect to vaccine efficacy  yields
∂Rv
∂














































where 3 = ((((1 − )τktλw)/μw) + γ + μt).
We further simplify the right-hand side (RHS) of (37) bymaking the following represen-
tations: let1 = μr(μm + ((βrλr)/μr)), 2 = ((((1 − )τkcλw)/μw) + μc) and4 =
(1 + ((dτλw)/μw)). This results in
∂Rv
∂












where  = (1/(1 − )τλwkckt). We observe that (∂Rv/∂) < 0 when μcμw2(γ + μt) >
τkcktλw2(1 − ). Rv is therefore a decreasing function of the blood stage vaccine . This
means that an efficacious BSV reduces the density of IRB cells within the human host.
Figure 4 shows the profiles of the density of blood trophozoites and blood schizonts as a
function of the efficacy of the BSV, . The concentration of infected erythrocytes decreases
with increasing values of .
4. Numerical simulation
4.1. Vaccine efficacy
Lemma 4.1: The vaccination threshold Rv < 1 whenever  > c
When the efficacy of the BSV is higher than the critical vaccine efficacy c, the mero-
zoites are eradicated from the blood stream. Under this setting, the capacity of the blood
stage vaccine to eradicate malaria parasites in the host’s blood stream is guaranteed by
Lemma 4.1. The results of Lemma 4.1 is shown numerically in Figure 3(a) and (b) using
different values of . In Figure 3, a blood stage vaccine with a minimum efficacy of
94% is needed to control the blood stage parasites. Using the provided parameter values
and expression (13), we observe that under this condition, Rv is less that unity. That is
Rv = 0.58 < 1.
Lemma 4.2: The vaccination threshold Rv > 1 whenever  < c
When the efficacy of the blood stage vaccine is lower than the critical efficacy ( < c),
the rate of infection of susceptible infected red blood cells is higher. This leads to increased
density of infected red blood cells (blood trophozoites and blood schizonts) as shown in
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Figure 3. Graphs showing the density of (a) blood trophozoites T(t) and (b) blood schizonts C(t)when
the blood stage vaccine efficacy,  = 0.94 > c = 0.86 and Rv = 0.58 < 1. The parameter values are
available in Table 4.
Figure 4. Graphs showing the density of (a) blood trophozoites T(t) and (b) blood schizonts C(t)when
the efficacy of blood stage vaccine,  = 0.5 < c = 0.86 and Rv = 1.27 > 1. The used parameters
values are available in Table 4.
Figure 4. Using the parameter values in Table 4 and the expression for the vaccine repro-
duction number, we observe that the above condition is only guaranteed whenRv is greater
than unity. That is, Rv = 1.27 > 1.
Only a highly efficacious blood stage vaccine, ( > 90%) would guarantee the achieve-
ment of a malaria free equilibrium as shown in Figure 5. A blood stage vaccine with
lower efficacy, ( < 50%) is likely to be less effective in clearing the malaria parasites.
A malaria persistent steady state is hence probable (see Figure 5). The concentration
of gametocytes in the blood stream is indirectly influenced by the blood stage vac-
cine. Higher vaccine efficacy minimizes the concentration of gametocytes that are later
sucked up by feeding anopheles mosquitoes. As the efficacy of blood stage vaccine dimin-
ishes, higher concentration of gametocytes is observed in the blood stream as shown is
Figure 6.
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Table 4. Parameter values used in the numerical simulations and sensitivity analysis.
Parameter Value Range Units Source
P 16 (15–20) /erythrocytes/day Diebner et al. (2000)
kx 0.01 (0.001–0.9) /day Chiyaka et al. (2008)
kt 0.01 (0.001–0.9) /day Chiyaka et al. (2008)
kc 0.000001 (0.001–0.9) /day Chiyaka et al. (2008)
μr 0.083 (0.05–0.1) /day Anderson et al. (1989)
βr 2.0 × 10−1 (0.07–0.3) /mm3/day Dondorp, Kager, Vreeken, and
White (2000)
βs 1.0 × 10−3 (0.001–0.2) /mm3/day Selemani, Luboobi, and Nkansah-
Gyekye (2016)
π 0.2 (0.1–0.9) unitless Talman, Domarle, McKenzie, Ariey,
and Robert (2004)
μh 0.029 (0.01–0.5) /day Estimated
μx 0.02 (0.01–1) /day Selemani et al. (2016)
λr 3 × 103 (3 × 103 − 3 × 108) cells/ml/day Li et al. (2011)
λh 3 × 105 (3 × 105 − 3 × 108) cells/μl−1/day Tumwiine, Mugisha, and
Luboobi (2008)
λw 30 (10–40) /μl−1/day Chiyaka, Garira, and Dube (2010)
μm 48 (46–50) /day Li et al. (2011)
 30 (18–35) sporozoites/day Selemani et al. (2016)
μs 1.2 (1.0 − 2.4) /day Selemani et al. (2016)
μt 0.5 (0.01–0.8) /day Magombedze et al. (2011)
μc 0.5 (0.01–0.9) /day Magombedze et al. (2011)
μg 0.0000625 (6.0 × 10−5 − 7.0 × 10−5) /day Selemani et al. (2016)
μw 2 (0.05–3) /day Chiyaka et al. (2010)
δx 1e-5 (1e-5–1e-7) mm−3/day Chiyaka et al. (2010)
δt 0.05 (0.01–0.08) mm−3/day Chiyaka et al. (2010)
δc 0.05 (0.01–0.08) mm−3/day Chiyaka et al. (2010)
γ 1.5 (0.1–2) /day Selemani et al. (2016)
χ 0.2 (0–1) unitless Assumed
 0.45 (0–1) unitless Birkett (2016)
ν 0.3 (0–1) unitless Assumed
τ 1.5 (1–2) unitless Niger and Gumel (2011)
b 0.2 (0–1) unitless Niger and Gumel (2011)
a 0.2 (0–1) unitless Niger and Gumel (2011)
d 0.0005 (0.00005–0.02) unitless Magombedze et al. (2011)
N 10,000 (8000–20,000) /day Tumwiine et al. (2014)
Figure 5. Simulations showing the effect varying the parameter  on the density of infected red blood
cells. All other parameter values are in Table 4.
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Figure 6. Simulations showing the effect varying the parameter on the concentration of gametocytes
in blood. All other parameter values are in Table 4.
The effect of BSV-induced reduction of merozoites released per bursting blood schizont
is monitored by differentiating Rv with respect to a. This gives
∂Rv
∂a














where 3 = ((((1 − )τktλw)/μw) + γ + μt).
We make the following observations: the vaccine reproduction number Rv decreases
with increasing value of a. As less blood schizonts burst, less merozoites are released and
hence less secondary infections that increase the severity of the disease as displayed in
Figure 7. This leads to the reduction in the vaccine reproduction number and hence the
density of infected red blood cells in the blood stream.
Figure 7. Simulations showing the effect varying the parameter a on the density of (a) blood tropho-
zoites T(t) and (b) blood schizonts C(t). All other parameter values are in Table 4.
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The effect of the BSV-induced enhanced production of CD8+ T cells is monitored by
the partial derivatives of Rv with respect to τ .
∂Rv
∂τ




















































where 3 = ((((1 − )τktλw)/μw) + γ + μt).


















∗ = (1 − π)(1 − a)γP(1 − e)2dkcktμcβrλrλw.
We observe from (40) that Rv decreases with increasing τ . As more CD8+ T cells are acti-
vated, more trophozoites and blood schizonts are killed through phagocytosis, leading to
reduction in the severity of malaria infection as shown in Figure 8.
The effect of the BSV-induced reduction in the burst size P of infected red blood cells is
shown by the following formula:
∂Rv
∂P

















where 3 = ((((1 − )τktλw)/μw) + γ + μt).
Figure 8. Simulation showing the density of (a) blood trophozoites T(t) and (b) blood schizonts C(t) for
varying values of blood stage vaccine-induced enhanced production parameter τ . All other parameter
values are in Table 4.
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Figure 9. Simulations showing how the infected red blood cell burst size P affects the density of (a)
blood trophozoites T(t) and (b) blood schizonts C(t). All other parameter values are in Table 4.
Note that (∂Rv/∂P) > 0 and Rv decreases (increases) with decreasing (increasing)
value of P. The higher the density of released merozoites from bursting blood schizonts,
the higher the rate of secondary invasions at the blood stage. The concentration of infected
red blood cells in blood is observed to increase with increasing value of P as shown in
Figure 9. An efficacious malaria vaccine would be necessary in minimizing secondary and
future invasions that occur at the blood stage of malaria infection.
4.2. Threshold analysis and vaccine impacts
TheMalaria Vaccine Technology Roadmap updated inNovember 2013 has two key strate-
gic goals targeting P. falciparum and P. vivax malaria by the year 2030: (1) to develop
vaccines with over 75% protective efficacy against clinical malaria and (2) to develop
transmission blocking vaccines thereby reducing new cases of human malaria infec-
tions (MVFG, 2018). A combination of malaria vaccines (pre-erythrocytic, blood stage
Figure 10. Timeprofile of the total concentration of infected red blood cells (a) and the concentration of
infected liver hepatocytes (b) in the absence of malaria vaccines ( = χ = ν = 0). All parameter values
are in Table 4.
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and transmission blocking vaccines) could help in achieving the over 75% strategic goal
(Miura, 2016).
A highly efficacious blood stage vaccine has a potential to significantly reduce the num-
bers of gametocytes in the blood stream, thereby minimizing parasite transmission to
mosquitoes and subsequently to other human beings. In the following section, we investi-
gate the possible impacts of different malaria vaccine combinations with varying degrees
of efficacy.
In the absence of malaria vaccines,  = χ = ν = 0, we observe from Figure 13 that
the concentration of infected red blood cells increases rapidly and settles at the parasite
persistent equilibrium point. This trend is also observedwith the infected liver hepatocytes
(see Figure 10b). The concentration of infected liver hepatocytes rises due to invasion by
Figure 11. Time profile of the total concentration of (a) blood trophozoites and blood schizonts (b) for
 = χ = 0.45 with varying efficacy of pre-erythrocytic vaccine ν. The set of parameter values is given
in Table 4.
Figure 12. Time profile of the total concentration of (a) blood trophozoites and blood schizonts (b) for
 = χ = 0.9 with varying efficacy of pre-erythrocytic vaccine ν. The set of parameter values is given in
Table 4.
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Figure 13. Simulation showing the profile of infected liver hepatocytes in the presence of perfect
malaria vaccines ( = χ = 0.9). The efficacy of the pre-erythrocytic vaccine ν is varied from 0 to 1. The
set of parameter values is given in Table 4.
sporozoites for about a week. This is followed by a slight decline in density and subsequent
persistent concentration at the liver stage.
A malaria vaccine with an efficacy of 45% may not be adequate in eliciting sufficient
immune response to reduce and clear infections as shown in Figure 11. More plasmodium
parasites are likely to persist in the blood stream, raising the severity of infections.
A combination of an imperfect blood stage vaccine (efficiency ≥ 90%) and an imperfect
transmission blocking vaccine (efficiency ≥ 90%) is likely to result in rapid eradication of
the infected infected red blood from the human host as displayed in Figure 12. Observe
that the parasite free equilibrium is highly probable irrespective of the efficacy of the pre-
erythrocytic vaccine in this context.
Similarly, the concentration of gametocytes in the blood stream is observed to diminish
quickly in the presence of efficacious malaria vaccine combinations (see Figure 13).
5. Discussion
Using numerical simulation, we observe that the activated CD8+ T cells and malaria
vaccines have a considerable effects on malaria control. Vaccination reduces the basic
reproduction number by a constant factor. An imperfect blood stage vaccine with an
efficacy of at least 90% is shown to be very effective in controlling in-host P. falciparum
malaria.
We further observe that malaria vaccines that minimize the total number of merozoites
released per bursting infected liver hepatocytes, reduce the concentrations of blood tropho-
zoites and blood schizonts. Similarly, a highly efficacious vaccine greatly reduces the burst
size of the blood schizonts, so that less merozoites are released from the infected red blood
cells. This has the potential to reduce malaria severity and hence malaria transmission to
the mosquito vector.
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An efficacious blood stage vaccine should maximize the rate of activation of CD8+ T
cells. We notice that the higher the vaccine potential to activate these immune cells, the
lower the concentration of infected red blood cells in the host.
Our analysis further shows that different vaccine combinations yield different results.
In the absence of vaccine therapy, the concentration of infected red blood cells (blood
trophozoites and blood schizonts) is shown to increase and stabilize at the parasite per-
sistent equilibrium. An imperfect pre-erythrocytic vaccine with an efficacy of at least 90%
is also shown to guarantee the attainment of a parasite free equilibrium.
Like many other epidemic models, the presented in-host malaria model is formulated
based on several model assumptions. The parameter values used in the study are also
obtained from past literature. The results of our study should therefore be approached
with some discretion. The presented model ignores the biology of CD8+ T activation and
assumes constant parameter values. It would therefore be difficult to predict with higher
accuracy, the optimal malaria vaccine efficacy. In spite of the stated shortcomings, the pre-
sented in-host malaria model provides useful insights on the need to improve the efficacy
of current malaria vaccines in development and the need to try vaccine combinations in
controlling clinical P. falciparummalaria infection.
Although the normalized forward sensitivity approach is helpful in identifying impor-
tant parameters in the dynamics of the disease, it fails to explain the considerable uncer-
tainties in estimating parameter values and hence parameter influences on specific output
variables/states in the model. For future improvement of the above model, we recom-
mend the inclusion uncertainty and sensitivity analysis with respect to infected cells
of the in-host malaria model based on Latin Hypercube Sampling and Partial Rank
Correlation Coefficient.
6. Conclusion
We have presented a mathematical model for in-host malaria dynamics subject to malaria
vaccines. The analysed model provides useful insights in individual and combined vaccine
impacts in reducing the severity of clinical malaria. The notion of critical vaccine efficacy
is key in the development of malaria vaccines with the potential to eliminate or eradicate
P. falciparummalaria in individuals infected with the disease.
In order to achieve a substantial reduction in malaria mortality and morbidity, the
efficacy of the malaria vaccine should be higher than the corresponding critical vaccine
efficacy. For instance, when the efficacy of the blood stage vaccine is lower than the criti-
cal efficacy ( < c), the rate of infection of susceptible infected red blood cells is higher
and clinical malaria persists. However, the concentration of blood trophozoites and blood
schizonts decreases drastically if the efficacy of the blood stage vaccine is higher than the
critical blood stage vaccine efficacy.
The combined administration of malaria vaccines (Miura, 2016) and antimalarial drugs
is likely to provide the much needed therapeutic control against P. falciparummalaria. The
general and specific impacts generated by vaccine–WHO–antimalarial drugs combination
will also form part of our future investigation.
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Abstract
Results of uncertainty and sensitivity analysis have significant epidemiological importance in
malaria control. In this paper, the efficient technique of latin hypercube sampling (LHS) and
partial rank correlation coefficient is applied to an in-host Plasmodium falciparum malaria
model. Sensitivity indices of the basic reproduction number are derived using the normalised
forward approach. By a theoretical analysis, we show the existence and stability of the
model steady states based on threshold value R0. Our results show that the in-host model is
sensitive to variations in the efficacyofmalaria vaccines. The rates of parasite to cell invasions,
the density of merozoites released per bursting infected erythrocyte and the proportions of
merozoites that become gametocytes are highly significant in determining the severity of
malaria infection. Moreover, a highly effective vaccine combination is critical for malaria
disease elimination goal. This study further shows that the long term precise predictions of
the concentrations of infected cells during malaria infection would be difficult until these key
parameters are correctly determined. These results are vital in the on-going malaria vaccine
development.
Keywords Sensitivity analysis · Hepatocytes · Erythrocytes · P. falciparum · Vaccine
combination
Introduction
During disease model formulation, we are bound to make simplifications and assumptions
on the model itself and on the parameters that represent the different transitions and inter-
actions in the model. Owing to uncertainty on parameter values, it is important to correctly
understand the possible effects of the such parameter values to the anticipated model out-
put [21,52]. Uncertainty in the set of parameter values generates variability in the model’s
predictive capabilities. The lower the number of uncertain parameters in a model, the lower
the significance of variability introduced into a model. On the other hand, a higher number
of uncertain parameters result into a higher significance of variability introduced [21].
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In-host malaria transmission models have become very complex. Unlike simple models,
complex models may best be understood by numerical analysis [8]. Uncertainty and sensitiv-
ity analysis are instrumental in analyzing the dynamics of such structurally complex models
that experiences high levels of uncertainty in the estimation of their input parameter values.
The concept of uncertainty analysis enables us to evaluate the variability in the output [30].
Conversely, a sensitivity analysis helps us to discern important parameters in the dynamics of
infection under study. There are three techniques of uncertainty and sensitivity analysis [30].
These include: (i) latin hypercube sampling/partial rank correlation coefficient (LHS/PRCC),
(ii) response surface methodology, and (3) differential analysis. The more sophisticated and
efficient approach of LHS/PRCC [9,30] that permits synchronous variation of all input vari-
ables is considered in this study.
LHS/PRCC sensitivity analysis is a synergy of Latin Hypercube Sampling [38] and the
Partial Rank Correlation Coefficient [26]. It aims to identify and rank pivotal model parame-
ters whose uncertainties contribute to prediction imprecision [21]. In this paper, uncertainty
and sensitivity analysis is applied to an in-host malaria model subject to malaria vaccines.We
endevour to identify influential parameters in determining malaria disease progression and
control within the human host. See [2,50] for a rigorous description of the different malaria
vaccines.
Malaria is a mosquito-borne infectious disease caused by Plasmodium parasite. The dis-
ease is typically transmitted through the bite of an infectedmosquito vector [20]. The injected
sporozoites traverse host dermis and enter the liver hepatocytes for further asexual develop-
ment. Hepatocite—invading sporozoites, grow, divide mitotically and differentiate into liver
merozoites [12]. The release of these merozoites into blood stream marks the beginning of
the blood stage cycle. Themerozoites invade susceptible erythrocytes to feed on hemoglobin.
Like the liver stage, the merozoites also differentiate, causing infected erythrocytes to burst
open, releasing more merozoites into blood stream. Higher densities of blood merozoites
increases the severity of clinical malaria. The daughter merozoites quickly invade other red
blood cells to renew the cycle or develop into male or female gametocytes [13]. This cycle is
associated with malaria characteristics symptoms [17,69]. See [6,49] for a detailed discus-
sion on stages of malaria infection. Although malaria is both preventable and curable, severe
malaria may lead to seizures, coma and death [22].
Currently, there are more than 30 malaria vaccine candidates under development [68].
These vaccines are generally categorised into: (1) pre-erythrocytic vaccines (PEV), (2) blood
stage vaccines (BSV) and (3) transmission blocking vaccines (TBV) [6]. RTS,S/AS01 (also
known asMosquirix) is the onlymalaria vaccine that has received a positive scientific opinion
from the European Medicines Agency (EMA) [18]. This pre-erythrocytic vaccine has been
evaluated in large phase 3 trial in sub-Saharan Africa. The vaccine showed a 45.7% (95%
CI, 41.7–49.5) efficacy against all episodes of clinical P. falciparum malaria across all sites
in the 5–17 month age category [54]. Despite positive assessment from EMA, the World
HealthOrganization (WHO) recomments further evaluation ofRTS,S/AS01 in a series of pilot
implementations before it can be introduced on a wide scale [70]. Nonetheless, an efficacious
malaria vaccine forms a crucial component of future malaria control and elimination tool.
Several research studies [1,13,14,23,25,27,29,39–41,55] have focused on understanding
the dynamics and control of P. falciparum infections. Although most of these models have
investigated parameter importance in driving malaria infection, this is mainly based on the
basic reproduction number of the model, which often do not have all the model parameters.
Sensitivity analysis for the entire parameter space provides the right rigour for parameter eval-
uation in driving the disease progression. Previous studies [44,71], used parameter-driven
LHS/PRCC procedure to ascertain important parameters and their relative importance in
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the disease model output. In [21], LHS/PRCC procedure is coupled with the optimal control
numerical procedure to simultaneously examine the effects parameters on the objective func-
tional value. In this paper, the LHS/PRCC uncertainty and sensitivity analysis applied to an
in-host P. falciparum malaria model with vaccine controls. Moreover, multi-component and
multi-stage vaccine combinations is evaluated to establish optimal vaccine combinations.
This paper is organised as follows: we provide details of the in-host malaria transmis-
sion model and its properties such as non-negativity and boundedness of solutions in “The
Model” section.We carry out model analysis including model steady states and their stability
conditions in “Model Analysis” section. In “Uncertainty and Sensitivity Analysis” section,
we derive sensitivity indices of the basic reproduction number relative to model parameters.
We also perform uncertainty and sensitivity analysis of model parameters subject to infec-
tive and infected state variables. The existence of model equilibrium points is numerically
demonstrated in “Numerical Simulation” section. Numerical evaluation of multi-component
andmulti-stage vaccine cocktail completes “Numerical Simulation” section. A discussion on
epidemiological implications of uncertainty, sensitivity analysis and vaccine combinations
completes the paper in “Epidemiological Implications and Conclusion” section.
TheModel
We consider an in-host P. falciparum malaria model. The model anayses the dynamics of
interactions between the human red blood cells (erythrocytes), the liver hepatocytes, the
malaria parasite (P. falciparum) and the cytotoxic CD8+ T-cells in the presence of multi-
component and multi-stage vaccine antigens. The compartmental deterministic model is an
extension of in-most malaria model by the authors in [49]. The model is thus composed
of nine compartments: the malaria sporozoites S(t), the susceptible hepatocytes H(t), the
infected hepatocytes X(t), the susceptible erythrocytes R(t), the infected red blood cells
T (t), the malaria gametocytes G(t), the malaria merozoites M(t), unactivated CD8+ T-cells
Wn(t) and activated CD8+ T-cells Wa(t).
The activation of CD8+ T-cells is caused by the presence of infected hepatocytes and
infected erythrocytes only. This activation is further assumed to occur at a constant rate λw
for both X and T . Unactivated CD8+ T-cells are produced at a fixed rate  from the thymus.
Unlike the model in [49], we have assumed that a proportion q of infected erythrocytes and a
proportion ρ of infected hepatocytes get eradicated by the CD8+ T-cells before they develop
to the bursting stage. The rest of infected hepatocytes develop asexually and burst open to
release blood stage merozoites. We assume that some of the newly generated merozoites
develop into gametocytes. This proportion is denoted by the parameter π . The commitment
to gametocytogenesis is presumably made during the immediately preceding cycle of blood
schizogony [13]. These blood floating gametocytes are transmitted to the mosquito vector
during feeding, marking the onset of the sporogonic cycle (not considered in this study).
During blood meal, infected mosquito injects  sporozoites into the skin of the human
host. The sporozoites traverse the skin and invade the hepatocytes H at the rate βs to
generate infected hepatocytes X at the liver stage (see [64] for detailed description of the
pre-erythrocytic stage infection). We assume a natural death rate of μs for malaria sporo-
zoites. Although hepatocytes are generated at a rate λh from the bone marrow, we assume
that both the infected and uninfected hepatocytes experience natural death at the rates μx
and μh , respectively.
Three malaria vaccines are considered in this model to reduce the severity of P. falciparum
malaria infection. These are: pre-erythrocytic vaccine (PEV) (see, [6,7,46]), blood stage
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Table 1 Description of the state
variables
Variable Description
Wn(t) Concentration unactivated CD8+ T-cells
Wa(t) Concentration activated CD8+ T-cells
H(t) Concentration of susceptible (uninfected) liver
hepatocytes
X(t) Concentration of infected hepatocytes
S(t) Population of malaria sporozoites
R(t) Concentration of susceptible (healthy) erythrocytes
T (t) Concentration of infected erythrocytes
M(t) Population of merozoites in blood
G(t) Concentration of gemetocytes in blood
vaccine (BSV) (see [5,42,47]), and transmission blocking vaccines (TBV) (see [3,28]). The
leading PEV, BSV and TBV considered in this study are RTS,S/AS01, merozoite surface
protein 3 (MSP3), P. falciparum ookinete surface antigens (Pfs25), respectively. The PEV,
BSV and TBV vaccines are assumed to posses efficacies denoted by ν, 	 and χ , respectively,
where 0 < ν < 1, 0 < 	 < 1 and 0 < χ < 1.
A summary of the descriptions of the state variables and model parameters is as shown
in Tables 1 and 2 , respectively. Furthermore, the compartmental flow diagram for the in-
host malaria model is provided in Fig. 1. We are motivated by the structural complexity
of the in-host malaria model to apply LHS/PRCC technique for uncertainty and sensitivity
analysis. The structural complexity in the model could lead to high levels of uncertainty in
approximating the initial values of the input parameters.
Based on the dynamics described in Fig. 1, the following deterministic system describe
the dynamics of the in-host malaria infections with multi-stage malaria vaccines:
dS
dt
= (1 − χ) − μs S − βs SH ,
dH
dt
= λh − μh H − βs(1 − ν)SH
1 + dWa ,
dX
dt
= βs(1 − ν)SH
1 + dWa − μx X −
ρXWa
1 + ε0X ,
dR
dt
= λr − (1 − 	)βr RM
1 + dWa − μr R,
dT
dt
= (1 − 	)βr RM
1 + dWa − μt T −
qTWa
1 + ε1T ,
dM
dt
= P(1 − q)(1 − π)(1 − a)μt T
1 + dWa + (1 − ρ)(1 − b)Nμx X − μmM − βr RM,
dG
dt
= P(1 − q)(1 − a)πμt T
1 + dWa − μgG,
dWn
dt
=  − τλw(X + T )Wn − μnWn,
dWa
dt
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Table 2 Table showing model
parameters and their descriptions
Parameter symbol Parameter description
P Number of merozoites released per bursting
erythrocyte
N Number of merozoites released per bursting
hepatocytes
 Injection rate for sporozoites
μh Death rate of susceptible liver hepatocytes
μx Death rate of susceptible erythrocytes
μs μm Death rates of sporozoites and merozoites
respectively
λh The recruitment rate of hepatocytes
λr The recruitment rate of erythrocytes from the
bone marrow
π A proportion of merozoites that develop into
gametocytes per dying infected red blood cell.
ρ Immunosensitivity of infected hepatocytes
q Immunosensitivity of infected erythrocytes
βs , βr Rate of infection of hepatocytes and
erythrocytes, respectively
b A rate accounting for PEV-induced reduction of
merozoites released per bursting infected
hepatocyte
μr Death rate of susceptible erythrocytes
μt Mortality rate of infected erythrocytes
μg , μm Mortality rate of gametocytes and merozoites,
respectively
χ, 	, ν Vaccine efficacies
d Inhibition rate of CD8+ T-cells response
 Recruitment rate of unactivated CD8+ T-cells
from the thymus
λw Immunogenicity of IRBCs and infected
hepatocytes
1/ε0 A saturation (half) constant for infected
hepatocytes
1/ε1 A saturation (half) constant for infected red
blood cells
τ A rate accounting for vaccine-induced increased
generation of activated CD8+T-cells
μn , μa Death rates of unactivated and activated CD8+
T-cells respectively
a A rate accounting for BSV-induced reduction of
merozoites released per bursting erythrocyte
with the general initial conditions:
S(0) ≥ 0, H(0) > 0, X(0) ≥ 0, R(0) > 0, T (0) ≥ 0, M(0) ≥ 0,
G(0) ≥ 0, Wn(0) > 0, Wa(0) ≥ 0. (2)
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Fig. 1 A compartmental representation of the dynamics of in-host malaria infection with vaccine controls
Properties of theModel
Positivity of Solutions
The long term behaviour of any dynamical system is instrumental in the understanding of
the system. The model system (1) monitors changes in the concentrations of blood cells,
hepatocytes, malaria parasite and CD8+ T-cells. To warrant biological sense, the state vari-
ables of system (1) should be non-negative. Specifically, we show that all solutions of model
system (1) with non-negative initial conditions will remain non-negative for all time t ≥ 0.
Theorem 1 Given non-negative initial conditions in Eq. (2), the in-host model (1) has a
non-negative solution (S(t), H(t), X(t), R(t), T (t), M(t),G(t),Wn(t),Wa(t)), for all time
t ≥ 0.
Proof From the first equation in system (1), we can clearly see that
dS
dt
≥ −(μs + βs H)S. (3)
Upon integrating equation (3), we get





(μs + βs H(s))ds
}
. (4)
Therefore, S(t) ≥ 0 for all t ≥ 0. 
Similarly, from the last equation in system (1), we have
dWa
dt
≥ −μaWa . (5)
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Upon integrating the separable equation in (5), we obtain
Wa(t) = Wa(0) exp(−μat) ≥ 0.
Using the same argument, the rest of the state variables can similarly be shown to be
non-negative for all time t ≥ 0. That is, H(t) > 0, X(t) ≥ 0, R(t) > 0, T (t) ≥ 0, M(t) ≥ 0,
G(t) ≥ 0 and Wn(t) > 0 ∀t ≥ 0. This completes the proof.
Boundedness of Solutions
The non-negative solutions to model system (1) must be well posed in regions of biological
sense. We therefore prove that the solutions are bounded.
Let Nr be the sum of the density of susceptible and infected erythrocytes in the host. We
thus have Nr (t) = R(t) + T (t). Therefore,
dNr
dt
= λr − μr R − μt T − qTWa, (6)
≤ λr − μ̂Nr where μ̂ = min{μr , μt }. (7)
Using the initial condition Nr (0) = Nr0 > 0, Eq. (7) is solved by integration factor
method to obtain















Again, let Np(t) = S(t) + M(t) + G(t), be the sum of malaria parasites at any time t
during clinical P. falciparum infection. So that,
dNp
dt
= (1 − χ) + P(1 − q)(1 − π)(1 − a)μt T
1 + dWa + (1 − ρ)(1 − b)Nμx X
+ P(1 − q)(1 − a)πμt T
1 + dWa − μs S − μmM − μgG − βs SH − βr RM,
≤ (1 − χ) + 1(t) − μ̄Np where μ̄ = min{μs, μm, μg}, and (8)
1(t) = P(1 − q)(1 − π)(1 − a)μt T
1 + dWa + (1 − ρ)(1 − b)Nμx X
+ P(1 − q)(1 − a)πμt T
1 + dWa . (9)
Upon solving (8), we obtain:





e−μ̄t1(t)dt + C1e−μ̄t ,
where the constant of integration C1 is given by,
C1 =
(













. The above procedure can similarly be
applied to the total concentrations of the liver hepatocytes Nl(t) = H(t) + X(t) and that of
CD8+ T-cells Nw(t) = Wa(t) + Wn(t) so that we arrive at:
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dNl
dt
≤ λh − μ∗Nl and dNw
dt
≤  − μwNw, (10)
where μ∗ = min{μh, μx } and μw = min{μa, μn}.













for all time t ≥ 0.
Therefore, all feasible solutions of in-host malaria model (1) enter the region:
D =
{



























which is a positively invariant set of model system (1). This implies that all solutions in D
remain in D ∀t ≥ 0. It thus suffices to study the dynamics of model system (1) in D.
Model Analysis
Existence and Stability Analysis of Disease-Free Equilibrium Point (DFE)
The disease-free equilibrium E0 occurs when there is no P. falciparum infection within the
human host. At E0,  = 0 and there are no activated CD8+-T cells; that is, Wa = 0.
By setting the right hand-side of system (1) to zero, we obtain the following disease free
equilibrium:















The disease-free steady state is very crucial in the understanding of in-host malaria
infection dynamics. In order to eradicate in-host malaria, we have to identify and estab-
lish necessary conditions for E0 to be stable. This stability could be achieved through the
use of effective anti-malarial drugs such as ACT or by using highly efficacious Plasmodium
falciparum malaria vaccines.
Next, we apply the next generation matrix (NGM) approach (see [14,63] for detailed
explanation of this technique) to compute the basic reproduction number R0 of the in-host
model (1). The NGMmethod presumes the local stability of E0 for R0 < 1 and instability for
R0 > 1. R0 is the spectral radius of the next generation matrix (FV−1) of system (1); that is,
R0 = ρ(FV−1). Adopting the matrix notations in [63], the matrices F and V are respectively
given by:
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0 0 0 0 0 0 0
0 (1−ν)βsλh
μh
0 0 0 0 0
0 0 0 (1−	)βrλr
μr
0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0






























+ μs 0 0 0 0 0 0
0 μx 0 0 0 0 0
0 0 μt 0 0 0 0
0 −(1 − ρ)(1 − b)Nμx A1 βrλrμr + μm 0 0 0


























where A1 = −P(1 − π)(1 − q)(1 − a)μt .
Thus, the basic reproduction number R0 is given by
R0 = ρ(FV−1) = max{R01, R02}
where




R02 = P(1 − π)(1 − a)(1 − 	)(1 − q)βrλr
βrλr + μmμr . (16)
Observe that R01 is the contribution of new cell invasions at the liver stage due to mortile
sporozoites and R02 is the contributions of new cell invasions at the blood stage due to
merozoite parasites. From Eqs. (15) and (16), it is evident that new cell invasions occur both
at the liver stage (as depicted by R01) and at the blood stage (as depicted by R02). This
implies that clinical control of P. falciparum malaria should target the parasite at both stages
of its life cycle within the human host. An anti-malarial drug with the capacity to eradicate
the sporozoites at the pre-erythrocytic stage and merozoites at the erythrocytic stage is most
recommended. Furthermore, malaria vaccine development should equally focus on both
stages of parasite development. A novel malaria vaccine should begin parasite eradication
from the pre-erythrocytic stage and this should continue to the blood stage. This result is
very important to the ongoing research and development of malaria vaccines.
The global stability of the disease-free equilibrium is established using a suitableLyapunov
candidate function [34,35,48]. We thus have the following theorem.
Theorem 2 The disease-free equilibrium E0 is globally asymptotically stable in R9+ if R0 <
1.
Proof Let V (X , T , S, M,G) = ψ1X +ψ2T +ψ3S+ψ4M+ψ5G be a candidate Lyapunov
function for some non-negative coefficients ψ1, ψ2, ψ3, ψ4 and ψ5. The derivative of V with
respect to time is by
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(1 − 	)βr RM




+ ψ3 ((1 − χ) − μs S − βs SH)
+ ψ4
(
P(1 − q)(1 − π)(1 − a)μt T




P(1 − q)(1 − a)πμt T
1 + dWa − μgG
)
,
= (−μx (Nψ4(b(−ρ) + b + ρ − 1) + ψ1) − 
μn
(ρψ1 + qψ2))X
+ (−μt ((a − 1)P(q − 1) ((π − 1)ψ4 − πψ5) + ψ2))T
+ (ψ3 (−μs) − λh
μh
((ν − 1)ψ1 + ψ3) βs)S
+ (ψ4 (−μm) − λr
μr
((e − 1)ψ2 + ψ4) βr )M
+ (−μgψ5)G.

Setting the coefficients of X , T , S, M and G to zero and solving, we get
ψ1 = N (1 − b)(1 − ρ)μx (1 − 	)βrλrμ
2
a − q(βrλr + μmμr )μa









N (1 − b)(1 − ρ)μx (1 − 	)βrλrμ2a − q(βrλr + μmμr )μa












ψ4 and ψ5 =
1
1−	 − P(1 − a)(1 − π)(1 − q) + μmμrβrλr (1−	)
π P(1 − a)(1 − q) ψ4.
Using these coefficients, the time derivatives of the Lyapunov function is given as
dV
dt
= − (q + (1 − b)(1 − 	)N (1 − ρ)ρ)βrλr + qμmμr )(μa + μn)μx
(1 − 	)βrλrμn(ρ + μaμx ) X
− μmμrμt (1 + (1 − 	)
2λ2r )
(1 − e)βrλr T −
μg(1 − 	)λrμmμr
πβr (1 − a)(1 − q)G(1 − R0).
(17)
If R0 < 1 in (17) then [μg(1 − 	)λrμmμr ]/[πβr (1 − a)(1 − q)](1 − R0) > 0. We thus
obtain dVdt ≤ 0. Furthermore, dVdt = 0 if and only if T = X = G = 0. Therefore, V is a
Lyapunov function inD. Given thatD is positively invariant and attracting, it follows that the
maximum invariant set in {(S, H , X , R, T , M,G,Wn,Wa) ∈ D : V̇ = 0} is the singleton
E0. By LaSalle’s Invariant principle [33], E0 is globally asymptotically stable in D provided
that R0 < 1.
TheMalaria Persistent Steady State
We establish the malaria persistent equilibrium Ep for model system (1) in the presence
of CD8+ T-cells by equating the right hand side of system (1) to zero. Using Mathematica
software [31], model system (1), exhibits a malaria-persistent equilibrium point
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Ep = (S†, H∗, X∗, R∗, T ∗, M∗,G∗,W ∗n ,W ∗a ),
where
H∗ = (1 + dW
∗
a )λh
(1 − ν)βs S∗ + (1 + dW ∗a )μh
, (18)
R∗ = (1 + dW
∗
a )λr




τλw(X∗ + T ∗) + μn , (20)
W ∗a =
τλw(X∗ + T ∗)W ∗n
μa
, (21)
G∗ = P(1 − q)(1 − a)πμt T
∗
μg(1 + dW ∗a )
, (22)
M∗ = (1 + dW
∗
a )[(1 − b)2(1 − 	)N X∗βrμmμx − (1 + dW ∗a )μr ] ±
√

2(1 − 	)(1 + dW ∗a )βr
, where
m = (1 + dW ∗a )
{
(−(e − 1)βr (−4(1 − π)(1 − a)P(1 − q)T ∗μt
+(1 − b)2N X∗(1 + dW ∗a )βrμx (4(1 + dW ∗a )λr + (1 − b)2(1 − e)N X∗μ2mμx ))
−2(1 − b)2(1 − e)N X∗(1 + dW ∗a )2μmβrμrμx + (1 + dW ∗a )3μ2r
}
, (23)




2s + 4((1 − ν)βsμs)((1 − χ)(1 + dW ∗a )μh)
}
,
where s = βs((1 − χ)(1 − ν) − (1 + dW ∗a )λh) − (1 + dW ∗a )μhμs, (24)







where t = βs((1 − χ)(1 − ν) − (1 + dW ∗a )λh) − (1 + dW ∗a )μhμs;
∗T = 2t + 4ε1μt ((1 − 	)βr M∗ + (1 + dW ∗a )μr )(βrλr (1 − 	)M∗) and (25)
X∗ = x ±
√
2x + 4ε0((1 − ν)βs S∗ + (1 + dW ∗a )μh)μx )(1 − ν)βsλh S∗
2ε0((1 − ν)βs S∗ + (1 + dW ∗a )μh)μx
, where
x = (1 − ν)(ε0λh − μx )βs S∗ − dρW ∗2a μh − μhμx
− W ∗a ((1 − ν)ρβs S∗ + μh(ρ + dμx )). (26)
Based on the formulated model in Eq. (1), the activated CD8+ T-cells only exists due to
the presence of infected erythrocytes and infected liver hepatocytes. Hence, in the absence of
malaria infection (X = T = 0), Wa = 0. Moreover, non of the malaria parasites exists; that
is S∗ = M∗ = G∗ = 0. We further observe that when S∗ = M∗ = X∗ = T ∗ = W ∗a = 0, the
susceptible erythrocytes, susceptible hepatocytes and the unactivated CD8+ T-cells become
H∗ = λh
μh
, R∗ = λr
μr
and W ∗n = μn respectively. We thus arrive at an equilibrium point
called the disease free equilibrium point of model (1) illustrated in Eq. (12). From the above
computations, it is evident that the analytical expressions of Ep is too complex. We shall
therefore provide a numerical illustration of the model equilibrium points in “Numerical
Simulation” section.
Theorem 3 The malaria persistent steady state Ep is locally asymptotically stable if R0 > 1
in the interior of the biologically feasible region D.
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Proof The stability of the malaria persistent equilibrium Ep (when R0 > 1 but close to 1)
is proved using the center manifold theory (CMT) presented by Castillo-Chavez and Song
in [11]. Adopting the notations used in [11] and without re-stating the theorem, we calculate
the values of arguments a and b. The signs (+ or −) of a and b determine the local dynamics
of system (1) around Ep [66].
Suppose we consider β∗ to be our bifurcation parameter, then at R0 = 1, we have β∗ =
max{β∗s , β∗r }, where
β∗r =
μmμr




(1 − ν)λh . (27)

In applying the CMT, we begin by transforming the state variables (S, H , X , R, T , M,G,
Wn,Wa) into (x1, x2, x3, x4, x5, x6, x7, x8, x9) respectively. The model system (1), is hence
represented as dgdt = g(x), where x = (x1, x2, x3, x4, x5, x6, x7, x8, x9). The model sys-
tem (1) thus becomes
ẋ1 = (1 − χ) − μs x1 − βs x1x2,
ẋ2 = λh − μhx2 − βs(1 − ν)x1x2
1 + dx9 ,
ẋ3 = βs(1 − ν)x1x2
1 + dx9 − μx x3 −
ρx3x9
1 + ε0x3 ,
ẋ4 = λr − (1 − 	)βr x4x6
1 + dx9 − μr x4,
ẋ5 = (1 − 	)βr x4x6
1 + dx9 − μt x5 −
qx5x9
1 + ε1x5 ,
ẋ6 = P(1 − q)(1 − π)(1 − a)μt x5
1 + dx9 + (1 − ρ)(1 − b)Nμx x3 − μmx6 − βr x4x6,
ẋ7 = P(1 − q)(1 − a)πμt x5
1 + dx9 − μgx7,
ẋ8 =  − τλw(x3 + x5)x8 − μnx8,






x1(0) ≥ 0, x2(0) ≥ 0, x3(0) ≥ 0, x4(0) ≥ 0, x5(0) ≥ 0, x6(0) ≥ 0, x7(0) ≥ 0, x8(0) ≥ 0,
x9(0) ≥ 0.
The new model system (28) with the bifurcation point β∗ has a simple zero eigenvalue.
This attribute enables us to use the CMT to analyze the stability of system (28) near β∗ =
max{β∗s , β∗r } = max{βs, βr }.
Therefore, a right eigenvector w = [w1, w2, w3, w4, w5, w6, w7, w8, w9]T associated
with the simple zero eigenvalue is obtained from the linearization matrix corresponding to
the zero eigenvector as follows:
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−A2 0 0 0 0 0 0 0 0
−A3 −μh 0 0 0 0 0 0
A3 0 −μx 0 0 0 0 0 0
0 0 0 −μr 0 −A4 0 0 0
0 0 0 0 −μt A4 0 0 0
0 0 0 0 A0 −A5 0 0 0
0 0 0 0 A1 0 −μg 0 0






























































































































(1 − a)P(1 − π)(1 − q)μt , w7 =








(1 − a)P(1 − π)(1 − q)μt ,
w4 = − (1 − 	)βrλr
μ2r
, w8 = τλw














, w1 = w2 = w3 = 0.
Similarly, upon solving for the left eigenvector v = [v1, v2, v3, v4, v5, v6, v7, v8, v9]T
associated with the zero eigenvalue in system (28), we obtain
v1 = v2 = v3 = v4 = 0, v5 = P(1 − a)(1 − π)(1 − q), v6 = 1, v7, v8, v9 = 0.





















= −(1 − ν)βs, ∂
2g2
∂x1∂x9





= −(1 − 	)βr ,
∂2g4
∂x6∂x9








= (1 − 	)βr ,
∂2g5
∂x6∂x9





= −βr , ∂
2g6
∂x5∂x9
= P(1 − a)(1 − π)(1 − q)dμt ,
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∂2g7
∂x5∂x9













Thus, the expression for a is:




























We repeat the above procedure in computing the values of b. The non-zero partial deriva-































Upon substituting these derivatives into Eq. (30), it follows that








(P(1 − a)(1 − π)(1 − q)(1 − 	) + 1) > 0. (32)
Thus, a is positive (a > 0) and b is negative (b < 0). Based on item (iv) of theorem 2
in [11], the malaria persistent equilibrium Ep is locally asymptotically stable for R0 > 1,
but close to 1.
Uncertainty and Sensitivity Analysis
Sensitivity Analysis of Infected and Infective States of the In-Host Malaria Model
The in-host malaria model in this paper has numerous unknown parameters, coupled with
limited data. Therefore, there is a considerable uncertainty [9] in estimating the values of the
30 transmission parameters in model system (1). The uncertainty in the input values allows
significant variability in the model predictions of the future malaria parasite density within
the human host and the concentrations of the infected red blood cells and hence the severity of
clinical P. falciparummalaria. Consequently, we perform the LHS/PRCC sensitivity analysis
to evaluate variabilities in model predictions. With LHS/PRCC technique, we are able to
explore the entire parameter space of model (1), with minimal computer simulation.
We simultaneously examine the effects of the LHS parameters on the two infected state
variables: the infected liver hepatocytes X(t) and the infected erythrocytes T (t) and the
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three infective parasite states: sporozoite S(t), merozoites M(t) and Gametocytes G(t) in
model system (1). The PRCCs are used to identify the key parameters contributing to the
imprecision in predicting the future density of infected liver hepatocytes and infected red
blood cells [9].
The process of performing LHS on disease models is described elsewhere [8,38] and
references cited therein. Following PRCC methodology described in [52], we rank the LHS
parameters in the LHS matrix together with the outcome measures: T (t), X(t), M(t), G(t)
and S(t). Two linear regression models are generated in response to each parameter and
outcome measure. A Pearson rank correlation coefficient for the residuals from the two
regression models gives the PRCC values for that specific parameter. Due to lack of data
on the distribution function, we consider a uniform distribution for all model parameters in
Table 3.
Results of Analyzing the LHS/PRCC for the In-Host Malaria Model
Using 1000 runs of Latin hypercube sampling, the PRCC and p value data from the 30
parameters in model system (1) are summarized in Appendices A, B, C, D and E. The
PRCC and p values are computed based on the regression coefficient for outcome measures
(T (t), X(t), M(t), S(t) and G(t) and displayed in Tables 5, 6, 7 8 and 9 , respectively.
The size of PRCC shows the importance of the uncertainty in estimating the value of the
specific variable in contributing to the prediction imprecision [9]. The PRCC sign (+ or
−), however, shows the qualitative relationship between the input parameter and the output
variables. Parameters with large PRCC values (PRCC from 0.5 to 1 or PRCC from −1 to
−0.5) coupled with a corresponding small p value (p value < 0.05) are considered as the
most influential [21].
A slight change in a highly influential parameter is likely to produce a significant change
in the outcome variable. The symbol (∗) indicates less influential parameters with p values
< 0.05 and PRCC values in the range (−0.1 to −0.49 or 0.1 to 0.49). Further, the symbol
(∗∗) is used to indicate moderately critical parameters in prediction imprecision, and have
p value < 0.05 and PRCC values in the range (−0.5 to −0.79 or 0.5 to 0.79). Lastly, the
symbol (∗ ∗ ∗) indicates the most critical and likely contributors to uncertainty, with PRCC
values in the range (−0.8 to −0.99 or +0.8 to +0.99).
Results in Appendices A, B, C, D and E indicate that the rate of invasion bymerozoites βr ,
the rate of invasion of liver hepatocytes βs , malaria vaccine efficacies (	, ν, and χ) and the
recruitment rates for the hepatocyte and erythrocytes λh and λr respectively are statistically
significant in determining thevariationof concentrations of erythrocytes, infectedhepatocytes
and the density of malaria parasites (sporozoites, merozoites and gametocytes). The infected
erythocyte burst size P and the number of merozoites released per bursting sporozoite N is
shown to significantly increase the the density of the merozoites and the concentration of
infected red blood cells T in blood. Clinical malaria controls should thus target these infected
cells for eradication before they mature to bursting stage.
Moreover, fromAppendicesA andD, the proportion ofmerozoites that develop into game-
tocytes per dying infected erythrocyte π and immunosensitivity of infected erythrocytes q
are shown to have significant influence in determining the concentrations of gametocytes and
merozoites, respectively, during clinical P. falciparum infection. An efficacious blood stage
vaccine coupled with a transmission blocking vaccine antigens has the potential of reducing
the density of gametocytes during clinical malaria. This reduces parasite transmission to
mosquito vector.
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Table 3 Table showing the numerical values of model parameter values used in sensitivity analysis and
numerical simulations
Symbol Value Min Max Unit Source
 30 20 35 Sporozoites/day [56]
μs 1.2 0.8 1.5 /day [56]
λr 3E5 3E3 3E6 cells/ml/day [36]
λh 3E5 3E3 3E6 cells/µl
−1/day [61]
βr 8E−5 8E−7 8E−3 /mm3/day [15]
βs 5E−4 5E−5 5E−3 /mm3/day [56]
μh 0.029 0.01 0.03 /day [49]
μx 0.02 0.01 0.05 /day [56]
π 0.2 0.1 0.9 Unitless [59]
μr 8.3E−5 8.3E−6 0.0001 /day [1]
μm 48 46 49 /day [36]
μt 0.7 0.5 0.8 /day [37]
μg 0.0625 0.5 0.78 /day [56]
χ 0.6 0 1 Unitless Assumed
	 0.45 0 1 Unitless [6]
ν 0.7 0 1 Unitless Assumed
d 5E−4 1E−4 0.001 Unitless Assumed
τ 1.5 1.2 1.9 Unitless [45]
λw 30 25 35 /unitless/day [45]
b 0.17 0.2 0.5 Unitless [45]
a 0.16 0.2 0.4 Unitless [45]
P 16 13 20 /erythrocytes/day [13]
N 10,000 8000 11,000 /day [60]
ε0 1E−5 1E−6 1E−4 /day [60]
ε1 1E−5 1E−6 1E−4 /day [60]
q 0.01 0.001 0.02 Unitless [45]
ρ 0.3 0.2 0.45 Unitless [45]
μn 0.4 0.3 0.72 /day [1]
μa 0.4 0.3 0.72 /day [36]
 30 24 33 Unitless [37]
Figures 2 and 3 illustrates Monte Carlo simulations for some of the parameters with the
greatest PRCC values against model R0.
It is evident that a highly efficacious pre-erythrocytic vaccine such as RTS,S/SA01 (with
efficacy ν) and blood stage vaccine such as MSP3 (with efficacy ε) could effectively help in
reducing parasitemia andmalaria severity during clinicalP. falciparum infections. Sporozoite
invasion rate βs and themerozoite invasion parameter βr are also shown to increase themodel
R0 and hence the severity of the disease within the human host.
Although the LHS/PRCC technique is useful in identifying significant parameters in the
in-hostmalariamodel, it fails to rank the parameters in order of their contribution to variations
and disease progression. This ranking is very crucial in the design of clinical interventions
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Fig. 2 The Monte Carlo simulations for some of the parameters with the greatest PRCC magnitudes, using
values in Table 3 and 1000 simulations per run. The parameters are: a sporozoite invasion rate βs and b efficacy
of pre-erythrocytic vaccine ν
Fig. 3 The Monte Carlo simulations for some of the parameters with the greatest PRCC magnitudes, using
values in Table 3 and 1000 simulations per run. They are: a proportion of parasites that become gametocytes
π , bmerozoite invasion rate βr , c efficacy of blood stage vaccine e and d the number of merozoites produced
per bursting blood schizont P
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Table 4 The sensitivity results Parameter S.I Parameter S.I
P +1 a −0.785714
βs +1 π −0.785714
λh +1 βr +0.62402
μh −1 λr +0.62402
μx −1 μm −0.62406
	 −0.785714 μr −0.62406
ν −0.785714 q − 0.428571
and in the development of malaria vaccines. In response, we consider the normalized forward
sensitivity index of the model reproduction number in (15) and (16) against LHS parameters
in Table 3 in the next section.
Sensitivity Analysis Based onModel R0
We adopt the normalized forward sensitivity (NFS) index technique described in [4]
to compute the sensitivity indices of the model R0 with respect to input parameters
P, βr , βs, λh, λr , μh, μr , μx , μm, 	, a, π, ν are presented in Table 4. The sensitivity indices
(S.I) are evaluated inMathematica software based on the baseline parameter values in Table 3.
From Table 4, we observe that the population of malaria merozoites that are released
per bursting infected erythrocyte P , the rates of invasions of healthy erythrocytes βr and
hepatocytes βs , the rate of recruitment of susceptible hepatocytes λh and erythrocytes λr
have a direct effects on the severity of clinical malaria. A 10% increase (or decrease) in the
magnitude of P , increase (or decrease) model R0 by 10%. Clinical malaria control should
aim at eradicating or reducing these parameters. On the other hand, malaria vaccines (	 and
ν) are shown to reduce R0 when their efficacies are improved. An increase (or decrease) in the
immunosensitivity of infected red blood cells q is similarly shown to reduce (or increase) the
model R0. By rank, the parameters P, βs, λh are the most influential in model (1), followed
by the vaccine efficacies 	 and ν. Clinical considerations should thus favour these parameters
in the development of malaria vaccines.
In conclusion, the LHS/PRCC technique is robust and considers the entire parameter
space in determining significant parameters in a disease model. However, it fails the ranking
test. On the other hand, although the NFS index technique is beneficial in discerning and
ranking significant parameters in a model, it does not explain the considerable uncertainties
in estimating parameter values. It therefore fails to uncover parameter effects on particular
variables or populations in the model. Due to the importance attached to the significance
and rank of each parameter in the model, we advise that both approaches be used in future
analysis of parameter uncertainty and sensitivity analysis in disease models.
Numerical Simulation
In this section, we illustrate numerically the dynamics of the in-host model system (1).
When the basic reproduction number R0 is less than unity, clinical P. falciparum malaria is
observed to die out (see Figs. 4, 5) and the malaria-free state E0 = (0, 5 × 105, 0, 0, 5 ×
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Fig. 4 The dynamics of model (1) when the basic reproduction number R0 = 0.8881 < 1, the malaria-free
equilibrium E0 is globally asymptotically stable
106, 0, 0, 0, 0, 0) is globally asymptotically stable. Additionally, only an efficacious BSV
has the chance to totally eradicate the merozoites from the blood stream of the human host.
Notice that even if R0 is less than unity, some activated CD8+ T-cells Wa(t) still exists (see
Fig. 4e). This shows that individual-level acquired immunity againstmalaria ismaintained for
some period of time even if all malaria parasites are eradicated from the host. All simulations
are performed using parameter values in Table 3.
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(a) (b)
(c)
Fig. 5 Polulation dynamics of the liver hepatocytes and the sporozoites when the reproduction number R0 =
0.8881 < 1. Parameter values are available in Table 3
Similarly, the density of sporozoites decline rapidly when R0 = R01 < 1, leading to a
corresponding decrease in the density of infected hepatocytes as shown in Fig. 5.
The persistent steady state, Ep = (S∗, H∗, X∗, R∗, T ∗, M∗,G∗,W ∗n ,W ∗a ) = (103, 3 ×
105, 3 × 103, 5 × 106, 5 × 103, 103, 5 × 102, 5 × 103, 5 × 103) is shown to be stable when
R0 is greater than unity, R0 = 1.3364 > 1 (See Figs. 6, 7). We observe that the densities of
sporozoites, merozoites, gametocytes, infected hepatocytes and infected erythrocytes grow
and persists both at the pre-erythrocytic and blood stages of parasite development.
Multi-component andMulti-stageVaccine Cocktail
Here, we illustrate the need to develop a multi-component and multi-stage P. falciparum
malaria vaccines with sufficient prospect to minimize the severity of malaria infection
from human host. Several strategies have been considered in the development of efficient
multi-component and multi-stage P. falciparum vaccine formulations [16,51,53,57,58,67].
A synthetic peptide (SPf66) that combines antigens from the blood stages of malaria linked
together with an antigen from the sporozoite stage reduced the number of first attacks with P.
falciparum by 28% in South America [24]. High level of sterile efficacy and safety of com-
bining pre-erythrocytic vaccine, RTS,S/AS01B with vectored vaccines are reported in [53].
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Fig. 6 When the reproduction number R0 = 1.3364 > 1, the malaria-persistent equilibrium point Ep is stable
for the chosen set of parameter values. The model parameter values are available in Table 3
Plasmodium falciparum chimeric protein 2.9 which is a combination of the C-terminal
regions of domain III of AMA-1 and 19-kDa of MSP1 induced both anti-MSP1–19 and anti-
AMA-1(III) Abs at levels 11- and 18-fold higher, respectively, than individual components
did [51]. Studies in [19] have also shown that a combination of multiple vaccine candidates
in fusion proteins may lead to improved characteristics of the vaccine.
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(a) (b)
(c)
Fig. 7 When the reproduction number R0 = 1.3364 > 1, the malaria-persistent equilibrium Ep is stable
Synergism from combination of transmission blocking vaccines is shown in [67] to confer
protection by simultaneously inducing multiple, independent immune responses directed
towards P. falciparum sporozoites. This ensures high levels of vaccine efficacy against the
parasite. The need for multi-stage malaria vaccine is also emphasised in [16] where DNA
vaccines are shown to have high capacity to induce CD8(+) cytotoxic T lymphocytes and
interferon-gamma responses in humans during P. falciparum infection [62].
From these studies, it is evident that amulti-stage specific vaccine cocktail has the potential
to prevent initial malaria infection at the pre-erythrocytic stage, reduce or eradicate clinical
manifestation and prevent the transmission of gametocytes from infected human hosts to
susceptible feeding female anopheles mosquito [10]. We therefore evaluate numerically the
effects of malaria vaccine combinations on the severity of P. falciparum malaria infection.
The vaccines are broadly categorized as: pre-erythrocytic vaccines, blood stage vaccines and
transmission blocking vaccines. The vaccines are assumed to have an optimal efficacy of
75%. We chose this figure in consistency with the WHO strategic goal of developing a P.
falciparum vaccine with atleast 75% efficacy [43].
Results in Fig. 8, shows the effects of all the three vaccines combined with a constant
optimal efficacy of 75%. The density of infected erythrocytes T and infected hepatocytes X
is shown to fall significantly. The severity of malaria infection is therefore highly reduced
when the three vaccine antigens are combined.
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T(t) with e = v =  = 75%
(a)

















X(t) with e = v =  = 75%
X(t) without vaccines
(b)
Fig. 8 Impact of a 75% efficacious combined malaria vaccines on the dynamics of infected red blood cells T
and infected hepatocytes X . The simulations are performed when R01 = 2.564 > 1, and R02 = 5.564 > 1























T(t) with e = v = 0% and  = 75%
T(t) with e = v =  = 75%
(a)
























X(t) with e = v = 0% and  = 75%
X(t) with e = v =  = 75%
(b)
Fig. 9 Impact of a 75% efficacious transmission blocking vaccine on the dynamics of infected red blood cells
and infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and R02 = 5.564 > 1
The use of only one vaccine is shown in Figs. 9, 10 and 11 to have minimal effects on the
severity of malaria infection.
Finally, a combination of any two vaccines (with different antigens) is likely tomoderately
reduce the severity of malaria infection. The effects of paired—vaccine combinations are as
shown in Figs. 12, 13 and 14. Unlike infected hepatocytes, transmission blocking vaccines
are shown to have minimal effects on the density of infected red blood cells (see Fig. 10).
A combination of an efficacious pre-erythrocytic vaccine and an effective blood stage
vaccine antigens has the potential to significantly reducemalaria severity as shown in Fig. 14.
Moreover, a combination of antigens from transmission blocking vaccine and those of pre-
erythrocytic vaccine at the liver stage, as shown in Fig. 12b, are very effective in suppressing
the density of infected hepatocytes in the liver.
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T(t) with  = e = 0% and v = 75%
T(t) with e = v =  = 75%
(a)
























X(t) with  v = 75% and e=  = 0%
X(t) with e = v =  = 75%
(b)
Fig. 10 Impact of a 75% efficacious pre-erythrocytic vaccine on the dynamics of infected red blood cells and
infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and R02 = 5.564 > 1























T(t) with  = v = 0% and e = 75%
T(t) with e = v =  = 75%
(a)
























X(t) with  = v = 0% and e = 75%
X(t) with e = v =  = 75%
(b)
Fig. 11 Impact of a 75% efficacious blood stage vaccine on the dynamics of infected red blood cells and
infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and R02 = 5.564 > 1























T(t) with  = v = 75% and e = 0%
T(t) with e = v =  = 75%
(a)
























X(t) with  = v = 75% and e = 0%
X(t) with e = v =  = 75%
(b)
Fig. 12 The effect of combining a PEV and TBV that are both 75% efficacious on the dynamics of infected
red blood cells and infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and
R02 = 5.564 > 1
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T(t) with e =  = 75% and v = 0%
T(t) with e = v =  = 75%
(a)
























X(t) with e =  = 75% and v = 0%
X(t) with e = v =  = 75%
(b)
Fig. 13 The effect of combining a TBV and a PEV that are both 75% efficacious on the dynamics of infected
red blood cells and infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and
R02 = 5.564 > 1























T(t) with  v = e = 75% and  = 0%
T(t) with e = v =  = 75%
(a)
























X(t) with  v = e = 75% and  = 0%
X(t) with e = v =  = 75%
(b)
Fig. 14 The effect of combining a PEV and a BSV that are both 75% efficacious on the dynamics of infected
red blood cells and infected hepatocytes. The simulations are performed when R01 = 2.564 > 1, and
R02 = 5.564 > 1
Epidemiological Implications and Conclusion
Results of uncertainty and sensitivity analysis have significant epidemiological importance
in malaria control. The presented model is shown to be sensitive to variations in vaccine effi-
cacies χ, 	 and ν. Only efficacious malaria vaccines have a chance to eradicate P. falciparum
malaria or to reduce its severity, significantly, during clinical infection. Sensitivity indices
based on the model reproduction number indicates that the rate of invasion of susceptible
erythrocytes by merozoite parasites βr and the rate of invasion of liver hepatocytes by the
sporozoites βs are highly sensitive to malaria disease progression. Malaria vaccines must
therefore target and eradicate the infective parasites and infected cells. Other parameters
such as the proportions of merozoites that become gametocytes per dying blood schizont
π and the average number of merozoites released per bursting blood schizonts P are also
shown to have a considerable impact on the model R0 and hence the severity of infection.
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A highly efficacious blood stage vaccine is necessary to lower the rate π . A reduction in the
density of blood gametocytes has the potential of lowering malaria transmission from the
human host to the mosquito vector.
Given the protective capacity of liver stage-specific CD8+ T-cells [65], a lot more research
that focuses on developing an efficacious blood stage vaccine that would prime blood
trophozoite-specific CD8+ T-cells is called for. The parameter τ which accounts for vaccine-
induced production of CD8+ T-cells is shown to have significant negative effects on the
concentration of infected hepatocytes. The more efficient the pre-erythrocytic vaccine is, the
lower the density of released merozoites into the host’s blood. Moreover, a rapid eradication
of parasitized liver hepatocytes is likely to result into less infected erythrocytes at the blood
stage. An efficacious pre-erythrocytic vaccines has a potential to eradicate infected liver hep-
atocytes. Such efficacious liver stage vaccines may also reduce the overall burst size of an
infected hepatocyte, leading to reduced erythrocytic schizonogy and hence the severity of
clinical P. falciparum malaria.
Multiple combination of malaria vaccine antigen has a great potential in reducing the
severity of malaria infections due to P. falciparum parasite. The synergy of combining pre-
erythrocytic vaccines, blood stage vaccines and transmission blocking vaccines antigens
induces multiple immune responses with the potential to prevent or eradicate malaria infec-
tion. As highlighted in [32], our study shows that a highly effective vaccine combination is
critical for P. falciparum malaria disease elimination goal.
Although efficacious malaria vaccines are shown to be very effective in reducing severity
of clinical malaria, our results further confirm the need to combine vaccine with existing anti-
malarial therapy to achieve a complete eradication of the parasites from the host. Finally, the
LHS/PRCC analysis revealed that the prediction imprecision was mainly due to certain key
parameters. Long term precise predictions of the concentrations of infected liver hepatocytes
and infected red blood cells would be difficult until these key parameters are correctly deter-
mined. A great understanding of parameter uncertainty and sensitivity analysis of in-host
malaria in humans is necessary in order to develop effective vaccines against P. falciparum
pathogen.
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Table 5 PRCC between infected red blood cells T and each parameter
Parameter PRCC p value Parameter PRCC p value
 0.040124 0.69185 ν −0.35423∗ 0.0001255
μs 0.092654 0.35921 d −0.021968 0.82825
λh 0.16815 0.094459 λw 0.02639 0.79438
λr 0.99993∗∗∗ 1.2467E−191 τ 0.028815 0.77596
βr 0.60394∗∗ 0.0030343 a −0.033076 0.7439
βs −0.072861 0.47128 b −0.037844 0.70854
μh 0.045043 0.65633 P 0.28652
∗ 0.0038515
μx 0.022164 0.82674 N 0.50348∗∗ 0.0003056
π 0.24376 0.14528 ε0 −0.050167 0.62012
μr −0.54174∗∗ 5.8708E−9 ε1 0.0092028 0.92759
μt −0.043585 0.66677 ρ 0.087162 0.38852
μm −0.08574 0.39634 q −0.261905∗ 0.00154063
μg −0.13006 0.19715 μn −0.093091 0.35694
χ −0.13607 0.17706 μa −0.054864 0.58771
	 −0.30701 0.0018909  0.041721 0.68024
The results are significant at the 0.05 level
Appendix B: PRCC Between InfectedHepatocytes X and Each Parameter
See Table 6.
Table 6 PRCC between infected hepatocytes X and each parameter
Parameter PRCC p value Parameter PRCC p value
 −0.034437 0.73375 ν −0.307831∗ 0.00093836
μs 0.071002 0.48269 d −0.1442 0.15231
λh 0.9749
∗∗∗ 9.5419E−66 λw −0.094174 0.35135
λr 0.06407 0.52654 τ −0.20137∗ 0.000044531
βr −0.080809 0.42415 a −0.075135 0.45751
βs 0.53926∗∗ 0.00016701 b 0.061933 0.54045
μh −0.87273∗∗∗ 2.7908E−23 P 0.076347 0.45026
μx 0.14762 0.14273 N 0.10516 0.29776
π −0.045846 0.6506 ε0 0.21125 0.034877
μr 0.094998 0.34713 ε1 −0.16583 0.09918
μt 0.12588 0.21205 ρ 0.033235 0.74272
μm 0.13493 0.18073 q 0.095106 0.34658
μg 0.033064 0.74399 μn 0.039223 0.69843
χ −0.28902 0.0035417 μa −0.052237 0.60575
	 −0.061742 0.5417  0.10411 0.30264
The results are significant at the 0.05 level
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Appendix C: PRCC BetweenMerozoitesM and Each Parameter
See Table 7.
Table 7 PRCC between merozoites M and each parameter
Parameter PRCC p value Parameter PRCC p value
 0.013086 0.89718 ν −0.61866∗∗ 6.9194E−12
μs 0.12012 0.23389 d 0.12239 0.22509
λh − 0.005884 0.95367 λw −0.30208 0.0022545
λr −0.78852∗∗ 2.0731E−22 τ −0.11155 0.26918
βr −0.77199∗∗ 5.3565E−21 a 0.14416 0.15243
βs 0.10834 0.28328 b −0.18907 0.059575
μh 0.080773 0.42436 P 0.28652
∗ 0.0038515
μx 0.46617∗ 1.0183E−06 N −0.50348∗∗ 0.0003056
π −0.29849 0.0025577 ε0 −0.23892 0.01667
μr 0.060227 0.55168 ε1 −0.057548 0.56955
μt −0.05975 0.55485 ρ −0.25708 0.0098207
μm −0.090522 0.37042 q −0.047855 0.63635
μg 0.18256 0.069072 μn −0.0015737 0.9876
χ −0.67251∗∗ 1.8298E−14 μa 0.1363 0.17632
	 −0.024582 0.80818  −0.12172 0.22769
The results are significant at the 0.05 level
Appendix D: PRCC Between Gametocytes G and Each Parameter
See Table 8.
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Table 8 PRCC between gametocytes G and each parameter
Parameter PRCC p value Parameter PRCC p value
 0.09861 0.32902 ν −0.54919∗∗ 3.2858E−09
μs −0.18356 0.067537 d −0.33627 0.00062476
λh 0.16929 0.092216 λw −0.14215 0.15831
λr −0.79454∗∗∗ 5.8878E−23 τ −0.080527 0.42578
βr −0.76958∗∗ 8.4228E−21 a −0.16499 0.10092
βs −0.021251 0.83378 b −0.31287 0.0015279
μh 0.060337 0.55095 P 0.059063 0.55941
μx 0.40198∗ 3.3899E−05 N 0.24601 0.013619
π 0.698883∗∗ 0.0032768 ε0 −0.28727 0.0037563
μr −0.022582 0.82353 ε1 0.075806 0.45349
μt 0.075502 0.45531 ρ −0.047433 0.63933
μm 0.067991 0.50149 q 0.12264 0.22416
μg −0.084857 0.40124 μn −0.12368 0.22021
χ −0.55186∗∗ 2.6601E−09 μa 0.17443 0.082611
	 −0.55799∗∗ 1.6273E−09  0.15261 0.12956
The results are significant at the 0.05 level
Appendix E: PRCC Between Sporozoites S and Each Parameter
See Table 9.
Table 9 PRCC between sporozoites S and each parameter
Parameter PRCC p value Parameter PRCC p value
 0.31314∗ 0.00097533 ν 0.0067811 0.94661
μs −0.68707∗∗ 0.0094591 d 0.010905 0.91425
λh −0.012635 0.90071 λw 0.0043436 0.96579
λr 0.03593 0.72266 τ 0.023508 0.81642
βr 0.025432 0.80168 a 0.0065303 0.94859
βs −0.0091069 0.92835 b −0.017604 0.86199
μh 0.022838 0.82156 P −0.019561 0.84683
μx 0.0056574 0.95545 N −0.015923 0.87505
π −0.0047473 0.96261 ε0 −0.00027845 0.99781
μr 0.00025243 0.99801 ε1 −0.0003386 0.99733
μt −0.011016 0.91338 ρ −0.031317 0.75709
μm 0.0096995 0.9237 q −0.0037326 0.9706
μg −0.023075 0.81974 μn 0.030253 0.7651
χ −0.699368∗ 0.0001184 μa −0.0042258 0.96672
	 0.01863 0.85403  −0.0052564 0.95861
The results are significant at the 0.05 level
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+e emergence of parasite resistance to antimalarial drugs has contributed significantly to global human mortality and morbidity
due to malaria infection. +e impacts of multiple-strain malarial parasite infection have further generated a lot of scientific
interest. In this paper, we demonstrate, using the epidemiological model, the effects of parasite resistance and competition
between the strains on the dynamics and control of Plasmodium falciparummalaria. +e analysed model has a trivial equilibrium
point which is locally asymptotically stable when the parasite’s effective reproduction number is less than unity. Using contour
plots, we observed that the efficacy of antimalarial drugs used, the rate of development of resistance, and the rate of infection by
merozoites are the most important parameters in the multiple-strain P. falciparum infection and control model. Although the
drug-resistant strain is shown to be less fit, the presence of both strains in the human host has a huge impact on the cost and
success of antimalarial treatment. To reduce the emergence of resistant strains, it is vital that only effective antimalarial drugs are
administered to patients in hospitals, especially in malaria-endemic regions. Our results emphasize the call for regular and strict
surveillance on the use and distribution of antimalarial drugs in health facilities in malaria-endemic countries.
1. Introduction
+e emergence of parasite resistance [1–4] to antimalarial
drugs has contributed significantly to human mortality and
morbidity due to malaria infection, worldwide [5–7]. A
global malaria control strategy of 1992 [8] that advocated for
early diagnosis and prompt treatment has been heavily
compromised by the emergence of parasite resistance to
antimalarial drugs. +e evolution of parasite resistance has
been described in [9] as an example of a Darwinian evo-
lution. Parasites undergo mutations in their genome in
response to the drug-treated human host. +ese mutations
reduce the rate of parasite elimination from the host and
increase their survival chances [9]. +e most extensively
used antimalarial drugs against the deadly Plasmodium
falciparum malaria are chloroquine (CQ) and sulfadoxine-
pyrimethamine (SP) [10, 11]. +ese drugs are cheap, easily
available, and slowly eliminated from the human body [11].
However, the extensive use of CQ and SP has resulted in
P. falciparum resistance. +is has led to global increase in
malaria cases and mortality [12]. In response, the World
Health Organization (WHO) in 2006 recommended the use
of artemisinin-based combination therapies (ACTs) as
a first-line treatment for uncomplicated P. falciparum
malaria [13]. Resistance to ACTs which are currently the
standard treatment for P. falciparum is likely to cause global
health crisis especially in African regions where P. falcipa-
rum malaria is endemic [11].
+e emergence of parasite resistance to malaria therapy
dates back to the 19th century. Quinine (1963) was the first-
line antimalarial drug against P. falciparum [14]. High
mortality cases coupled with high parasite resistance led to
the introduction of a second drug, chloroquine (CQ), in
1934 [15]. A decade later, CQ was considered the first-line
antimalarial drug by several countries until 1957, when the
first focus of P. falciparum resistance was detected along the
+ai-Cambodia border [16]. In Africa, P. falciparum re-
sistance to CQ was first discovered among travelers from
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Kenya to Tanzania [17]. By 1983, CQ resistance had spread
to Sudan, Uganda [18], Zambia [19], and Malawi [20].
Unlike Africa, CQ was replaced for the first time with
sulfadoxine-pyrimethamine (SP) as a first-line antimalarial
drug in+ailand in 1967. Several other countries in Asia and
South America followed thereafter [10]. Resistance to SP
was, however, reported the same year [21] in the region. In
1988, CQ was replaced for the first time in Africa. KwaZulu-
Natal Province of South Africa replaced CQ with SP [22]. In
1993, the Malawian government changed the treatment
policy from CQ to SP. Other African countries followed
thereafter: Kenya, South Africa, and Botswana (in 1998);
Cameroon and Tanzania (in 2001); and Zimbabwe (in 2000)
[23]. +e effectiveness of SP was equally undermined by
resistance. Unlike CQ, P. falciparum resistance to SP was
mainly attributed to the long half-life of the drug [24].
Confirmed resistance to the artemisinin derivatives was first
reported in Cambodia and Mekong regions in 2008 [25].
To leverage on parasite resistance, cost of treatment,
and burden of malaria infection to communities and
governments, the WHO recommends the use of artemi-
sinin-based combination therapies (ACTs) as the first- and
second-line treatment drugs for uncomplicated P. falci-
parum malaria [25]. ACT is a combination of artemisinin
derivatives and a partner monotherapy drug. Artemisinin
derivatives include artemether, artesunate, and dihy-
droartemisinin. +ese derivatives reduce the parasite
biomass within the first three days of therapy, while the
partner drug, with longer half-life, eliminates the
remaining parasites [26]. +eWHO currently recommends
five different ACTs: (1) artesunate-amodiaquine (AS +AQ),
(2) artesunate-mefloquine (AS +MQ), (3) artesuna-
te + sulfadoxine-pyrimethamine (AS + SP), (4) artemether-
lumefantrine (AM-LM), and (5) dihydroartemisinin-
piperaquine (DHA+PPQ). Additionally, artesunate-
pyronaridine may be used in regions where ACT treatment
response is low [26]. Access to ACT has been tremendous
in the last 8 years, with a recorded increase of 122 million
procured treatment courses for the period 2010–2016.
However, resistance to currently used ACTs has important
public health consequences, especially in the African re-
gion, where resistant P. falciparum is predominant.
Numerous cross-sectional studies [27, 28] have revealed
the possible impacts of multiple strains of P. falciparum on
the development of resistance to ACTs. In [29] and citations
therein, drug-sensitive parasites are shown to strongly
suppress the growth and transmission of drug-resistant P.
falciparum parasites. Although high-transmission settings
such as sub-Saharan Africa account for about 90% of all
global malaria deaths, resistance to antimalarial drugs has
been shown to emerge from low-transmission settings, such
as Southeast Asia and South America [29]. Causes of parasite
resistance to ACTs are diverse. Historical studies [30, 31]
indicate that antimalarial-resistant parasites could emerge
from a handful of lineages. It is argued elsewhere [32, 33]
that recombination during sexual reproduction in the
mosquito vector could be responsible for the delayed ap-
pearance of multilocus resistance in high-transmission re-
gions. Moreover, owing to repeated exposure for many
years, individuals in high-transmission settings are likely to
develop clinical immunity to malaria, leading to stronger
selection for resistance [34]. Studies in [29] also support the
hypothesis that in-host competition between drug-sensitive
and drug-resistant parasites could inhibit the spread of
resistance in high-transmission settings. Owing to their
integral role in the recent success of global malaria control,
the protection of efficacy of ACTs should be a global health
priority [35].
Mathematical models of in-host malaria epidemiology
and control constitute important tools in guiding strategies
for malaria control [36, 37] and the associated financial
planning [38]. While some researchers have focussed on
probabilistic models [39, 40], others have investigated the
effects of drug treatment and resistance development using
dynamic models [41, 42]. A deterministic model by Esteva
et al. [43] monitored the impact of drug resistance on the
transmission dynamics of malaria in a human population. In
[29], the impacts of within-host parasite competition are
shown to inhibit the spread of resistance [44, 45]. On the
contrary, some models [39, 46] have suggested that within-
host competition is likely to speed up the spread of resistance
in high-transmission settings due to a phenomenon called
“competitive release.” In this paper, we provide theoretical
insights using mathematical modelling of the impacts of
multiple-strain infections on resistance, dynamics, and
antimalarial control of P. falciparum malaria.
+e rest of the paper is organized as follows: In Section 2,
we formulate the within-humanmalaria model that has both
the drug-sensitive and drug-resistant P. falciparum parasite
strains subject to antimalarial therapy. In Section 3, we
analyze the model based on epidemiological theorems.
Within-host competition between parasite strains and the
effects of antimalarial drug efficacy on parasite clearance are
discussed in Section 4. Sensitivity analysis and multiple-
strain infection and its effects on resistance and malaria
dynamics are demonstrated in Section 5. We conclude the
paper in Section 6 by emphasizing the need for antimalarial
therapy with the potential to eradicate multiple-strain in-
fection due to P. falciparum.
2. Model Formulation
We present in this paper a deterministic model that de-
scribes the within-human-host competition and trans-
mission dynamics of two strains of P. falciparum parasites
during malaria infection. +e compartmental model con-
siders the coinfection and competition between the drug-
sensitive (dss) and the drug-resistant (drs) P. falciparum
strains in the presence of antimalarial therapy. +e drs arise
presumably from the dss. +e rare mechanism here could
possibly be due to single point mutation [47]. Both drs and
dss initiate immune responses that follow density-dependent
kinetics.
Our model is composed of eight compartments: sus-
ceptible/healthy/unparasitized erythrocytes (red blood cells)
X(t), parasitized/infected erythrocytes (Yr(t) and Ys(t)),
merozoites (Ms(t) and Mr(t)), gametocytes (Gs(t) and
Gr(t)), and immune cells W(t). +e healthy erythrocytes
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(RBCs) make up the resource for competition between the
drug-resistant and drug-sensitive parasite strains. +e in-
fected red blood cells (IRBCs) and different erythrocytic
parasite life cycles are categorized based on the strain of the
infecting parasite. +e merozoites are therefore categorized
into drug-sensitive and drug-resistant strains, denoted by
Ms(t) and Mr(t), respectively. +e merozoites invade the
healthy erythrocytes during the erythrocytic stage, leading to
formation of infected erythrocytes. +e variable Ys(t) de-
notes the red blood cells (RBCs) infected with drug-sensitive
merozoites, whereas Yr(t) refers to the RBCs infected with
drug-resistant merozoites. Similarly, the variables Gs(t) and
Gr(t) represent drug-sensitive and drug-resistant gameto-
cytes, respectively. Owing to saturation in cell and parasite
growth, we consider the nonlinear Michaelis–Mented–
Monod function described in [48, 49] and used in [50–53] to
model the reductive effects of the immune cells on the
parasite and infected-cell populations.
+e density of the healthy RBCs is increased at the rate λx
per healthy RBC per unit time from the host’s bone marrow,
and healthy RBCs die naturally at a rate μx. Following parasite
invasion by free floating merozoites, the healthy erythrocytes
get infected by both drug-sensitive and drug-resistant mero-
zoite strains at the rates β and δrβ, respectively. +e parameter
δr (with 0< δr < 1) accounts for the reduced fitness (in-
fectiousness) of the resistant parasite strains in relation to the
drug-sensitive strains.+e destruction of the healthy red blood
cells is however limited by the adaptive immune cellsW.+is is
represented by the term 1/(1 + cW), where c is a measure of
the efficacy of the immune cells. +e equation that governs the
evolution of the healthy RBCs is hence given by
dX
dt
� λx − μxX−
βX
1 + cW
Ms + δrMr( 􏼁. (1)
+e parasitized erythrocytes are generated through mass
action contact (invasion) between the susceptible healthy
erythrocytes X and the blood floating merozoites (Mr and Ms).
+e merozoites subdivide mitotically, within the infected
erythrocytes, into thousands of other merozoites, leading to cell
burst and emergence of characteristic symptoms of malaria.
Additionally, a single infected erythrocyte undergoes hemolysis
at the rate μys to produceP secondarymerozoites, sustaining the
erythrocytic cycle.+e drug-sensitive IRBCs (Ys) burst open to
generate more drug-sensitive merozoites or drug-sensitive
gametocytes at the rate σs. Similar dynamics are observed with
the drug-resistant IRBCs, where the drug-resistant gametocytes
are generated at the rate σr from IRBCs. Treatment with ACTis
assumed to disfranchise the development of the merozoite
within the infected erythrocyte. +e drug-infested erythrocytes
are hence likely to die faster. +is is represented by the term
(1−ωs)
−1, where 0<ωs < 1 represents the antimalarial-specific
treatment efficacy. In this paper and for purposes of illustration
and simulations, ωs corresponds to the efficacy of artemether-
lumefantrine (AL), which is the recommended first-line anti-
malarial ACT drug for P. falciparum infection in Kenya. We
assume that no treatment is available for erythrocytes infected
with the resistant parasite strains.+e time rate of change forYs





















− μyrYr − σrYr.
(2)
+e drug-resistant merozoites Mr and the drug-resistant
gametocytes Gr die naturally at the rates μmr and μgr, re-
spectively. It is further assumed that drug-sensitive mero-
zoites Ms and gametocytes Gs may develop into drug-
resistant merozoites Mr and gametocytes Gr at the rates Ψ1
and Ψ2, respectively. +e cost of resistance associated with
AL is represented by the parameter αs. Parasite resistance to
antimalarial drugs exacerbates the erythrocytic cycle and
increases the cost of treatment [54, 55]. +e higher the
resistance to antimalarial therapy, the higher the density of
malarial parasites in blood. We therefore model this decline
in drug effectiveness by rescaling the density of merozoites
produced per bursting parasitized erythrocyte P by the factor
(1− αs), where αs � 1 implies no resistance; that is, the ACT
is highly effective in eradicating the parasites. If αs � 0
corresponds to maximum resistance, the used ACT drug is
least effective in treating the infection. +e converse of these
descriptions applies to the drug-resistant P. falciparum
parasite strains.+e equations that govern the rate of change
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dMr
dt












− Ψ2 + μgs + η􏼐 􏼑Gs,
dGr
dt





Antimalarial therapy increases the rate of elimination of
drug-sensitive merozoites and gametocytes. +is is repre-
sented by the nonnegative enhancement parameters ζ and η,
respectively.
Although the innate immunity is faster, it is often limited
by the on and off rates in its response to invading pathogens
[56, 57]. +e adaptive immunity, on the contrary, is very
slower at the beginning but lasts long enough to ensure no
parasite growth in subsequent infections [27]. We assume an
immune system that is independent of the invading parasite
strain. For purposes of simplicity, we only consider the
adaptive immune system, which is mainly composed of the
CD8 + T cells [58]. We adopt the assumption that the
background recruitment of immune cells is constant (at the
rate λw). Additionally, the production of the immune cells is
assumed to be boosted by the infective and infected cells
(Gr, Gs), (Mr, Ms), and (Yr, Ys) at constant rates hg, hm, and
hy, respectively. Circulating gametocytes, infective
Computational and Mathematical Methods in Medicine 3
merozoites, and infected erythrocytes are removed phag-
ocytotically by the immune cells at the rates kgW, kmW, and
kyW, respectively. +e immune cells also get depleted
through natural death at the rate μw. +e equation for the
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Following invasion by the merozoites, the IRBCs either
produce merozoites or differentiate into gametocytes upon
bursting. +e total erythrocyte population at any time t,
denoted by C(t), is therefore given by
C(t) � X(t) + Ys(t) + Yr(t). (5)
Similarly, the sum total of P. falciparum parasites,
denoted by P(t), within the host at any time t is described by
the following equation:
P(t) � Ms(t) + Mr(t) + Gs(t) + Gr(t). (6)
+e above dynamics can be represented by the schematic
diagram in Figure 1. +e list of model variables and model
parameters is provided in Tables 1 and 2, respectively.
2.1. Model Equations. Based on the above model de-
scriptions and schematic diagram shown in Figure 1, the
model in this paper consists of the following nonlinear
system of ordinary differential equations:
dX
dt
� λx − μxX−
βX
1 + cW
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dMs
dt
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dGr
dt
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W(0)> 0, for i � s, r.
(15)
3. Model Analysis
3.1. Positivity and Uniqueness of Solutions. +e consonance
between a formulated epidemiological model and its bi-
ological reality is key to its usefulness. Given that all the
model parameters and variables are nonnegative, it is only
sound that the model solutions be nonnegative at any future
time t≥ 0 within a given biological space.
Theorem 1. 8e regionR8+ with solutions of system (7)–(14) is
positively invariant under the flow induced by system (7)–(14).
Proof. We need to show that every trajectory from the re-
gion R8+ will always remain within it. By contradiction,
assume ∃t∗ (where t∗ refers to time) in the interval [0,∞),
such that X(t∗) � 0, X′(t∗)< 0 but for 0< t< t∗, X(t)> 0,
and Yi(t)> 0, Mi(t)> 0, Gi(t)> 0, and Wi(t)> 0 for
i � r, s{ }. Notice that, at t � t∗, X(t) is declining from the
original zero value. If such an X exists, then it should satisfy
the differential equation (7). +at is,
dX
dt




1 + cW t∗( )
Ms t
∗
( 􏼁 + δrMr t
∗
( 􏼁( 􏼁
� λx > 0.
(16)
We arrive at a contradiction, i.e., X′(t∗)> 0. +is shows
the nonexistence of such t∗. +is argument can be extended
to all the remaining seven variables (Ys, Yr, Ms, Mr,
Gs, Gr, W). +e process of verification is however simpler.
We can follow the steps as presented in [59, 60]. Let the total




≤ λx − μcC, (17)
where μc � min μx, μys, μyr􏽮 􏽯. Similarly, the total density of
malarial parasites P(t) is described by
dP
dt
≤P 1− αs( 􏼁μysYs + 1− αr( 􏼁μyrYr􏽮 􏽯 + σsYs + σrYr − μpP,
(18)
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where μp � min μms, μmr, μgs, μgr􏽮 􏽯.


























σs + σr( 􏼁μp









⎩− 1− αs( 􏼁μys 􏽚
t
0











Here,C(0) � X(0) + Ys(0) + Yr(0) and P(0) � Ms(0) +
Mr(0) + Gs(0) + Gr(0) represent the initial total pop-
ulations of erythrocytes and malarial parasites, respectively.
We observe that all the solutions of equations (14), (17), and
(18) remain nonnegative for all future time, t≥ 0. Moreover,
the total populations are bounded: 0≤C(t)≤max C(0),{
(λx/μc)}, 0≤W(t)≤max W(0), λw/μw􏼈 􏼉 and P(t)≤max
(P(0), ((σs + σr)μp)/((1− αs)μys + (1− αr)μyr)). +us, all the
state variables of model system (7)–(14) and all their cor-
responding solutions are nonnegative and bounded in the
phase space φ, where












σs + σr( 􏼁μp





























Figure 1: A model flow diagram. Drug-sensitive variables are shown in green colours while the drug-resistant variables are indicated in
orange colours. Non-strain-specific variables like susceptible RBCs and immune cells are shown in blue colour. Solid lines indicate the
movement of populations from one compartment to another. Dotted lines show possible interactions between the different populations.
Table 1: Description of the state variables of model system
(11)–(18).
Variable Description
X Population of uninfected/unparasitized red bloodcells (erythrocytes)
Ys
Population of red blood cells infected by drug-
sensitive merozoites
Yr
Population of red blood cells infected by drug-
resistant merozoites
Ms Population of drug-sensitive merozoites
Mr Population of drug-resistant merozoites
Gs Population of drug-sensitive gametocytes
Gr Population of drug-resistant gametocytes
W Population of strain-independent immune cells
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It is obvious that φ is twice continuously differentiable
function. +at is, φi ∈ C
2. +is is because its components
φi, i � 1, 2, . . . , 8, are rational functions of state variables
that are also continuously differentiable functions. We
conclude that the domain φ is positively invariant. It is
therefore feasible and biological meaningful to study model
system (7)–(14).
Theorem 2. 8e model system (7)–(14) has a unique
solution.
Proof. Let x � (X, Ys, Yr, Ms, Mr, Gs, Gr, W)
T ∈ R8+ so that
x1 � X and x2 � Ys as presented in system (7)–(14). Simi-
larly, let g(x) � (gi(x), i � 1, . . . , 8)
T be a vector defined in
R8+. +e model system (7)–(14) can hence be written as
dx
dt
� g(x), x(0) � x0, (22)
where x: [0,∞)⟶ R8+ denotes a column vector of state
variables and g : R8+⟶ R
8
+ represents the right-hand side
(RHS) of system (7)–(14). +e result is as follows.
Lemma 1. 8e function g is continuously differentiable in x.
Proof. All the terms in g are either linear polynomials or
rational functions of nonvanishing polynomials. Since the
state variables (X, Ys, Yr, Ms, Mr, Gs, Gr, W) are all contin-
uously differentiable functions of t, all the elements of
vector g are continuously differentiable. Moreover, let L(x,
n, θ) � x + θ(n− x) : 0≤ θ≤ 1{ }. By the mean value theorem,
‖g(n)− g(x)‖∞ � g′(m;n− x)
����
����∞, (23)
where m ∈ L(x,n, θ) denotes the mean value point and g′

















where ei is the ith coordinate unit in R8+. We can clearly see
that all the partial derivatives of g are bounded and that there







≤U, for all m ∈ L. (25)
+erefore, there exists U> 0 such that
‖g(n)− g(x)‖∞ ≤U‖n− x‖∞. (26)
+is shows that the function g is Lipschitz continuous.
Since g is Lipschitz continuous, model system (7)–(14) has
a unique solution by the uniqueness theorem of Picard
[61].
3.2. Stability Analysis of the Parasite-Free Equilibrium Point
(PFE). +e in-host malaria dynamics are investigated by
studying the behaviour of the model at different model
equilibrium points. Knowledge on model equilibrium points
is useful in deriving parameters that drive the infection to
different stability points. +e model system (7)–(14) has
a parasite-free equilibrium point E0 given by









Using the next-generation operator method by van den
Driessche andWatmough [62] andmatrix notations therein,
we obtain a nonsingular matrix Q showing the terms of
transitions from one compartment to the other and a non-
negative matrix F of new infection terms as follows:
Table 2: Description of model parameters.
Parameter Description
λx +e rate of recruitment of red blood cells
ωs Antimalarial treatment efficacy
αs, αr Parasite strain-specific fitness cost
λw Background recruitment rate of immune cells
eg, em, ey Hill parameters in Gi, Mi, and Yi dynamics (i � s, r)
μx
Per capita natural mortality rate of unparasitized
erythrocytes
μys Natural mortality rate of drug-sensitive IRBCs
μyr Natural death rate of drug-resistant IRBCs
ζ, η Rate of antimalarial eradication of merozoites andgametocytes, respectively
μms Death rate of drug-sensitive merozoites
μmr Mortality rate of drug-resistant merozoites
μgs
Per capita mortality rate of drug-sensitive
gametocytes
μgr Mortality rate of drug-resistant gametocytes
μw Natural mortality rate of immune cells (CD8+Tcells)
β +e rate of infection of susceptible RBCs by bloodfloating merozoites
σr, σs
Rate of formation of gametocytes from the infected
RBCs
P Number of merozoites produced per dying infectedRBC
hy Immune cell proliferation rate due to IRBCs
hm
Immune cell proliferation rate due to asexual
merozoites
hg Immune cell proliferation rate due to gametocytes
ky Phagocytosis rate of IRBCs by immune cell
km Phagocytosis rate of merozoites by immune cell
kg Phagocytosis rate of gametocytes by immune cell
Ψ1
Rate of development of resistance by drug-sensitive
merozoites
Ψ2
Rate of development of resistance by drug-sensitive
gametocytes
δr
Accounts for the reduced fitness of the resistant
parasite strains
c
Efficiency of immune effector to inhibit merozoite
infection
1/a Half-saturation constant for Y(t), M(t), and G(t)








cλw + μw( 􏼁μx
0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0





v1 0 0 0 0 0
0 v2 0 0 0 0
−P 1− αs( 􏼁μys 0 v3 0 0 0
0 −P 1− αr( 􏼁μyr −Ψ1 v4 0 0
−σs 0 0 0 v5 0





where v1 � ((kyλw/μw) + σs + (μys/1−ωs)), v2 � ((kyλw/
μw) + σr + μyr), v4 � (μmr + (kmλw/μw) + (δrβλxμw/(cλw +
μw)μx)), v3 � (ζ + μms + Ψ1 + (kmλw/μw) + (βλxμw/(cλw +
μw)μx)), and v5 � (η + μgs + (kgλw/μw) + Ψ2), v6 � (μgr +
(kgλw/μw)).
+e effective reproduction number RE of model system
(7)–(14) associated with the parasite-free equilibrium is











0 0 0 0






P 1− αs( 􏼁μysΨ1
v1v3v4





















RE � ρ FQ
−1
􏼐 􏼑 � max Rs, Rr􏼈 􏼉, (31)
where
Rs �
P 1− αs( 􏼁μysβλxμw
kyλw/μw􏼐 􏼑 + σs + μys/1−ωs􏼐 􏼑􏼐 􏼑 ζ + μms + kmλw/μw( 􏼁 + Ψ1 + βλxμx/ cλw + μw( 􏼁μx( 􏼁( 􏼁 cλw + μw( 􏼁μx
,
Rr �
P 1− αr( 􏼁μyrδrβλxμw
kyλw/μw􏼐 􏼑 + σr + μyr􏼐 􏼑 μmr + kmλw/μw( 􏼁 + δrβλxμw/ cλw + μw( 􏼁μx( 􏼁( 􏼁 cλw + μw( 􏼁μx
.
(32)
From equation (31), it is evident that, in a multiple-strain
P. falciparummalaria infection, the progression of the disease
depends on the reproduction number of different parasite
strains. If the threshold quantity Rs >Rr, the drug-sensitive
parasite strains will dominate the drug-resistant strains and
hence the driver of the infection. To manage the infection in
this case, the patient should be given antimalarials that can
eradicate the drug-sensitive parasites. Conversely, if Rr >Rs,
the infection is mainly driven by the drug-resistant parasite
strains. In this scenario, the used antimalarial drugs should be
highly efficacious and effective enough to kill both the drug-
resistant and drug-sensitive parasite strains in the blood of the
human host. +is result is quite instrumental in improving
antimalarial therapy for P. falciparum infections. +e best
antimalarials should be sufficient enough to eradicate both
parasite strains within the human host.
Based on +eorem 2 in [63], we have the following
lemma.
Lemma 2. 8e parasite-free equilibrium point E0 is locally
asymptotically stable if RE < 1 (Rs < 1 andRr < 1) and un-
stable otherwise.
+e Jacobian matrix associated with the in-host model
system (7)–(14) at E0 is given by




cλw + μw( 􏼁μx
−δrβλxμw




cλw + μw( 􏼁μx
0 0 0 0
0 0 −v2 0
βλxμw
cλw + μw( 􏼁μx
0 0 0
0 P 1− αs( 􏼁μys 0 −v3 0 0 0 0
0 0 P 1− αr( 􏼁μyr Ψ1 −v4 0 0 0
0 σs 0 0 0 −v5 0 0


















where the terms v1, . . . , v6 are as defined in (30). It is clear from
matrix (33) that the first four eigenvalues are−μx (from column
1), −μw (from column 8), −(μgr + (kgλw/μw)) � −v6 (from
column 7), and −(η + μgs +(kgλw/μw)) � −v5 (from column
6). +ey are all negative. +e remaining four eigenvalues are
obtained from the roots of the following quartic equation:




+ p3λ + p4, (34)
where
p1 � v1 + v2 + v3 + v4( 􏼁> 0, (35)
p2 � v3v4 + v2 v3 + v4( 􏼁 + v1 v2 + v3 + v4( 􏼁
−
Pβλxμw
cλw + μw( 􏼁μx













v3v4( 􏼁 + v2 v3 + v4( 􏼁􏼂 􏼃K−P 1− αr( 􏼁μyrδrβλxμw⎤⎦,
(37)
p4 �




Due to complexity in the coefficients of the polynomial
(34), we shall rely on the Routh–Hurwitz stability criterion
[64], which provides sufficient condition for the existence of
the roots of the given polynomial on the left half of the plane.
Definition 1. +e solutions of the quartic equation (34)
are negative or have negative real parts provided that
the determinants of all Hurwitz matrices are positive [64].
Based on the Routh–Hurwitz criterion, the system of
inequalities that describe the stability region E0 is presented
as follows:
(i) p1 > 0
(ii) p3 > 0
(iii) p4 > 0
(iv) p1p2p3 >p23 + p21p4
From (35), it is clear that p1 > 0. Upon simplifying p2 in
(36), we obtain









where B1 � −P(1− αs)μys andB2 � −P(1− αr)μyr.
+us,








� v1 + v3( 􏼁 v2 + v4( 􏼁 + v1v3 1−Rs􏼂 􏼃
+ v2v4 1−Rr􏼂 􏼃> 0, if and only if Rs, Rr < 1.
(40)
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Similarly, the expression for p4 can be rewritten as
follows:
p4 � v1v3 +
B1βλxμx
K




� v1v3 1 +
B1βλxμw
v1v3K




� v1v3 1−Rs􏼂 􏼃v2v4 1−Rr􏼂 􏼃> 0, if and only if Rs, Rr < 1.
(41)
Lastly, upon simplifying equation (37), we obtain
p3 � v2v3v4 + v1v3v4 + v1v2 v3 + v4( 􏼁
+
βB1λxμw v2 + v4( 􏼁
K
+



































� v1v3 v2 + v4( 􏼁 1−Rs􏼂 􏼃 + v2v4 v1 + v3( 􏼁 1−Rr􏼂 􏼃> 0,
if and only if Rs, Rr < 1.
(42)
Since all the coefficients of the quartic equation (34) are
nonnegative, all its roots are therefore negative or have
negative real parts. Hence, the Jacobian matrix (33) has
negative eigenvalues or eigenvalues with negative real parts if
and only if the effective reproduction number RE is less than
unity. Equilibrium point E0 is therefore locally asymptoti-
cally stable when RE < 1 (when both Rs < 1 and Rr < 1). +is
implies that an effective antimalarial drug would cure the
costrain infected human host, provided that the drug re-
duces the effective reproduction number to less than 1.
Lemma 2 shows that P. falciparum malaria can
be eradicated/controlled within the human host if the
initial parasite and cell populations are within the
basin of attraction of the trivial equilibrium point E0.
To be certain to eradicate/control the infection irre-
spective of the initial parasite and cell populations, we
need to prove the global stability of the parasite-free
equilibrium point. +is is presented in the following
section.
3.3. Global Asymptotic Stability Analysis of the Parasite-Free
Equilibrium Point. Following the work by Kamgong and
Sallet [65], we begin by rewriting system (7)–(14) in
a pseudotriangular form:





where X1 is a vector representing the densities of non-
infective population groups (unparasitized erythrocytes
and immune cells) and X2 represents the densities of
infected/infective groups (infective P. falciparum para-
sites and/or infected host cells) that are responsible for
disease transmissions. For purposes of clarity and sim-
plicity to the reader, we shall represent (X1, 0) with X1
and (0, X2) with X2 in R8+ × R
8
+. We assume the exis-
tence of a parasite-free equilibrium in φ: X∗ � (X∗1 , 0).
+us,
X � X1, X2( 􏼁,
X1 � (X, W),











We analyze system (43) based on the assumption that
it is positively invariant and dissipative in φ. Moreover,
the subsystem X1 is globally asymptotically stable at X∗1 on
the projection of φ on R8+. +is implies that whenever
there are no infective malarial parasites, all cell pop-
ulations will settle at the parasite-free equilibrium point
E0. Finally, D2 in (43) is a Metzler matrix that is irre-
ducible for any X ∈ φ. We assume adequate interactions
between and among different parasites and cell com-
partments in the model.
+e matrices D1(X) and D2(X) are easily computed
from subsystem _X1 in (43) so that we have








cλw + μw( 􏼁μx
−δrβλxμw


















We can easily see that the eigenvalues of matrix D1 are
both real and negative (−μx < 0, −μw < 0).+is shows that the
subsystem _X1 � D1(X)(X−X∗1 ) + D2(X)X2 is globally
asymptotically stable at the trivial equilibrium X∗1 . Addi-









cλw + μw( 􏼁μx
0 0
P 1− αs( 􏼁μys 0 −v3 0 0 0
0 P 1− αr( 􏼁μyr Ψ1 −v4 0 0
σs 0 0 0 −v5 0




Notice that all the off-diagonal entries of D3(X) are
nonnegative (equal to or greater than zero), showing that
D3(X) is a Metzler matrix. To show the global stability of the
parasite-free equilibrium E0, we need to show that the square
matrix D3(X) in (46) is Metzler stable. We therefore need to
prove the following lemma.






where K11 and K22 are square matrices. 8e matrix K is
Metzler stable if and only if K11 and K22 −K21K−111K12 are
Metzler stable.





cλw + μw( 􏼁μx
0 −v2 0


























10 Computational and Mathematical Methods in Medicine







v1v3 + Pβ αs − 1( 􏼁λxμwμys􏼐 􏼑/ cλw + μw( 􏼁μx( 􏼁
0 −
βλxμw





P αs − 1( 􏼁 cλw + μw( 􏼁μxμys
v1v3 cλw + μw( 􏼁μx + Pβ αs − 1( 􏼁λxμwμys
0 −
v1











where v4 � (μmr + (kmλw/μw) +(δrβλxμw/(cλw + μw)μx)),
v5 � (η + μgs + (kgλw/μw) +Ψ2), and v6�(μgr + (kgλw/μw)).
From equation (50), it is evident that all the diagonal
elements of matrix K22 −K21K−111K12 are negative and the
rest of the elements in the matrix are nonnegative. +is
shows that matrix K22 −K21K−111K12 is Metzler stable, and
the parasite-free equilibrium point E0 is globally asymp-
totically stable in the biologically feasible region φ of model
system (7)–(14). Epidemiologically, the above result implies
that when there is no malaria infection, different cell pop-
ulations under consideration will stabilize at the parasite-
free equilibrium. However, if there exists a P. falciparum
infection, then an appropriate control in forms of effective
antimalarial drugs would be necessary to clear the parasites
from the human blood and restore the system to the stable
parasite-free equilibrium state.
3.4. Coexistence of Parasite-Persistent Equilibrium Point.
+e existence of a nontrivial equilibrium point represents
a scenario in which the P. falciparum parasites are present
within the host and the following conditions hold:
X∗ > 0, Y∗s ≥ 0, Y
∗
r ≥ 0, M
∗
s ≥ 0, M
∗
r ≥ 0, G
∗
s ≥ 0, G
∗
r ≥ 0, and
W∗ > 0. Upon equating the right-hand side of system (7)–
(14) to zero and solving for the state variables, we obtain














1 + cW∗( 􏼁λx
β M∗s + δrM
∗


























r δr + cW
∗
+ 1( 􏼁μx( 􏼁< 0,
(52)









c � βM∗s 1−ωs( 􏼁λx > 0, (54)




r δr + cW
∗
+ 1( 􏼁μx( 􏼁< 0,
(55)





+ βM∗r δr + cW
∗μx + μx)− σ2 + μyr􏼐 􏼑
· βM∗s + cW
∗μx + μx( 􏼁,
(56)






























a2 � −aμg2 < 0,
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a3 � −( aβM
∗
r δr ζ + μms + Ψ1( 􏼁 + acW
∗μmsμx + aμmsμx
+ aβP 1− αs( 􏼁μysY
∗
s + Ψ1 a cW
∗
+ 1( 􏼁μx + β( 􏼁






r δr a αs − 1( 􏼁PY
∗
s μys + ζ + W
∗
km + μms + Ψ1􏼐 􏼑
− αs − 1( 􏼁βPY
∗
s μys − βλx − cW
∗
+ 1( 􏼁μx(a αs − 1( 􏼁PY
∗
s μys
+ ζ + W∗km + μms + Ψ1),
(63)




r δr + cW
∗
+ 1( 􏼁μx( 􏼁> 0, (64)
a4 �−(aβM
∗
s Ψ1δr + μmr( 􏼁 + μmr a cW
∗
+ 1( 􏼁μx + βδr( 􏼁






s Ψ1 + M
∗
s (−β aδrλx + μmr( 􏼁 + a 1− αr( 􏼁βPY2μy2
+ Ψ1 a cW
∗
+ 1( 􏼁μx + βδr( 􏼁) + 1− αr( 􏼁PY2μy2
· a cW
∗













s Ψ1 + M
∗
s ( 1− αr( 􏼁βPY2μy2 + βδrλx
+ Ψ1 cW
∗
+ 1( 􏼁μx) + 1− αr( 􏼁PY2 cW
∗






μwΔ− hg G∗s + G
∗











where Δ � (eg + G∗s + G
∗









Using Descartes’ “Rule of Signs” [66], it is evident that
irrespective of the sign of b in (53), b in (56), b1 in (59), b2 in











r can only have one real positive
solution. +is shows that the model system (7)–(14) has
a unique parasite-persistent equilibrium point E1.
3.5. Stability of the Coexistence of Parasite-Persistent Equi-
librium Point. Here, we shall prove that the coexistence of
parasite-persistent equilibrium E1 is locally asymptotically
stable when RE > 1 (orwhen Rs > 1 andRr > 1). We shall
follow the methodology by Esteva and Vargus presented in
[67], which is based on the Krasnoselskii technique [68].+is
methodology requires that we prove that the linearization of
system (7)–(14) about the coexistence of parasite-persistent




where S0 � (S1, S2, . . . , S7), (Si, ξ) ∈ C, and the real part of ξ
is nonnegative (Re(ξ)≥ 0). Note that C is a set of complex
numbers.
Next, we substitute a solution of the form (69) into the
linearized system (7)–(14) about the coexistence of parasite-



























+ μyr + σr􏼠 􏼡S2
+














β C∗ −Ys −Yr( 􏼁
1 + cW
+ k1􏼠 􏼡S3,
ξS4 � Ψ1S3 +
δrβMr
1 + cW
+ P 1− αr( 􏼁μyr􏼠 􏼡S2
−

















ξS7 � λ +
hg Gs + Gr( 􏼁
Gs + Gr + eg
+
hy Ys + Yr( 􏼁
Ys + Yr + ey
+
hm Ms + Mr( 􏼁
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where (C∗ −Ys −Yr) � X, k1 � (Ψ1 + μms + ζ), and
k2 � (Ψ2 + μgs + η).
Upon simplifying the equations in (70), we obtain
1 +
(1 + cW) 1 + aYs( 􏼁 1−ωs( 􏼁
Δ1
ξ􏼢 􏼣S1 �










ξ(1 + cW) 1 + aYr( 􏼁
Δ2
􏼢 􏼣S2 �










(1 + cW) 1 + aMs( 􏼁
Δ3
ξ􏼢 􏼣S3 �









ξ(1 + cW) 1 + aMr( 􏼁
Δ4
􏼢 􏼣S4 �










1 + aGs( 􏼁
kgW + k2
ξ􏼢 􏼣S5 �




1 + aGr( 􏼁
kgW + μgr
ξ⎡⎣ ⎤⎦S6 �
1 + aGr( 􏼁
kgW + μgr










hg S5 + S6( 􏼁
Gs + Gr + eg
+
hy S1 + S2( 􏼁
Ys + Yr + ey
+
hm S3 + S4( 􏼁




Δ1 � βMs 1 + aYs( 􏼁 1−ωs( 􏼁 + kyW 1−ωs( 􏼁(1 + cW)
+ μys 1 + aYs( 􏼁(1 + cW) + σs 1 + aYs( 􏼁
1−ωs( 􏼁(1 + cW),
Δ2 � δrβMr 1 + aYr( 􏼁 + kyW(1 + cW)
+ μyr + σr􏼐 􏼑 1 + aYr( 􏼁(1 + cW),
Δ3 � 1 + aMs( 􏼁 β C
∗ −Ys −Yr( 􏼁( 􏼁 + kmW(1 + cW)
+ k1 1 + aMs( 􏼁(1 + cW),
Δ4 � 1 + aMr( 􏼁 δrβ C
∗ −Ys −Yr( 􏼁( 􏼁
+ kmW(1 + cW) + μmr 1 + aMr( 􏼁(1 + cW).
(72)
Separating the negative terms, we obtain the following
system:
1 + Fj(ξ)􏽨 􏽩Sj � (HS)j, for j � 1, 2, . . . , 7, (73)
where
F1(ξ) �











































































P 1− αs( 􏼁μys 0
βC∗
1 + cW
+ k1 0 0 0 0
0 P 1− αr( 􏼁μyr Ψ1 0 0 0 0
σs 0 0 0 0 0 0
0 σr 0 0 0 0 0




Note that X∗ � C∗ −Y∗s −Y
∗
r and all the elements in the
square matrixH are nonnegative. +e coordinates of E1 are all
positive, and the jth coordinate of the vector H(S) is described
by the notation H(S)j for j � 1, . . . , 7. Additionally, the












E1 � HE1. If we assume, for example, that system (73) has
a solution of the form S, then there exists a small positive real
number ϵ, such that |S|≤ ϵE1, where |S| � (|S1|, |S2|, . . . , |S7|).
Note also that |.| is a norm in the field of complex numbers.
Next, we show that Re(ξ)< 0. To do so, we apply proof
by contradiction. We let ξ � 0 and ξ ≠ 0. For the case when
ξ � 0, the determinant (∇) of (70) is given by
∇ �
v5v6μw v2v4 cλx + μw( 􏼁μx + Pβ 1− αr( 􏼁λxμwμyr􏽮 􏽯 v1v3 cλx + μw( 􏼁μx + Pβ 1− αs( 􏼁λxμwμys􏽮 􏽯
cλx + μw( 􏼁
2μ2x
, (76)
where the positive terms v1, . . . , v6 are as defined in matrix
(29).
It is clear that the above determinant is nonnegative
(∇> 0). Consequently, the system (70) can only have the trivial
solution S � (0, 0, 0, 0, 0, 0, λw/μw). On the contrary, for ξ ≠ 0,
we assume Re(ξ)≥ 0 and define F(ξ) � min|1 + Fj(ξ)|,
j � 1, 2, . . . , 7. +is implies that F(ξ)> 1 and ϵ/F(ξ)< ϵ. +e
minimality of ϵ means that |S|> ϵ/F(ξ)E1. While considering
the nonnegativity property ofH, if we assume the norms on the
two sides of (73), we shall have
F(ξ)|S|≤H|S|≤ εHE1 � εE1. (77)
+is implies that |S|≤ ϵ/F(ξ)E1 ≤ ϵE1, which is a con-
tradiction. +erefore, Re(ξ)< 0 and E1 is locally asymp-
totically stable when RE > 1.
4. Numerical Simulations
4.1. Boundary Equilibrium Points. In this section, we show
by means of numerical simulation the existence and stability
of a positive parasite-persistent equilibrium point that in-
volves only one of the parasite strains under study.
4.1.1. Drug-Sensitive-Only Persistent Equilibrium Point Es.
+is is an equilibrium point where only the drug-sensitive
parasite strains are present in the infected human host. +at
is, the populations Yr � Mr � Gr � 0. +is steady state is
only feasible if no resistant parasites emerge from infected
red blood cells and the use of antimalarial treatment does not
lead to resistance development; that is, Ψ1 � Ψ2 � 0. +e
original model (7)–(14) is thus reduced to
dX
dt







































































Numerically, this equilibrium point is illustrated, as
shown in Figure 2.
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4.1.2. Drug-Resistant-Only Persistent Equilibrium Point Er.
In this case, the population of the drug-sensitive parasite
strains declines to zero as the density of the resistant strains
grows and stabilizes at an optimal population size. +is is
also illustrated numerically, as shown in Figure 3.
4.2. Within-Host Competition between Parasite Strains.
We investigate the competitive exclusion principle by sim-
ulating the model system (7)–(14) under different values of
the threshold quantities Rs and Rr in (31). Model (7)–(14) is
simulated so that Rs � 4.022 and Rr � 0.3131, and we achieve
a convergence to the drug-sensitive-only endemic equilib-
rium point Es, as shown in Figure 4(a). Again, using the
parameter values in Table 3 with Ψ1 � 0.9 and (Rs � 0.022,
Rr � 3.0098), the solutions of Ys and Yr converge to the drug-
resistant-only endemic equilibrium point Er (Figure 4(b)).
Provided that both Rs and Rr are greater than 1 (as shown
in Figure 4(c)), the parasite-infected red blood cells remain
persistent in the host. +is implies that the merozoites (both
drug-sensitive and drug-resistant) continue to multiply in the
absence of antimalarial therapy, ωs � 0, or in the presence of
ineffective antimalarial drugs. Similar results are observed in
the dynamics of merozoites (Ms and Mr), as shown in
Figure 5. It should be noted that the dominant merozoite
strains are likely to drive the infection under these conditions.
As the density of one strain increases, the population of the
other strain is likely to decrease due to a phenomenon known
as competitive exclusion principle.+emost fit parasite strain
survives as the weaker competitor dies out, as shown in
Figure 5(a). Both drug-sensitive and drug-resistant mero-
zoites would remain persistent if poor-quality antimalarial
drugs are administered to P. falciparum malaria patients.
+us, in the absence of efficacious antimalarial drugs like
ACTs with the potential to eradicate resistant merozoites, we
are likely to experience an exponential growth in the density
of drug-resistant merozoites, as displayed in Figure 5(b). +is
may lead to severe malaria and eventual death of the patient.
+e bifurcation analysis of both scenarios is presented in
Figure 6 (with and without competition between the parasite
strains). When there is competition between the parasite
strains, as shown in Figure 6(a), we observe that the strain
with a higher threshold quantity R0 would exclude the other
strain. A decrease in the population of the drug-sensitive
strain would pave way for a surge in the population of the
drug-resistant strains, and vice versa. +is is despite the fact
that some drug-resistant strains emerge from the drug-
sensitive strains as a result of mutation [77]. In Figure 6(b),
we observe coexistence of the strains that do not compete
with each other. Like the resistance strains, the sensitive
strains are only present when their threshold quantity, Rs, is
greater than unity. Both strains are however present when
Rr > 1 and Rs > 1. Additionally, when Rr < 1 and Rs < 1, we
arrive at the parasite-free equilibrium (PFE) point, as shown
in Figures 6(a) and 6(b).
4.3. Antimalarial Drug Effects and Parasite Clearance.
+e effects of antimalarial drug treatment are monitored by




βμ1μ2P 1− αs( 􏼁μwλx
1−ωs( 􏼁
2μx cλw + μw( 􏼁 kyλw/μw􏼐 􏼑 + μ2/ 1−ω1( 􏼁( 􏼁 + σs􏼐 􏼑
2
ζ + kmλw/μw( 􏼁 + μms + βλxμ2x/ cλw + μw( 􏼁( 􏼁 + Ψ1( 􏼁
< 0.
(79)
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Figure 2: Simulations of model system (11)–(18) showing the existence of drug-sensitive-only equilibrium point. All parameter values are as
presented in Table 3.
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+us, Rs is a decreasing function of ωs (the efficacy of the
antimalarial drug used). +erefore, using a highly efficient
antimalarial drug could lead to a scenario where Rs < 1 and
Rr < 1 (disease-free state shown in Figure 7(c)). In
Figure 7(a), model system (7)–(14) is simulated by varying
the efficacy of the antimalarial drug ωs and other model
parameters chosen such that Rr � 3.221 and Rs � 2.221. +e
higher the efficacy of the used antimalarial, the lower the
density of infected erythrocytes. +us, governments and
ministry of health officers should only roll out or permit the
administration of antimalarials or ACTs that can eradicate
(totally) both the drug-resistant and the drug-sensitive
strains of P. falciparum parasites.
+e rate of development of resistance by the drug-
sensitive merozoites, Ψ1, is shown to have very minimal
impact on the dynamics of infected red blood cells Yr as long
as Rs > 1 and Rr > 1 (Figure 7(b)). Nevertheless, analytical
results indicate that the higher the rate of development of
resistance, the lower the severity of future malaria infections.




βμ1P 1− αs( 􏼁μwλx
μx cλw + μw( 􏼁 kyλw/μw􏼐 􏼑 + μ2/ 1−ω1( 􏼁( 􏼁 + σs􏼐 􏼑 ζ + kmλw/μw( 􏼁 + μms + βλxμ2x/ cλw + μw( 􏼁( 􏼁 + Ψ1( 􏼁
2 < 0. (80)
Other parameters that have direct negative impacts on
the progression of malaria infection are the efficacy of the
immune effectors, c, and the rate of therapeutic elimination
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βμ2P 1− αr( 􏼁δrλwμ3wλx kmλw + μmrμw( 􏼁
μx kyλw + μw μ2 + σr( 􏼁􏼐 􏼑 cλw + μw( 􏼁 kmλw + μmrμw( 􏼁 + βδrμwλxμ2x( 􏼁
2 < 0. (82)
Further simulations based on contour plots (see [78] for
theory on contour plots) are used to ascertain the relational
effects of selected pairs of model parameters on the disease
threshold quantities Rs and Rr. In Figure 8(a), both β and μw
increase the reproduction number due to drug-sensitive P.
falciparum parasite strains. A direct relationship exists between
the two parameters: the higher the decay rate of the immune
cells, the higher the rate of infection of healthy erythrocytes.
In Figure 8(b), we observe the least increase in Rs with
respect to an increase in ωs relative to μys. Antimalarial
therapy is shown to be very effective in reducing the severity
of P. falciparum infection. Conversely, the number of
merozoites produced per dying blood schizont, P, is shown
in Figure 8(c) to have a very high positive impact on Rs and
hence on the severity of malaria infection due to drug-
sensitive parasite strains. Clinical control should target and
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Figure 3: Simulations of model system (11)–(18) showing the existence of drug-resistant-only equilibrium point. All parameter values are as
presented in Table 3.
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eradicate infected red blood cells to diminish the erythro-
cytic cycles of infections.
We observe in Figure 9(b) that the rate at which mer-
ozoites develop resistance due to treatment failure has no
resultant effects on the rate of formation of gametocytes that
undergo sexual reproduction within the mosquito vector.
+e higher the value of Rr, the higher the cost of resistance,
as shown in Figure 9(a). +e higher the density of drug-
resistant parasite strains, the higher the level of resistance
and hence the cost of disease control. Unfortunately, highly
effective antimalarial drugs (such as ACTs) that can eradicate
both parasite strains are slightly expensive in several
P. falciparum malaria-endemic regions [79]. Like the pa-
rameter P, the parasite infection rate β is shown to have
a direct positive effect on the threshold quantityRr (Figure 9(c))
due to drug-resistant parasite strains. Effective antimalarials
should hence target new cell infections and eliminate re-
crudescence (by killing already infected erythrocytes).
5. Effects of Multiple-Strain Infection and
Fitness Cost on Parasite Clearance
Numerous studies [27, 80] have suggested the negative im-
pacts of drug resistance on the fitness and ability of the
parasite to dominate the P. falciparum infection. Resistance to
antimalarial drugs imposes fitness cost on the drug-resistant
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Rs = 1.066 > 1
Drug-sensitive infected erythrocytes, Ys
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(c)
Figure 4: Simulations of model system (11)–(18).+e figures show the dynamics of drug-sensitive and drug-resistant infected red blood cells
under different conditions of the threshold values Rs and Rr. In Figure 4a, Rs >Rr. In Figure 4b, Rr >Rs, Ψ1 � 0 and all other parameter
values are as presented in Table 3.
Computational and Mathematical Methods in Medicine 17
experience impaired growth within the human host [29]. +e
cost of resistance is further exacerbated due to the compe-
tition between parasite strains within an infected human host.
In Figure 10(a), the area under the curve for the drug-resistant
strain or the number of infected erythrocytes is lower than
that of the drug-sensitive strains. However, in a multiple-
strain infection (Figure 10(b)), the area difference is much
bigger. +is implies that competition between the parasite
strains within the human host could result in elimination of
one of the parasite strains provided that both Rs and Rr are
less than unity.
+e presence of multiple strains of P. falciparum para-
sites is likely to complicate and worsen the severity of
malaria disease infection in humans. Figures 11 and 12 show
the simulated model (7)–(14) for single- and multiple-strain
infections, in the absence of preexisting immunity and
antimalarial drugs. +e persistence of gametocytes in
Figures 11(b) and 12(b) is consistent with the actual ob-
servations of human malaria infection in the absence of
antimalarial therapy [81]. Acquired immunity is shown in
Figure 11(c) to increase and eventually level-off at higher

















































Rr = 3.2221 > Rs
Rs = 1.066 > 1
(b)
Figure 5: Simulations of model system (11)–(18). +e figures show the dynamics of the merozoites under different conditions of the
threshold values Rs and Rr. Competitive exclusion among the parasite strains is shown in (a). In (b), both parasite strains coexists and
Rr >Rs, Ψ1 � 0. Other parameter values are available in Table 3.
Table 3: Baseline values and range for parameters of model (11)–(18).
Parameter Value Range Units Source
λx 3 × 103 (3 × 103 − 3 × 108) Cells/μl−1/day [69]
λw 30 (10–40) Cells/μl/day [70]
ωs 0.5 (0-1) Unitless Assumed
αs 0.4 (0.1–1) Unitless Assumed
αr 0.2 (0.01–1) Unitless Assumed
eg, em, ey 104 (103−105) Unitless [71]
μx 1/120 (0.05–0.1) day
−1 [72]
μys 0.5 (0.3–0.8) day
−1 [73]
μyr 0.3 (0.3–0.8) day
−1 Assumed
μms, μmr 48 (46–50) day
−1 [69]
μgs, μgr 0.0625 (0.05–0.1) day
−1 [74]
μw 0.05 (0.02–0.08) day
−1 [74]
δr 0.7 (0.01–0.99) Unitless Assumed
ζ, η 0.5 (0-1) day−1 [73]
P 16 (15–20) Erythrocytes/day [34]
β 6.5 × 10−7 4.8 × 10−7–6.8 × 10−7 Merozoites/day [75]
σr, σs 0.02 (0.01–0.03) day
−1 [75]
hy, hm, hg 0.05 (0.01–0.08) mm−3/day [70]
ky, km, kg 0.000001 (0.001–0.9) day
−1 [51]
Ψ1 0.2 (0.01–2.2) day
−1 Assumed
Ψ2 0.01 (0.001–0.1) day
−1 Assumed
δr 0.3 (0-1) Unitless Assumed
c 0.5 (0-1) Immune cell/μl Assumed
1/a 0.2 (0-1) Unitless [76]
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Figure 7: +e effect of varying the efficacy of antimalarial drug used ωs and the rate of development of resistance by the drug-sensitive
merozoitesΨ1, on the density of infected erythrocytes (Ys, Yr).+e value of ωs ranges from 0 to 1.+e rest of the parameter values are available


























Figure 6: Bifurcation diagrams showing competitive exclusion (a) and coexistence equilibrium (b) for the drug-sensitive and drug-resistant
P. falciparum parasite strains under different values of threshold quantities Rs and Rr. Both parasite strains coexists when Rs > 1 and Rr > 1
(see part (b)).
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Although the aspect of timing is key in these multiple-
strain infections, we assumed here that the two strains are
introduced at the same time. In the long run, it is evident in
Figures 10 and 12 that the sensitive strain overtakes the
resistant strain. We argue that this could be as a result of
strain-specific adaptive responses that symmetrically affect
the sensitive parasites.
Unlike single-strain P. falciparum parasite infections, data
on multiple-strain infections are not readily available. Nev-
ertheless, amultiple-strain infection (drug-sensitive and drug-
resistant) as presented in this paper is biologically reasonable
and consistent with that of P. Chabaudi described in [82].
5.1. Sensitivity Analysis. In this paper, the primary model
output of interest for the sensitivity analysis is the infected
erythrocytes (Ys, Yr). However, the effective reproduction
number RE is a threshold quantity which represents on
overage the number of secondary infected erythrocytes due
to merozoite invasions. We can therefore measure the
sensitivity indices of the effective reproduction number of
model system (7)–(14) relative to model parameters. For
example, the sensitivity of RE relative to the parameter Ψ1 is








Using the parameter values in Table 3, the expressions for
sensitivity for all the parameters in RE are evaluated and
presented in Table 4. +e higher the numerical value of the
sensitivity index (S.I), the greater the variational impact of the
parameter on the disease progression. A parameter with
a negative index decreases the model RE when they are in-
creased. On the other hand, a parameter with a positive index
would generate a proportional increase in RE when they are
magnified. Results shown in Table 4 indicate that the rate of
infection of healthy erythrocytes by the merozoites β, the
density of merozoites generated from each of the bursting
schizonts P, the efficacy of antimalarial drug used ωs, and the
rate at which drug-sensitive merozoites develop resistance Ψ1
are the four most influential parameters, in determining the
disease dynamics as presented in model system (7)–(14).
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Figure 8: Contour plot of Rs as a function of (a) β and μw, (b) ωs and μys, (c) P and c.
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Results from sensitivity analysis emphasize the use of
highly efficacious antimalarial drugs such as ACTs in
malaria-endemic regions. +is would mitigate the many
cases of malaria in the region and further help to reduce
emerging cases of parasite resistance to existing therapies.
Drugs with a higher parasite clearance rate would greatly
reduce resistance, which is associated with longer parasite
exposure to antimalarial drugs. It is imperative, therefore,
that governments and ministry of health personnel in
malaria-endemic countries enforce the use of efficient an-
timalarial drugs that not only cure infected malaria patients
but also eliminate the chance of P. falciparum parasites to
develop resistance to existing therapy.
6. Conclusion
In this paper, a deterministic model of multiple-strain P.
falciparum malaria infection has been formulated and
analysed. +e parasite strains are categorized as either drug-
sensitive or drug-resistant. +e infected erythrocytes and the
malaria gametocytes are similarly grouped according to the
strain of the parasite responsible for their existence. +e
immune cells are incorporated to reduce the invasive
characteristic of the malaria merozoites. Antimalarial
therapy is applied to the model but only targets red blood
cells infected with drug-sensitive merozoites. Based on the
next-generation matrix method, we computed the effective
reproduction number RE of the formulated model. Based on
RE, it is evident that the success of P. falciparum infection in
the presence of multiple-parasite strains is directly de-
pendent on the ability of the individual parasite strains to
drive the infection. +e parasite strain with a higher
threshold value, R0, is likely to dominate the infection.
Prescribed antimalarial drugs should therefore be effective
enough to eradicate both drug-sensitive and drug-resistant
parasite strains in vivo. Linearization of the model at the
parasite-free equilibrium reveals the local asymptotic sta-








































































































Figure 9: Contour plot of Rr as a function of (a) αr and μyr, (b) Ψ1 and σr, (c) P and β.
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Figure 10: Dynamics of drug-sensitive (blue) and drug-resistant (orange) strains in a single infection (a) and in a multiple infection (b) in
a naive human-host with no malaria therapy (ωs � 0). +e density of the resistant strain is lower than that of drug-sensitive strain for




















































































Figure 11: Dynamics of infected erythrocytes, gametocytes, and the immune cells with a single-strain P. falciparum infection. Here, we do
not have preexisting immunity. +e rest of the parameter values are as displayed in Table 3.
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By rewriting the model in the pseudotriangular form, the
parasite-free equilibrium is also shown to be globally as-
ymptotically stable. Although the parasite-persistent equi-
librium exists, its expression based on a single-model
variable proved to be mathematically intractable. +e use of
antimalarial treatment may eradicate one parasite strain so
that we arrive at either a drug-sensitive-only persistent
equilibrium point or a drug-resistant-only persistent equi-
librium point.
To assess the impacts of the different parasite strains to
disease dynamics, the model is simulated for different values
of the threshold quantities Rs andRr.We observed that when
Rr > 1 and Rs > 1, then both parasite strains are persistent
and the infection becomes severe. If Rr > 1 and Rs < 1, then
the drug-sensitive parasites would decline to zero as the
drug-resistant strains continue to multiply and remain
persistent, increasing the severity of infections. On the other
hand, if Rs > 1 and Rr < 1, then the drug-resistant parasite
strains would be eradicated. Moreover, provided that the
threshold quantities Rs and Rr are less than unity, the use
of an efficacious antimalarial drug would help eradicate
P. falciparum infection.
+e efficacy of antimalarial drug is shown to have direct
negative impact on the density of infected red blood cells.
+e higher the efficacy of administered antimalarial drug,
the lower the population of infective merozoites and the
smaller the density of infected erythrocytes. +is ensures
prompt recovery from malaria infections. +is result is
consistent with that in [72, 83]. +e efficacy of antimalarial
drug is however shown to have least effect on the population
of drug-resistant infected erythrocytes. +e rate of devel-
opment of resistance by drug-sensitive parasites is also
shown to drive the infection due to resistant parasite strains.
Using contour plots and results from sensitivity analysis, we
observe that the efficacy of antimalarial drug used ωs, the































































































Figure 12: Within-human dynamics of single- and multiple-strain dynamics of infected erythrocytes, gametocytes, and the immune cells in
the absence preexisting immunity and with no antimalarial treatment (ωs � 0). +e rest of the model parameter values are in Table 3.
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erythrocyte P, the rate of development of resistance Ψ1, and
the rate of infection by merozoites β are the most important
parameters in the disease dynamics and control.
Finally, although the drug-resistant strain is shown to be
less fit, the presence of both strains in the human host has
a huge impact on the cost and success of antimalarial
treatment. To reduce the emergence of resistant strains, it is
vital that only effective antimalarial drugs are administered
to patients in hospitals, especially in malaria-endemic re-
gions. To improve malaria therapy and reduce cases of
parasite resistance to existing therapy, our results call for
regular and strict surveillance on antimalarial drugs in
clinics and hospitals in malaria-endemic countries.
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